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Cancer is now the leading cause of death in the world. In the U.S., one in two men and 
one in three women will be diagnosed with a non-skin cancer in their lifetime. Cancer 
patients are living longer than ever before. For instance, when detected early, the five-
year survival for breast cancer is 98%, and it is about 84% in patients with regional 
disease. However, the diagnosis and treatment of cancer is very distressing. Cancer 
patients frequently suffer from pain, disfigurement, depression, fatigue, physical 
dysfunctions, frequent visits to doctors and hospitals, multiple tests and procedures with 
the possibility of treatment complications, and the financial impact of the diagnosis on 
their life. This book presents a number of ways that can help cancer patients to look, feel 
and become healthier, take care of specific symptoms such as hair loss, arm swelling, and 
shortness of breath, and improve their intimacy, sexuality, and fertility.
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“You have cancer,” these words almost always cause devastation in the lives of their 
recipients. Feelings of uncertainty and loss of control over one's life are common 
reactions. Over time, cancer patients face several challenges that disrupt their quality 
of life. Examples include: making sense of complex medical information; making 
difficult treatment decisions; dealing with treatment side effects; living with the fear of 
recurrence; and for some, facing the possibility of impending death. Thus, in addition 
to prolonging survival, a key goal of cancer care is to minimize the impact of the 
disease and treatment on patients’ functioning and well-being.  
Cancer survivors are all those patients who have ever been diagnosed with cancer. The 
term “survivor” connotes that patients have been through a harrowing experience. 
Newly-diagnosed patients are included because this experience begins with the 
moment of diagnosis. From that time quality of life is almost constantly at peril 
because of uncertainties and side effects associated with diagnostic and treatment 
procedures, chronic pain, frequent hospitalizations, disfigurement, depression, and 
bodily dysfunctions. The spectrum of threats is wide, and so is the potential to address 
these threats.  
In this book, authors present a variety of interventions ranging from the effect of 
cancer and its treatment on physical appearance and function, expectations regarding 
survival, mood, sexuality, fertility, and immune function, and describe lifestyle 
interventions to mitigate these effects and solutions for specific symptoms such as 
alopecia and lymphedema.  
 
Assoc. Prof. Dr. Ravinder Mohan 
Full-time Clinical Faculty, 
Department of Family and Community Medicine, 




Living With and Beyond Cancer: 
New Challenges 
Neel Bhuva, Sonia P. Li and Jane Maher 
Mount Vernon Cancer Centre, Northwood, Middlesex, 
UK 
1. Introduction 
‘An illness in stages, a very long flight of steps that led assuredly to death, but whose every step 
represented a unique apprenticeship. It was a disease that gave death time to live and its victims time 
to die, time to discover time, and in the end to discover life.’ Hervé Guilbert 
The incidence of cancer is increasing with most current published statistics suggesting that 
approximately 300,000 new cases are being diagnosed annually in the UK. 1 in 3 will 
develop cancer during their lifetime. However, despite the incidence of cancer rising by 
almost 25% in the last 30 years, mortality rates have fallen by almost 20% in the same time 
period. In the UK, the overall cancer mortality rate in 2008 stood at just over 150,000 (Cancer 
Research UK, 2010). At present it is thought that two million people have cancer in the UK 
and as survival rates continue on an upward trend, this figure will only continue to rise 
(Table 1, Figures 1 and 2). This means that more and more people are living with or beyond 
a diagnosis of cancer especially with improving cure rates. Cancer is no longer a death 
sentence for an increasing number of patients. 
 
 UK % ENGLAND 
Total 2,000,000 100 1,670,000 
Male 800,000 40 670,000 

















Breast 550,000 28 460,000 
Colorectal 250,000 12 210,000 
Prostate 215,000 11 180,000 
Lung 65,000 3 54,000 
Other 920,000 46 766,000 
Kings College London, MacMillan Cancer Support and National Cancer Intelligence Network,Cancer Prevalence 
in the UK, 2008 
Table 1. Number of people living in the UK and England who have had a cancer diagnosis 
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Relative five-year estimates based on survival probabilities observed during 2000-2001, by 












1Cancer Research UK, Cancer Stats 
2Coleman MP et al. Trends and socioeconomic inequalities in cancer survival in England and Wales up 
to 2001.Br J Cancer, 2004. 90(7): 1367-73 
Fig. 1. Relative 5-year survival rates1,2 
 




(1) 1971-1991 Cohort Analysis – actual survival, (2) 2007 Hybrid Analysis – predicted survival 
1Coleman MP et al. Research commissioned by Cancer Research UK, 2010 
Fig. 2. Ten year relative survival (%), adults (15-99 years), selected cancers, England and 
Wales: survival trends for selected cancers 1971-2007 
In fact, survival is increasing and we extrapolate that by 2030 the number of cancer 
survivors will rise to 4 million (Armes et al., 2009). For the most part, these individuals 
remain well and healthy but a small number will experience changes to their well-being. As 
more people live with cancer the proportion of this latter group will go up as well. Cross-
sectional studies of populations with chronic illnesses reveal similar health and wellness 
profiles to populations in whom cancer is present but not active (Birgisson et al., 2008) This 
suggests that we are living long enough to develop conditions related to the treatment as 
well as the cancer itself and that we must focus on the quality of survival after different 
treatments. 
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A quarter of cancer patients will experience long-term effects that compromise their quality 
of life. These effects may manifest up to 10 years later and range from minor ailments in the 
majority to complex and debilitating problems for an unlucky few. Treatments now used to 
cure patients may no longer be considered ideal when treatment related adverse effects are 
taken into account and although most will be able to cope with minor conditions, a 
substantial minority will not. As a result, we must recognise and address the needs of these 
individuals. Early detection of symptoms, appropriate management and patient education 
are all key aspects to this. As curative approaches to different cancers become increasingly 
widespread, the focus needs to be more on quality of survival and reducing the disability 
associated with them. This is our challenge for the future. 
At present it is estimated that almost half a million cancer survivors in the UK suffer from a 
chronic treatment related condition which impacts their quality of life. In the United States, 
a National Health Interview study (Hewitt et al., 2003) compared 5,000 cancer survivors 
with 90,000 people without any history of cancer. It found that cancer survivors were more 
likely to report being in poor health both psychologically and physically. As we move 
forward, this will translate into a huge burden on our health resources, especially in the 
primary care setting. These findings are mirrored by results of similar studies in the UK 
which have also highlighted the financial impact on cancer patients as a result of no longer 
being able to work or who are subject to extra costs incurred due to their treatment and/or 
long-term disability (Fobair, 2007; Macmillan Cancer Support, 2006; Yabroff et al., 2007). It is 
important therefore, that measures are put in place now to minimise this. 
2. Addressing the late effects of cancer treatment  
2.1 Definition of late effects 
There is currently no agreed definition for the late effects of treatment with some 
differentiating between long term effects (those occurring during treatment and persisting 
after completion) and late effects (toxicities not apparent during primary treatment but 
manifesting some time later). However, the internationally accepted classification of adverse 
effects of treatment, the Common Toxicities Common Adverse Effects criteria (CTCAE) does 
not distinguish “acute” and “late” effects. 
In response to this, the National Cancer Survivorship Initiative Late Effects workstream has 
proposed the following definition that “late effects are the long-term consequences of cancer 
and its treatment, including those which appear during, or soon after treatment, as well as 
those which appear months or years later”. 
These effects include: 
 Heart (e.g. heart failure following anthracyclines and herceptin) 
 Lungs (e.g. radiotherapy, bleomycin) 
 Kidneys (e.g. cisplatin) 
 Gastrointestinal tract (eg pelvic radiotherapy) 
 Musculoskeletal system (eg amputations) 
 Lymphatic system (eg lymphoedema) 
 Brain (eg impact on cognition following chemotherapy or radiotherapy) 
 Peripheral nerves (eg neuropathy related to platinum based drugs) 
 Endocrine system (eg growth, fertility, thyroid deficiency, early menopause) 
 Sexual interest and function 
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 Genitourinary system (e.g. following pelvic radiotherapy) 
 Second cancers (e.g. breast cancer following radiotherapy for Hodgkin’s disease) 
 Emotional impact of long-term and late effects of cancer and its treatment. 
2.2 Treatment related late effects 
Surgery, chemotherapy and radiotherapy all have consequences, which may become 
apparent immediately or after several years. These include urinary, bowel and sexual 
dysfunction, neuropathy, cardiovascular and endocrine abnormalities. Those treated as 
children are at greater risk of complex and inter-related issues arising after a substantial 
period of time with the risk of a second malignancy becoming an increasingly real threat. 
Surgery and radiotherapy can result in significant ongoing co-morbidities. For those 
patients, for example, who underwent bowel resections, gastrointestinal sequelae of 
treatment can be severe and most often manifest as loose stool and incontinence. Pelvic 
radiotherapy has led to increasing cure rates of many cancers but the incidence of long term 
gastrointestinal problems is even higher (Flentje & Guckenberger, 2006) than with surgery 
including problems such as urgency, flatulence, abdominal pain and intermittent or regular 
soiling. Studies report that only a third of patients report normal or good bowel function 
(Lundby et al., 2005; Marijnen et al., 2005). Despite this, only few gastroenterologists feel 
adequately trained to deal with such side effects of treatment.  
Management of long-term gastrointestinal effects is poorly represented in the literature with 
little research in the field. Such problems are often very embarrassing to patients and 
therefore under-reported. Patients may feel that nothing can be done and physicians may 
not encourage patients to discuss these issues due to their minimal experience in dealing 
with them (Andreyev et al., 2003a, Andreyev et al., 2003b; Putta & Andreyev, 2005). Such 
patients inevitably withdraw from social interaction from fear of uncontrollable symptoms 
(Faithfull, 1995). It is not just bowel related difficulties that these patients face but also 
urological and sexual dysfunction. Furthermore, fractures, neurological issues and thrombo-
embolic phenomena are also seen, although less frequently. 17,000 patients a year are 
treated with radiotherapy to the pelvis with almost 80,000 survivors of this treatment in the 
UK. Almost half of these individuals feel that sequelae of treatment has had an impact on 
their quality of life with 27,000 describing this impact as moderate to severe. These figures 
are probably an underestimation, particularly as follow-up times for most studies preclude 
the true magnitude of late effects. Furthermore, few patients freely admit to diarrhoea or 
incontinence unless directly asked and therefore questionnaires may be too insensitive and 
not reproducible. The British Society of Gastroenterology is due to publish guidelines on the 
management of treatment-related late effects this year. 
The formation of RAGE (Radiotherapy Action Group Exposure) campaign was to address 
and improve conditions for patients with breast cancer who experienced late radiation 
injury as a consequence of radiotherapy at a time when there were no national standards in 
the United Kingdom. Although radiation damage is relatively rare, serious injuries such as 
those to the brachial plexus nerves causing weakness of the ipsilateral shoulder, arm and 
hand and vascular compromise have been reported. Less serious consequences such as rib 
fractures and skin discoloration may also arise. However, with many women now alive 
more than a decade after their diagnosis, the consequences of treatment of radiotherapy are 
becoming an increasing reality and a burden. Macmillan Cancer Support UK have focused 
on six main areas in response to RAGE (Hanley & Staley, 2006). 
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1. The development of a national register of consequences of treatment. 
2. The improvement of communication between primary and secondary care. 
3. Increasing the support to patients by providing information and assistance to patients 
in understanding the potential changes in their own health after treatment and on when 
to seek help. 
4. The development of easily accessible pathways to access multidisciplinary specialist 
expertise to patients with late side-effects. 
5. The development of an expert patient program for chronic treatment related conditions. 
6. The development of innovative commissioning models to help patients get the care they 
need. 
It is not just surgery and radiotherapy that have consequences. Chemotherapy is toxic and 
mutagenic, causing short-term multi-organ toxicity and increasing the risk of secondary 
malignancy. Two of the biggest hurdles women with breast cancer face after treatment is the 
fatigue associated with the cumulative effect of months of treatment and the after-effects of 
chemotherapy, together with mild cognitive impairment such as memory deficits, often 
termed “chemobrain” (Tannock et al., 2004). Furthermore, ongoing treatments in patients 
with breast cancer such as endocrine therapies which are often continued for at least five 
years, can affect recovery, leaving patients with physical problems such as fatigue, hot 
flushes, weight gain, joint pains and muscle aches. Tamoxifen can cause endometrial 
hyperplasia and increase the risk of endometrial malignancy. Osteoporosis and arthalgia are 
potential adverse effects that can arise from the use of aromatase inhibitors. Although 
hospital based follow-up systems have been developed to help monitor and detect any late 
toxicities, it may actually be more effective to educate patients to recognize problems. It is 
also important that adaptive strategies are discussed with patients in order to help them 
cope with these side-effects. 
2.3 Complex treatment related late effects 
A small proportion will suffer from severe or complex problems associated with treatment 
requiring specialist input. Some of these could be avoided through the prompt recognition 
and correct management of symptoms thereby avoiding the potential distressing 
complications resulting from inappropriate procedures. Occasionally, there may be people 
with unexpected effects associated with treatments which may require a national process of 
recall, reassessment and commissioning of new services. An example of this is in the group 
of young patients who received “Mantle” field radiotherapy for Hodgkin’s lymphoma 
which was subsequently associated with a high incidence of breast cancer. There are 
challenges both in identifying which patients should be recalled as well as how to link them 
to appropriate specialist multidisciplinary management. 
2.4 Secondary malignancies  
Secondary malignancies can develop as a consequence of primary treatment, in particular, 
for patients who received treatment for a childhood cancer. Treatment for Hodgkin’s 
lymphoma is associated with secondary leukaemia and breast cancer. Secondary 
malignancies are the sixth most common cancer in the USA (after skin, breast, prostate, 
bowel and lung cancers) and a cancer survivor has twice the risk of a comparable individual 
without cancer of developing another primary. This makes it all the more important to 
educate patients and GPs about potential warning signs of another malignancy. 
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3. Surviving cancer 
Mullan (1985) in his seminal paper “Seasons of Survival” describes the evolving process of 
surviving cancer as beginning from diagnosis and involving the following 3 phases (Mullan, 
1985):  
 Acute Survival: the first year, recovery from the diagnosis and treatment. 
 Extended Survival: five years after treatment. 
 Permanent Survival: the long term. 
The acute phase is particularly difficult with a multitude of physical and psychosocial issues 
that patients may face. The organic side effects of treatment are the first hurdle but with the 
completion of treatment, a whole host of unexpected emotions such as uncertainty, fear of 
recurrence and abandonment may surface (Pelusi, 1997). There are huge psychological 
hurdles that patients may need to deal with; a sustained mortal threat, unrelenting personal 
and domestic turmoil, long difficult medical treatments and a prolonged uncertainty about 
the future. At this point, patients may find that they need to face up to the realities from 
being an ill person to being a survivor, from feeling time is unlimited to a having finite 
lifespan and from being fully able to living with a disfigurement or disability. Returning to 
work can be a huge physical and mental challenge. Patients’ view of themselves may have 
changed and side effects of treatment such as mood changes and hot flushes may make 
social interaction difficult (Charmaz, 1983; Wyatt 1996). Hospitals form a protective bubble, 
having become a familiar and comfortable place in which patients often feel a sense of 
togetherness and reassurance. The sudden foray into the world outside can therefore be 
lonely and unpredictable. As time passes, most begin to feel a sense of security return and 
find that their health becomes more predictable. However a significant proportion, 
approximately 20-30%, will still suffer from continuing distress (Absolom, 2009; Foster, 
2009) and will require increasing support in the community. Predictors of persistent, 
moderate and severe problems with daily living may include a high level of unmet physical 
needs, fear of recurrence, stress of looking after a family and increasing imposition on their 
health by unrelated co-morbidities or iatrogenic interventions. 
Extended survival is the period where active hospital based surveillance is the mainstay of 
follow-up. However, these first five years after treatment has ended also represent the 
period of highest recurrence risk. Reduced levels of activity and less acute symptomatology 
may persist which over time could erode into the ability to enjoy life and maintain 
relationships. For example, menopausal symptoms are experienced by 70% of patients 
treated for breast cancer and can persist for several years impacting severely on quality of 
life (Carpenter & Andrykowski, 1999; Fenlon et al., 2009; Hunter et al., 2004; Walker et al., 
2007). An online survey found that over 30% of breast cancer survivors stopped adjuvant 
aromatase inhibitor therapy due to their side effects (Zivian & Salgado, 2007). Long term 
sexual difficulties are also a challenge, with loss of libido, decreased orgasm and physical 
difficulties (retrograde ejaculation and impotence in men on GHRH antagonists, 
dyspareunia in women on endocrine therapy). Such issues are often considered taboo or 
difficult to discuss with medical professionals. Many more women are being diagnosed at a 
younger age due to screening programmes and therefore wish to maintain fertility. Access 
to fertility preserving facilities is variable and simply potentiates an already sensitive issue 
(Amir & Ramati, 2002; Bloom et al., 2004; Broeckel et al., 2002). 
Permanent survival refers to treatment related problems that emerge years or decades after 
the initial diagnosis. This is most apparent in children, a group in whom, as cancer treatment 
has become more successful, has an increasing number of survivors developing treatment 
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related sequelae such as premature ischaemic heart disease and dyslipidemia after radiation to 
the heart. Ominously, a similar pattern is developing in adults also. Survivors of breast cancer 
who were given radiotherapy at a relatively young age are now demonstrating an increased 
incidence of cardiac problems with age. Despite evidence suggesting that these patients are 
also at a significantly higher risk of recurrence of a second primary later on in life, many are 
not receiving more intense screening than the normal population. 
4. Responding to the changing cancer story: Focus on the future 
In the past and even in the present, cancer services continue to focus predominantly on the 
acute recovery phase with little emphasis on a five or even ten-year support plan. The first 
year after treatment is merely the ‘tip of the iceberg’ and it is crucial that our approach to 
treating cancer is more visionary and holistic, viewing cancer as a chronic illness rather than 
an acute condition. 
A recent UK survey concluded that at present, follow-up is primarily a check for signs of 
recurrence or spread (Theis et al., 2010), and checking for recurrence is perceived by the 
patient as the most important reason for engaging in follow-up. Several studies are currently 
underway exploring different follow-up methods. What is clear, particularly in the case of 
colorectal cancer, is that more intense follow-up in the first two years does improve survival, 
as evidenced by five out of six recent systematic reviews (Figueredo et al., 2003; Richard & 
Mcleod, 1997; Rosen et al., 1998, Tjandra & Chan, 2007). However, what is not clear is which 
aspects of follow-up are associated with this. Within the NHS in the UK, consensus 
meetings have concluded that many follow-up appointments are not required and for many, 
the common cancers signs of recurrence are as easily and reliably detectable by the patients 
as they are by expensive surveillance investigations. As long as there is a robust method of 
feedback to the clinician, i.e. through a specialist nurse, unnecessary appointments can be 
avoided thus releasing resources and achieving a system, which is more geared to focus on 
assessment of the cancer, rehabilitation and dealing with the emotional, psychosocial and 
financial burdens of patients. We need a more bespoke service tailored to the needs of the 
individual person rather than a ‘one size fits all’ approach. 
The English National Cancer Survivorship Initiative (NCSI) aims to address this issue and 
provides a vision for better care and support for cancer survivors in the UK. It highlights the 
importance of recognition and self-management of ongoing problems and raises awareness 
of the longer-term consequences of cancer (DH, Macmillan Cancer Support & NHS 
Improvement, 2010). The NCSI is a partnership between Macmillan Cancer Support and the 
Department of Health and sets out five key shifts in its Vision document of January 2010, 
outlining ways to assess need, plan care and support cancer survivors to recognise and 
manage ongoing problems: 
 A cultural shift with greater focus on recovery, health and well-being after cancer 
treatment. 
 A shift towards personalized assessment, information provision and care planning. 
 A shift towards support for self management. 
 A shift from a single model of clinical follow-up to tailored support that enables early 
recognition and preparation for both the signs of further disease and the longer-term 
consequences of treatment. 
  A shift towards using Patient Reported Outcome Measures as well as clinical measures. 
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This should raise awareness and allow intervention to help deal with the longer term 
consequences of cancer treatment, including the recognition that survivors of cancer have 
particular risks in relation to unhealthy lifestyles. Some long term cancer survivors express a 
preference for hospital-based services including telephone based services and those who 
have experience of such services are generally very positive about them. Furthermore, as 
part of the National Cancer Survivorship Initiative, different ways to deliver after cancer 
treatment care such as “end of treatment care packages” including information about “what 
to expect”, written care plans, description of symptoms indicating a need for tests, coping 
strategies and a variety of educational interventions are being investigated and these will be 
reported in 2011-12 to aid in the commissioning of new pathways.  
If change is to be successfully implemented it will require coordination of services and 
teamwork between secondary care, primary care and the patients themselves. The 
transitions between the three phases of survivorship according to Mullan’s model have been 
dubbed as ‘teachable moments’ (Denmark-Wahnefried et al., 20045). These are seen to be 
opportunities for giving information on health surveillance and healthy living. Cancer 
survivors are receptive to any initiatives that will improve their health, but many are not 
aware that lifestyle changes are especially important for them, given that they are at an 
increased risk of chronic illnesses and further malignant disease. Not only do we need to 
equip patients to know what symptoms to look for and when they require to be seen by a 
medical professional, but we must also unlock these gateways in order that they may benefit 
from programmes supporting lifestyle change, such as smoking cessation, weight loss and 
exercise. 
Primary care will also need to play an increasingly important role. General practitioner 
should no longer see cancer in simple terms i.e. ‘cured and back to normal’ or ‘incurable and 
terminal’. Many general practitioner have not received any training or education about the 
long-term consequences of cancer and its treatment and therefore may not always make the 
connection between a symptom or series of symptoms and past cancer treatment. 
Furthermore, in some cases, they may not view it as their responsibility to identify and 
manage these consequences. Progressive, complex problems related to rare conditions 
and/or obsolete treatments may often go unrecognised. Symptoms of all patients with a 
cancer history should be considered as possibly relating to that cancer. Furthermore, 
practices must employ up-to-date and accurate recording of patients so that previous 
cytotoxic or radiation treatments are highlighted on computer systems. Visual alerts can 
bring an individual’s cancer diagnosis to the forefront of the primary care physician’s mind 
during a consultation. The flow of information between oncologist and GP is vital with one 
of the mandates of the NCSI specifically addressing how this can be improved. GPs also 
need to be educated on being pro-active in asking about physical symptoms, such as those 
with heart disease, as well as providing and facilitating psychological support. It is crucial 
that GPs and patients are given access to freely available information regarding the long 
term sequelae of oncological treatments, and those patients identified as being at higher risk 
are more closely monitored and receive appropriate lifestyle advice. 
5. Transition 
The landscape of cancer treatment is changing. In today’s world we do not just treat cancer – 
we live with it. In tomorrow’s world we will survive it. 
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‘Survival machines which can simulate (i.e.imagine) the future are one jump ahead of survival 
machines who can learn only by trial and error…’ 
Richard Dawkins 
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1. Introduction 
Human beings have always been interested in their appearance. Most of us make active 
efforts to influence the way we look: we exercise, we lose or put on weight, we use make-up 
and dye our hair, we dress in certain ways, and some of us even have surgery to change 
parts of the body with which we are dissatisfied. Changes in appearance are sometimes 
desired, and sometimes not. According to Giddens, the body is easily changeable and 
reflects our identity (Giddens 1991). Individuals therefore have the ability to change their 
bodies, if they so wish. The healthy body symbolises a healthy society, while the sick or 
imperfect body represents a sick society. In advertising, good-looking models are often 
used, as it is expected that this will cause us to buy the product they are advertising 
(Rumsey N. & Harcourt D. 2005). Visual appearance is sometimes also linked with inner 
values. Most societies have their own traditional links; in Western society, for example, red 
hair is associated with a hot temper, and a link has been found between appearance and the 
chance of being convicted in court through false consensus (Miyake & Zuckerman 1993). 
Stereotypical conceptions of links between visual appearance and a person’s inner qualities 
have also been experienced by patients (Rumsey N. 2003). Plough Hansen has, for example, 
described how women with chemotherapy-induced hair loss experienced this as a loss of 
womanhood, associated with sickness and death, and therefore used wigs and make-up to 
control and minimize the effects of the changed appearance (Hansen H.P. 2007). Jutel and 
Buetow argue that outer appearance and a tendency to focus on first impressions may imply 
a tendency for health care professionals to use this as an indicator of health, with the risk 
that this could harm medical practice (Jutel & Buetow 2007). However, although there is an 
emphasis on visual appearance in our society, such norms as “true beauty comes from 
within”, “do not judge a book by its cover” or “beauty lies in the eye of the beholder” are 
often more acceptable. People do not generally wish to be regarded as being overly 
concerned about their appearance, or as someone who judges others on their appearance. 
This makes it difficult for patients to talk about issues of appearance. It might therefore also 
seem a contradiction that many smokers continue to smoke rather than risk gaining an extra 
five kilos, even though the health risk from smoking is many times greater than that of a 
small amount of extra weight. Similarly, young amateur bodybuilders risk taking anabolic 
steroids in order to increase their muscle mass, even though this affects their bodies in many 
ways, and may involve the risk of impotence. In a study of patients attending a cancer 
rehabilitation centre, it was found that the lack of communication about appearance was 
experienced as a socially-accepted norm, supported by the taboo on speaking out about 
cancer (Rasmussen, Hansen, & Elverdam 2009). 
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Visual appearance affects first impressions when two people meet. In addition, another 
determinant is how those impressions are understood and socially returned. It has for 
example been shown that people who undergo facial changes experience social encounters 
in ways that are different from others, with behaviour or rules of social conduct that differ 
from the norm, e.g. greater standing distance (Rumsey N., Bull R., & Gahagan D. 1982), 
staring and comments, or differences expressed in “silent language” such as body 
movements and gestures (Macgregor F.C. 1990). This is an example of how reactions are 
determined, not only by the actual physically changed appearance, but also by social 
interaction between people. In patients who have undergone a changed appearance after 
surgery for head, neck or eye cancer, this was described in their first year post-operatively 
as “interactional integration” (Konradsen H. 2010). The integration of disfigurement was 
affected not only by the attitudes of the patients themselves, but equally by their social 
interaction with the surrounding society, also described as the movement from becoming 
disfigured, to being a disfigured person, to becoming a person with a disfigurement.  
One of the first philosophers to talk about the body was Plato, who lived from 427 – 347 BC. 
He regarded the body and mind as two separate entities, and this dualistic view of body and 
mind still underlies much of our health care today. Others have criticised this approach. The 
anthropologists Scheper-Huges and Lock (Scheper-Hughes & Lock 1987), for example, view 
the body on three levels: the individual body, the social body and the political body. 
According to them, society socialises us and our bodies, and our bodies therefore represent 
our ability to live up to these norms. This puts a great deal of pressure on those who fall ill. 
In the early 1990s, Bob Price developed the “Body Image Care Model” (Price 1990). This 
model focuses on how we experience our bodies, and our reaction to how others regard us. 
The model describes our body image as influenced by three dimensions: body ideal, body 
reality and body appearance (Figure 1) 
Subsequently, other people have developed other models. Professor Robert Newell, for 
example, has developed the “fear-avoidance model” (Newell 1999). His model can help to 
evaluate body image-related concerns and provide possible suggestions for intervention. 
(Figure 2). 
In healthcare research, the use of the concept of body image began in the nineteen-sixties, 
and was at first mainly related to social psychology, with the main emphasis on eating 
disorders. Most research at that time focused on how the disturbed body image or body 
ideal was perceived by the person herself: the fact that you did not see yourself as others 
saw you. This way of looking at body image-related concerns is for example reflected in the 
NANDA classifications (Ackly & Ladwig 2008). Here, disturbed body image is defined as 
“confusion in the mental picture of one’s physical self”. More recently, the concept of body 
image has received wider clinical application. Today, we know that bodily changes, and 
related body image concerns, occur independently of medical diagnosis. Most diseases 
cause bodily changes, whether they are temporary, recurrent or chronic. These changes may 
be visible or invisible, physical or psychological, and may interfere in various ways with our 
everyday lives. Such bodily changes are not merely objective visible changes, but are also 
subjective, and are linked to the ways in which we see our bodies, the world and our 
relationships with others. Health-related quality of life studies have explored this and have 
shown how changed appearance in relation to illness is an important issue, for example in 
cases of HIV and AIDS (Huang et al. 2006b; Huang et al. 2006a), as well as obstetrics 
(Hawighorst-Knapstein et al. 2004). It is also important irrespective of patients’ age, gender, 
social situation or ethnicity (Cash T.F. & Pruzinsky T. 2002). 
 




Fig. 1. The body-image care model. Arrows indicate direction, influence or interaction. 
(Price 1990) 
Facial disfigurement as a result of surgical treatment for head, neck or eye cancer, for 
example, poses a great challenge to the person experiencing it. The face is a major 
contributor to what is labelled “first impressions”, and it expresses a great deal of our 
personality (Bar M., Neta M., & Linz H. 2006;Hess U., Adams R.B., & Kleck R.E. 
2009;Naumann L.P. et al. 2009). Changes in the face cannot be hidden, and are therefore 
often more difficult for patients to deal with than changes elsewhere in the body (Dropkin 
M.J. 1999). According to Callahan, facial disfigurement poses a challenge, in that the patient 
must deal with both a changed appearance and an altered sense of self (Callahan C. 2004). 
Facial disfigurement is associated with a high degree of psychosocial problems and a lower 
self-reported quality of life. The problems occur irrespective of the patient’s age or the extent 
of the disfigurement (Blood G.W. et al. 1995;Tebble N.J., Thomas D.W., & Price P. 2004), and 
include anxiety, depression and social isolation (D`Antonio L. et al. 1998;Rumsey N. 
2003;Rumsey N. et al. 2004) Marks 2000, Tebble 2006). Close family members or partners 
may also be affected (Drabe N. et al. 2008;Krouse H.J. et al. 2004;Verdonck-de Leeuw I.M. et 
al. 2007;Vickery L.E.Latchford G. et al. 2003). In relation to quality of life, socio-cultural 
factors seem to matter more than physical dysfunction (Morton R.P. 2003). In 1983, Dropkin 
(Dropkin M.J. et al. 1983) found no differences in the evaluation of men’s and women’s 
degree of disfigurement after identical surgical treatment, whereas Lockhart found such 
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differences in 1999, and based the explanation of the results on a generally increased focus 
in society on “the perfect female body” (Lockhart J.S. 1999).  
 
 
Fig. 2. A fear-avoidance model of psychosocial difficulties following disfigurement. (Newell 
1999). 
When we encounter illness our attention is directed towards the body, a mechanism Leder 
calls “the dysappearing body” (Leder D. 1990). When our body is changing, or not 
functioning as we expect, our attention is drawn towards it. Others have found that the 
experience of bodily change is influenced by various underlying self-schemas (Thompson A. 
& Kent G. 2001), the degree to which people have a negative view of themselves (Moss T. & 
Carr T. 2004), or social self-efficacy (Hagedoorn & Molleman 2006).  
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Cancer, i.e. the disease itself, its treatment and side effects, significantly interferes with the 
body. There are bodily changes associated with the specific cancer site, but in addition to 
this, many cancer patients also struggle with symptoms such as tiredness, pain, etc. Due to 
the seriousness of the disease, psychosocial concerns are also of great importance and 
influence the way in which the body is perceived. 
In general, body image is a multidimensional concept which is used in many different ways. 
In 2002, White wrote that “much of the literature on body image and cancer is observational, 
atheoretical, and anecdotal. Though more empirical research has recently emerged, it is 
often of poor quality, resulting in inconsistent findings” (Cash T.F. & Pruzinsky T. 2002). 
This is still partly true, but body image as a research subject has been attracting increasing 
attention.  
2. What we know 
In the following, the literature relating to body image and cancer is briefly reviewed. What 
do we know about body image in relation to cancer patients? And what are the benefits and 
limitations of the research? 
The research studies examined date from 1997 to 2010. As the aim is to understand how 
issues and concerns relating to bodily changes are experienced by adults, only studies which 
employed a qualitative approach have been examined. In order to obtain an overview, all of 
the studies were arranged according to the Matrix Method (Garrad J. 2011). The research 
includes studies of adult women, men, both men and women, and families. The medical 
diagnoses included breast cancer, gynaecological cancer, head and neck cancer, testicular 
cancer and colorectal cancer. A few also included persons with a mixture of different 
diagnoses. This indicates that the research has mainly concentrated on diagnoses for which 
treatment most often results in a visibly changed body.  
2.1 Body image and gender 
Overall, most of our knowledge about body image and cancer is related to the diagnosis of 
breast cancer, and thereby relates specifically to women. Breast cancer has been described as 
associated with the fear of losing one’s attractiveness and desirability (Elmir et al. 2010), and 
has been seen as a threat to intimate relationships (Ashing-Giwa et al. 2006) and as 
challenging a person’s female identity (Piot-Ziegler et al. 2010). Studies focusing on men are 
rare. A few studies have been undertaken of testicular cancer, e.g. (Chapple & McPherson 
2004), and of male breast cancer (Pituskin et al. 2007). Even fewer studies have been 
undertaken of how the cancer experience relates to body image when gay or lesbian patients 
are involved; one example is a study by Katz (Katz 2009). In relation to body image 
concerns, it seems that the emphasis is on gender as a sexual component, and little is known 
about how women and men experience bodily changes in relation to cancer diseases that are 
not related to a person’s specific gender.  
2.2 Body image as a static or changing problem 
Problems relating to body image are often described as a static issue, clearly associated in 
time with the period after cancer treatment. A few studies have examined changes in body 
image pre- and post treatment, e.g. Adamsen’s study of how young athletes regain their 
bodily control and identity through exercise, and Bredin’s study of women with breast 
cancer, and how they experienced their body image in combination with therapeutic 
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massage (Adamsen et al. 2009; Bredin 1999). Body image problems are also often presented 
as being static post-treatment. In general, the findings give a picture of BI-related concerns 
at a specific point in time. We know that adjustment to other chronic diseases must be 
viewed over a substantial period of time if they are to be fully understood. Adjustment is 
the psychosocial adaptation to a life change, as expressed in the Nursing Outcome 
Classification (Johnson M., Maas M., & Moorhead S. 2000), so if body image is regarded as a 
chronic or stable situation, this approach could prove fruitful. In the case of multiple 
sclerosis, for example, patients diagnosed at least five years previously stated that it was a 
process that “one can learn to live with” in time (Irvine H. et al. 2009). For patients adjusting 
to lower-limb amputation, it has been found to be a question of developing an altered sense 
of self and identity over the months and years following the amputation (Horgan O. & 
MacLachlan M. 2004). In an article, Morse describes findings from a study of patients who 
survived traumatic injury, covering their experiences from the initial impact of the surgery 
until recovery (Morse J.M. & O'Brian B. 1995). She describes a four-stage process of 
vigilance, disruption, enduring the self, and striving to regain the self. In the final stage, the 
participants learned to redefine the self as a disabled person by accepting the consequences 
and reformulating their expectations. Learning to see oneself as a disabled person is also one 
of the end-points in a qualitative meta-analysis of the individual’s responses to acute or 
chronic illness or injury (Morse J.M. 1997).  
The elucidation and exploration of body image is also seen as a static problem, in that only a 
few studies describe the late effects of cancer and how these are experienced. Frid found that 
lower limb lymphedema exerts a considerable influence on the psychosocial situation of 
cancer patients in palliative care (Frid et al. 2006). There are very few studies that examine 
how a patient’s body image concerns change over time. One example is the study by Roing 
on the experiences of patients with oral cancer of their illness and treatment (Roing, Hirsch, 
& Holmstrom 2007). The study found that the need of patients for support increased during 
treatment, and it was suggested that this need might be greatest at the conclusion of 
radiotherapy, when the patients returned home. This is an example of how the degree and 
extent of patient concerns can be greatest at the time of discharge, rather than, as is often 
thought, at the time of admission to hospital. Another way of elucidating change in body 
image over time is described by Frith in a study of chemotherapy-induced hair loss among 
patients treated for breast cancer (Frith, Harcourt, & Fussell 2007). Here it was shown that 
the women made use of the anticipation of altered appearance as a form of anticipatory 
coping.  
A more detailed picture is required of interventions targeted at specific problems relating to 
body image; how do the problems change over time, and when is the most appropriate time 
for intervention? 
2.3 Context-related or universal 
In most of the studies, context is very sparsely elucidated. In some studies the cultural 
aspect is described, examining such issues as religious approaches in newly-diagnosed 
Iranian women coping with breast cancer (Taleghani, Yekta, & Nasrabadi 2006), how 
spiritual belief is part of the cancer belief among Asian American women with breast cancer 
(Tam et al. 2003), or how culture and the role of the woman in Lebanese families creates a 
foundation for various coping strategies among women with breast cancer (Doumit et al. 
2010). Another study described women from a low-income socio-economic group with 
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early-stage breast cancer and their various styles of decision-making (McVea, Minier, & 
Johnson Palensky 2001). While it is plausible that body image-related concerns could have a 
universal inner structure, it is also plausible that body image-related concerns could be 
highly culturally dependent. The latter is suggested by a study of Jewish/Middle Eastern 
cancer patients from Israel, where religious belief systems, amongst other things, can 
influence how patients deal with existential concerns (including body image-related 
concerns) (Blinderman & Cherny 2005). It seems evident that body image-related concerns 
are not only dependent on how an individual experiences her own body. The surrounding 
society and the people with whom one interacts also have a substantial influence - an 
influence that is often overlooked in research.  
2.4 Multiple effects 
Body image is very often described as a concept that relates to the visible, objective signs of 
changed appearance: the absence of a breast or hair, deterioration in muscle function, or a 
change in bodily functions such as amenorrhoea or loss of control over bodily functions. 
When body image is addressed in a study’s results, the terms in which it described are often 
powerful, such as identity-changing, hopelessness, fear, poor self-esteem, frustration and so 
on. The concept of body image itself is rarely defined, and is most often used without a 
theoretical basis. One of the few studies to actually define the term body image as it used is 
Jenks et al (Jenks, Morin, & Tomaselli 1997), who state that the definition of body image they 
employ is based on the individual’s own perception of the physical appearance and physical 
functions of the body.  
However, as with any other concept in research, the use of the body image concept is 
strongly linked to how the concept is defined. This may be exemplified by examining three 
different studies. 
In 1983, Dropkin developed a visual scale to measure the perception of the severity of 
visible disfigurement and dysfunction following head and neck cancer surgery (Dropkin et 
al. 1983). Evaluations were made by measuring how nurses assessed a certain disfiguring 
surgical procedure. The study argues that quantitative measurement of the grade of 
disfigurement could be used to foresee the course of a patient’s rehabilitation. This thus 
implies that the way in which others perceive a person with a disfigurement is an important 
factor in the rehabilitation process.  
Later, Newell developed his fear-avoidance model of psychosocial difficulties following 
disfigurement (Newell 1999). This model suggests that the problems experienced by patients 
with disfigurement could be compared to those experienced by patients with phobias. It 
therefore recommends cognitive behavioural therapy. The model thus implies that a person’s 
own perception of himself or herself and their own way of behaving are important factors. 
The third study is from 2006; here Furness argues that social support and a person’s ability 
to cope with challenging situations are important (Furness P.J. et al. 2006). This study 
implies that social interaction and a person’s own psychological resources are important 
factors.  
These three studies present different theoretical perspectives on the psychosocial issues 
relating to disfigurement. These theoretical views contribute to determining how one might 
regard, elucidate and examine these problems, how data is collected and analysed, and 
where to look for data. Determining and describing the theoretical view of the concept of 
body image thus seems to be important in order to assess the results of the study. Doing so 
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could potentially strengthen the whole body of knowledge within this clinical area and 
improve the possibilities for developing adequate and effective interventions which will 
target the patients’ problems.  
2.5 Relationships 
One major theme that emerges in connection with how patients with body image-related 
concerns relate to health care professionals is that of lack of support. In head, neck and eye 
cancer, for example, this is described by Konradsen (Konradsen, Kirkevold, & Zoffmann 
2009) as an issue that is silenced in the communication between patient, relatives and 
professionals. In a study of patients surgically treated for laryngeal cancer, it was found that 
for a period of three years, the most difficult areas of psychosocial adaptation were work 
and family relationships (Ramirés M.J. et al. 2003), while in patients with orofacial injury, it 
was found that the perception of a diminished level of social support was associated with a 
higher risk of post-traumatic stress (Lui A., Glynn S., & Shetty V. 2009). Others have found 
that patients’ family members also go through a process of adjustment, from being 
concerned about the survival of the patient to becoming concerned with how disfigurement 
might affect the patient socially (Bonanno A. et al. 2010). 
It seems that for cancer patients, body image-associated issues relate to some of the basic 
and fundamental structures of a person’s identity, and thereby also to social interaction in a 
broad sense. For patients with colorectal cancer, the experience of having to deal with a 
stoma is described as a loss of adulthood (Rozmovits & Ziebland 2004), which also 
influences their sense of dignity, independency and sexual confidence.  
3. Future research 
With the exception of one study’s additional use of journal narrative, the research has 
exclusively employed individual interviews or focus group interviews for data collection. 
These are data collection methods which are well established in qualitative research, and are 
capable of collecting valuable data. However, a wider range of data collection methods 
might enrich the body of knowledge in the field of body image. 
A closer look at changing body ideals in the surrounding society of patients might also be 
beneficial. How does the changing body ideal among both women and men influence the 
experience of bodily change? If more is learned about this, it might be possible to develop 
better patient trajectories.  
All of the studies included an adult population, but few included old people. As an 
example, it has been shown that body image is important when older women are making 
treatment decisions about breast cancer, and that treatment outcomes influenced body 
image two years after treatment (Figueiredo et al. 2004). It might therefore be of great 
interest to examine the impact on body image of experiencing cancer either as an older 
person, or how this changes (or does not change) in the course of a lifetime. Collecting this 
knowledge and obtaining an overview might help the health care system to improve both 
the overall and the individual quality of treatment and care.  
4. Interventions 
Measuring body image implies a wide range of challenges. The definition of the term ‘body 
image’ reflects what is being measured. One proposal for a means of measuring body image, 
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specifically in relation to cancer patients, has been advanced by Hopwood (Hopwood et al. 
2001). The scale focuses on how body image is experienced by the patients themselves. It is a 
valuable scale, but it may omit the contribution of relatives and society generally to the way 
in which patients experience their own body image. The scale can provide valuable 
knowledge about the extent of body image concerns among cancer patients. It has for 
example been used to describe how half of a multi-ethnic population of women in the USA 
diagnosed with breast cancer experienced two or more body image problems during the 
early months after diagnosis (Fobair et al. 2006). Another scale is Dropkin’s 
disfigurement/dysfunction scale, which measures how others view the extent of a patient’s 
disfigurement. This is also important, and has been used to show how body image 
reintegration is critical to subsequent quality of life after head and neck cancer surgery 
(Dropkin M.J. 1999).  
Qualitative studies are important when developing intervention studies targeted at the 
psychosocial problems experienced by cancer patients in relation to body image. In many 
areas there is a lack of effective intervention methods. In relation to head and neck cancer, 
for example, reviews have shown that no intervention method has so far been successful 
(Semple et al. 2004). Another example is in relation to gynaecological cancer patients; in this 
context there is only weak evidence to suggest an effect from cognitive behavioural 
interventions for body image-related concerns (Hersch et al. 2009). Overall, Bessell 
concluded in a review of the effectiveness of psychosocial interventions targeting 
individuals with visible disfigurement unrelated to diagnosis that none of the studies 
demonstrated adequate clinical effectiveness in the interventions (Bessell & Moss 2007).  
Qualitative studies have the potential to direct the researcher’s attention to possible 
elements of future interventions. Studies using grounded theory as a research method have 
for example demonstrated this in other contexts, such as diabetes care (Zoffmann & 
Lauritzen 2006). To demonstrate how this can be viewed, a case is presented elucidating 
how a longitudinal study of patients with facial disfigurement as a result of surgical 
treatment for head, neck or eye cancer could point to possible elements of future 
interventions (Konradsen H. 2010).  
In the study, the researcher met and interviewed the participating patients several times 
during the first postoperative year. Grounded theory analysis of the early patient-nurse 
interaction during hospitalisation revealed that disfigurement in this context was silenced, 
and this situation continued. The researcher, on the other hand, brought up disfigurement 
as a central theme in every interview. The fact that the researcher became a familiar person 
who accompanied the patients throughout their trajectory also meant that the researcher 
knew the patient’s history and was aware of his or her concerns. While hospitalised, the 
patients met various nurses, albeit a limited number, whereas during outpatient treatment 
they met a different nurse at almost every visit. In contrast to this, the researcher was the 
same person throughout the entire process.  
Throughout the study, there were numerous signs of the patients’ willingness to participate, 
e.g. repeatedly devoting their spare time to talking to the researcher, inviting the researcher 
to their homes and serving coffee and cake, wishing to continue talking after the interview 
was completed, and so on. Regardless of not being asked about the benefits of participation 
in the study, six of the twelve patients spontaneously stated that they had benefited from 
this. The positive effects were related to the patients’ feeling that there was someone who 
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was willing to listen to their story, the feeling of being able to look to the future with some 
confidence, and a sense of being able to exert some kind of influence over how to tackle the 
possible obstacles the patient would meet in the future.  
The positive effects of participation in the study indicate and help to point out various 
possible effective components of interventions, which future intervention studies may 
subsequently evaluate. Examples are shown in table 1.  
 
 
Table 1. Possible elements in interventions targeting psychosocial concerns related to body 
image 
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was willing to listen to their story, the feeling of being able to look to the future with some 
confidence, and a sense of being able to exert some kind of influence over how to tackle the 
possible obstacles the patient would meet in the future.  
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possible effective components of interventions, which future intervention studies may 
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Table 1. Possible elements in interventions targeting psychosocial concerns related to body 
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1. Introduction  
Worldwide, breast cancer is the predominant form of malignancy in women (Hortobagyi et 
al., 2005). However, when diagnosed in an early stage, women have a good chance to 
survive for a longer period of time. Therefore, it is important to focus on the impact of breast 
cancer and its treatment on long-term psychosocial outcomes. In recent years, quality of life 
(QOL) has become a primary endpoint in oncology (Movsas, 2003, Sprangers, 2002).  Body 
image is an important aspect of QOL, especially in breast cancer patients (Avis et al., 2005), 
because of the mutilating effect  surgical treatment may have. Body image  is  a component 
of the self-concept of a woman, which includes feeling attractive and feminine (Fobair et al., 
2006). Body image is defined in different ways, but typically conceived as a 
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1. Introduction  
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(QOL) has become a primary endpoint in oncology (Movsas, 2003, Sprangers, 2002).  Body 
image is an important aspect of QOL, especially in breast cancer patients (Avis et al., 2005), 
because of the mutilating effect  surgical treatment may have. Body image  is  a component 
of the self-concept of a woman, which includes feeling attractive and feminine (Fobair et al., 
2006). Body image is defined in different ways, but typically conceived as a 
multidimensional construct, consisting of perceptual, attitudinal, and behavioral 
aspects.(Jolly et al., , Sarwer and Cash, 2008) Body image evaluation (e.g., satisfaction or 
dissatisfaction) and body image investment (i.e., the psychological importance of one’s 
appearance to his or her sense of self or self-worth) are the most central body image 
dimensions.(Sarwer and Cash, 2008) Patients experience a body image problem when a 
marked discrepancy exists between the actual or perceived appearance or function of a 
discrete bodily attribute(s) and an individual’s expressed ideal regarding this bodily 
attribute(s).(White, 2000) A positive body image is related to patients’ ability to cope with 
cancer (Pikler and Winterowd, 2003). In this study, the focus will be on the dimension of 
body image evaluation.  
Women with breast cancer often experience a decrease in satisfaction with body image after 
surgery, irrespective of type of surgical treatment (Brandberg et al., 2008, Ganz et al., 1992, 
Kraus, 1999, Lindop and Cannon, 2001). There is no consensus whether the type of surgery 
received is related to dissatisfaction with body image after surgery. Some studies found that 
women receiving MTC report lower scores on body image compared with women receiving 
BCT (Anagnostopoulos and Myrgianni, 2009, Engel et al., 2004, Ganz et al., 1992, Janni et al., 
2001, Janz et al., 2005, Kenny et al., 2000, Schou et al., 2005). However, a number of studies 
did not find type of surgery to be a relevant factor in satisfaction with body image (Fobair et 
al., 2006, Goldberg et al., 1992, Schover et al., 1995, Wolberg et al., 1989). Furthermore, 
previous research was also inconsistent regarding adjuvant therapy. Although most studies 
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showed that chemotherapy (Fehlauer et al., 2005, Joly et al., 2000), hormone therapy (Ganz et 
al., 1998), and radiotherapy (Fehlauer et al., 2005, Hopwood et al.) did not negatively affect 
body image, Schover et al. (Schover et al., 1995) concluded that chemotherapy did have a 
negative impact on body image, while hormonal and radiation therapy did not. 
Women’s perception about their bodies may be influenced by the length of time since 
treatment. In general, most studies found that body image improved over time (Hopwood et 
al.), for MTC and BCT (Ganz et al., 1992, King et al., 2000).  However, in a more recent study, 
it was found that most body image scores were quite stable, especially for MTC patients. 
Only BCT patients felt more attractive and feminine after two years (Engel et al., 2004). 
Information about the effect of surgery across time is lacking and few studies measured 
body image before diagnosis making it impossible to know the effect of treatment on 
patients’ body image. Therefore, the first aim of this prospective follow-up study was to 
examine changes in body image across one year, starting before diagnosis and comparing 
women with benign breast problems (BBP group) with women with breast cancer (MTC and 
BCT). 
The impact of disease and treatment on general QOL seems to vary with age, marital status, 
and educational level, with younger women and women with lower levels of education 
reporting lower QOL scores when patients received chemotherapy (Janz et al., 2005, King et 
al., 2000). Two studies reported a strong relationship between age and body image (Al-
Ghazal et al., 1999, King et al., 2000, Yeo et al., 2004). The largest negative impact of MTC on 
body image was found amongst young, married women (King et al., 2000, Yeo et al., 2004). 
In contrast, other studies did not find differences in scores on body image between younger 
and older women (Engel et al., 2004, Hartl et al., , Kenny et al., 2000, Zimmermann et al., 
2009).  
Body image is not only influenced by life events such as having breast cancer, but also by 
culture, socio-economic status, and personality (Diener et al., 2003). The personality traits 
extraversion (the disposition towards cheerfulness, sociability, and high activity) and 
neuroticism (the tendency to experience distressing emotions, such as fear, guilt, and 
frustration) may have an effect on QOL (Diener et al., 2003). Only one study examined these 
characteristics and found that neuroticism was acting as a vulnerability factor for anxiety 
and/or depressive symptoms one year after breast cancer surgery (Millar et al., 2005). 
Besides, Costa et al. (Costa et al., 1992) found that neuroticism was correlated with a 
negative body image and extraversion was correlated with a positive body image. However, 
there is a lack of prospective data on possible relationships between psychological, clinical, 
and demographic factors and body image (Hartl et al., 2003, Zimmermann et al., 2009). 
Therefore, the second aim of this prospective study was to examine the effects of 
personality, sociodemographic factors, and type of surgery on body image in breast cancer 
patients at different time points after treatment over a one-year period. In contrast with 
previous studies on satisfaction with body image in breast cancer patients, this study 
examined which factors from a combination of factors (age, marital status, educational level, 
work status, disease stage, type of surgery, chemotherapy, radiotherapy, hormone therapy, 
neuroticism, extraversion, agreeableness, openness to experiences, conscientiousness) 
predicted body image. It is hypothesized that body image problems arise from surgery and 
are most commonly experienced following MTC. In addition, body image problems are a 
function of personality (i.e., neuroticism).  
 





Women with a palpable lump in the breast or an abnormality on a screening mammography 
were referred by their general practitioner to the outpatient clinic of the St. Elisabeth 
Hospital (Tilburg), the Maasland Hospital (Sittard; since August 2004), or the Jeroen Bosch 
Hospital (Den Bosch; since January 2006) in the Netherlands between September 2002 and 
September 2007. Women were included if they had an abnormality in the breast, were able 
to read, speak and write Dutch, and were 18 years or older. Women who had a history of 
abnormalities in the breast, benign or malignant, or had a breast tumor that was too large 
(>5 centimeter) for BCT, were excluded from the study.  After written informed consent and 
before the first appointment with the surgeon, the participating women completed a set of 
questionnaires. Thus, women completed the first set of questionnaires when the diagnosis 
was still unknown. After this baseline measurement (Time-1), a set of questionnaires was 
also completed one (Time-2), three (Time-3), six (Time-4), and 12 months (Time-5) after 
diagnosis (BBP) and/or surgical treatment (BC). The breast cancer group consisted of 219 
patients; the women with benign breast problems (BBP group) consisted of 381 patients (See 
Figure 1). Non-participants (57.8 ± 10.1 yrs) were older than participants (55.0 ± 10.4 yrs; 
p=.001) in the study. They did not differ on other sociodemographic (i.e., living with a 
partner, having children, educational level) or clinical characteristics (i.e., disease stage, type 
of surgery, adjuvant therapy). The length of the questionnaires and the amount of stress the 
women experienced during the diagnostic period were the reasons for not participating in 
the study. This study was approved by the local ethics committee. 
2.2 Questionnaires 
All women completed questionnaires on personality factors (only at baseline) and the 
WHOQOL-100 Body Image and Appearance facet (all time points). The BC group also 
completed the EORTC-QLQ-BR23 Body image subscale from Time-2 onwards. Both 
instruments were chosen since both subscales complement each other, i.e., the Body and 
Appearance facet covers more general concerns (satisfaction with they way the body looks, 
acceptance of bodily appearance, and inhibition by own looks), while the Body image subscale 
covers feelings of low attractiveness and femininity as a result of cancer or treatment. 
The Neuroticism-Extraversion-Openness Five Factor Inventory (NEO-FFI) (Costa and 
McCrae, 1992, Hoekstra et al., 1996) was developed to study an individual’s personality by 
testing the five domains of the Five Factor or Big Five Model: neuroticism (i.e., the tendency 
to experience distressing emotions, such as fear, guilt, and frustration), extraversion (i.e., the 
disposition towards cheerfulness, sociability, and high activity), openness (i.e., the tendency 
to have a receptive orientation towards varied experiences and ideas), agreeableness (i.e., 
the inclination towards interpersonal trust and consideration of others) and 
conscientiousness (i.e., the tendency towards persistence, sense of duty, organizing, 
planning, and self-discipline). This self-report questionnaire consists of 60 statements. Each 
statement is rated on a 5-point scale ranging from 1 (strongly disagree) to 5 (strongly agree), 
resulting in dimension scores ranging from 12 to 60. The psychometric properties are 
acceptable to good.(Costa and McCrae, 1992)  
The World Health Organization Quality of Life assessment instrument-100 (WHOQOL-100) 
(De Vries and Van Heck, 1997, WHOQOL Group, 1998) is a cross-culturally developed 
generic multi-dimensional quality of life measure. This questionnaire consists of 100 items 
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that are divided in 24 facets covering four domains (Physical health, Psychological health, 
Social Relationships, and Environment) and an Overall Quality of Life and General Health 
facet. Each facet is measured with four items using 5-point Likert scales. In the present 
study, only the facet Body Image and Appearance was used. The facet body image consists 
of four items, for instance ‘Are you able to accept your bodily appearance?’ A high facet 
score indicates good body image (score range: 4 - 20). The reliability and validity are 
adequate and sensitivity is high. (De Vries and Van Heck, 1997, Den Oudsten et al., 2009b, 
O'Carroll et al., 2000) The Cronbach’s alpha coefficients of the facet Body Image and 
Appearance in this study were .85 (BCT group), .87 (BBP group), and .88 (MTC group). 
 
 
Fig. 1. Flow chart 
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The EORTC QLQ-BR23 is a 23-item disease-specific questionnaire measuring health status 
in breast cancer patients.  The BR-23 is a supplementary module of the EORTC QLQ C30, 
which covers the physical, personal, cognitive, emotional, and social domains.(Montazeri et 
al., 2000, Sprangers et al., 1996) The EORTC QLQ BR-23 incorporates two functional scales 
(Body Image and Sexual Functioning) and three symptom scales (Arm Symptoms, Breast 
Symptoms, and Systematic Therapy Side Effects). The remaining items assess sexual 
enjoyment and being upset by hair loss. The reliability and validity are adequate(Montazeri 
et al., 2000, Sprangers et al., 1996, Yun et al., 2004). In this study, only the scale Body Image 
was used. The Body Image scale consists of four items, for instance ‘Did you feel less 
feminine as a consequence of your illness or treatment?’ This scale was linearly transformed 
(score range 0-100). A higher score represent higher levels of functioning. The reliability and 
validity of this scale is adequate.(Sprangers et al., 1996, Yun et al., 2004) The Cronbach’s 
alpha coefficients of the Body Image scale in this study were .87 (BCT group) and .89 (MTC 
group). 
Patients were asked to respond to a number of questions concerning age, marital status, 
having children, and years of education. Marital status was dichotomized in two categories, 
i.e. being involved in a relationship or not being involved in a relationship.  
Data concerning diagnosis, type of surgical treatment (BCT or MTC), disease stage, and type 
of adjuvant treatment (chemotherapy, hormone therapy, and radiotherapy) were obtained 
from the medical records of the included patients. 
2.3 Statistical procedures 
Student t-tests and chi-square tests were used to examine differences between participants 
and non-participants and women who had undergone BCT and MTC. General linear model 
for repeated measures was used to examine if scores on Body Image changed over time, if 
scores on Body Image were different for (women with a benign diagnosis,) women who 
undergone BCT or MTC, and if the pattern of Body Image scores over time was different for 
BCT and MTC. Subsequently, multivariate analysis of covariance (MANCOVA) with 
repeated measures was performed to adjust for the effect of potential confounders on the 
relationship between body image and group (benign breast problems, MTC, BCT). 
Radiotherapy and disease stage were selected as covariates based on statistical differences 
between treatment groups on baseline characteristics. Post-hoc paired samples t-tests were 
conducted to determine differences in body image for group separately. Linear regression 
analyses were performed to examine which, and to what extent, sociodemographic, clinical, 
and personality variables predicted the scores on body image (WHOQOL-100, EORTC 
QLQ-BR23). For the time points, one, three, six, and 12 months after surgery, a hierarchical 
multiple regression analysis (method: enter) was conducted. As a first step, aiming at 
minimizing the number of independent variables in the final regression analysis, separate 
preliminary regression analyses were performed with sociodemographic (age, marital 
status, educational level, work status), clinical (disease stage, type of surgery, 
chemotherapy, radiotherapy, and hormone therapy), psychological (body image at 
baseline), and personality factors (neuroticism, extraversion, agreeableness, openness to 
experiences, conscientiousness) as independent variables. Subsequently, significant 
predictors (p<.05) were entered in the final regression analysis. Chemotherapy, 
radiotherapy, and hormone therapy were not entered at Time-2 as a factor, since women 
with breast cancer did not yet received adjuvant therapy at that time. Mean and standard 
deviations are provided as (M ± SD). SPSS 17.0 was used for all calculations. 
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Adjuvant therapy¹     
Chemotherapy  - 20 (18.9%) 41 (36.3%) .01 
Radiotherapy - 96 (90.6%) 20 (17.7%) <.0001 
Hormone therapy - 32 (30.2%) 52 (46.0%) .02 
Psychological      
Body image WHOQOL2 [range: 4-20] 
Neuroticism [range: 12-60] 
Extraversion  [range: 12-60] 
Openess to experience [range: 12-60] 
Agreeableness [range: 12-60] 
Conscientiousness [range: 12-60] 
16.0 ± 3.3 
31.1 ± 6.9 
40.1 ± 5.8 
36.7 ± 5.4 
43.7 ± 4.2 
45.4 ± 4.9 
16.6 ± 2.8 
30.7 ± 7.5 
40.6 ± 5.7 
36.2 ± 6.6 
43.7 ± 4.2 
45.9 ± 5.6 
16.5 ± 3.1 
29.4 ± 7.1 
41.9 ± 5.4 
35.0 ± 4.9 
43.3 ± 4.2 







Note: 1 more than one treatment possible; 2 higher scores on body image indicate higher quality of life 
Abbreviations: BBP: Benign Breast Problems; BCT: Breast-Conserving Therapy; MTC = mastectomy 
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Patients who underwent MTC were more often treated with chemotherapy and hormone 
therapy, compared to patients who received BCT (p <.05). As expected, based on standard 
treatment, women with BCT were more often treated with radiotherapy (p<.0001) and 
differed regarding disease stage (p<.0001). No other differences between the surgical groups 
were found with regard to other sociodemographic, clinical, and psychological variables. 
Figure 2 shows the change in scores on WHOQOL-facet Body Image. Body Image changed 
significantly over time [F(4,239) = 3.0; p =.020], after correcting for potential confounders. 
Furthermore, an interaction effect was found for time by surgical treatment, indicating that 
the pattern of change over time in Body Image is different for women with MTC, women 
with BCT, and women with BBP [F(8,480) = 2.8; p =.004]. From Time-1 to Time-2, women 
with MTC reported a significant deterioration in their Body Image (p=.035), while women 
with BCT and BBP were stable. Although their Body Image improved in time, they had 
significantly lower scores at Time-5 when compared to Time-1 (p = .004). Radiotherapy and 
disease stage did not interact with Body Image (p >.05). Overall, women with BBP and 







Fig. 2. Mean scores on Body Image and Appearance (WHOQOL-100) across time for women 
who undergonebreast-conserving therapy (BCT) and mastectomy (MTC) and women with a 
benign diagnosis  
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Figure 3 shows the change in scores on EORTC QLQ BR-23 subscale Body Image. In the 
adjusted analysis, Body Image improved significantly over time when correcting for 
potential confounders [F(3,93) = 2.8; p =.043]. Scores on Time-4 (85.2 ± 20.3), and Time-5 
(86.4 ± 18.4) were statistically higher compared with the scores on Time-2 (79.7 ± 23.1; 
ps<.05). On average, women with BCT and MTC scored differently on Body Image, i.e. 
women with BCT scored significantly higher on Body Image [F(1,95) = 7.4; p =.008]. 
However, no interaction effect was found, indicating that the pattern of change over time in 
Body Image was not significantly different for both groups (p =.348). Radiotherapy and 
disease stage did not interact with Body Image (p >.05). 
 
 
Fig. 3. Mean scores on Body Image (EORTC QLQ-BR23) across time for women who 
undergone breastconserving therapy (BCT) and mastectomy (MTC) 
Table 2 shows those factors associated with Body Image (WHOQOL-100) scores across time. 
Being older, receiving chemotherapy, high scores on neuroticism, and low scores on 
agreeableness were significantly associated with lower Body Image scores at all time points. 
The regression models at different time points explained 26% to 32% of the variance. Table 3 
shows those factors associated with Body Image (EORTC QLQ BR23) scores across time. 
High scores on neuroticism were significantly associated with lower Body Image scores at 
all time points. The regression models at different time points explained 16% to 30% of the 
variance. Chemotherapy, radiotherapy, and hormone therapy were not entered in the 
regression analysis at Time-2 and Time-3, since women not received this treatment yet.  
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Timepoint Factor β-value R2 Adjusted R2 p-value 
Time-2* Age .31 .34 .32 <.0001 
 BCT/MTC -.21   .005 
 Neuroticism -.31   <.0001 
 Agreeableness .20   .011 
Time-3* Age .35 .27 .26 <.0001 
 Disease stage -.25   .001 
 Neuroticism -.29   <.0001 
Time-4 Age .18 .29 .26 .024 
 Educational level .08   .328 
 Chemotherapy -.28   .001 
 Neuroticism -.23   .006 
 Agreeableness .24   .003 
Time-5 Age .22 .30 .28 .006 
 Chemotherapy -.16   .038 
 Neuroticism -.30   <.0001 
 Agreeableness .26   .001 
Note: *chemotherapy was not entered at Time-2 and Time-3 as a factor, since women with breast cancer 
had not yet received chemotherapy  
Table 2. Final results of hierarchical multiple regression analysis with body image 
(WHOQOL-100) as the dependent variable, for one (Time-2), three (Time-3), six (Time-4), 
and 12 months after surgery (Time-5) 
4. Discussion 
Body image is an important aspect of QOL in women with breast cancer. For years, it was 
hypothesized that MTC contributed to some extent to the development of psychological 
problems of women with breast cancer. It was intuitively thought that BCT would remove 
some of the stress because of its less mutilating effect compared to MTC.(Meyer and 
Aspegren, 1989) Until now, body image was mostly studied in cross-sectional designs. 
Therefore, this prospective study examined the impact of surgical treatment, personality, 
and sociodemographic factors on body image during a follow-up period of one year after 
primary surgical treatment. In addition, this study examined if scores on body image were 
lower in women who received MTC compared to women who underwent BCT or women 
with benign breast problems. In general, a temporary decrease was found in body image 
scores due to treatment. Although we found that scores of women with MTC were lower 
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with benign breast problems. In general, a temporary decrease was found in body image 
scores due to treatment. Although we found that scores of women with MTC were lower 
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compared with women with benign breast problems and women with BCT, the results were 
only significant at one month after surgery. Type of surgical treatment predicted body 
image at one month (WHOQOL-100; EORTC QLQ-BR23), three months (EORTC QLQ-
BR23), and six months after surgical treatment (EORTC QLQ-BR23). Most studies found 
BCT to be superior with regard to scores on body image, which is in line with our study. 
(Avis et al., 2004, Ganz et al., 2002, Hartl et al., 2003, King et al., 2000, Schou et al., 2005, Yeo et 
al., 2004) BCT patients were more satisfied with their appearance than patients who received 
MTC. (Engel et al., 2004, Janni et al., 2001)  
 
      
Timepoint Factor β-value R2 Adjusted R2 p-value 
Time-2* BCT/MTC -.29 .18 .16 .001 
 Neuroticism -.24   .008 
 Agreeableness .16   .079 
Time-3* Age .26 .33 .31 <.0001 
 BCT/MTC -.30   <.0001 
 Neuroticism -.43   <.0001 
 Conscientiousness -.29   <.0001 
Time-4 Age .28 .34 .30 .001 
 Educational level .07   .400 
 BCT/MTC -.21   .007 
 Chemotherapy -.16   .044 
 Neuroticism -.32   <.0001 
 Agreeableness .19   .024 
 Conscientiousness -.22   .007 
Time-5 Age .22 .23 .20 .006 
 Neuroticism -.25   .004 
 Agreeableness .27   .002 
 Conscientiousness -.29   .001 
Note: *chemotherapy was not entered at Time-2 and Time-3 as a factor, since women with breast cancer 
had not yet received chemotherapy  
Table 3. Final results of hierarchical multiple regression analysis with body image (EORTC-
QLQ BR23) as the dependent variable, for one (Time-2), three (Time-3), six (Time-4), and 12 
months after surgery (Time-5) 
Studies in this field show a wide variation with regard to the methodological aspects. First, 
different instruments were used to assess body image. There is a wide variation in body 
image scales, and they are composed of different items. For example, some instruments 
contain items assessing satisfaction with body image, as the breast specific module from the 
European Organization for Research and Treatment of Cancer (EORTC QLQ-
BR23)(Fehlauer et al., 2005, Janz et al., 2005), or with the Cancer Rehabilitation Evaluation 
System (CARES). (Avis et al., 2004, Ganz et al., 1992) Others constructed their own scale or 
 
Changes in Body Image in Women with Early Stage Breast Cancer 
 
37 
added questions to general questionnaires to measure body image.(Engel et al., 2004, Hartl 
et al., 2003, Janni et al., 2001, King et al., 2000) In this study, a generic QOL instrument 
(WHOQOL-100) and a disease-specific health status instrument (EORTC QLQ BR-23) were 
used. The results based on both instruments indicated that body image scores changed 
significantly over time, irrespective of diagnosis/treatment. However, this effect was partly 
explained by the differences in scores between the baseline measure and the first follow-up 
measure (WHOQOL-100), when body image scores dropped considerably in the MTC 
group. Body image scores measured with the EORTC-QLQ BR23 also improved 
significantly; but, this measure could not register the drop in body image scores between 
Time-1 and Time-2, since it can only be assessed in a cancer population. In our study, the 
baseline assessment was before diagnosis.  (Engel et al., 2004) Our findings are in line with 
other studies. For instance,  Ganz et al. (Ganz et al., 1992) reported an improvement in body 
image one year after surgery in both surgical groups, just as Bloom et al. (Bloom et al., 2004) 
did between baseline (soon after diagnosis) and five year follow-up. In our study, body 
image scores completely returned to baseline values, except for the body image scores of 
women with MTC. It is possible that a study in which a longer follow-up is taken, body 
image will further improve. 
Older women were more satisfied with their bodies, which is in line with the majority of 
other studies in this field. (Al-Ghazal et al., 1999, Fehlauer et al., 2005, Janz et al., 2005, Kenny 
et al., 2000, King et al., 2000) However, it should be noted that the results on the direction of 
the relationship between age and body image in the literature is inconsistent. That is, several 
studies did not find differences in body image scores between age groups(Engel et al., 2004, 
Schou et al., 2005) or found that body image issues may be particularly salient for younger 
women(Avis et al., 2005).  Since older women are often excluded from clinical studies, future 
studies should examine the psychosocial concerns in this age group.  
Adjuvant therapies, like radiotherapy and hormone therapy were not strongly related to 
body image. Chemotherapy predicted scores on body image at all time points included. 
From the few studies that are available on this topic, women who received chemotherapy 
reported lower scores on body image (Janz et al., 2005, Schover et al., 1995), probably due to 
the loss of hair that is accompanied by this type of treatment.  
Personality characteristics (neuroticism and agreeableness) played an important role in 
predicting outcome in this study. Neuroticism contributed in a negative way to scores on 
body image at all follow-up measures, after controlling for all other variables. This result is 
consistent with other research on personality in breast cancer, in which patients, who 
experienced high levels of chronic stress one year after treatment for breast cancer, were 
characterized by higher levels of neuroticism. (Millar et al., 2005) In other studies, this trait 
also in part explained the variance in depressive symptoms after breast cancer surgery (Den 
Oudsten et al., 2009a, Golden-Kreutz and Andersen, 2004), as well as of poor adjustment to 
mastectomy. (Morris et al., 1977)  
After discussing the results of the study, certain limitations and strengths should be 
acknowledged. Strength of the underlying study is the baseline measurement, before the 
diagnosis is known. At the same time, this is also a weakness, because women are probably 
scared and nervous because an abnormality has been seen on the mammography (i.e., only 
applies for those women who had a screening mammography) or that a lump (whether it is 
benign or malign) is in the breast. However, in this study the BBP group showed stable 
scores regarding body image. The optimal moment for the baseline measurement would be 
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before visiting the doctor or taking a mammography, and then it is probably of better 
prospective value. The one-year follow-up period is another advantage of this study, 
because body image is a concept that probably changes over time when a woman is 
confronted with a threat to her body image. Moreover, this study included also a control 
group consisting of women with benign breast problems. Few studies have included a 
comparison group. (Andrykowski et al., 1996) Finally, the data was collected in several 
hospitals in the Netherlands, which may facilitation generalization in women with breast 
cancer. Studies, like the current one, often show relatively high attrition(Arving et al., 2008). 
Our study had 73.5% of the women with early stage BC in the study at one-year after 
surgical treatment. This may have influenced our results. However, women with breast 
cancer who dropped out of the study did not differ from women remaining in the study, 
except for age with women staying in the study being significantly younger. A limitation of 
this study is that a specific body image scale would have been appropriate, for instance 
Body Image Scale(Hopwood et al., 2001). In addition to the EORTC QLQ BR23 items on 
body image, this scale includes also items on change in self-consciousness with appearance, 
less sexually attractive, less feminine, dissatisfaction with appearance when dressed, 
dissatisfaction with scars, body feeling less whole, and avoidance of people because of 
appearance. These topics were not assessed in our study.  However, it should be noted that 
the women with BBP could not have been assessed on body image. 
More longitudinal studies need to focus on body image, whether body image in the MTC 
group will eventually return to baseline values (i.e., before the breast cancer diagnosis), but 
also examine the associations with self-esteem, sexual functioning, and quality of life. In 
addition, studies should also include elderly women. Moreover, it is also reasonable to take 
women’s partners into account, since patients and partners coping with cancer will 
exchange experiences and influencing each others acceptation process. (Manne and Badr, 
2008, 2009) Recently, Zimmerman et al. (Zimmermann et al., 2009) have shown that dyadic 
factors are important. They found that women’s depressive symptoms, women’s age and 
men’s marital satisfaction predicted women’s body image, explaining 24% of the variance. 
Given the importance of the marital relationship in adaptation, a greater understanding of 
this dyadic process may aid in the development of psychosocial interventions for couples 
adapting to breast cancer who may be at risk for distress. 
5. Conclusion 
In conclusion, results from this study confirm previous findings that breast cancer 
temporarily affects satisfaction with body image in a negative way. Results are more 
obvious for women who underwent MTC, than for women who have had BCT. Older 
women seemed to have more problems with body image after surgery. Overall, it is 
important for women facing breast cancer to get assistance in adjusting to alterations in 
body image. (Kraus, 1999) Personality factors that influence these changes should be taken 
into account. 
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before visiting the doctor or taking a mammography, and then it is probably of better 
prospective value. The one-year follow-up period is another advantage of this study, 
because body image is a concept that probably changes over time when a woman is 
confronted with a threat to her body image. Moreover, this study included also a control 
group consisting of women with benign breast problems. Few studies have included a 
comparison group. (Andrykowski et al., 1996) Finally, the data was collected in several 
hospitals in the Netherlands, which may facilitation generalization in women with breast 
cancer. Studies, like the current one, often show relatively high attrition(Arving et al., 2008). 
Our study had 73.5% of the women with early stage BC in the study at one-year after 
surgical treatment. This may have influenced our results. However, women with breast 
cancer who dropped out of the study did not differ from women remaining in the study, 
except for age with women staying in the study being significantly younger. A limitation of 
this study is that a specific body image scale would have been appropriate, for instance 
Body Image Scale(Hopwood et al., 2001). In addition to the EORTC QLQ BR23 items on 
body image, this scale includes also items on change in self-consciousness with appearance, 
less sexually attractive, less feminine, dissatisfaction with appearance when dressed, 
dissatisfaction with scars, body feeling less whole, and avoidance of people because of 
appearance. These topics were not assessed in our study.  However, it should be noted that 
the women with BBP could not have been assessed on body image. 
More longitudinal studies need to focus on body image, whether body image in the MTC 
group will eventually return to baseline values (i.e., before the breast cancer diagnosis), but 
also examine the associations with self-esteem, sexual functioning, and quality of life. In 
addition, studies should also include elderly women. Moreover, it is also reasonable to take 
women’s partners into account, since patients and partners coping with cancer will 
exchange experiences and influencing each others acceptation process. (Manne and Badr, 
2008, 2009) Recently, Zimmerman et al. (Zimmermann et al., 2009) have shown that dyadic 
factors are important. They found that women’s depressive symptoms, women’s age and 
men’s marital satisfaction predicted women’s body image, explaining 24% of the variance. 
Given the importance of the marital relationship in adaptation, a greater understanding of 
this dyadic process may aid in the development of psychosocial interventions for couples 
adapting to breast cancer who may be at risk for distress. 
5. Conclusion 
In conclusion, results from this study confirm previous findings that breast cancer 
temporarily affects satisfaction with body image in a negative way. Results are more 
obvious for women who underwent MTC, than for women who have had BCT. Older 
women seemed to have more problems with body image after surgery. Overall, it is 
important for women facing breast cancer to get assistance in adjusting to alterations in 
body image. (Kraus, 1999) Personality factors that influence these changes should be taken 
into account. 
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1. Introduction 
Disruption of the axillary nodes and closure of arm lymphatics can explain the significantly 
high risk of early and late lymphatic complications after axillary dissection, especially the 
most serious complication that is arm lymphedema which occurs in about 25% (ranging 
from 13 to 52%) of patients. Sentinel lymph node (SLN) biopsy has reduced the severity of 
swelling to  nearly 6% (from 2 to 7%) and, in case of positive SLN, complete axillary 
dissection (AD) is still required. That is why ARM method was developed aiming at 
identifying and preserve lymphatics draining the arm. It consists in injecting intradermally 
and subcutaneously a small quantity (1-2 ml) of blue dye at the medial surface of the arm 
which helps in locating the draining arm lymphatic pathways. ARM technique allowed to 
find variable clinical anatomical conditions from what was already generally known, that is 
the most common location of arm lymphatics below and around the axillary vein. In about 
one-third of the cases, blue lymphatics can be found till 3-4 cm below the vein, site where 
SLN can easily be located, justifying the occurrence of lymphedema after only SLN biopsy. 
ARM procedure showed that blue nodes were almost always placed at the lateral part of the 
axilla, under the vein and above the second intercostals brachial nerve. Leaving in place 
lymph nodes related to arm lymphatic drainage would decrease the risk of arm 
lymphedema, but not retrieving all nodes, the main risk is to leave metastatic disease in the 
axilla. Conversely, arm lymphatic pathways when they enter the axilla, cannot be site of 
breast tumoral disease and their preservation would certainly bring about a significant 
decrease of lymphedema occurrence rate (1-4). 
2. Lymphangiogenesis and other local changes 
Another important aspect to point out is that, in the axilla, new lymphatic vessel formation 
(lymphangiogenesis) occurs in response to the ligation of lymphatic vessels involved in 
lymph node retrievement. Lymphangiogenesis and lymphatic hypertension were 
demonstrated experimentally in case of lymphatic drainage obstruction. And, in response to 
lymphatic hypertension, lympho-venous shunts open and provide alternative lymphatic 
pathways when the main ones are obstructed. These mechanisms represent an adaptive 
response to lymphatic hypertension but are not enough to restore normal flow parameters. 
Furthermore, chronic obstruction to lymph flow progressively leads to a reduced lymphatic 
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contractility, lymphatic thrombosis and fibrotic changes, at a different degree according to 
variable constitutional predisposition (5-9) 
3. Surgical preventive procedures 
Recent advances in the treatment of breast cancer, specifically as concerns the prevention of 
lymphatic complications following sentinel lymph node biopsy and axillary dissection 
brought to the proposal of a new technique to primarily prevent lymphedema by 
microsurgical lymphatic-venous anastomoses. ARM technique allows to identify arm 
lymphatics and lymph nodes which can therefore be preserved even though there is the risk 
to leave undetected metastatic disease in the axilla. But, it is almost impossible to preserve 
efferent lymphatics from the blue nodes because they join the common axillary nodal basin 
draining the breast. Thus, not preserving efferent lymphatics makes practically impossible 
to preserve arm lymphatic flow. So, on the basis of our wide experience in the treatment of 
lymphedema by microsurgical lymphatic-venous anastomoses (LVA), we thought to 
perform LVA immediately after finishing nodal axillary excision. The surgical technique 
proposed for patients with operable breast cancer requiring an axillary dissection consisted 
in carrying out LVA between arm lymphatics identified by injecting blue dye in the arm and 
an axillary vein branch simultaneously (Lymphatic Microsurgical Preventive Healing 
Approach – LY.M.P.H.A.) (10). It is almost always possible to find blue lymphatics and also 
to find a vein branch long enough to be connected to arm lymphatics which are usually 
locate very laterally.  
Patients are followed up both clinically by volumetric assessment and by 
lymphangioscintigraphy performed before surgery and after 18 months. Blue nodes in 
relation to lymphatic arm drainage can be identified in almost all patients after blue dye 
injection at the arm. All blue nodes must be resected and 2 to 4 main afferent lymphatics 
from the arm can be prepared and used for anastomoses. Lymphatics are introduced inside 
the vein cut-end by a U-shaped stitch. Other few stitches are given to fix the lymphatic 
adventitia to the vein wall. The operation takes only 15-20 minutes averagely, since both 
lymphatics and the vein are prepared during nodal dissection. LVA proved not only to 
prevent lymphedema but also to reduce early lymphatic complications (i.e. lymphorrhea, 
lymphocele) thanks to the reduced regional intralymphatic pressure. Drain tubes can be 
removed after about 7-10 days at the utmost. Post-op lymphangioscintigraphy allowed to 
demonstrate the patency of microvascular anastomoses after over 1 year and half from 
operation. 
4. Clinical experience 
Study design 
Among fortynine consecutive women from March 2008 to September 2009 addressed to 
complete AD, performed by surgeons of the same Beast Unit, who used the same technique, 
46 were randomly divided in two groups, the other 3 were not analyzed because refused to 
perform lymphoscintigraphy (LS) pre-operatively. Twentythree underwent LYMPHA 
technique, performed by a surgeon skilled in lymphatic microsurgery, for the prevention of 
arm lymphedema (LYMPHA group – LG). The other 23 patients had no preventive surgical 
approach (control group – CG). No wrapping neither compression therapy was used in any 
of the patients of both groups. 
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The average age was 57 years (range 39-80 years). In order to be included in this prospective 
study, patients with unilateral breast cancer had to be addressed to complete AD due to 
clinically or ultrasonographic positive axillary limph nodes or positive SLN. Exclusion 
criteria were cases in whom only SLN biopsy technique was performed and SLNs were 
negative. 
In the LYMPHA group (LG), 16 patients there were lymph nodal metastasis and therefore 
lymphatic venous anastomosis were performed during the primary surgery together with 
breast cancer treatment, sentinel lymph node biopsy, intraoperative frozen sections 
(showing the metastasis) and axillary dissection (AD). In other 7 patients there were no 
lymph nodal metastasis demonstrated by intraoperative frozen sections and therefore 
LYMPHA technique was planned after finding micrometastasis by following 
immunohistochemical investigations. Thus, in this last group of patients we could perform 
LYMPHA during the complete lymph nodal dissection in the second time surgery. 
Operating technique 
Patients signed a specific consent form indicating the kind of operation, possible risks, and 
complications to participate or not in the LYMPHA procedure. The blue dye (Lymphazurin) 
was injected in the volar surface of the upper third of the arm in a quantity of about   1-2 ml 
intradermally, subcutaneously and under muscular fascia. Usually after 5-10 minutes it is 
already possible to visualize arm blue lymphatics. Axillary nodal dissection was performed 
usually starting far from the upper lateral part of the axilla which was removed nearly at the 
end of the dissection in order not to damage the lymphatic pathways coming from the arm. 
This lymphatics were temporally clipped near their afference to the nodal capsule and thus 
prepared for anastomosis. 
During lymph nodal dissection also one or two collateral branches of the axillary vein are 
prepared with a length suitable for reaching the lymphatic vessels. The microsurgical 
technique of lymphatic venous anastomosis has already been described (11). The vein was 
averagely 2 mm in diameter and lymphatics about half mm. the number of lymphatics 
anastomosed varied from 2 to 4. The technique is the “sleeve” procedure: lymphatics are put 
into the vein cut-end. A collateral of the axillary vein is used for anastomoses. In some cases 
a big gap inbetween the vein  and the lymphatics can be found, but in these cases it is 
usually enough to better dissect the vein and above all the lymphatics from the surrounding 
tissues. In case it is necessary one of the subscapular or thoraco-dorsal veins which are 
usually long enough can also been used. A particular attention must be paid in placing the 
drain tube in order not to damage the anastomosis (Fig.1). Lymphatic-venous anastomoses 
take only 15-20 minutes to be performed and in our study were performed by a surgeon 
skilled in lymphatic microsurgery. There is no increased rate of blood loss, wound infection 
and seromas compared to standard ALND (Fig. 2). 
Clinical and lymphoscintigraphic assessment 
All patients of the two groups were preoperatively studied clinically by volume 
measurements (using the formula of a truncated cone according to Kuhnke method) (10) 
and by lymphoscintigraphy. Lymphedema, was defined as a difference in excess volume of 
at least 100 ml compared to preoperative VOL  measurements. The follow up included 
volumetry at 1, 3, 6, 12 and 18 months postoperatively in  both groups. 
Lymphoscintigraphy was carried out in 21 cases in the LG and in 20 cases of the CG after 18 
months postoperatively (Fig. 3). 
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Fig. 1. Lymphatic-venous-anastomoses (rectangle) to prevent arm lymphedema (LYMPHA). 
Note the blue dye (*) injected at the upper third of the volar surface of the arm to visualise 
arm lymphatics. The patency of lymphatic-venous anastomosis is proved by the passage of 
the blue dye into the vein branch (arrow). 
 




Fig. 2. Patient who underwent axillary lymphnodal dissection and primary surgical 
prevention of secondary lymphedema by LYMPHA procedure.  
Statistical analysis  
Non-parametric tests were used to explore the variable relationships between groups and 
between timing. The comparison between groups of quantitative variables age, BMI, Preop 
LS, lymphonodes retrived, metastatic lymphnodes (MLS LN) and volume at baseline was 
performed using Wilcoxon test. Nominal baseline variables surgical procedure, 
radiotherapy and presence of cellulitis were compared using Chi square or Fisher’s Exact 
Test. 
The comparison of difference between baseline and volume after 1, 3, 6, 12 and 18 months 
from operation in LG and CG was performed using Wilcoxon test (between groups) and 
matched pair test (between timing). The volume difference between baseline and different 
timing in LG and CG was represented by box plots showing 10°, 25°, 75° and 90° percentiles. 
Number of patients with lymphedema, defined as a difference in excess volume of at least 
100 ml, at 18 months in PG and CG were compared using 2-sided Fischer’s Exact Test. 
Results 
Lymphedema appeared in 1 patient in the LG after 6 months from the operation (4,34 %) 
and persisted till 18 months later. It occurred in a patient who underwent radiotherapy and 
became stable with time without any inflammatory complications. In the CG lymphedema 
occurred in 7 patients (30,43 %) and appeared mostly after 3 months from operation. 
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Beginning from month 3, the proportion of patients with lymphedema was statistically 
higher in CG (p-value=0.047). Table 1 summarizes baseline characteristics of all participants, 
according to treatment group. There were no significant differences between the two groups 
in the baseline values of measures of demographic and anthropometric data, in disease 
characteristics and in type of surgery, and in the proportion of women who undertook to 
radiotherapy and had a cellulitis. In Figure 4, volume difference between baseline and 
different timing in LG and CG is represented by box plots showing 10°, 25°, 75° and 90° 
percentiles. 
When compared with previous volume measure, no significant difference in the arm 
volume were observed in LG during follow-up, while the arm volume in CG showed a 
significant increase after 1 (mean difference 11.61 ml, S.E. 3.87, p-value<0.01) , 3 (mean 
difference 22.82 ml, S.E. 5.9, p-value<0.01) and 6 months (mean difference 31.56 ml, S.E. 5.78, 
p-value<0.01) from operation. No significant changes in arm volume were observed at 
month 12 and 18, in comparison with data registered at month 6 and 12, respectively, in CG. 
Significant higher volume with respect to baseline after 1, 3, 6, 12 and 18 months from 





Fig. 3. Lymphoscintigraphic patterns before and after axillary lymphnodal dissection 
associated with LYMPHA technique.  
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Duplex scan allowed to exclude a venous pathology in all patients. LS allowed to confirm 
the lymphostatic nature of the edema. To quantify visual  findings in LS, the Kleinhans 
transport index (TI) was used (4,13,14). The TI  includes the following parameters: transport 
kinetics (K), distribution of the tracer (D),  appearance time of lymph nodes in minutes (T), 
visualization of lymph nodes (N), visualisation of lymph vessels (V); TI = K + D + (0,04 x T) 
+ N + V (Table 2). Normal lymphoscintigraphy pattern corresponded to TI less than 10. An 
impaired LS pattern in our study had a mean TI of 16 (range 12-19). 
Moreover, pre-operatively LS had a significant predictive value (TI) in terms of risk of  
lymphedema appearance. To this regard LS proved to be an instrumental criteria to select 
patients at risk for secondary lymphedema. 
Post-operatively LS demonstrated the patency of microlymphaticvenous anastomosis 
(patency rate: 95,6%) both through direct (visualization of preferential lymphatic pathway, 
disappearance of the tracer passing into the blood stream) and indirect (early liver uptake of 
the tracer) parameters in the LG group.  In the CG on the other hand LS allowed to point out 
lymphatic drainage impairment in patients with secondary lymphedema. 
5. Discussion 
Notwithstanding the wide variability in lymphedema prevalence, the incidence of 
secondary arm lymphedema is significant. Sentinel lymph node biopsy (SLNB) was 
introduced and carried out to prevent lymphedema but, recent studies demonstrated that 
even with SLNB alone lymphedema rates are not negligible (13,17). 
Therefore, prevention is of key importance to avoid lymphedema occurrence.  
Axillary Reverse Mapping (ARM) procedure represents an attempt to identify and preserve 
arm lymphatic drainage. Success of this technique in preventing lymphedema will require 
ongoing follow-up and studies (6).  Blue nodes were always located in the same position, at 
the lateral part of the dissection, under the axillary vein and just above the second 
intercostal brachial nerve (7). The main issue remains to make sure that the nodes identified 
are not metastatic and can be preserved during AD. Since the lymphatic pathways from the 
arm cannot be involved by metastatic process of the primary breast tumor, its preservation 
should not imply any risk of leaving undetected diseases in the axilla (1). With ARM 
technique the detection rate of blue lymphatics and nodes is 61-71%, and the preservation 
rate of 47% (1,6,7). The question is: can we spare what we find? The identification of afferent 
lymphatics and nodes belonging to the arm lymphatic pathways appears feasible. 
Nevertheless, the identification of the efferent lymphatics, which is mandatory to truly 
preserve the lymphatic flow of the arm, is almost impossible since the lymphatics departing 
from the blue nodes join the common lymphatic pathways draining the breast. Therefore, 
the preservation is practically impossible. That’s why we conceived and carried out 
LYMPHA technique, which consist in performing LVA between arm lymphatics and 
collateral branches of the axillary vein at the same time as AD. Lymphatic-venous 
anastomoses are performed at the upper lateral part of the axilla, thus somehow protected 
from the negative effect of postop radiation. In fact, postop radiation did not cause any 
relevant problem in the patients with lymphatic-venous anastomoses in this study. Only in 
two patients, a transitory (for 3 and 5 days respectively) slight arm edema was observed 
which disappeared spontaneously. Patients were followed by volume measurements which 
allowed to demonstrate the absence of any negative effect of postop radiation. Furthermore, 
postop lymphoscintigraphy proved the patency of anastomoses long after surgery and 
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radiation. The preservation of arm lymphatics carries no risk of leaving disease in the axilla 
undetected, and it permits the prevention of lymphedema (10). Patients candidate for 
LYMPHA are those one addressed to AD with either clinical axillary N+ or SLN+. In pre-




Fig. 4. Clinical and instrumental criteria to select patients for LYMPHA technique 
History and physical esamination of the patients, together with BMI, could allow to select 
patients at risk for lymphedema and this suspect could be confirmed by LS, using 
semiquantitative evaluation which is represented by TI (15-19). Preop 
lymphoscintigraphy is useful to select patients at risk for arm lymphedema. LS  shows 
lymphatic impairment (in terms of transport index) compared to the contralateral arm 
already present pre-operatively. 
The quality of life is gaining more and more importance thanks to the prolongation of 
survival brought about by advanced and combined treatment of different tumors. Surgery 
 
Surgical Prevention of Arm Lymphedema in Breast Cancer Treatment 
 
51 
has to be more and more conservative and try to maintain organ function and reduce 
morbility. LYMPHA technique proved to represent a new strategy of treatment to reduce 
morbility of axillary lymph nodal dissection when it is not possible to preserve arm 
lymphatic pathways due to the risk to leave tumoral diseases correlated to the breast cancer.  
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1. Introduction  
Chemotherapy-induced alopecia (CIA) is a frequent toxicity and arguably the most feared 
side effect of cancer chemotherapy (Carelle et al., 2002). The incidence of CIA is 
approximately 65% of all patients (Wang et al., 2006). CIA could be easily noticeable by self 
and others in a relative short time, thus it is linked with having cancer and chemotherapy. 
CIA compromises patient quality of life, especially for female and children, leading to poor 
therapeutic outcome. Despite significant progresses and substantial efforts in CIA research 
and development, no reliable and effective preventive treatment has become available. This 
limitation has been attributed to the lack of basic understanding of CIA pathogenesis and 
appropriate experimental models. This chapter will provide an overview of the basic and 
clinical aspects of CIA including hair follicle biology, characteristics of CIA along with the 
state-of-the-art experimental models and treatment strategies. Experimental approaches for 
pharmacologic inhibition of CIA including drug-specific antibodies, hair growth cycle 
modifiers, cytokines, growth factors, antioxidants, cell cycle modifiers, and apoptosis 
inhibitors will be discussed. Current understanding in the molecular mechanisms of CIA 
and the role of specific genes, e.g. p53 and Fas, in the process will also be discussed. The 
chapter will conclude with the perspective on the prevention and management of CIA.  
2. Hair follicle biology 
Chemotherapy causes structural damage of human scalp hairs. The effects may vary from 
altered hair appearance, decreased rate of hair growth, partial or complete hair loss 
(alopecia). To discuss the advances in the pathogenesis of CIA, an overview of hair follicle 
biology is first covered.   
2.1 Hair follicle structure 
Hair follicle structure changes during the various stages of hair growth cycle (see Section 2.2 
for review). In the anagen phase, hair structure is composed of two distinct components, 
hair follicle and hair shaft (Fig. 1a). The hair follicle is embedded in the connective tissue 
and subcutaneous fat. Contained within the hair follicle bulb is the pluripotent keratinocytes 
of hair matrix. Matrix cells in the lower part of hair bulb constantly divide at a high mitotic 
rate, whereas the matrix cells in the upper part of hair bulb have a low mitotic rate and 
could differentiate to form the inner root sheath (IRS) and hair shaft (HS), which are the 
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middle and innermost layer of hair follicle, respectively. Outer root sheath (ORS), is the 
outermost layer of hair follicle that separates the whole organ from dermis and is believed to 
contain epithelial stem cells at its bulge region (Hardy, 1992; Krause and Foitzik, 2006; 
Alonso and Fuchs, 2006). Pigmentation of hair shaft depends on melanocytes, which reside 
in the hair matrix of hair follicle. Melanocytes transfer the melanin granule to keratinocytes 
of the growing hair shaft (Ohnemus et al., 2006). Besides the epithelial cells, hair follicle also 
contains the mass of mesenchymal dermal papilla (DP) cells at its base (Fig. 1b). The DP cells 
are connected to capillaries to derive nutrients from the blood and also function as a 
regulator of hair cycle (Sakita et al., 1995). Moreover, substantial evidence supports the 
correlation between DP cell number and the size of hair follicle and shaft (Elliot et al., 1993; 
Ishino et al., 1997). 
 
 
Fig. 1. Diagrammatic representation of hair follicle structure in its mature anagen phase. (a) 
A full-length longitudinal view of hair follicle. (b) Hair follicle bulb. Abbreviations: APM, 
arector pili muscle; B, bulge; CTS, connective tissue sheath; CTX, cortex of hair shaft; CU, 
cuticle of hair shaft; DP, dermal papilla; E, epidermis; HM, hair matrix; HS, hair shaft; IRS, 
inner root sheath; M, melanocytes; ORS, outer root sheath; S, sebaceous gland. 
2.2 Hair growth cycle 
Each hair follicle undergoes rhythmic changes through the three phases of hair cycle, which 
are anagen, catagen and telogen (Fig. 2). Anagen is an active growth phase of hair follicle. 
During anagen, daughter cells of pluripotent keratinocytes move upwards and adapt into 
one of the six epithelial lineages, namely Henley, Huxley and cuticle of the IRS and cuticle, 
cortex and medulla of the HS. As the HS cells become fully differentiated, they extrude their 
organelles and are tightly packed to form cysteine-rich hair keratins. The IRS and HS 
interlock via their cuticle structures, however, the IRS degenerates in the upper follicle, 
thereby releasing the HS that continues to move towards the skin surface. Subsequently, the 
hair follicle enters the catagen or regression phase. During catagen, there are extensive 
apoptosis of epithelial cells in the hair follicle bulb and ORS, leading to the formation of 
epithelial strands. The HS hence stops differentiation and forms the club hair, which moves 
up until it reaches the bulge region. Dermal papilla cells are condensed and move upwards 




















HS exhibits no significant proliferation, apoptosis or differentiation. The transition from 
telogen to anagen occurs when the bulge stem cells are activated (Cotsaleris and Millar, 
2001; Krause and Foitzik, 2006; Alonso and Fuchs, 2006; Ohnemus et al., 2006). 
 
 
Fig. 2. Hair growth cycle. A new hair shaft is produced during anagen, and the old hair is 
released from the follicle as the new shaft develops. Anagen VI (mature anagen) is the stage 
where new HS reaches the skin surface and continues to grow through the rest of anagen. 
During catagen, the lower two thirds of the epithelial follicle are regressed. The hair 
develops a club structure, which retains the hair in the follicle. Then, the follicle enters a 
telogen phase until a new growth cycle is activated. Abbreviations: B, bulge; DP, dermal 
papilla; HS, hair shaft.  
3. Chemotherapy-induced alopecia 
CIA or hair loss caused by chemotherapy is the most common cutaneous side effect of 
chemotherapy. CIA ranks among patients as a severe side effect that affects their quality of 
life.   
3.1 Impact on cancer therapy 
CIA has an enormous psychological and social impact on patients, which can be summarized 
as: (i) symbol of cancer for self (constant reminder of their treatment) and others (outwardly 
visible); (ii) personal confrontation of being ill or mortality; (iii) vulnerability; (iv) 
powerlessness; (v) shame; (vi) loss of privacy; (vii) punishment, and (viii) change in self and 
other perception (Freedman, 1994; Pozo-Kaderman et al., 1999). Female and children have 
more difficulties coping with the CIA. Indeed, up to 8% of women are reported to reject 
chemotherapy for fear of CIA (Mundstedt et al., 1997; McGarvey et al., 2001). CIA also results 
in reduced social activities since hair partly plays a role in social and sexual communications 
(Batchelor, 2001). Additionally, these negative impacts of CIA may contribute to poor 
therapeutic outcome, as stress and depression lowers the body’s immune function and is 
highly associated with cancer progression (Spiegel and Giese-Davis, 2003; O’Leary, 1990).  
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The basic principle of chemotherapy is to impair the mitotic and metabolic process of cancer 
cells. Unfortunately, certain normal cells and tissues with rapid metabolic and mitotic rates 
such as the hair follicles are also affected by the chemotherapy. Up to 90% of hair follicles 
undergo anagen, an active growth phase, at a given time. The rapid hair growth as well as 
the high blood flow rate around the hair bulb leading to the accumulation of drugs is a key 
predisposing factor for rapid and extensive alopecia (Batchelor, 2001). In humans, CIA 
usually begins approximately 2 to 4 weeks and is complete at 1 to 2 months after the 
initiation of chemotherapy (Batchelor, 2001). Hair might be easily depilated as early as 1 to 2 
weeks after the treatment due to the weakening and breakage of hair shaft. The hair would 
fall out upon combing and in the bedding area. The degree of CIA depends on the type of 
chemotherapy, dosage regimen and route of administration. Almost all chemotherapies 
cause alopecia but with varying degrees of severity and frequency (Apisanthanarax and 
Duvic, 2003) as summarized in Table 1.  
 








































Table 1. Chemotherapeutic agents associated with alopecia.  
A high-dose intravenous chemotherapy is commonly associated with more rapid and 
extensive alopecia. By contrast, oral therapy at lower doses on a weekly schedule tends to 
cause less alopecia even though the total dose may be large (Wilkes, 1996). Combination 
therapy consisting of two or more chemotherapeutic agents normally causes a higher 
incidence and more severe CIA compared to single agent therapy. Long-term chemotherapy 
may also result in the loss of pubic, axillary and facial hair. 
CIA is usually reversible with the hair regrowth generally occurring 3 to 6 months after the 
end of treatment. However, in most cases the new hair is grey or differs in color, 
representing the distortion of pigmentation process. Moreover, the new hair typically 
exhibits some changes in hair structure and texture, e.g. coarser, slow growth, and reduced 
density (Wang et al., 2006; Trueb, 2009). Permanent alopecia has been reported but rarely 
occurs (Betcheler, 2001).  
4. Experimental models 
4.1 Animal models 
Due to the ethical problems in obtaining scalp biopsies from chemotherapy patients, little is 





about the CIA comes mostly from animal models. The commonly used animal models are 
neonatal rats and adult mice. However, there are some differences in human and rat/mouse 
hair growth pattern. In humans, the hair growth cycle occurs in a mosaic or asynchronous 
pattern, where the growth cycle of individual hair follicles is independent of neighbouring 
hair follicles. In contrast, rodent hair growth occurs in a wave pattern, beginning from the 
head and moving towards the tail. A group of hair follicles at a specific area are usually in 
the same stage of hair cycle. In general, only 10% of hair follicles in adult mice or rats are in 
the anagen phase as compared to 90% in adult humans. Some animals including guinea pigs 
and Angora rabbits exhibit a mosaic hair growth pattern but are not commonly used due to 
their insensitivity to CIA.  
4.1.1 Neonatal rat model 
The early model for CIA was established in newborn rats (Hussein et al., 1990; Hussein, 
1993). Seven to eight-day old Sprague Dawley rats exhibit spontaneous anagen hair growth 
for about a week. In this model, administration of chemotherapeutic agents such as cytosine 
arabinoside, doxorubicin, cyclophosphamide, and etoposide induces alopecia one week 
after the treatment with the severity of CIA depending on the agents (Hussein et al., 1990; 
Hessein, 1991; Jimenez and Yunis, 1992).  
The major advantage of neonatal rat model is the rapid and easily noticeable CIA due to 
progressive hair loss from the head and throughout the body in about 2 days. Several 
drawbacks and limitations of this animal model have been reported. For examples, the 
level of growth factors and cytokines and the hair follicle structure in neonatal rats differ 
substantially from those in mature animals, thus altering the response of hair follicles to 
treatment agents. Also, the lack of hair pigmentation in Sprague Dawley rats, which have 
a white fur, limits the study of drug effects on melanocytes. Indeed, some observations in 
newborn rats appear irrelevant to humans. For instance, the protective effect of topical 
application of 1,25-dihydroxyvitamin D3 on alopecia induced by cyclophosphamide was 
observed in neonatal rats but not in humans (Jimenez and Yunis, 1992; Hidalgo et al., 
1999). 
4.1.2 Adult mouse model 
The adult black C57BL/6 mouse model for CIA was first developed in 1994 (Paus et al., 
1994). In this mouse strain, the skin melanocytes are confined to hair follicles and the stage 
of hair growth is indicated by the skin color, i.e., pink during the telogen phase and black 
during the anagen phase. To mimic human hair scalp, depilation is performed to induce the 
mouse hair follicles at telogen phase to enter anagen phase, which is normally achieved in 
about 9 days. At around 16 days after the depilation, morphological signs of catagen are 
detectable. At day 20 after the depilation, all hair follicles are in the telogen phase. The CIA 
model was used to study the effect of cyclophosphamide (120-150 mg/kg, ip) on day 9 after 
the depilation (anagen phase). Cyclophosphamide was found to induce premature catagen 
development, dystrophic follicles, and complete alopecia in 6 days. In the past decade, 
progress in the understanding of hair follicle damage and pathogenesis of CIA has been 
obtained largely by using this model. On a cellular level, cyclophosphamide induces 
massive apoptosis of keratinocytes and melanocytes, although the precise mechanism of 
induction is largely unknown (Hendrix et al., 2005).  
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induction is largely unknown (Hendrix et al., 2005).  
 
Topics in Cancer Survivorship 
 
58
4.2 Culture models 
4.2.1 Organ culture model 
Although animal models have provided valuable information regarding the pathogenesis of 
CIA, the animal physiological and pathological conditions do not necessarily mimic human 
conditions. The first human organ-culture hair follicle model for CIA was developed in 2007 
(Bodo et al., 2007). In this model, mature anagen (anagen VI) human hair follicles are micro-
dissected intact from the occipital scalp of healthy adults. The isolated hair follicles are 
maintained in William’s E medium containing L-glutamine, hydrocortisone, and insulin. 4-
Hydroperoxycyclophosphamide (4-HC), a key cyclophosphamide metabolite, was used to 
verify key in vivo characteristics of CIA since clinical and animal data of cyclophosphamide-
induced CIA are well established. 4-HC was shown to induce melanin clumping and 
incontinence, reduce keratinocyte proliferation, induce keratinocyte and dermal papilla cell 
apoptosis, and induce premature catagen, resembling in vivo hair follicle dystrophy. 
Comparison of the test results in adult mouse model and organ culture model in response to 
cyclophosphamide is shown in Table 2. The human organ-culture hair follicle system could 
be used to study the pathogenesis and potential treatment of CIA, i.e., to identify key 
molecular targets and inhibitors of CIA.   
 
Key clinical parameters Adult mouse model Organ culture model 
Inhibition of hair shaft elongation 
Increased apoptosis of matrix 
keratinocytes 
Decreased proliferation of matrix 
keratinocytes 
Catagen induction 
















Table 2. Comparison of adult mouse model and organ culture model. 
4.2.2 Cell culture model 
Keratinocytes, dermal papilla cells, and melanocytes constitute the major cell types in the 
hair follicle. In CIA, massive apoptosis of keratinocytes occurs; thereby cultured 
keratinocytes are commonly used as a predictive model for chemotherapy-induced hair 
follicle damage. Primary and immortalized normal human keratinocytes (HaCaT) have been 
used to test the effects of chemotherapeutic agents and protectants (Matsumoto et al., 1995; 
Braun et al., 2006; Janssen et al., 2008). However, since different hair follicle cells interact and 
affect each other cell growth and cycling (Rogers and Hynd, 2001), the effects of 
chemotherapeutic agents on other cell types, e.g., dermal papilla cells and melanocytes, 
should also be evaluated, i.e., through the use of a co-culture system. Furthermore, current 
cell culture models lack biological measures of hair growth and cycling; however, they offer 
the advantages of gene manipulation, ease of use, high throughput, and low cost. 
5. Approaches to prevent CIA 
Several approaches have been investigated to overcome CIA. These approaches can be 





5.1 Physical prevention 
5.1.1 Scalp torniques 
Scalp torniques are the application of bands around the head to occlude the superficial 
blood flow to scalp, thus reducing the amount of drugs delivered to the hair follicles. The 
torniques range from 10 mmHg above systolic pressure to 300 mmHg around the scalp. 
These torniques are applied 5-10 minutes prior to or at the time of chemotherapy until up to 
30 minutes after the drug administration (Cline, 1984). Although reports described mild to 
moderate prevention of CIA induced by vincristine, cyclophosphamide, and doxorubicin, 
this technique is no longer recommended due to patient discomfort (Wang et al., 2006).  
5.1.2 Scalp cooling  
Scalp cooling or hypothermia is the application of cold to the scalp using a device (cap) that 
is pre-cooled in a freezer or exchanges coolant with reservoir. A period of cooling lasts from 
5 minutes prior to chemotherapy until an hour or more after the drug administration. Many 
studies have shown that the efficacy of scalp cooling can range from 0-90% (for review, see 
Grevelman and Breed, 2005). A recent study reported that scalp cooling helps reduce major 
CIA in patients receiving doxorubicin (60 mg/m2), docetaxel (80 mg/m2), or combination of 
5-fluorouracil (600 mg/m2), epirubicin (60 mg/m2), and cyclophosphamide (600 mg/m2) for 
6 to 9 cycles (Auvinen et al., 2010). The current hypotheses of the protective effect are: (i) 
cooling reduces blood flow to hair follicles by vasoconstriction, resulting in a decrease in the 
amount of drugs available for uptake; and (ii) cooling decreases cellular metabolism and 
drug uptake. Scalp cooling to 20°C was shown to reduce blood flow to 20% of normal flow; 
however, further decrease in the temperature (<18°C) did not result in further decrease in 
scalp blood flow (Janssen et al., 2007). Recent in vitro studies indicate the significant role of 
temperature on keratinocyte cell viability upon doxorubicin chemotherapy; however, there 
is no difference in cell survival between 10°C and 22°C (Janssen et al., 2008). Based on these 
findings, it appears that there is an optimal temperature for scalp cooling (~20°C), and that 
increasing the cooling will only result in patient discomfort. Other factors affecting the 
effectiveness of this method include drug regimen, application and duration of cooling, and 
the cool conductivity (Betcheler, 2001). 
Scalp cooling is practically ineffective if the chemotherapeutic agent is administered as a 
continuous infusion over a prolonged period. Additionally, scalp cooling increases the risk 
of scalp metastasis, and is therefore contraindicated in patients with hematological 
malignancies and cutaneous T-cell lymphoma (Dean et al., 1979; Apisanthanarax and Duvic, 
2003).  
5.1.3 Heat treatment 
Stress protein response is one of the cellular protective mechanisms against various adverse 
conditions. Enhanced expression of stress proteins such as Hsp90, Hsp70, and Hsp25 has 
been observed in response to certain physical and chemical stresses, which has been linked 
to increased stress tolerance. Previous in vitro studies have shown that heat treatment and 
overexpression of stress response proteins, e.g., Hsp70 and Hsp27, could protect against the 
cytotoxic effects of anticancer drugs such as doxorubicin, cyclophosphamide, etoposide, and 
taxol (Kampinga, 1995; Jaattela et al., 1998; Kwak et al., 1998; Ito et al., 1999; Xia et al., 1999), 
leading to the investigation of the protective effect of stress protein activation on CIA in 
neonatal rats (Jimenez et al., 2008). In this study, heat was locally applied to the skin with a 
copper cylinder through which heated water was circulated. Conducting gel (Vaseline) was 
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applied to the skin to improve heat conductance. Heat treatment at 48-48.5°C for 20 minutes 
increases Hsp70 and subsequently protects against CIA in response to various treatments as 
summarized in Table 3. The protective effect of heat treatment was confirmed in an adult 
mouse model receiving cyclophosphamide. Additionally, localized heat treatment was 
shown not to interfere with the anti-tumor activity of drugs. These findings suggest that 
localized activation of stress proteins in the hair follicles might be an effective strategy 
against CIA without affecting the anti-tumor efficacy. 
 






I.P. 2.5 µg/g twice 
I.P. 35.5  µg/g twice 
I.P. 20-30 µg/g once/2.5-4.5 µg/g twice 





Table 3. Localized, heat-induced protection against CIA in neonatal rats. 
5.2 Pharmacological prevention 
Currently, there are no FDA-approved drug treatments for CIA but several pharmacological 
strategies have been proposed. Many of these strategies have shown promising results in 
animals but their clinical use will require further investigations.  
5.2.1 Tumor targeting delivery 
Differences in the molecular machinery of normal cells and tumor cells as a result of cell 
transformation dominate the tumor targeting delivery arena. Tumor-specific ligands and 
antibodies have been used to provide targeting ability to drug carriers such as liposomes. 
Accordingly, these liposomes can protect patients from the side effects of chemotherapy, 
including hair loss. Examples of the targeting moieties are folate receptor (FR) for ovarian, 
colorectal, and breast cancer; transferrin for pancreatic cancer; anti-HER2 antibody for breast 
cancer; anti-CD19 for malignant B cells; anti-GD2 for neuroblastoma and melonoma; and 
prostate-specific membrane antigen (PMSA) aptamer for prostate cancer and tumor vascular 
endothelium (Huges et al., 2001; Yu et al., 2009). 
5.2.2 Drug-specific antibodies 
MAD11 monoclonal antibody (MAb) is an anti-anthracycline antibody that reacts with 
doxorubicin and other anthracycline chemotherapeutics. Topical administration of 
liposomes containing MAD11 MAb was shown to prevent CIA in doxorubicin-treated 
neonatal rats at the frequency of 31 in 45 rats (Balsari et al., 1994). MAD11 MAb was 
encapsulated into liposomes to facilitate absorption through the stratum corneum and to 
delay systemic distribution of the antibody. Topical MAD11 MAb was found to be nontoxic 
and does not induce systemic activation of cytokines. Thus, MAD11-loaded liposomes 
might be an effective strategy in preventing anthracycline-induced alopecia in cancer 
patients. However, the advantage of this strategy is limited in combination therapy since the 





5.2.3 Hair growth cycle modifiers 
5.2.3.1 Cyclosporine A 
Cyclosporine A is an immunosuppressive immunophilin ligand used in the treatment of 
autoimmune diseases and in post-organ transplantation to reduce patients’ graft rejection. In T-
lymphocytes, cyclosporine A forms complex with cyclophilin and inhibits calcineurin, leading 
to the inhibition of Go to G1 cell cycle transition and proliferation. The use of cyclosporine A in 
alopecia originates from its common side effect of excessive hair growth called hypertrichosis. 
Cyclosporin A induces anagen and inhibits catagen of the hair cycle, leading to the promotion 
of hair growth under normal and pathologic conditions such as alopecia areata and 
androgenetic alopecia (Paus et al., 1989; Taylor et al., 1993; Lutz et al., 1994).  
The effect of cyclosporine A on CIA has been investigated in neonatal rat and adult mouse 
models. In neonatal rats, topical administration of cyclosporine A prevents CIA induced by 
cyclophosphamide, cytosine arabinoside and etoposide (Hussein et al., 1995). In adult mice 
given cyclophosphamide, topical or systemic administration of cyclosporine A retards CIA, 
prevents the progression of damaged hair into telogen, and thus induces faster hair 
regrowth.  
5.2.3.2 AS101 
AS101, ammonium trichloro (dioxoethylene-o,o') tellurate, is a synthetic  immunomodulator 
that has been shown to protect mice from hemopoietic damage caused by chemotherapeutic 
agents such as cyclophosphamide, 5-fluorouracil, doxorubicin and etoposide. In phase II 
clinical trials, AS101 was shown to protect against CIA in patients with non-small cell lung 
cancer (NSCLC) receiving a combination therapy of carboplatin and etoposide (Sredni et al., 
1996). The results of this study are summarized in Table 4. 
 
Treatments No.  
of patients 
% of patients in alopecia grade 
No Mild Moderate Severe Total 














Table 4. Prevention of alopecia in AS101-treated NSCLC patients. 
The mechanism of action of AS101 was investigated in neonatal rats receiving cytosine 
arabinoside (Sredni et al., 1996). The study demonstrated that the protective effect of AS101 
was through macrophage-derived factors such as interleukin-1 (IL-1). IL-1 induces the 
secretion of other cytokines such as keratinocyte growth factor (KGF) which stimulate the 
proliferation and differentiation of keratinocytes within the hair follicles.  
5.2.3.3 Minoxidil 
Minoxidil is one of the FDA approved drug for the treatment of androgenetic alopecia. 
Topical minoxidil shortens the telogen phase by inducing the entry of resting hair follicles 
into the anagen phase, thereby stimulating hair growth (Messenger and Rundegren, 2004). 
Minoxidil also prolongs the duration of anagen phase and enlarges hair follicles, probably 
by its proliferative and anti-apoptotic effects on dermal papilla cells (Han et al., 2004). 
Several studies have also investigated the effect of minoxidil on CIA. In neonatal rats, local 
injection of minoxidil protects against CIA induced by cytosine arabinoside but not by 
cyclophosphamide. However, topical minoxidil (2%) does not protect against CIA. In one 
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randomized clinical trial, topical minoxidil (2%) was shown to shorten the duration of CIA 
in breast cancer patients receiving 5-fluorouracil, doxorubicin, and cyclophosphamide 






Baseline to maximal hair loss 
Baseline to maximal regrowth 
Maximal hair loss to first regrowth (period of baldness) 













Table 5. Minoxidil shortens duration of CIA. 
5.2.4 Cytokines and growth factors 
Hair follicle cells express receptors for multiple cytokines and growth factors that regulate 
hair growth cycle (Trueb, 2002). These regulators include fibroblast growth factors (FGF), 
transforming growth factors (TGF), insulin-like growth factors (IGF), epidermal growth 
factors (EGF), interferon and interleukins (Stenn and Paus, 2001).  Moreover, hair cycle is 
regulated by androgens and parathyroid hormone (PTH) (Sawaya, 2001). 
IL-1 and ImuVert, a biological response modifier derived from S. Marcescens, were reported 
to protect against CIA induced by cytosine arabinoside and doxorubicin in neonatal rats 
(Hussesin, 1993). Both agents can induce the release of multiple cytokines and growth 
factors. It was suggested that the protection of CIA by ImuVert is mediated through IL-1. 
Similarly, EGF and FGF-1 have been shown to protect against CIA induced by cytosine 
arabinoside but not by cyclophosphamide in neonatal rats (Jimenez and Yunis, 1992). In 
contrast, FGF-7 and KGF partially protect against CIA by cytosine arabinoside by retarding 
hair loss (Danilenko et al., 2000). In organ-culture human scalp hair follicles and HaCaT 
keratinocytes, KGF protects against the cytotoxicity of mafosfamide, the cell culture active 
derivative of cyclophosphamide (Braun et al., 2006). The mechanism of action of KGF has 
been proposed to involve specific signaling pathways including PI3K and ERK1/2. 
PTH antagonists reduce cell apoptosis in the hair bulb matrix and delay the onset of CIA in 
adult mice, whereas PTH agonists enhance the apoptosis and accelerate hair regrowth after 
CIA. However, neither PTH agonists nor antagonists prevent CIA (Peters et al., 2001). 
5.2.5 Antioxidants 
Broad spectrum antioxidant N-acetyl cysteine (NAC), an analog and precursor of 
glutathione, when administered topically or parenterally, protects against CIA induced by 
cyclophosphamide in neonatal rats. In contrast, NAC could not protect adult mice from CIA 
induced by doxorubicin (Wang et al., 2006).  
-Tocopherol or vitamin E is an important lipid-soluble antioxidant. Several studies have 
reported the protective effect of high-dose vitamin E in patients receiving doxorubicin; 
however, conflicting results have also been reported. For example, A clinical study reported 
that 69% of the patients did not experience CIA when co-treated with vitamin E, while 





5.2.6 Cell cycle or proliferation modifiers 
Rapid proliferation of keratinocytes during the anagen phase of hair follicle is one the main 
predisposing factors of CIA. Thus, one approach to protect against CIA is to arrest the cell 
cycle and inhibit cell proliferation.  
5.2.6.1 Calcitriol 
Multiple effects of calcitriol (1,25-dihydroxyvitamin D3) on keratinocytes, i.e., inhibition 
of DNA synthesis, Go/G1 cell cycle arrest, and induction of cell differentiation, have been 
reported (Kobayashi et al., 1998; Wang et al., 2006). Thus, it is likely that calcitriol induces 
changes in keratinocyte proliferation and/or terminal differentiation, subsequently 
altering cellular susceptibility to apoptosis. In neonatal rats, topical administration of 
calcitriol reduces CIA induced by cyclophosphamide, etoposide, and a combination 
treatment of cyclophosphamide and doxorubicin (Jimenez and Yunis., 1992). In adult mice 
receiving cyclophosphamide, topical calcitriol however fails to prevent or retard CIA, but 
somehow reduces massive apoptosis of hair matrix keratinocytes, a key feature of CIA, 
and enhances the regrowth of normal hair shaft. (Paus et al., 1996;  Schilli et al., 1998). In 
humans, calcitriol has a protective effect against CIA induced by paclitaxel (Jimenez and 
Yunis, 1996), but not by a combination of 5-fluorouracil, doxorubicin and 
cyclophosphamide (Hidalgo et al., 1999)   
5.2.6.2 CDK2 inhibitor 
Cyclin-dependent kinase 2 (CDK2) is a member of the serine/threonine protein kinase 
family that plays a key role from late G1 to late G2 of the cell cycle. Potent small inhibitors of 
CDK2 have been synthesized and tested for their effect on CIA. One of these synthetic 
inhibitors was shown to inhibit the progression from late G1 into S phase in human diploid 
fibroblasts and also inhibit apoptosis induced by etoposide, 5-fluorouracil, taxol, cisplatin 
and doxorubicin. In neonatal rats, topical application of the inhibitor reduces hair loss at the 
site of application in 50% of the rats having etoposide-induced CIA and in 33% of the rats 
with CIA induced by cyclophosphamide and doxorubicin (Davis et al., 2001). Histological 
examinations of the skin from etoposide-treated rats show that the inhibitor increases the 
number of viable hair follicles and dermal papilla, reduces the level of inflammation and 
amount of damage to epithelium, reduces the thickening of epidermis and decreases the 
number of apoptotic cells in the hair follicle matrix. However, in subsequent studies the 
authors reported that they were unable to reproduce the results in the neonatal rat model 
(Davis et al., 2002), thus the use of this inhibitor in CIA becomes questionable, although the 
idea of using CDK2 inhibitors is still ongoing.  
5.2.7 Inhibitor of apoptosis 
5.2.7.1 Caspase3 inhibitor 
Various chemotherapeutic agents induce apoptosis of hair follicle cells and cause CIA, 
although the underlying mechanisms are unclear. Caspase-3 is a key executor of apoptosis 
and its activation is normally used as an indicator of caspase-dependent apoptosis (Porter 
and Janicke, 1999). M50054, 2,2’-methylenebis, is an inhibitor of caspase-3 activation that 
was shown to inhibit etoposide-induced apoptosis in human monocytes. In neonatal rats, 
topical administration of M50054 reduces CIA induced by etoposide (Tsuda et al., 2001).  
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topical administration of M50054 reduces CIA induced by etoposide (Tsuda et al., 2001).  
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5.2.7.2 Anti-death FNK protein 
FNK protein constructed from rat Bcl-xL by site-directed mutagenesis 
(Y22F/Q26N/R165K) localizes to mitochondria and functions to maintain mitochondrial 
membrane potential (Aosh et al., 2000). Mitochondrial membrane potential regulates the 
release of cytochrome C, which once binds to caspase-activating proteins such as Apaf-1 
initiates the intrinsic caspase cascade and apoptosis (Li et al., 1997). Recently, FNK protein 
has been fused to protein transduction domain (PTD) to improve its cellular entry. 
Subcutaneous injection of PTD-FNK protects against CIA induced by etoposide in the 
neonatal rat model. The fusion protein helps retain hair follicle structures, prevent hair 
follicle regression and maintain the anagen duration upon etoposide treatment 
(Nakashima-Kamimura et al., 2008). Indeed, its protective effect on CIA suggests that it 
could penetrate the epidermis and reach the dermal hair follicles. Localized 
administration of FNK fusion protein has been suggested as a potential protein therapy 
for CIA without affecting the chemotherapy efficacy. 
6. Molecular mechanisms of CIA 
Molecular mechanisms of CIA are not well understood, in part due to the lack of 
appropriate experimental models that mimic human CIA. Much of our understanding on 
CIA is based on animal and cell culture models, some of which are described below.   
6.1 DNA damage 
Most chemotherapeutic agents including cyclophosphamide, doxorubicin and cisplatin 
induce DNA damage and kill both normal and cancer cells by apoptosis (Muller et al., 1998). 
p53 is a transcription factor and tumor suppressor protein that plays a critical role in cell 
cycle progression and apoptosis. Activation of p53 in response to DNA damage is associated 
with the degradation of Mdm2/p53 complex, leading to increased availability of p53 to bind 
DNA and consequently transcriptional activation of p53 target genes. Many p53 target 
genes, including Fas, Bax, Bcl-2, insulin-growth factor receptor type I (IGFR1), and insulin-
like growth factor binding protein 3 (IGF-BP3), are expressed in the hair follicles (Lindner et 
al., 1997). In the adult mouse model for CIA, p53 was shown to be essential in the hair 
follicle response to DNA damage induced by cyclophosphamide. Specifically, hair loss was 
not observed and hair follicle cells remained active in p53-deficient mice, as shown by a 
large volume of hair bulb and dermal papilla, and active keratinocyte proliferation in the 
hair matrix (Botchkarev et al., 2000).  
6.2 Apoptosis 
Chemotherapy-induced apoptosis of hair follicle cells is one of the major findings from CIA 
animal studies. Although the mechanism of apoptosis is not well understood, p53 and Fas 
signaling pathways are believed to play a key role. 
In adult mice, cyclophosphamide-treated hair follicles show a strong up-regulation of p53 in 
the hair matrix, particularly in TUNEL-positive apoptotic keratinocytes (Botchkarev et al., 
2000). By contrast, in p53-deficient mice, apoptosis in the matrix keratinocytes was not 
detected after cyclophosphamide treatment, indicating the involvement of p53 in the 
apoptotic process. The precise mechanism of p53-dependent apoptosis in the hair follicles 





p53-deficient mice show strongly down-regulated Fas in the hair follicle keratinocytes and 
highly up-regulated Bcl-2 in the dermal papilla as compared to wild-type mice. The role of 
Fas in the control of cyclophosphamide-induced apoptosis in keratinocytes was also 
investigated using Fas-deficient mice (Sharov et al., 2004). These mice show significantly 
reduced CIA and a parallel decrease in apoptotic keratinocytes and FADD and caspase-8 
expression. Similarly, anti-Fas ligand neutralizing antibody inhibits cyclophosphamide-
induced keratinocyte apoptosis. These studies indicate that Fas signaling is an important 
pathway in mediating the apoptosis induced by cyclophosphamide and suggest the cross-
talk between p53 and Fas death signaling. However, the eventual hair loss observed in Fas-
deficient mice points to the lower resistance of hair follicles to cyclophosphamide as 
compared to p53-deficient mice. Thus, it is likely that Fas signaling represents only a 
component of the p53-dependent apoptosis machinery in the hair follicles and that other p53 
targets are also involved. Cyclophosphamide treatment also alters the expression of 
melanogenic proteins and causes apoptosis of hair follicle melanocytes (Sharov et al., 2003). 
In contrast to matrix keratinocytes, the melanocytes undergo apoptosis primarily through 
Fas signaling but not p53 signaling. 
6.3 Reactive oxygen species 
The observation that antioxidants such as NAC protect against CIA in animals suggest the 
involvement of reactive oxygen species (ROS) in CIA. Various chemotherapeutic agents 
induce oxidative stress through multiple mechanisms, i.e., activation of NADPH oxidase 
system and mitochondrial respiration chain. Agents that induce a high level of ROS include 
anthracyclines (e.g., doxorubicin, epirubicin, and daunorubicin), alkylating agents (e.g., 
cyclophosphamide), platinum coordination complexes (e.g., cisplatin, carboplatin, and 
oxaliplatin), and epipodophyllotoxins (e.g., etoposide) (Conklin, 2004). Interestingly, 
anthracyclines, alkylating agents, platinum complexes, and epipodophyllotoxins also induce 
CIA more frequently and more severely than most other agents, suggesting a relationship 
between ROS generation and CIA. The exact mechanism of how ROS induces or promotes 
CIA is unclear, but likely involves apoptosis regulation since apoptosis of hair follicles is a 
hallmark of CIA and since ROS generation is generally required for the induction of 
apoptosis by chemotherapeutic agents (Simon et al., 2000).  
7. Perspectives 
CIA is a major side effect that compromises patient quality of life, particularly for females 
and children. Overcoming CIA remains a major challenge in the management of cancer 
patients. Significant progresses in the pathobiology and molecular mechanisms of CIA have 
been made during the past decade, and several physical and pharmacological approaches to 
treat CIA have been attempted. However, effective treatment strategies have yet to be 
developed. A key to this success is a better understanding of the human CIA mechanisms 
which requires the development of more predictive experimental models. Animal models 
have been useful but have limitations and may not be predictive of human CIA. The newly 
developed organ culture system using human hair follicles is promising and could lead to 
the development of more effective treatment strategies for CIA. The recent success in 
combination chemotherapy also provides mechanistic insights to combating CIA through 
the use of different combination strategies.  
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Even if CIA cannot be completely prevented, it can be managed. Healthcare providers and 
patient family could help patients prepare for the sudden loss of hair, thus minimizing the 
negative impact on patients. Patients should receive the information regarding self-care 
strategies to take control and cope with CIA. Patients with long hair should be encouraged 
to try short hair style to make a better transition to total CIA. Patients are also advised to 
avoid physical and chemical trauma to the hair (e.g. bleaching, coloring and perming) and 
to shave their hair once the hair loss becomes prominent. Appropriate head covering may be 
used, depending on individual preference (Bachelor, 2001; Trueb, 2010).  
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Even if CIA cannot be completely prevented, it can be managed. Healthcare providers and 
patient family could help patients prepare for the sudden loss of hair, thus minimizing the 
negative impact on patients. Patients should receive the information regarding self-care 
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1. Introduction 
1.1 The impact of cancer on sexuality and intimacy: A key aspect of quality of life  
In 2006, more than 106,000 new cases of cancer were diagnosed in Australia, with the 
number of new cases in New South Wales alone expected to grow to 40,116 by 2011 (AIHW 
et al., 2007, Tracey et al., 2005).  It is now widely recognised that cancer and its treatment can 
have a significant effect on the quality of life of both people with cancer (Stommel et al., 
2004) and their family members, in particular their intimate partner (Hodges et al., 2005). 
Sexuality and intimacy are important aspects of an individual’s quality of life (World Health 
Organisation, 1995), and there is a growing body of evidence to show that cancer can result 
in dramatic changes to sexuality, sexual functioning, relationships, and sense of self, 
regardless of cancer type. Indeed, these changes can be experienced as the most significant 
in the person with cancer’s life (Anderson et al., 2000).  
For women, treatments for gynaecological, colorectal, or breast cancer can alter patterns of 
fertility, have a negative impact on arousal and orgasm, reduce vaginal lubrication and 
elasticity (Jvaskova et al., 2003), precipitate negative changes to body image and sense of 
self, or precipitate ‘sexual dysfunction’ (Maughan et al., 2002, Sundquist, 2002, Baider et al., 
2000).  For men, prostate and testicular cancer can impact on  fertility, ejaculatory capacity, 
and erectile potential (Gurevich et al., 2004), as well as provoking  diminished confidence, 
fear, and embarrassment associated with sexual ability (Bokhour et al., 2001). The fatigue 
caused by cancer and certain treatments, such as chemotherapy and radiotherapy, is also 
typically associated with diminished desire (Rolland, 1994).  
Changes to sexuality post-cancer have ramifications beyond sex as an activity. It has been 
argued that when sexual intercourse ceases after illness, touching and other forms of 
affectionate physical contact also diminish (Kuyper et al., 1998), because of a perception 
amongst some couples that these forms of affection necessarily lead to sexual intercourse, 
which is either not possible, or deemed inappropriate (Hughes, 2000). Equally, if all forms of 
sexual intimacy within the couple relationship disappear, couples facing cancer can feel 
isolated, anxious, depressed (Germino et al., 1995), inadequate  (Anllo, 2000), or emotionally 
distant from their partner (Rolland, 1994). Conversely, sexual intimacy has also been found 
to make the experience of cancer more manageable and assist in the recovery process 
(Schultz et al., 2003), or be central to couple closeness and quality of life in palliative care 
(Lemieux et al., 2004).  
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1.2 The experience of cancer on partners’ sexuality 
Whilst the experiences of partners are often neglected in research on sexuality and intimacy 
post-cancer (Reichers, 2004), there is growing acknowledgement of their unmet needs in this 
area (De Groot et al., 2005, Perez et al., 2002, Soothill et al., 2003). Reported disruptions, 
include decreases in their own sex drive; fear of initiating sex with their partner; difficulty 
regaining a level of ‘normality’ within the sexual relationship; and feeling unwanted and 
unattractive because of cessation of sex (Maughan et al., 2002, Harden et al., 2002, Sanders et 
al., 2006).  
Whilst the inclusion of partners in research on sexuality and cancer goes someway to 
addressing the issue of ‘carer blindness’ (Parker, 1990), one of the limitations of existing 
research in this area is the focus on cancers that affect sexual organs, primarily prostate, 
breast and gynaecological cancer. There is a need for research examining the experiences of 
partners across a range of cancer types, as cancers that do not involve parts of the body 
designated as ‘sexual’ may also impact on sexuality (Reichers, 2004). Equally, the focus of 
research to date has been on the physiological effects of cancer and its treatment upon the 
sexuality of partners. However, sexuality is a material-discursive phenomenon (Ussher, 
1997a), and thus the dynamics of the care-giving relationship, and social constructions 
surrounding what constitutes ‘appropriate’ or ‘taboo’ sexual conduct post-cancer, may also 
interfere with a couples’ sexual relationship. Partners who provide a great deal of intimate 
physical care to the person with cancer (such as helping with toileting or feeding) can 
experience difficulties in continuing to see them as a sexual person (Pope, 1999), 
repositioning them as a ‘patient’ (Kelly, 1992) or as asexual (D'Ardenne, 2004).  
Broader cultural constructions of normative sexuality may also be influential in determining 
the ability of couples to renegotiate sexuality and intimacy post-cancer, particularly when 
sexual intercourse is no longer possible. As Judith Butler (1993) has argued, our 
understanding of sexual subjectivity is confined within a ‘heterosexual matrix’, within 
which masculinity and femininity are performed through engagement in normative sexual 
practices, described as the “coital imperative” (Gavey et al., 1999), with failure to perform 
coitus positioned as ‘dysfunction’, and other practices as not “real sex” (Few, 1997). This 
provides a theoretical framework for understanding why many heterosexual couples who 
cannot physiologically engage in sexual intercourse following diagnosis and treatment of 
cancer cease all expression of sexual intimacy. It also suggests that the dynamics and 
pressures of the caring role, as well as constructions and beliefs about what is acceptable or 
appropriate sexually post-cancer, are worthy of investigation across cancer types. This is one 
of the aims of the present chapter. 
1.3 Pathways to difficulty or re-negotiation of sexuality post-cancer 
Much of the existing research in this area simply documents changes in sexuality and 
intimacy post-cancer, however, there have been some attempts to examine pathways to 
difficulty or re-negotiation, primarily within a uni-linear model, with each study focusing 
on one specific construct.  Qualitative research has reported associations between cessation 
of sexuality and intimacy post-cancer and difficulties in couple communication about sexual 
matters (Arrington, 2003, Foy et al., 2001, Holmberg et al., 2001), often for fear of creating 
feelings of guilt in the person with cancer (Kuyper et al., 1998), and one quantitative study 
reported an association between communication, relationship satisfaction, and sexuality 
(Hannah et al., 1992). Equally, interviews with partners of a person with cancer, recently 
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conducted by the authors, revealed that successful re-negotiation of intimacy post-cancer 
was associated with good communication and positive relationship context (Gilbert et al., 
2010a).  
Until recently, research examining the impact of cancer on sexual wellbeing and intimacy 
has focused on the physical changes (Wilmoth, 2001), using quantitative methods of data 
collection – primarily surveys. Whilst quantitative methods can provide information on 
changes in large samples of individuals, they negate the lived experience and negotiation of 
sexual wellbeing after  cancer (Gilbert et al., 2010b). At the same time, research has focused 
narrowly on ability to engage in satisfying sexual activity, satisfaction with the frequency of 
that activity (Wilmoth, 2001, Hensen, 2002), and the level of their sexual ‘dysfunction’ post-
cancer, where functional sexuality is narrowly conceptualised as penile/vaginal intercourse 
(Fobair et al., 2006). Recent research has shown, however, that engaging in sexual 
intercourse may not be the primary focus of sexual concern after a cancer diagnosis, and that 
engagement in sexual intercourse does not necessary equate to sexual satisfaction (Wilmoth, 
2001). Moreover, the primary focus on the physical effects of cancer or cancer treatment on 
sexual behaviour assumes that the  experience of sexuality is limited to its corporeal 
dimensions, negating the influence of the social and relational construction of sexuality and 
illness (Meyerowitz et al., 1999), and the ways in which the meaning of sex is negotiated by 
individuals (Gilbert et al., 2010a). 
1.4 Prevention and intervention for issues of sexuality and intimacy post-cancer 
Recognition of sexual changes and their consequences, and of pathways to difficulty, is only 
the first step: We then need to use this knowledge to develop, and evaluate, programs of 
prevention and intervention to ameliorate difficulty and facilitate re-negotiation of sexuality 
post-cancer. Equally, whilst a range of psycho-social interventions have been developed for 
both people with cancer and their carers, few interventions include consideration of 
sexuality and intimacy, and even if they do, sexuality is positioned as merely one aspect of 
the cancer experience that couples need assistance with (e.g. Helgeson et al., 2006, Wardle et 
al., 2003). It has thus been argued that there is a need for psycho-education, which focuses 
specifically on the effects of cancer and its treatments on sexuality and intimacy (Rees et al., 
1998). Since 2003, psychosocial guidelines for the care of people with cancer include 
recognition of the need for support in relation to changes in sexual functioning post-cancer 
(Initiative, 2003). However, these guidelines do not provide practical strategies for the 
application of such support in clinical practice, and sexuality is still rarely addressed by 
health professionals (Hordern et al., 2007b). 
Equally, those psycho-educational interventions that do exist tend to focus on restoring 
sexual functioning, rather than on examining the quality of intimate physical contact, or 
renegotiation of sexual relationships through the development of alternative practices 
(Hordern et al., 2007b). Interventions also focus on ‘sexual’ cancers, such as prostate (Manne 
et al., 2004), or breast cancer (Manne et al., 2007, Marcus et al., 1998, Lethborg et al., 2003), 
with little offered to address the needs and concerns of couples living with other types of 
cancer, and no analysis of the relative efficacy of interventions across cancer types. This 
chapter will address this significant gap in the research literature, by outlining the issues 
that need to be considered in psycho-educational interventions which address issues of 
intimacy and sexuality with people with cancer and their partners. 
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cancer, and no analysis of the relative efficacy of interventions across cancer types. This 
chapter will address this significant gap in the research literature, by outlining the issues 
that need to be considered in psycho-educational interventions which address issues of 
intimacy and sexuality with people with cancer and their partners. 
 





The study described in this chapter is part of a larger cross sectional project evaluating the 
needs and experiences of informal cancer carers in New South Wales, Australia. This 
chapter focuses on the experiences of a sub-set of carers who were caring for their partners. 
All participants completed standardised questionnaires measuring depression and anxiety, 
burden of care, as well as questions regarding changes in sexuality post-cancer. Participants 
who reported changes in sexuality after the diagnosis of cancer, completed open-ended 
questions describing the changes. From these participants, a sample was selected to take 
part in in-depth interviews to examine these issues in more detail.  
2.1.1 Recruitment and participants 
The larger study from which the participants were drawn was advertised via cancer and 
carer-specific newsletters, websites, and organisations, as well as through media releases, 
cancer support groups and cancer clinics across New South Wales. Family members, partners 
or friends of people with cancer, who self identified as providing care, and who volunteered to 
take part in the research, were asked to complete an online or postal questionnaire. A subset of 
the participants, who indicated willingness, were invited to take part in an in-depth interview. 
Ethical approval was granted from all relevant Committees including 10 Area Health Services 
across New South Wales, Australia, The Cancer Council New South Wales, and the University 
of Western Sydney. Three hundred and twenty nine carers participated in this larger study. 
This paper draws upon a sub-sample of 156 (55 men, 101 women) participants who were 
caring for their partners and responded to the question ‘does their cancer impact on your 
sexual relationship?’. One hundred and twenty-two participants (43 men, 79 women), or 78% 
of this sub-sample reported that the onset of cancer had negatively impacted upon their 
sexuality and their sexual relationship and completed open-ended questions describing the 
changes. When we examined the type of cancers associated with changes to sexuality post-
cancer, the rate was 90% for partners of men with prostate cancer, 71% for partners of women 
with gynaecological cancer, and 78% for partners of women with breast cancer. Overall, the 
percentage of partner carers of partners with ‘non-sexual’ cancers who reported an impact on 
the sexual relationship was 76%, and the percentage of those caring for partners with cancers 
involving ‘sexual’ sites was 84%. Forty-six percent of partner carers indicated a willingness to 
be interviewed about sexuality and 20 were selected on the basis of whether they had been 
involved in, or were currently involved in, a sexual or intimate relationship with the person for 
whom they care/d, and self-reported changes to sexuality since the diagnosis of their partner’s 
cancer, stratified by gender, cancer stage and type.  
Sample characteristics are presented in Table 1. Ninety-six percent of the participants 
reported being in a heterosexual relationship, with the remaining in a lesbian relationship, 
and 1 participant in a gay male relationship. Participant ages ranged from 28 to 79, with a 
mean age of 57 (SD = 10.73; skewness = -.47), with their partner ages (person with cancer) 
displaying a comparable profile ranging from 29 to 93, with a mean age of 59 (SD = 11.83; 
skewness = -.15). Colorectal/digestive, breast and haematological cancer types account for 
44.2% of the reported cancer types, 35% indicating an advanced stage of cancer, and the 
average time since diagnosis was 3.49 years. Carer partners reported spending an average of 
10 hours per day providing direct care. There were 26 bereaved participants (11 men, 15 
women), with the time of partner’s death ranging from 1 month to 4 years, who reported 
retrospectively on their experience of caring for their partner.  
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2.2 Quantitative methods and analyses 
2.2.1 Measures  
The Hospital Anxiety and Depression Scale (HADS) (Zigmond et al., 1983), was used to 
provide a brief measure of the presence of anxiety and depression. The HADS has very well 
established psychometric properties and is a reliable and valid instrument, with Cronbach 
alphas at .80 to .93 for the anxiety and .81 to .90 for the depression subscales (Herrmann, 
1997, Janda et al., 2008). Higher scores indicate higher psychological disturbances. 
The Caregiver Reaction Assessment Scale (CRA) (Nijboer, 1999) was used to examine 
caregiver burden. Subscales include: Disrupted Schedule, Financial Problems, Lack of 
Family Support, Health Problems, and Self-Esteem. As an assessment of both positive and 
negative reactions to care-giving by partners of patients with cancer, the CRA has been 
described as a reliable and valid instrument, with Cronbach alpha coefficients ranging from 
.62 to .83 for the separate subscales (Nijoboer, 1999). A higher score indicates a stronger 
impact of the attribute. 
Questions on sexuality were also developed for the study, in consultation with the study’s 
steering advisory committee, which comprised of two carer representatives from an 
independent advocacy organisation (Cancer Voices New South Wales), professionals 
providing support services to cancer patients and their carers, an oncologist, and researchers 
working in the field of psycho-oncology, sexuality, health, and gender. Three dichotomous 
questions (no, yes), asked participants: if they were in a sexual relationship with the patient; 
have there been changes to the sexual relationship post-cancer; and if so, have issues about 
sexuality been discussed with a health care provider?  
2.2.2 Statistical analyses   
Cronbach alpha coefficients were calculated to assess the internal consistency of HADS and 
CRA subscales. Cronbach alpha values above .80 were considered estimates of good 
reliability, while scores above .60 were considered adequate. A multivariate logistic 
regression with backward selection was conducted to determine the relationship between 
CRA subscales and impact on the sexual relationship to test the research question of the 
impact of burden of care on changes to the sexual relationship post-cancer. Univariate linear 
regressions with impact on the sexual relationship as a predictor and HADS Anxiety and 
Depression subscales as outcome variables, were conducted to assess the association 
between changes to the sexual relationship and psychological well-being. This analysis 
excluded data from the 26 bereaved participants, given that the HADS measures 
psychological well-being over last 7 days. To examine the potential moderating influence of 
participant gender, age, hours of provided direct care, and cancer type (dichotomised as 
non-sexual or sexual type), a series of multiple regressions were conducted where 
interactions with these variables were examined in addition to the main effect of impact on 
the sexual relationship. Cancer stage was not examined, due to the small cell size in early 
stage cancer. Equations with continuous predictor variables were centred as suggested by 
Howell (2002). An alpha level of .05 was used for all analyses. 
2.3 Qualitative methods and analysis 
2.3.1 Measures  
Two open-ended questionnaire items concerning changes in sexuality post-cancer were: 
please describe the changes to your sexual relationship; and, if your role as carer has made 
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any difference to your sexual relationship, please describe this difference. Participants who 
were interviewed were asked the same set of questions, with scope to elaborate on topics or 
issues as they arose. 
A semi-structured interview, audio-recorded and conducted on a face-to-face or telephone 
basis, lasting approximately 1 hour, was used to examine in depth partners’ experiences of 
sexuality post-cancer. The interview discussion focused on: changes to partners' 
intimate/sexual relationship; feelings about their intimate/sexual relationship; 
communication with the person with cancer about intimacy; and experiences with health 
care professionals. In accordance with established protocols in qualitative research, 
sampling was discontinued when information redundancy was reached, and no additional 
information was forthcoming (Miles et al., 1994). 
2.3.2 Analysis of open-ended questions and interviews 
All of the interviews were transcribed verbatim, and thematic analysis was used to analyse 
the data (Braun et al., 2006). After transcription, the interviews and open-ended 
questionnaire responses were independently read by two researchers, in order to ascertain 
the major themes, and to develop a coding frame. Following discussion between the 
researchers, and other members of the research team, the coding system was used to 
organise the data into conceptual categories which were based on participants’ stories and 
responses. The research was, therefore, largely inductive, where the concepts and categories 
came from the data, rather than being deductive or informed by existing preconceptions 
about cancer caring and sexuality (Janesick, 1994). The interviews and responses were then 
coded thematically by two of the researchers, using consensus discussion, with a third 
researcher available to discuss any disagreements. NVivo software, a program which allows 
for qualitative data to be organised thematically, as well as across demographic, or other key 
variables, was used to organise the coded data. The coding frame focused on the following 
major themes: Nature of changes to sexuality (cessation; reduction; renegotiation); Reasons 
given for changes to sexuality (Impact of cancer or cancer treatment: caring role; re-
positioning of person with cancer as patient); and Feelings about such changes (positive and 
negative). Discussion and competing explanations between the two researchers during the 
coding process, as well as discussions with the broader team, allowed the coding frame to be 
refined (Barbour, 2001). Responses from the questionnaire were also tabulated and counted 
to identify frequency and patterning within and across groups, specifically gender and 
cancer type.  
3. Results 
3.1 Quantitative results 
3.1.1 Reliability estimates 
HADS Anxiety and Depression subscales displayed good reliability with Chronbach alpha 
scores >.80 (.87 and .81 respectively), while the CRA subscales ‘Disrupted Schedule’ (.77) 
and ‘Lack of Family Support’ (.67) had adequate internal consistency with scores >.60).  
Cronbach alpha scores for the remaining CRA subscales were <.60 (‘Self Esteem’ at .56; 
‘Financial Problems’ at .44; and ‘Health Problem’ at -.17). Descriptive statistics for the HADS 
and CRA subscale scores are presented in Table 1.   
 
Sexuality and Intimacy in the Context of Cancer 
 
79 
Variable N Mean S.D. Range 
Partner carer age 153 57 10.63 28 - 79 
Person with cancer age 154 59 11.83 29 - 93 
Hours of direct care per day 116 10.25 9.06 0 – 24 
Years since diagnosis 153 3.48 4.36 2mths – 23yrs 
CRA subscale scores:     
 Disrupted schedule 152 17.17 5.18 0 – 25 
 Health problems 153 13.23 2.56 3 - 19 
 Lack of family support 155 9.28 4.75 0 - 25 
 Financial problems 152 8.30 3.26 0 - 15 
 Self esteem 152 26.19 4.49 5 - 35 
 HADS subscale scores:     
 Anxiety 126 10.79 4.40 1 - 20 
 Depression 125 7.38 4.11 0 - 19 
 N %   
Sexual orientation:     
 Heterosexual 149 95.5   
 Lesbian / Gay 7 4.5   
Ethnicity:     
 White European 
/Aust 
141 90.4   
 Asian 3 1.3   
 Not stated 12 7.7   
Cancer type:     
 Colorectal/Digestive 24 15.4   
 Breast 23 14.7   
 Haematological 22 14.1   
 Multiple Non-Sexual 15 9.6   
 Multiple Sexual 10 6.4   
 Prostrate 10 6.4   
 Other* 52 33.4   
Stage of disease:     
 No longer detectable 29 18.6   
 Early 10 6.4   
 Advanced 56 35   
 Not sure/applicable 61 39   
 
 * “Other” includes: Respiratory, Gynaecological, Brain, Mesothelioma, Pancreatic and missing. 
Table 1. Sample characteristics for partner carer and person with cancer 
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3.1.2 Predictors of changes to the sexual relationship 
Table 2 summarises the odds ratios (Exp(B)) for CRA subscales as predictor variables in a 
model predicting changes to the sexual relationship post-cancer. The CRA subscale 
“Disrupted Schedule’ was the single significant predictor of changes to the sexual 
relationship (Exp(B) = 1.20, p = .002, CI = 1.05 – 1.22), indicating that a person with a one-
point increase in CRA “Disrupted Schedule’ would be 1.2 times more likely to report that 
the sexual relationship had changed post-cancer. No other CRA subscales emerged as 
predictors of change to the sexual relationship post-cancer. 
 
CRA Subscale Exp(B) Significance 95% CI 
Variables in the model    
          Disrupted Schedule 1.20 .002 1.05 – 1.22 
Variables not in the model    
          Health Problems .02 .86 .85 – 1.22 
          Lack of Family Support .07 .16 .97 – 1.19 
          Financial Problems .03 .73 .88 – 1.20 
          Self Esteem -.02 .64 .89 – 1.07 
          Constant -.73 .26  
Note: Model significant at the level of 0.01; -2 log likelihood = 145.84; X2 = 10.21. 
Table 2. Multivariate logistic regression results for factors associated with a change in the 
sexual relationship post cancer (N = 146) 
3.1.3 Impact of changes in the sexual relationship upon psychological well-being 
Table 3 presents the results of univariate regression analyses conducted to examine the 
contribution of the predictor variable ‘changes to the sexual relationship post-cancer’ on 
participant’s HADS Anxiety and Depression scores. Changes to the sexual relationship was 
a significant predictor of HADS Anxiety scores (t(124) = 2.04, p = .04) and HADS Depression 
scores (t(124) = 2.02, p = .04) respectively. Multiple regressions testing the main effect of 
changes to the sexual relationship and interaction terms representing potential moderating 
variables were conducted separately for gender, age, hours of provided direct care, and 
cancer type. No significant interaction effects were found predicting either HADS Anxiety 
or HADS Depression scores.  
 
 B SE B ß 
HADS Anxiety Subscale    
Change in the sexual relationship 1.82 .89 .18* 
    
HADS Depression Subscale    
Change in the sexual relationship 1.68 .83 .18* 
Note: For HADS Anxiety, R2 = .03; For HADS Depression, R2 = .03. * p < .05. 
Table 3. Univariate regression results for change in the sexual relationship upon 
psychological wellbeing (N = 124) 
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3.2 Qualitative results 
One hundred and twenty two partners, including 26 who were bereaved, elaborated on the 
changes to their sexual relationship they had experienced post-cancer, in open-ended 
responses. These responses concerned the status of the sexual relationship, perceived 
reasons for the changes, and partners’ feelings about the changed relationship. Each theme 
is reported below, illustrated by extracts from the questionnaires and the interviews. 
Demographic information is provided for longer quotes stemming from the interviews. For 
readability, these specific details are not provided for every questionnaire and interview 
quote. Percentages cited refer to the open ended questionnaire responses, completed by 122 
participants. 
3.2.1 Status of current sexual relationship 
Two major themes characterised accounts of the current status of the sexual relationship: 
cessation or decreased frequency of sex or intimacy; and re-negotiation of sex or intimacy. 
Cessation or decreased frequency of sex and intimacy. Complete cessation of sex, decrease in the 
frequency of sex, or a reduction in the frequency or quality of intimacy and closeness, was 
reported by 59% of women and 79% of men. The complete ‘end’ of the sexual relationship 
was reported by some participants as a sudden event: “Our sex life disappeared overnight”; 
“Gone from fantastic sex life to none”. For other participants, it was a gradual change: 
“Initially we found other ways to be intimate, however over time our sex life has ceased”. 
The impact of both the cessation of sex, and the loss of intimacy, was evident in the 
following interview extract: 
A big… big chunk of your life is lost, And I don’t just mean the physical aspects of it… I 
mean that’s… you can live with that or you can… or go without, but… the whole 
package is gone and I think that’s hard that, you’re a widow with somebody that’s still 
around. 
57 year old woman caring for 53 year old husband with brain cancer 
Of the participants who reported decreased sexual frequency, rather than complete 
cessation, many positioned their sexual relationship in ways that indicated that they had 
previously enjoyed an active sex life: “We had a very strong physical relationship up until 
the cancer was discovered and after it, it just faded away”; “Very poor, we use to have sex 5 
times a week, now maybe once in 3 or 4 months”. Others simply described a change in 
frequency: “Virtually non-existent”; “This aspect of our marriage has nearly stopped”. 
Many participants also reported decreased closeness and intimacy. Responses included: “…I 
couldn’t cuddle like we used to” and, “Often feel frustrated that it doesn’t happen like it 
used to – he is not as romantic either”. Participants also shared these sentiments in the 
interviews, for example: 
I don’t know whether you just take this huge step back and you’re not feeling that 
intimacy, because I think it comes from fear that you start to think well, maybe they 
won’t be around, and if this is the way it’s going to be then I should start preparing 
myself rather than being clingy and wanting to be in their space.  
52 year old woman caring for 55 year old husband with prostate cancer 
Renegotiation of sexual and non-sexual intimacy post-cancer.  Renegotiation of their sexual 
relationship, in terms of non-coital sexual practices, or the development of non-sexual 
intimacy, was reported by 19% of women and 14% of men. Men (12%) were more likely than 
women (1%) to report having developed alternative sexual behaviours to those practiced 
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scores (t(124) = 2.02, p = .04) respectively. Multiple regressions testing the main effect of 
changes to the sexual relationship and interaction terms representing potential moderating 
variables were conducted separately for gender, age, hours of provided direct care, and 
cancer type. No significant interaction effects were found predicting either HADS Anxiety 
or HADS Depression scores.  
 
 B SE B ß 
HADS Anxiety Subscale    
Change in the sexual relationship 1.82 .89 .18* 
    
HADS Depression Subscale    
Change in the sexual relationship 1.68 .83 .18* 
Note: For HADS Anxiety, R2 = .03; For HADS Depression, R2 = .03. * p < .05. 
Table 3. Univariate regression results for change in the sexual relationship upon 
psychological wellbeing (N = 124) 
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3.2 Qualitative results 
One hundred and twenty two partners, including 26 who were bereaved, elaborated on the 
changes to their sexual relationship they had experienced post-cancer, in open-ended 
responses. These responses concerned the status of the sexual relationship, perceived 
reasons for the changes, and partners’ feelings about the changed relationship. Each theme 
is reported below, illustrated by extracts from the questionnaires and the interviews. 
Demographic information is provided for longer quotes stemming from the interviews. For 
readability, these specific details are not provided for every questionnaire and interview 
quote. Percentages cited refer to the open ended questionnaire responses, completed by 122 
participants. 
3.2.1 Status of current sexual relationship 
Two major themes characterised accounts of the current status of the sexual relationship: 
cessation or decreased frequency of sex or intimacy; and re-negotiation of sex or intimacy. 
Cessation or decreased frequency of sex and intimacy. Complete cessation of sex, decrease in the 
frequency of sex, or a reduction in the frequency or quality of intimacy and closeness, was 
reported by 59% of women and 79% of men. The complete ‘end’ of the sexual relationship 
was reported by some participants as a sudden event: “Our sex life disappeared overnight”; 
“Gone from fantastic sex life to none”. For other participants, it was a gradual change: 
“Initially we found other ways to be intimate, however over time our sex life has ceased”. 
The impact of both the cessation of sex, and the loss of intimacy, was evident in the 
following interview extract: 
A big… big chunk of your life is lost, And I don’t just mean the physical aspects of it… I 
mean that’s… you can live with that or you can… or go without, but… the whole 
package is gone and I think that’s hard that, you’re a widow with somebody that’s still 
around. 
57 year old woman caring for 53 year old husband with brain cancer 
Of the participants who reported decreased sexual frequency, rather than complete 
cessation, many positioned their sexual relationship in ways that indicated that they had 
previously enjoyed an active sex life: “We had a very strong physical relationship up until 
the cancer was discovered and after it, it just faded away”; “Very poor, we use to have sex 5 
times a week, now maybe once in 3 or 4 months”. Others simply described a change in 
frequency: “Virtually non-existent”; “This aspect of our marriage has nearly stopped”. 
Many participants also reported decreased closeness and intimacy. Responses included: “…I 
couldn’t cuddle like we used to” and, “Often feel frustrated that it doesn’t happen like it 
used to – he is not as romantic either”. Participants also shared these sentiments in the 
interviews, for example: 
I don’t know whether you just take this huge step back and you’re not feeling that 
intimacy, because I think it comes from fear that you start to think well, maybe they 
won’t be around, and if this is the way it’s going to be then I should start preparing 
myself rather than being clingy and wanting to be in their space.  
52 year old woman caring for 55 year old husband with prostate cancer 
Renegotiation of sexual and non-sexual intimacy post-cancer.  Renegotiation of their sexual 
relationship, in terms of non-coital sexual practices, or the development of non-sexual 
intimacy, was reported by 19% of women and 14% of men. Men (12%) were more likely than 
women (1%) to report having developed alternative sexual behaviours to those practiced 
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prior to the cancer. This consisted of changed sexual positions when attempting intercourse: 
“I am obviously more careful, having adjusted positions”; as well as the development of 
“workable alternatives to achieve partner satisfaction... within restrictions caused by the 
treatments”, including oral sex, massage, masturbation, or the use of a vibrator.  
Women (18%) were more likely than men (5%) to report that re-negotiation involved non-
sexual intimacy, such as hugging and cuddling: “I’d put my legs up on his lap, and he’d put 
his arms around me, and I’d cuddle into him, and we’d watch TV”. 
The last week of my husband’s life, he wanted to make love, but physically could not 
due to his illness. We talked this over as we always did and he knew that hugs, cuddles 
and closeness were far more important than the actual act of making love. 
64 year old woman who cared for 64 year old husband with pancreatic cancer, bereaved 
The importance of this closeness to the well-being of both the partner and the person with 
cancer was emphasized by many of the interviewees. In the excerpt below, one partner 
describes how important it was to maintain physical closeness with her husband, despite the 
significant physical barriers that could have served to restrict the expression of intimacy. 
We deliberately had kept the double bed. And then, when he got sick, and they needed 
a more supportive bed, I brought my single bed in, and we got this special height, set at 
the same height, so that we was always next to me.  … I remember the morning he died, 
I remember cuddling him all night.  (…) Just to have your… to have your arm around 
him was just so, so good.   
59 year old woman who cared for 69 year old husband with mesothelioma, bereaved 
3.2.2 Reasons for changes in sexual relationships 
Many of the participants provided reasons for changes in their sexual relationship post-
cancer. These were: the impact of cancer treatment; exhaustion resulting from the caring 
role; and the re-positioning of the person with cancer as a patient, rather than as a sexual 
partner. 
Impact of cancer treatment.   Participants referred to “cancer” and then specified the impact of 
cancer treatment as the major reason for changes to the sexual relationship. Within this 
theme, reports of physical barriers to sex were reported by 30% of men and 33% of women. 
For some, the physical barriers were directly related to the physical outcomes of cancer 
treatment on sexual functioning, for example: “Hormonal treatment has the effect of 
chemical castration, i.e. my husband has no sexual function”; “her poor body has been so 
cut and chemo has affected her so much that sex is not even possible”; “…non-existent due 
mainly to the chronic pain syndrome and a less than full confidence in colostomy bags!” For 
others, abstinence was due to overall bodily restrictions: “… He is physically unable to 
position himself for sex now”.  
In June an epidural catheter was inserted into my husband’s chest and commenced on 
morphine 30 mgs three times a day. Not only was there no energy or inclination, 
because of the pain and reduced energy, there was now a ‘physical barrier’ to our 
relationship as well as all the side effects of morphine. 
59 year old woman who cared for 56 year old husband with mesothelioma, bereaved 
Many of the participants also described side effects of the treatment such as pain, fatigue, 
and exhaustion. Pain was described thus: “When he is unwell because of treatment I tend to 
be very careful in touching him in case it causes further pain/discomfort”. Descriptions of 
fatigue being given as a reason for changes to the sexual relationship included: “As a result 
of treatment (chemotherapy) my wife is tired more of the time and her libido is reduced”; 
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“He was just too exhausted”. The impact of cancer treatment on the self-esteem and self-
image of their partner was also identified as a reason for changes to the sexual relationship 
in a number of cases. For example, one partner commented that: 
As her health declined she had very low self esteem caused by loss of hair and muscle 
tone. When I did have sex at the beginning she would accuse me of not treating her the 
same as I did in the past and get depressed. 
61 year old man caring for 43 year old female partner with lung cancer, bereaved 
Exhaustion resulting from the caring role.  In citing reasons for changes to the sexual 
relationship, exhaustion resulting from the caring role was positioned as the cause by 16% of 
the women and 9% of the men.  The responses included: “We don’t really have any intimacy 
anymore for reasons including his health and my exhaustion”; “Exhaustion, brain still 
ticking about things to be organised”; “Even if he was still interested in the sexual side of 
our marriage I think I would have been too exhausted to have taken part”. Participants also 
commented on revised prioritisation, centred on coping and survival, leaving no time for 
sex or intimacy.  
…sexual relations of any sort were not an option as I had to be on the go all the time, 
looking after her. My sexual desires, needs or wants were not in my mind. 
62 year old man who cared for 64 year old wife with liposarcoma, bereaved 
Re-positioning of person with cancer as patient.   For 28% of women and 47% of men caring for a 
partner with cancer, the caring role was reported to have resulted in a re-positioning of the 
person with cancer as a patient, which subsequently influenced their sexual relationship. 
Many partners described emotional effects of the caring role, or concern for their partner’s 
feelings and health status. Comments included: “With all the worry and stress that my 
husband is most likely to die, I now have very little desire for sex”; “Curbed by concerns 
about inflicting pain or discomfort”;  
I just wanted to treat her the same as I always did but I couldn’t get the thought out of 
my head that she was terminally ill.  
61 year old man caring for 43 year old female partner with lung cancer, bereaved 
Participants also reported a redefined role or status as carer rather than lover. Examples 
included: “My role as a carer has overridden my role as a wife…”; “Having to spend more 
time on house/garden chores and be carer/nurse, one feels more like a housekeeper than a 
lover”. 
When you are a carer it’s hard to be a lover, for either party, when dealing with 
incontinence of both bowel and bladder infections, along with the daily grind of 
showering, dressing, shaving, etc, then transferring from bed to wheelchair and return. 
59 year old woman who cared for 63 year old male partner with haematological cancer, bereaved 
A number of male participants gave accounts which suggested sex was ‘inappropriate’ with 
a person with cancer: “I was very aware of my role as carer and never did anything to 
embarrass my wife. There was never any inappropriate behaviour”. This could result in 
ambivalent feelings in the face of the partners’ own desires.  
I feel disgusted with myself that I would inflict sex upon a dying woman, having said 
that my wife does not object and occasionally welcomes it, saying it is a life giving and 
loving act and a part of our sacrament…. I was never a fast lover, but now I try and get 
it over and done with for her. 
45 year old man caring for 44 year old wife with breast cancer 
In the interviews, a number of the women participants also described now positioning their 
partner as a child, which was antithetical to sexuality:  
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it’s like looking after …one of your children now.  That’s the feelings that you have, you 
know, you don’t have any ..sexual feelings for your children … (so) I just don’t have 
them anymore. 
57 year old woman, caring for 53 year old husband with advanced brain cancer. 
3.2.3 Partners’ feelings about their changed sexual relationship 
In the open-ended questions, a number of the participants made comments about the 
emotions they experienced in response to these changes in their sexual relationship post-
cancer. These were evenly divided between positive and negative responses. 
Positive responses.   Positive accounts were provided by 17% of women and 16% of men. 
Within this theme, participants described feelings of understanding or acceptance of the 
effects of cancer or caring on their sexual relationship.  
Treatment makes my partner feel sick and makes me worry about him so this means we 
don’t feel up to sex… This is not an issue – just a fact/reality of current situation. 
39 year old woman caring for 53 year old male partner with lung cancer 
A number of participants also reported affection and companionate devotion:  
Sexual urge had gone but my husband made me feel the most loved and cared for 
woman on this earth by his loving actions, his consideration, his caring attitude and the 
advice I sought even up till 12 hours before he died. I loved this man totally and he me. 
68 year old woman who cared for 69 year old husband with brain cancer, bereaved 
In the interviews, a number of participants reported that the cancer experience had actually 
brought them closer together, with one man saying he “probably has a more affectionate 
relationship at this point in our lives, and marriage” than prior to the onset of cancer, and 
another commenting “with the exclusion of sex, our intimacy is closer probably than it’s 
been for a long time”. A third male participant said that whilst he and his wife “haven’t had 
sex (intercourse) as frequently”, he feels that his relationship is “better”, he feels “happier”, 
and feels as if he is a “more attentive partner” and a “better father”. Increased emotional 
closeness, despite absence of sex, was also evident in a number of the women participants’ 
interviews:  
We are so much closer now than we were….we wouldn’t be as close now and we 
wouldn’t be able to talk about absolutely anything now…Just seeing him at night, just 
makes my heart just go hshshsh….  Whereas before I don’t think we appreciated that 
about each other.   
29 year old woman caring for 33 year old husband with brain cancer 
Negative responses.   Negative feelings were reported by 13% of the women and 21% of the 
men who said that there had been a change in their sexual relationship. These responses 
included self-blame, “No sex for 12 months – more my fault”, and rejection by their partners 
“I felt excluded and unwanted. Sex became a chore and mechanical”; “She has absolutely no 
sexual interest in me whatsoever”. A number of woman participants also expressed 
rejection toward their partners:  
I don’t feel the desire to have a physical relationship with my husband. It almost makes 
me feel ill to even contemplate it. His whole physical appearance repels me. 
52 year old woman caring for 55 year old husband with prostate cancer 
Participants also reported lack of fulfilment in relation to sex: “Not able to relax and enjoy”; 
“Often feel frustrated that it doesn’t happen like it used to”; “At times, I have considered 
having an affair purely for sexual gratification”. 
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 …leaves me less satisfied – there was a time shortly a few weeks after she was 
diagnosed with breast-bone cancer where I found it hard to orgasm/ejaculate – I would 
fail twice after some minutes, then succeed the next day. 
45 year old man caring for 44 year old wife with breast cancer 
Some participants mentioned feelings of perceived obligation. For men, it was usually in 
relation to feeling that their partner felt obliged to provide sex. Examples included: “On the 
infrequent occasions we now have sex she wants it over and done with as quickly as 
possible”; “She became less interested in sex and only accommodated me as if it was a wifey 
duty”. For women participants, obligation was positioned in terms of themselves feeling 
obliged to engage in sex. 
At the early stages of the diagnosis I felt that I couldn’t say no to him which put a lot of 
pressure on me. I had to make sure that I could respond to him and not give him any 
chance of feeling that I didn’t want to make love to him. 
 59 year old woman caring for 63 year old husband with gastric adenocarcinoma 
A small number of women participants shared negative feelings regarding family planning 
and fertility: 
Prostate cancer has required removal of the sac that produces sperm. I am 36 and had 
always taken for granted I would fall pregnant in the most natural and intimate way. 
Once my partner is stronger, we will seek advice from an IVF Clinic regarding artificial 
insemination (hence my partner has secured enough in the sperm bank!). Still this 
whole traumatic experience has left me feeling very upset. 
36 year old woman caring for 59 year old husband with prostate cancer 
Some participants reported feeling angry that their sexual relationship was ‘lost’, as one 
woman commented, “(I’m) so much crosser…because a big part of our relationship had just 
gone out the window”.  Sadness at the loss of their sexual relationship was also evident in 
many of the accounts: “There is just an enormous sadness that we can no longer have this 
intimacy…”; “Still this whole traumatic experience has left me feeling very upset”; “it’s 
profound sadness, I mean very, very sad”, resulting in feeling “terribly fragile and 
vulnerable and sad, and so sorry that it was all going”. 
3.2.4 Discussions of sexuality with health professionals 
In response to a question regarding whether there had been discussion of sexuality with a 
health professional, 20% of partners indicated that there had. The rate of discussion differed 
across cancer types, ranging from 50% of prostate cancer partner carers, to 0% of respiratory 
cancer. The rates across the other main cancer types were: 33% brain; 33% pancreatic; 30% 
breast; 29% gynaecological; 20% multiple – sexual; 17% colorectal/digestive; 17% 
mesothelioma; 15% multiple – non sexual; 15% other; and 9% haematological. Of those who 
had discussed sexuality with health care providers, 30% stated that they were not at all or 
not very satisfied, 33% said that they were neither satisfied nor dissatisfied, and 37% 
indicated that they were satisfied or very satisfied.    
In the interviews, a number of the partners commented on their discussions with health 
professionals, in each case giving a critical account. When they asked about sexual matters, 
partners reported being told “Oh you don’t need to know that and things like that”, or told 
that they were “irresponsible to be thinking about having children” in raising fertility as a 
concern. The majority, however, gave accounts of sexuality not being discussed at all:  “I 
haven’t got a lot of medical advice about how we should continue to conduct our intimate 
relationship”; “they did not educate us on anything… at all”.   
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partners reported being told “Oh you don’t need to know that and things like that”, or told 
that they were “irresponsible to be thinking about having children” in raising fertility as a 
concern. The majority, however, gave accounts of sexuality not being discussed at all:  “I 
haven’t got a lot of medical advice about how we should continue to conduct our intimate 
relationship”; “they did not educate us on anything… at all”.   
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it’s not properly addressed by the medical profession, it is just completely glossed over. 
And I can remember, you know, we were sitting when the diagnosis came through and 
the guy said well, you know, you’ll get these hormone pills and we’ll give you an 
injection into your stomach and of course that will be the end of your sex life; and we’re 
just sitting there (…) That was the end of the discussion. 
67 year old woman who cared for 85 year old husband with prostate, bowel, and lung cancer, 
bereaved. 
4. Conclusion 
This study examined changes to sexuality following the diagnosis and treatment of cancer, 
as well as the impact of such changes on psychological well-being, for informal carers who 
were the partner of a person with cancer. The mixed method design allowed for the extent 
and impact of changes to sexuality post-cancer to be measured using quantitative measures, 
and subjective experience of changes to sexuality to be evaluated using open-ended 
questionnaire items and interviews. Within a Critical Realist epistemological standpoint, 
each methodology is treated as equally valid in providing insight into the phenomenon 
under investigation. 
 The majority of participants reported that the cancer experience had impacted on their 
sexual relationship, resulting in a cessation or reduction of sexual activity, with only a 
minority renegotiating sexual intimacy post-cancer. This supports previous research which 
demonstrated that the impact of cancer and cancer treatment extends beyond the person 
with cancer (Baider et al., 2000, Gurevich et al., 2004, Juraskova et al., 2003, Maughan et al., 
2002, Rolland, 1994, Walsh et al., 2005), reinforcing the need for acknowledgement of the 
sexual and intimate needs of partners, as well as of people with cancer. Rather than 
restricting our sample to partners caring for person with cancer affecting the reproductive 
areas of the body, we examined changes to sexuality post-cancer across a range of cancer 
types. The majority of participants who were providing support to a person with prostate, 
breast or gynaecological cancer cited an impact, confirming previous research (Maughan et 
al., 2002, Harden et al., 2002, Sanders et al., 2006). However the finding that a high 
proportion of partners of a person with ‘non-sexual’ cancer also reported changes highlights 
the pressing need to attend to and further investigate the sexual concerns and needs of all 
partners who care for a person with cancer.   
The finding that partners who reported changes in sexuality post-cancer reported 
significantly higher levels of depression and anxiety than those who reported no sexual 
changes, adds support to the notion that sexuality is associated with cancer carers’ quality of 
life and psychological well-being (Foy et al., 2001). Depression and anxiety may be a cause, 
or a consequence, of changes in sexuality post-cancer; further research is needed to examine 
this issue in more depth, looking at the factors which may moderate and mediate changes to 
the sexual relationship in cancer carers and their partners, as well as the consequences of 
such changes for the couple. Future research would also benefit from examining changes in 
sexuality and their impact across cancer stage, which was not possible in the present study 
due to the low numbers participants caring for someone with early stage cancer.  
Whilst gender was not a significant moderator of impact of changes to sexuality on 
psychological well-being, there were some gender differences in the accounts of the nature 
of changes to the sexual relationship post-cancer. Reports of complete cessation of sex were 
more common for women than men, and very few women gave accounts of developing 
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alternative sexual practices if intercourse was no longer possible. This could be attributed to 
women being more likely to assume that they should subordinate their own needs to the 
needs of their partner (O'Grady, 2005), and to cultural constructions of normative 
heterosexuality which expect men to initiate sex (Ussher, 1997b). Previous research has 
found that partners are reluctant to initiate sexual intimacy if the person with cancer does 
not initiate (Maughan et al., 2002), and that heterosexual women partners do not wish to 
initiate sex, or discuss alternatives to coital sex, for fear of emasculating their partner if he 
can not ‘perform’ through sexual intercourse (Boehmer et al., 2001). This is consistent with 
research that has demonstrated that sexual performance is positioned as central to 
heterosexual constructions of ‘manhood’, with failure having negative consequences in 
terms of a man’s sense of self (Tiefer, 1994).  
Equally, the ‘male sex drive discourse’ which positions men as ‘needing’ sex (Hollway, 1989, 
Potts, 2002), may result in the sexual needs of male partners being classified by either or 
both members of the couple as being ‘important enough’ for sex to continue post-cancer, or 
for alternative sexual practices to be developed, in contrast to women partners who were 
more likely to report that re-negotiated intimacy was non-sexual. The phallocentric bias 
evident in the research and clinical literature on cancer and sexuality (Hyde, 2006), which 
serves to reinforce the notion that ‘normal’ sex = coitus, and emphasises sexual ‘functioning’ 
with little attention to alternative practices, needs to be challenged, as this potentially plays 
a significant role in the construction of truths about sexuality which people with cancer and 
their partners take up, limiting their exploration of alternatives to coitus post-cancer. 
However, in the present study, four of the six lesbian partners all reported complete 
cessation of sex, suggesting that even couples positioned outside of a heterosexual matrix 
(Butler, 1990) can experience changes to sexuality post-cancer.  
Whilst previous research has attributed changes in sexuality and intimacy post-cancer to the 
physiological effects of cancer or cancer treatment, a finding confirmed by many of the 
accounts in the present study, our findings also showed that the caring role also had an impact 
on the sexual relationship (Hawkins et al., 2009). Participants who reported changes in 
sexuality post-cancer reported significantly higher scores on the disrupted schedule sub-scale 
of the Caregiver Reaction Assessment Scale, suggesting aspects of burden of care were 
associated with such changes. In the interviews and open ended questions, these participants 
also associated sexual changes with stress, fatigue and exhaustion, revised prioritisation 
centred on coping and survival, and a redefined status as carer rather than lover. Past research 
that has explored carers’ experiences of stress and exhaustion primarily focuses on the impact 
upon carers’ general health and well-being. For example, Brown and Stetz (1999, p. 186) found 
that the initial period of ‘becoming a caregiver’ is particularly stressful, as carers are focused 
not only on their new role, but also have to ‘face the present’, negotiate their choice/or lack 
thereof to care, develop competency around their caring tasks, and evaluate their future. It is 
important to further investigate how the stresses involved in being a caregiver impact upon a 
carer’s sexuality, and how this may in turn impact on quality of life (Foy et al., 2001). The 
finding in the present study that women were more likely to report that exhaustion had an 
impact on sexuality is in line with previous research which found that women cancer carers 
experience greater personal costs from caring (Lutsky et al., 1994, Ussher et al., 2008). As these 
personal costs have been found to be associated with higher rates of depression and anxiety, as 
well as lower life satisfaction and quality of life ratings, (Hagedoorn et al., 2000, Bookwala et 
al., 2000), it is a serious health issue.  
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The impact of the re-positioning of the person with cancer as ‘patient’ or ‘child’, rather than 
as ‘lover’, is an important issue which requires further investigation. The finding that the 
physical symptoms of cancer, or the physical tasks associated with cancer caring, makes it 
difficult for many carers to continue to see their partner as a sexual person, confirms 
patterns found in other spheres of health care (Parker, 1990, Pope, 1999). This assignment of 
individuals with cancer with a ‘sick’ or ‘childlike’ identity, which is antithetical to an 
identity as a person with sexual desires and needs, can significantly impact on the sexual 
and intimate relationship of a couple facing cancer (Kelly et al., 1996). Sex can be positioned 
as ‘inappropriate’, or as a ‘frivolous activity’ (Holmberg et al., 2001), resulting in carers 
experiencing guilt in the face of their own sexual needs or desires, and the avoidance of any 
discussion or re-negotiation of sexual practices, as was reported in the present study. This 
could be seen as one aspect of a broader practice of self-silencing in cancer carers, where the 
needs of the carer are repressed, because the person with cancer has to be put first (Ussher et 
al., 2010). However, it is also associated with cultural discourses which position people with 
cancer as having limited sexual needs, or as asexual (D'Ardenne, 2004, Schildrick, 2005), 
resulting in a different set of norms being applied to what is acceptable behaviour (Wellard, 
1998). The finding that male partners were more likely to report an impact of re-positioning 
the person with cancer as a patient may result from the role of carer being a more unfamiliar 
position for men to take up, given the congruence between femininity and the caring role 
(O'Grady, 2005). It may thus be more difficult for men to eroticize a partner with cancer who 
is in need of care. This matter is worthy of further investigation in future research.  
As the majority of partners positioned these changes to their sexual relationship as 
problematic, confirming previous research (Kuyper et al., 1998, Perez et al., 2002, Reichers, 
2004, Soothill et al., 2003, Thomas et al., 2002), this suggests that education and information 
about sexuality post-cancer which challenges myths and provides a framework for re-
negotiation of sexual relationships, needs to be included in supportive interventions for 
partner carers. At present, there is a dearth of research in this area, with no published 
research examining cancer carer interventions with a sexual component (see Harding et al., 
2003). The finding in the present study that some partners reported increased closeness and 
intimacy emphasises the importance of helping couples to re-negotiate intimacy and 
sexuality post-cancer, as well as the importance of recognising, and reinforcing, the rewards 
of cancer caring (Hudson et al., 2005, Sinding, 2003). 
Whilst it has been recognised that health professionals need to discuss issues of sexuality 
and intimacy with patients in cancer and palliative care (Initiative, 2003), the findings of the 
present study confirm previous research which found that these discussions are not taking 
place for the majority of people with cancer or their partners (Stead et al., 2002), particularly 
for those outside the sphere of prostate cancer. Even when sexuality was discussed, this was 
not at a level which was satisfactory to the majority of participants in the present study. This 
confirms recent Australian research which reported mis-matched expectations and unmet 
needs in relation to communication about sexuality between health professionals and 
individuals with cancer (Hordern et al., 2007a, Hordern et al., 2007b), suggesting that further 
education and training of health professionals is required, in order that they will be able to 
advise couples affected by cancer on issues of sexuality and intimacy, and address their 
unmet needs in this arena (Rees et al., 1998). Without the legitimacy of being able to discuss 
potential or actual disruptions to the sexual relationship with a health care professional, 
partners may feel that they cannot discuss such issues with the person with cancer, and as a 
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result, may experience sadness, anger, and isolation (Gilbert et al., 2008), as was reported by 
many of the participants in the present study.  
A number of methodological issues need to be considered when evaluating the findings of 
this research. Firstly, the issue of selection bias needs to be examined. The present study 
used self-selection in response to advertisement or information sheets distributed by cancer 
organisations or clinics, and thus may not have tapped a representative sample of informal 
cancer carers. Indeed, as noted above, future research in this field needs to systematically 
examine sexuality post-cancer across cancer stage. However, there was a good distribution 
across cancer type, gender and age-group, in contrast to many previous studies of cancer 
and sexuality which focussed solely on cancers affecting the sexual organs. Equally, as the 
participants were recruited for a general study on cancer caring, answering questions on 
sexuality as part of a broader questionnaire or interview, it could be argued that we have 
recruited individuals who would not usually respond to requests to take part in a research 
study on sexuality, and thus have obtained a broader sample for our research. Secondly, this 
study did not use standardised measures of sexual functioning, sexual or relationship 
satisfaction, but rather focussed on subjective reports through open ended questionnaire 
items or interview. Future research in this field could usefully adopt these standardised 
measures along side qualitative measures, to allow for greater triangulation of data, in 
evaluating of the extent and impact of changes to sexuality post-cancer. Thirdly, the cross 
sectional design meant that all assessment of change were retrospective. A longitudinal 
design would more effectively allow for the evaluation of changes to sexuality across cancer 
stage, and allow pre-post cancer treatment changes to be evaluated more thoroughly. 
In conclusion, sexuality and intimacy are central aspects of quality of life that have often 
been neglected in examinations of the well-being of partners of a person with cancer. The 
findings of the present study add further support to the suggestion that sex should not be 
positioned as ‘inappropriate’ or ‘trivial’ in the context of cancer care, but rather be 
recognised as an aspect of couple relationships which is associated with well-being (Cort et 
al., 2004). Having health care professionals legitimate sexuality by ‘giving permission’ for 
couples to be sexually active or physically intimate when undergoing and recovering from 
treatment for cancer is one of the key strategies that could assist in this repositioning 
(Schwartz et al., 2002). The positive consequences of this may include increased feelings of 
well-being on the part of the partner carer, and closeness between the couple, which will 
have positive consequences for the physical and psychological well-being of the person with 
cancer (Hodges et al., 2005), the central aim of professional cancer care. There is thus no 
justification for sexuality and intimacy being ignored or dismissed: partner cancer carers are 
telling us that it is important, it is time for health professionals to recognise this need and to 
act accordingly.  
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1. Introduction 
Cancer (medical term: malignant tumor) is a major global health problem and a life-
threatening disease that accounts for ~13% of all deaths annually. The number of cancer 
deaths gradually increases year by year, and it is estimated that more than 11 million people 
will die from malignances in 2030. Various definitions of cancer have been proposed over 
the last few decades. In general, cancer displays several malignant features including the 
uncontrolled proliferation of abnormal cells, local invasion of normal tissue, and metastasis 
to a distant organ via the circulatory or lymphatic system. Environmental and genetic 
factors are considered to be the major causes of cancer. Cancer is believed to originate from 
a single normal cell through a multistage transformation that is assumed to take decades of 
development. Continuous exposure to some environmental factors (e.g., tobacco, unhealthy 
diet, radiation, chemical toxins, viruses, etc.) can potentially interact with gene changes in 
our bodies to enhance the formation of cancer (see http:// www.who.int/mediacentre/fac 
tsheets/ fs297/en/index.html). 
Conventional treatments include surgical resection, chemotherapy, and radiotherapy. 
Although these series of interventions can effectively control localized or disseminated 
tumors, there is still a high rate of metastatic recurrence, thus limiting a patient’s survival. 
Other strategies, such as immunotherapy, cytokine therapy, and adoptive cell therapy, have 
shown some promising results for malignances in animal models. Unfortunately, several 
phase I/II clinical trials have shown that most patients still fail to completely eliminate 
cancer (Aldrich et al., 2010). It is becoming increasingly clear that cancer cells express 
immunogenic antigens that can induce an effective immune response against tumor 
formation (Lowe et al., 2007); therefore, during the initial stages of disease, cancer cells 
could essentially be recognized and rejected by the immune system, which exerts host-
protective and tumor-modeling actions on developing tumors. Nonetheless, cancer cells also 
have numerous mechanisms to evade immunosurveillance (Burnet, 1970; Dunn et al., 2002), 
such as the downregulation of major histocompatibility complex (MHC) molecules or the 
antigen processing and presentation machineries, increasing the secretion of inhibitory 
cytokines, and the expression of inhibitory molecules to induce apoptosis in tumor-specific 
T cells (Dunn et al., 2004; Ferrara et al., 2003; Gabrilovich et al., 1996). On the basis of these 
phenomena, countless studies have confirmed the hypothesis that breaking self-tolerance 
and priming T lymphocytes are essential to treat cancer. Here, we discuss another possible 
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immunosurveillance evasion mechanism in which the immune system fails to eliminate 
tumors not because tumor antigens are absent, but rather that an inappropriate proportion 
of T lymphocytes with an “accelerated immunosenescence” status are present in cancer 
patients (Chen et al., 2010). Although cancer patients are often considered to have poor 
immunity, very few attempts have been made to examine the dysfunctional immune profile 
of these patients in detail. Thus, it is not surprising that there is a vast discrepancy in the 
responses of cancer patients to immunotherapy. This chapter will cover selected aspects of 
cancer-associated immune deficiency, emphasizing the cause and effect of accelerated 
immunosenescence in cancer patients. A better understanding of the immune profiles of 
cancer patients may inform more successful therapeutic strategies for the treatment of 
malignancies. 
2. Cancer-related immune deficiency 
When patients are diagnosed with cancer, a phenotypic classification might be very useful 
to evaluate their immune status and track the progression of the disease. The immune 
system exhibits characteristic changes during cancer growth and progression, and these 
changes are significant in some specific T-cell populations. Compared with normal 




Fig. 1. Immune profiles of cancer patients over the disease progression. A significant trend 
of decreasing functional T-cell populations including CD4, CD8, CD4:CD8 ratio, naïve T 
cells with the progression of cancer, and the accumulation of memory T cells and 
dysfunctional populations such as CD28- and CMV-specific T cells are observed in cancer 
patients. The decreased expression of IL-7R in cancer patients could be associated with 
underlying inflammatory cytokines, e.g., IL-6, and CMV reactivation. 
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2.1 Inverted CD4/CD8 ratio 
The antitumor immune responses are predominantly governed by the cell-mediated 
immunity. CD4 and CD8 T cells are the main types of lymphocytes in cell-mediated 
immunity and play a central role in the induction of efficient immune responses against 
tumors (Ho et al., 2002; Pardoll & Topalian, 1998; Toes et al., 1999). There are 2 different 
subsets of CD4 T cells, helper T cells (TH cells) and regulatory T cells (Treg cells), each with a 
different function. Once activated, TH cells mediate the activation of CD8 T cells. 
Conversely, Treg cells attenuate the immune reaction to maintain immunotolerance and 
suppress autoreactive T cells (Buckner, 2010). CD8 T cells, which are also called cytotoxic T 
cells (Tc cells), directly kill cancer and infected cells. Since CD4 TH cells play an important 
role in optimizing CD8 T cells activation, an adequate number of CD4 TH cells is therefore 
required to sustain the effector function against tumor cells by CD8 T cells. 
In normal adults, CD4 and CD8 T cells each constitute well over 20% of the total lymphocyte 
population, whereas the proportion of these cells in cancer patients is lower and appears to 
decline according to the cancer stage (Chen et al., 2010; Mozaffari et al., 2007). An 
inadequate amount of T cells indicates that cancer patients cannot generate a sufficient 
immune response, resulting in an increase in the frequency and severity of infectious 
diseases. The ratio of CD4/CD8 T cells has indeed been used as an indicator for evaluating 
an individuals’ immune function. In general, the CD4/CD8 ratio in healthy people is often 
>1; nonetheless, in patients with terminal cancer, this ratio drops significantly. Thus, an 
inverted CD4/CD8 ratio in cancer patients is one of the T-cell immune risk phenotypes 
(IRP) that is associated with increased morbidity and mortality (Wikby et al., 1998). 
2.2 Subpopulation shifts in the T cells 
The pattern of T cells differentiation may also serve as an important indicator for evaluating 
immune status in cancer patients. Naïve T cells are thought to be quiescent and capable of 
recognizing novel antigens (from tumor cells or pathogens) presented by antigen-presenting 
cells (APCs) to initiate the so-called adaptive immune response. Upon additional antigenic 
stimulation, primed T cells may start further differentiation leading to the clonal expansion 
of antigen-specific cells capable of executing immune response. Most of the activated T cells 
die rapidly through apoptosis; however, some may differentiate into memory T cells and 
survive for a long period of time. Once memory T cells encounter the same antigen, they 
will restart a faster and stronger immune response than the naïve T cells. Thus, it is of 
crucial importance for the immune system to have sufficient amounts of naïve T cells to 
respond to a variety of novel antigens. 
In humans, the expression patterns of C-C chemokine receptor 7 (CCR7) and leukocyte 
common antigen isoform (CD45RA) are associated with the naïve, memory, and effector 
function of human T cells (Fig. 2, upper panel) (Sallusto et al., 1999). In general, naïve T cells 
express CCR7+ and CD45RA+. Effector T cells, in contrast, have a CCR7- and CD45RA+ 
phenotype. Memory T cells can be further divided into 2 sub-populations according to the 
differential expression of CCR7. CCR7+ T cells can be considered as precursors of the CCR7– 
subgroup. CCR7+ T cells are identified as central memory (CM) cells that secrete the 
cytokine interleukin 2 (IL-2), while the CCR7– population has been referred to as effector 
memory (EM) cells that predominately express interferon ( IFN-) and interleukin-4 (IL-4). 
Both subgroups provide immunologic memory. TCM cells generally localize in lymphoid 
tissues and generate a rapid and vigorous immune response when an identical antigen is 
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encountered, whereas TEM cells patrol peripheral organs where they may also reach local 
lymph nodes through afferent lymph vessels (Mackay et al., 1990). It has been shown that 
TCM cells have a superior anti-cancer killing function than TEM cells. (Klebanoff et al., 2005) 
The distribution of T-cell subpopulations varies substantially in patients with cancer, from 
being normal in some early-stage to being increasingly disturbed at more advanced disease 
and in those whom have undergone chemotherapy. Typically, patients have a relative 
shrinkage of early T cells populations including the naïve and TCM cell, but an increased 
proliferation and differentiation toward TEM and effector T cells, one of the characteristic 
features of T-cell exhaustion (Klebanoff et al., 2006) (Fig. 2, lower panel). The distribution of 
 
 
Fig. 2. Alteration of T-cell subpopulations in advanced cancer patients. The expression of the 
phenotypic markers CD45RA and CCR7 was used to define naïve, central memory, effector 
memory, and effector subpopulations (upper panel). The relative proportions of T-cell 
subpopulations in normal individuals and advanced cancer patients (lower panel). N, naïve 
T cells; CM, central memory T cells; EM, effector memory T cells; E, effector T cells. 
T-cell subsets in cancer patients may explain the abnormal immune status that they suffer 
from: inadequate naïve and TCM cells cause a shortage in the source of T cells with higher 
plasticity, while the accumulation of TEM cells without appropriate TH cells to prime an 
efficient immune response causes immune exhaustion. Another possible explanation has 
been advanced in which the T-cell pool shrinks as dysfunctional T cells accumulate and 
compete for survival with naïve and TCM cells. While the total size of the T-cell pool remains 
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unchanged, some memory T-cell subsets that are present at a low frequency may be lost 
(Akbar et al., 2004). These phenomena indicate that a patient’s immune status is unfavorable 
against cancer. This is especially evident in advanced disease, particularly in patients 
extensively treated with chemotherapy. The immune system of such patients would suffer 
from chronic stimulation by relentless release of tumor or viral antigens resulted from 
disease progression and treatment. In time, this may lead to the impairment of naïve T-cell 
differentiation and a failure of adequate effector and proliferative capacity. Similar 
phenomena are observed in some chronic virus infection systems in humans (e.g., human 
immunodeficiency virus, and hepatitis C virus, etc.). Despite a vigorous immune response 
and subsequent generation of memory T cells in the early stages of viral infections, continue 
virus stimulation may serve as a driving force for the generation of virus specific T-cells. 
However, the activity of such T-cells is gradually lost during the persistent virus infection, 
eventually leading to the accumulation of exhausted T cells (Letvin & Walker, 2003; 
Pantaleo & Koup, 2004; Rehermann & Nascimbeni, 2005). 
2.3 Down-regulation of CD28 on T cells 
In general, the initiation of T-cell activation requires at least 2 signals. Antigen presenting 
cells (APCs) uptake foreign antigens (from tumor cells or infectious materials) and then 
present antigenic peptides that are bound to class I or class II MHC molecules to form the 
peptide-MHC complex. This complex and specific T-cell receptor (TCR) engagement 
provide a recognition signal (signal 1) for the activation of naïve T cells. However, signal 1 is 
not sufficient to fully activate an immune response on its own. Having received signal 1, the 
interaction of a co-stimulatory molecule with its ligand provides the verification signal 
(signal 2) (Allison, 1994; Liu & Linsley, 1992). Without signal 2, T cells will enter the anergy 
state (Harding et al., 1992; Mueller et al., 1989). CD28 is one of the co-stimulatory molecules 
on the surface of T cells and a critical component of the adaptive immune response against 
infections and tumors. Furthermore, naïve and TCM cells express CD28 on their cell surface, 
whereas TEM and effector T cells are predominantly CD28- (Pawelec et al., 2009). CD28 
provides a co-stimulatory signal to interact with B7 molecules expressed on APCs and 
amplifies the signals delivered via the TCR, including increased cytokine expression, 
promotion of T-cell proliferation, and survival (Okkenhaug et al., 2001; Viola et al., 1999). 
With cancer progression, the surface expression of CD28 on T cells is gradually 
downregulated, resulting in the accumulation of CD28- cells in the CD4 and CD8 T-cell 
populations. These cells, which are so-called senescent cells, have shortened telomeres, thus 
limiting the proliferative potential (Effros, 1997; Valenzuela & Effros, 2002) and may become 
apoptosis resistant (Brzezinska et al., 2004; Posnett et al., 1999). These indicate that cancer 
patients have a higher than normal proportion of mature T cells that are incapable of 
undergoing further differentiation. In addition, there is an irreversible loss of CD28+ cells, 
the proliferation of which is either limited or has ceased completely during APC priming. 
This, in turn, may result in hyporesponsive immunity in cancer patients. Thus, it would 
appear that further T-cell clonal expansion is inhibited in patients with advanced stage 
cancer. An important concept in immunotherapy is that CD28 cells are necessary for T cells 
to interact with APCs and proliferate effectively; therefore, the down-regulation of CD28 in 
patients with advanced disease suggests that attempts at immunotherapy, such as dendritic 
cell vaccines, may not be very effective as they simply may not have enough CD28+ T cells 
left to mount an adequate response to the antigen introduced by the vaccine. 
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2.4 Lower interleukin-7 receptor  chain (IL-7R) expression 
Interleukin-7 (IL-7) is a pleiotropic cytokine that preferentially maintains B, natural killer, 
and T-cell survival and homeostasis (Kim et al., 2008; Kittipatarin & Khaled, 2007; Surh & 
Sprent, 2008). It shares the use of the interleukin-2 receptor  chain (IL-2R) with interleukin 
2 (IL-2), but has its own IL-7R. IL-7R is mainly expressed by all naïve T cells (Fry & 
Mackall, 2005). IL-7R+ T cells enhance their proliferation in response to homeostatic signals 
compared with IL-7R- cells. In cancer patients, the decrease in the naïve T-cell population 
has been found to be associated with the down-regulation of IL-7R, but not the plasma IL-7 
level. Furthermore, the expression of IL-7R in naïve CD4 T cells is significantly lower than 
in naïve CD8 T cells. This may partly explain why CD4 is also at a lower level than CD8 in 
cancer patients. The mechanism underlying the down-regulation of IL-7R remains poorly 
understood. Some investigators suggested that the accumulation of TEM cells and 
prosurvival cytokines, such as interleukin-6 (IL-6), may suppress the expression of IL-7R 
(Park et al., 2004; van Leeuwen et al., 2005). Indeed, plasma IL-6 levels are higher in cancer 
patients than in healthy individuals, suggesting a possible association with the down-
regulation of IL-7R. Another possible explanation is that the down-regulation of IL-7R 
might be caused by a persistent viral infection as many persistent virus-specific T cells lack 
IL-7R (Wherry et al., 2004). In an in vitro study, van Leeuwen and colleagues showed that 
IL-7R- T cells fail to respond to IL-7, but survived and expanded after TCR stimulation. 
Therefore, it is suggested that IL-7R- T cells specific for persisting viruses are maintained 
via their intermittent contact with antigens derived from the latent virus (van Leeuwen et 
al., 2005). IL-7R- T cells may thus survive and accumulate in cancer patients because they 
are regularly triggered by antigens released during chemotherapy or due to the reduced 
immune status and, therefore, do not depend on IL-7 for their survival. Consequently, 
antigen-experienced effector and memory T subsets are replaced by expanded clones of cells 
that display a late differentiation phenotype, especially the CD8 subset. Likewise, the 
repertoire of cells available to respond to novel antigenic challenges shrinks. 
2.5 Higher IL-6 production 
IL-6 is one of the pro-inflammatory cytokines, e.g., interleukin-1  (IL-1, tumor necrosis 
factor- (TNF-, and IFN-, which regulate immune reactions to tissue damage and lead to 
inflammation (Kishimoto, 2010). IL-6 has been found to be a “two-edged sword＂ in a 
variety of human tumors, in that it can switch from behaving as a paracrine growth inhibitor 
to behaving as an autocrine growth stimulator with the same cells during malignant tumor 
cell proliferation (Knupfer & Preiss, 2007). Cancer patients often have prominent circulating 
levels of IL-6, but not TNF- and IFN-, compared with the levels in healthy individuals. 
However, the source of the circulating IL-6 in patients is not clear, but it may be produced 
by macrophages and T cells reacting to the tumor or by the tumor itself (Ebrahimi et al., 
2004). Recent reports showed a correlation between increased serum levels of IL-6 and 
advanced stage metastatic disease and poor outcomes in other types of cancer (Bellone et al., 
2006). On the other hand, IL-6 is considered a crucial pro-inflammatory cytokine in 
immunosenescence and involved in induction acute-phase of C-reactive protein (CRP) in the 
liver that is associated with the increased morbidity of elderly (Krabbe et al., 2004; Wikby et 
al., 2006).  
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2.6 Human cytomegalovirus (CMV) reactivation and CMV-specific CTLs 
CMV is a highly prevalent herpes virus that is chronically carried by more than 70% of the 
world’s population (Rawlinson, 1999). It appears to be the most immunodominant antigen 
confronted by a carrier’s immune system throughout life. The primary CMV infection 
usually occurs early in childhood, but seldom causes severe disease, and was long thought 
not to be a major human pathogen. However, the virus has mechanisms to evade immune 
surveillance and survive in an immunocompetent host. Once infected, the virus hides in the 
human body and the immune system is unable to eliminate it completely. A hallmark of 
latent CMV infection is its capacity to induce recurrent disease, mainly in 
immunocompromised individuals. Patients at high risk for reactivation of latent CMV 
include those with a human immunodeficiency virus infection, malignancies, organ 
transplant, or on immunosuppressive therapy (Alberola et al., 2001; Chemaly et al., 2004; 
Limaye et al., 2001). It has been suggested that CMV-specific effector T cells accumulate 
with aging in such large numbers that they may be the dominant T-cell population in the 
peripheral blood of healthy elderly individuals. In fact, CMV-specific CD8 T cells in such 
individuals may constitute as much as 50% of the entire CD8 T-cell repertoire (Khan et al., 
2002). 
In cancer patients, over 50% of patients on cancer chemotherapy experience CMV 
reactivation during the course of chemotherapy (Han, 2007; Kuo et al., 2008; Ogata et al., 
2011), with the average viral load peaking after the third course of treatment (Kuo et al., 
2008). Furthermore, CMV-specific IgG titers are simultaneously elevated with the increase in 
virus load. In addition, the clonal expansion of CMV-specific CD8 T cells is also observed in 
cancer patients; however, these cells are predominantly CD28-, indicating that the expanded 
CMV-specific T-cell clones are terminally differentiated cells, i.e., essentially hyporesponsive 
to CMV (Chen et al., 2010). These T cells not only suppress other memory T-cell populations 
through competition for space or growth factors but also reduce the overall T-cell diversity 
and function (Effros et al., 2005; Messaoudi et al., 2004). The adverse impact of CMV on the 
immune status of cancer patients, thus, may be due to the presence of clonally expanded, 
highly differentiated, dysfunctional CMV-specific T cells that inhibit the diversity and 
ability of the immune system to respond to other antigens (Wherry et al., 2007). In 
extensively treated patients with terminal cancer, a decrease in the population of early-
differentiated T cells, such as naïve and TCM cells, is associated with the expansion of a 
CMV-specific T-cell clone. In addition, IL-7R expression of the immune cells was inversely 
correlated to the intracellular viral load of CMV. Following chemotherapy, CMV 
reactivation left a fingerprint on the T-cell population, i.e., a significantly enhanced number 
of circulating cytolytic T cells in CMV carriers. The clonal expansion of CMV-specific T cells 
may thus shrink the repertoire of immune cells available for other antigens. In fact, this may 
be a contributory factor to the disease progression frequently seen in cancer patients. 
Therefore, CMV drives the expansion of T-cell subsets that are linked with 
immunosenescence, which may add to the chemotherapy-associated deterioration of 
immune function (Messaoudi et al., 2004; Wherry et al., 2007). 
3. Accelerated immunosenescence 
“Immunosenescence” has often been described as age-associated deterioration of the 
immune system in the elderly. The Swedish OCTO/NONA longitudinal studies of the very 
elderly (>85 years) identified some immune parameters, the so-called “immune risk profile,” 
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which predict the 2, 4, and 6 year mortality rates. Immune risk profiles (IRP) mainly include 
(Ferguson et al., 1995; Pawelec et al., 2004; Pawelec et al., 2006; Wikby et al., 1998): 
i. inverted CD4/CD8 ratio,  
ii. poor T-cell proliferative activity,  
iii. increased CD28-CD8 T cells,  
iv. persistent CMV infection,  








CD4/CD8 ratio - - 
Naïve T cells - - 
Memory T cells + + 
CD28- T cells + + 
CMV-specific T cells + + 
IL-7R Possible- - 
IL-6 + + 
CMV viral load + + 
Table 1. Comparison of the immune profiles in age-associated immunosenescence and 
aggressively treated cancer patients. +, increase; -, decrease. aPatients with various types of 
cancer were enrolled in the Mackay Memorial Hospital. None of the patients had received 
immunotherapy when the blood samples were collected, but all had received chemotherapy 
according to the standard treatment regimen for their specific cancer (Chen et al., 2010). 
It has been suggested that age-related dysfunction may not be the sole cause of 
immunosenescence, but the presence of an infectious component appears to be the force 
driving T cells towards senescence. Pawelec et al. has proposed that CMV infection is 
responsible for the development of immunosenescence in the elderly, not aging per se 
(Pawelec et al., 2006). The inflame-aging hypothesis in human ageing proposed by 
Franceschi et al. also suggests that immunosenescence is mainly driven by the chronic viral 
antigen stimulation (Franceschi et al., 2000). Repeated CMV infection induces significant 
expansion of late differentiated-stage of CD28-CD8 effector cells, leading to alteration of 
homeostatic T-cell (i.e., inverted CD4/CD8 ratio and T-cell subpopulations, etc.). An 
analysis of immunosenescence data revealed that elderly individuals had a decreased 
number of naïve T cells and an increased number of effector/memory and effector CD8 T 
cells compared to young individuals; however, both had a similar amount of TCM cells. Such 
large expansion would not only limit the number of clonal expansions of CMV-specific T 
cells but also result in shrinkage of clonal diversity (Hadrup et al., 2006; Pawelec et al., 2004). 
Thus, it is not surprising that old people have increased susceptibility to pathogens. The 
CMV-specific CD28-CD8 effector cells can secret IL-6 cytokine that prolong inflammatory 
activity during pathogen infections (O'Mahony et al., 1998). The increased levels of 
circulating IL-6 would potentially induce CRP that is significantly correlated with mortality 
of elderly (Krabbe et al., 2004; Wikby et al., 2006). Patients with cancer are more vulnerable 
than healthy individuals to have CMV reactivation. In fact, the immune status of cancer 
patients is very similar to IRP seen in the elderly. Our previous data have shown that 
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patients with cancer may suffer from a very high rate of CMV reactivation during 
chemotherapy (Kuo et al., 2008) that the pattern of IRP in age-associated immunosenescence 
can develop in a short period of time. Therefore, down-regulation of early differentiated 
subpopulations (naïve and TCM cells), accumulation of the CD28- population and CMV-
specific T cells, and high levels of CMV viral load and IL-6 secretion were observed in 
cancer patients who were extensively treated (Table 1). We propose that CMV reactivation 
(viral antigens) combined with cancer progression (tumor antigens) and treatment schedule 
may drive T cells toward senescence in cancer patients (Chen et al., 2010). These data refer a 
similar phenomenon of “accelerated immunosenescence”. Thus, it is not surprising that 
several clinical trials of immunotherapy still fail to completely eliminate cancer. The 
immune exhaustion of advanced cancer patients could be one of the reasons for the poor 
clinical outcome of immunotherapy. 
4. Conclusions 
In summary, we propose that patients with advanced cancer who received extensive 
treatment have an accelerated immunosenescence that may be clinically relevant for cancer 
treatment. Typically, there is a decrease in naïve and TCM cells, but an increase in the 
proliferation and differentiation of the TEM population. The immune impairment in these 
patients is associated with multiple factors such as the stage of cancer, impact of treatment 
schedules, and consequence of CMV reactivation. It has been suggested that, with aging, 
CMV-specific effector T cells accumulate in such large numbers that they may be the 
dominant T-cell population in the peripheral blood of healthy elderly individuals. These T-
cells are found to be specific for fewer epitope of CMV (Pawelec et al., 2005). 
In addition, CMV infection may induce a decrease in T-cell telomere length and lead to a 
shift in the composition of the T-cell pool (van de Berg et al., 2010). The deleterious effect of 
CMV persistence on the human immune system is usually insidious and requires decades to 
be recognized. By contrast, the immune systems of cancer patients are somehow rapidly 
driven to an analogous state of immunosenescence. Therefore, it is conceivable that patients 
who receive extensive chemotherapy would have a greater risk of repeated CMV exposure, 
leading to the accumulation of CMV-specific immune cells. The clonal expansion of CMV-
specific T cells may thus shrink the repertoire of immune cells available for other antigens 
and result in the chemotherapy-associated deterioration of immune function. 
With a more complete understanding of the immune profile of cancer patients, clinical 
investigators will be able to provide strategies to restore a robust immune response in the 
tumor-bearing host (active tumor immunity) or, alternatively, promote immunity by the 
adoptive transfer of activated effector cells or tumor-specific antibodies into the tumor-
bearing host (passive tumor immunity). In addition, certain biomarkers, such as the T-cell 
subpopulations, IL-7R, CD28, IL-6, CMV-specific T cells, CMV-specific IgG, and CMV viral 
load, may be useful for monitoring the immune status of patients during, or more 
importantly, before cancer treatment. Since CMV reactivation may in turn serve as the 
driving force for generating virus-specific T cells rather than tumor-specific T cells, we 
propose that even latent CMV infection may contribute to the immune tolerance of tumors. 
This raises the intriguing possibility that preemptive anti-CMV treatment could be an 
important adjunct in cancer treatment, especially during chemotherapy. Without consistent 
antigenic stimulation, TEM cells undergo apoptosis, resulting in a decrease in this cell 
population and an increase in committed effector cells. Prevention of CMV reactivation 
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before the initiation of conventional therapy or immunotherapy could promote immune 
reconstitution and therefore contribute to a better response once specific anti-cancer 
treatment is given. We believe that this strategy is worthy of further investigation. 
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1. Introduction  
In terms of prevalence, the most common cancers in men and women worldwide are breast 
cancer (3.9 million breast cancer cases) and colorectal cancers (2.4 million). Moreover, the 
worldwide incidence of breast and colorectal cancers is destined to increase substantially in 
the next few decades. Therefore, the prevention of the occurrence of these various types of 
cancers represents a real stake in public health for which physical activity could play an 
important role. Indeed, numerous studies showing an association between prevention of 
these cancers and physical activity have been published these last years. 
The number of survivors after treatment of a cancer ("cancer survivors") is also increasing. 
Since last years, different studies have rocked the research community involved in cancer 
survivorship. These studies reported a significant protective association between increased 
physical activity that occurred after the diagnosis of breast or colon cancer and recurrence, 
cancer-related mortality, and overall mortality among breast cancer or colon cancer 
survivors. 
This chapter will consider epidemiologic evidence regarding the association between 
physical activity and breast and colon cancer in primary prevention (cancer occurrence) and 
in tertiary prevention (cancer recurrence). The second aim of this chapter will be to discuss 
the type and characteristics (duration, intensity) of physical activity associated with these 
effects both in primary prevention of breast and colon cancer and in cancer survivors. In 
other words, what types of exercise are most beneficial? 
Evidence for the underlying mechanistic targets of physical activity interventions on the 
carcinogenesis process is also emerging. Studies suggest that exercise can exert its cancer-
preventive effects at many stages during the process of carcinogenesis, including both 
tumour initiation and progression. This will be discussed in the third part of this chapter. 
In the fourth part, the barriers to prescribe physical activity in physicians will be discussed 
as the published work provides sufficient evidence to suggest that physical activity is safe 
and well-tolerated even in cancer survivors and that oncologists can recommend to their 
patients physical activity after the completion of primary treatment. Finally we will discuss 
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on the current guidelines on physical activity for cancer prevention and for cancer survivors, 
with guidance based largely on proven associations that exist between physical activity and 
specific comorbid conditions (such as heart disease or osteoporosis) to which cancer 
survivors are especially prone, or associations between physical activity and other factors, 
such as quality of life, functional decline, and fatigue. Effective strategies to increase 
physical activity will be discussed. 
2. Physical activity and colon and breast cancer prevention  
2.1 Colorectal cancer  
2.1.1 Review of the evidence on physical activity and colon cancer prevention  
Colorectal cancer is the cancer for which there is the largest number of evidences on the 
beneficial effect of physical activity (Friedenreich et al., 2010;Roberts & Barnard, 2005). The 
overall level of scientific evidence on the beneficial effects of physical activity on the 
prevention of colon cancer is categorized as convincing (Friedenreich et al., 2010). This 
characterization is based on the definitions developed and used in the World Cancer 
Research Fund and American Institute for Cancer Research (the categories used are 
"convincing", "probable", "possible" and "insufficient"). Indeed on 51 studies conducted on 
colon and colorectal cancer, 43 demonstrated a reduction in cancer amongst the most 
physically active male and female participants with an average reduction from 20 to 30 % 
amongst both men and women. This protective effect of physical activity for colon cancer is 
not found for rectal cancer (Friedenreich et al., 2010). 
A recent meta-analysis (Wolin et al., 2009) measured the magnitude of the inverse 
association between physical activity and risk of colon cancer restricting analyses to studies 
where data for colon cancer alone were available (exclusion of rectal cancer). A total of 52 
studies were included, showing a 24% risk reduction overall, and generally similar risk 
reductions when men and women were examined separately.  
Evidence for a dose-response effect exists with greater risks reductions observed for higher 
levels of physical activity (Friedenreich et al., 2010).  
2.1.2 What type of physical activity is associated with prevention of colon cancer ? 
Although each study quantified activity differently limiting the ability to draw conclusion 
about the amount of physical activity necessary for the 24% risk reduction observed in the 
meta-analysis of Wolin et al. (2009) one example provides information. In the Nurses' Health 
Study, women who expended more than 21.5 metabolic-equivalent task (MET) hours per 
week (MET-h/wk) in leisure-time physical activity had a risk ratio (RR) of colon cancer of 
0.54 (95% CI, 0.33– 0.90), compared with women who expended less than 2 MET hours per 
week (Wolin et al., 2007). These levels are equivalent to brisk walking for some 5-6h per 
week in the most active and 0.5h per week in the least active. Interestingly, Wolin et al. 
(2009) were able to examine the effects of physical activity domain (occupational vs leisure-
time) and found that the results were similar. Additional research are needed on the type, 
intensity and duration of physical activity that may afford the greatest risk reduction. 
Overall, the results from all studies indicate a dose–response relation (higher levels of 
physical activity have been associated with a reduced risk of colon cancer) with risk 
reduction present across a wide range of physical activity frequency and intensity. 
Although a physically active lifestyle might be associated with other healthful behaviours, a 
number of characteristics of the findings indicate that higher levels of physical activity 
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directly prevent lower colon cancer. The association has been consistently reported in many 
studies of various designs, in diverse populations, for men and women, and after statistical 
control for a variety of other lifestyle factors. A compelling finding is that the inverse 
association has been observed for both leisure-time and occupational activities, for which 
patterns of potential confounding lifestyle characteristics are likely to differ. 
The characteristics of physical activity which could have a protective effect towards colon 
cancer remained controversial, the data of the literature being contradictory. The 
categorizations and the methods of measure of physical activity which differ between 
studies are probably at the origin of these inconsistencies. Measuring physical activity in all 
its components, type, intensity and duration is complex. Although the results are 
heterogeneous, the available evidence suggest that at least 30-60 minutes per day of 
moderate to vigorous intensity for at least 5 days per week is required to significantly 
reduce the risk of colon cancer (Friedenreich et al., 2010). 
Concerning the optimal period of life to practice physical activity to maximize its protective 
effect, the authors recommend a regular practice of physical activity throughout the life. 
2.2 Breast cancer  
2.2.1 Review of the evidence on physical activity and breast cancer prevention  
More than a dozen of cohort studies and an even more important number of case-control 
studies have examined the relations between physical activity and risk of breast cancer. 
More than three quarters of these studies have observed a beneficial of physical activity on 
breast cancer risk with a risk reduction about 25% when comparing the most to least active 
subjects. These results were confirmed and specified in a review of articles published 
between 1994 and 2006 on the relations between risks of breast cancer and physical activity 
(Monninkhof et al., 2007). The methodological quality of these articles was calculated on the 
basis of a statistical quality score and only articles of high quality were eligible: 19 cohort 
studies and 29 case-control studies. The higher quality cohort studies showed a risk 
reduction ranging from 20 to 40%. A more recent overview of the existing evidence relating 
physical activity to breast cancer risk has been recently published (73 studies) (Friedenreich 
et al., 2010). They found a consistent reduction of about 25% of breast cancer risk when 
comparing the most to least active study participants (Friedenreich et al., 2010). Moreover, 
there is consistent evidence of a dose-response effect of decreasing risk with increasing 
activity levels.  
2.2.2 What type of physical activity is associated with prevention of breast cancer ? 
Most studies have investigated the association between breast cancer and leisure physical 
activity (walking, cycling, swimming, gymnastics) but few studies have included low 
intensity leisure physical activity such as gardening, home repair, stair climbing or 
housework (cleaning, washing, cooking, child care…) which probably led to an 
underestimation of total energy expenditure, especially among women who do not have 
access to a sport activity. The inclusion in the physical activity questionnaires of household 
activity is important because it is one of the main sources of physical activity for women in 
most developed countries. This is highlighted in the European cohort EPIC (The European 
Prospective Investigation into Cancer and Nutrition study), which showed that the risk of 
breast cancer was reduced in women in the top quartile of household activities (>90 MET-
h/wk) compared with women in the lowest quartile activities (<28 MET-h/wk): -19% for 
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postmenopausal women (HR: 0.81; 95%CI, 0.70-0.93) and -29% for premenopausal women 
(HR: 0.71; 95%CI, 0.55-0.90) (Lahmann et al., 2007). These results based on a large and 
heterogeneous cohort (218 169 women from nine European countries, aged 20 to 80 years at 
baseline followed for an average period of 6.4 years) and which used standardized data 
collection of physical activity and that could control for all the potential confounding 
factors, provide additional evidence that moderate forms of physical activity, such as 
household activity, may be more important than less frequent more intense recreational 
physical activity in reducing breast cancer risk. 
Similarly, E3N French study, which is the French part of the EPIC, refers to a decrease in the 
relative risk of 18% when household activities are of light intensity while this decline is 38% 
when the activity is of high intensity (Tehard et al., 2006), a dose-response effect being also 
shown for these household activities. A negative trend in risk of breast cancer associated 
with total recreational activity (p trend <0.01) and total physical activity (p trend <0.05) was 
also observed.  
Moreover, in review of Monninkhof et al. (2007), a trend analysis showed that the risk of 
developing breast cancer decreased by 6% per hour of physical activity added per week 
(assuming that the activity would be sustained over a long period of time) showing that this 
is the total amount of physical activity which is essential. 
Overall, the analysis of the literature shows that at least 4 to 7 hours per week of moderate 
to vigorous physical activity would be required to produce a statistically significant 
decrease of the risk of breast cancer.  
Several studies have attempted to determine the existence of a period of life in which the 
protective effects of physical activity would be maximum. In the absence of conclusive 
studies (pubertal period for some practice, adulthood for others), sustained lifetime physical 
activity appears as the most suitable preventive means (Friedenreich et al., 2010). 
2.3 Summary of the evidence on the protective effects of physical activity on colon 
and breast cancer  
The available evidence suggest that: 
- at least 30-60 minutes per day of moderate to vigorous intensity for at least 5 days per 
week is required to significantly reduce the risk of colon cancer (24% risk reduction of 
colon cancer risk when comparing the most to least active study participants). 
- at least 4 to 7 hours per week of moderate to vigorous physical activity is required to 
produce a statistically significant decrease of the risk of breast cancer (reduction of 
about 25% of breast cancer risk when comparing the most to least active study 
participants).  
3. Effects of physical activity on colon and breast cancer survival 
Length of survival after colon cancer or breast cancer diagnosis varies widely, even after 
accounting for stage at diagnosis and treatment, suggesting other factors may also be 
important. Lifestyle habit such as physical activity is a modifiable behaviour with multitude 
of health benefits (Haskell et al., 2007) including beneficial effect on cancer survival. Indeed, 
several prospective studies have shown that the level of physical activity performed after 
the diagnosis of cancer significantly decreased overall mortality, cancer mortality and the 
number of recurrences of cancer. 
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3.1 Physical activity and breast cancer survival 
At least seven prospective studies have investigated the relations between physical activity 
and breast cancer survival (for a review see Barbaric et al., (2010).  
The cohort of the Nurses' Health Study (121 700 women followed since 1976) has been the 
support of the first important study. This study focused on 2987 women with 280 breast 
cancer deaths and 8 years median follow-up (Holmes et al., 2005). Physical activity was 
measured by questionnaire every 2 years. The risk of death by breast cancer or breast cancer 
recurrence was reduced by 20 to 50% among women who walk 3 to 5 h per week (compared 
to those who walk less than 3 h per week). There was also a reduced risk of breast cancer 
recurrence and total mortality (Holmes et al., 2005).  
The collaborative Women's Longevity Study (CWLS) of 4482 women with breast cancer 
followed for 6 years with 109 deaths reported a comparable decreased risk of breast cancer 
death and total death (Holick et al., 2008). These results were confirmed by the Women's 
Healthy Eating and Living Study (WHEL study) which reported a relative risk of recurrence 
reduced to 0.56 for women walking 30 minutes a day 6 times per week (Pierce et al., 2007).  
Two smaller sized cohorts reported a decreased risk for total mortality but not breast cancer 
mortality with greater physical activity: the Life after Cancer Eidemiology (LACE) (Sternfeld 
et al., 2009) and the Health, Eating, Activity and Lifestyle (Heal) study (Irwin et al., 2008). 
3.2 Physical activity and colon cancer survival 
Three studies investigated the effects of exercise on cancer survival in patients diagnosed 
with colon (Meyerhardt et al., 2006a) or colorectal cancer (Haydon et al., 2006;Meyerhardt et 
al., 2006b).  
Meyerhardt et al. (2006a) demonstrated that disease-free colon-cancer survival improved 
with increasing levels of physical activity (p trend <0.01). Based on the results of this study, 
it is suggested that a protective HR is observed with >18 total MET-h/wk or equivalent 
(HR= 0.51; 95% CI: 0.26–0.97, for 18 to 26.9 MET-h/wk); the protective HR does not improve 
beyond 27 MET-h/wk.  
Two studies investigated the effect of physical activity on mortality in patients diagnosed 
with colorectal cancer. Haydon et al. (2006) demonstrated that persons who exercised at 
least once a week had improved disease-specific survival (HR = 0.73; 95% CI: 0.54–1.00, p = 
0.05). The benefit of physical activity was largely confined to stage II–III tumours (HR = 0.49; 
95% CI: 0.30–0.79, p = 0.01), while no association was seen in stage I (least severe) or stage IV 
(most severe) tumours. The results of the study by Meyerhardt et al. (2006b) supported the 
role of post-diagnosis physical activity in decreasing cancer-specific mortality (p for trend = 
0.008) and overall mortality (p for trend= 0.003) (cohort of the Nurses' Health Study: 573 
women whose colon cancer has been diagnosed (stage I, II or III), followed on average 9.6 
years). Pre-diagnosis level of physical activity was not found to be predictive of mortality, 
whereas women who increased their activity level after diagnosis had an HR of 0.48 (95% 
CI: 0.24–0.97) for colorectal-cancer deaths and an HR of 0.51 (95% CI: 0.30–0.85) for all-cause 
mortality versus those with no change in activity. In contrast, among women who decreased 
their activity level there was a modest, though non-significant, increase in both cancer-
specific and overall mortality. 
All of these studies suggest that physical activity may confer additional benefits to those 
of the surgery, radiation therapy and/or chemotherapy for survival after treatment of 
breast or colon cancer. However, these results are observational and cannot formally 
identify a relationship of cause and effect. However the number of randomized trials 
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mortality versus those with no change in activity. In contrast, among women who decreased 
their activity level there was a modest, though non-significant, increase in both cancer-
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All of these studies suggest that physical activity may confer additional benefits to those 
of the surgery, radiation therapy and/or chemotherapy for survival after treatment of 
breast or colon cancer. However, these results are observational and cannot formally 
identify a relationship of cause and effect. However the number of randomized trials 
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testing physical activity interventions for cancer survivors is growing (Pekmezi et al., 
2011). Moreover different research have started examining the impact of physical activity 
on surrogate/biologic markers of survival. All these studies are needed and are still 
ongoing. 
3.3 What type of physical activity is associated with beneficial effect on survival after 
colon or breast cancer ? 
The review of literature shows that this beneficial effect of physical activity on survival is 
obtained regardless of the type of training: endurance, strength, or mixed. The intensity 
from which effects on survival are observed is >9 MET-h/wk which is equivalent to 30 min 
of brisk walking 5-7 times per week and this regardless of the level of physical activity 
before the diagnosis.  
It is necessary to take into account the state of fatigue of the patients before prescribing a 
program of physical activity. In all cases, the prescription must be individualized and 
implemented very gradually. Indeed, "the AP is well tolerated, without adverse effects and 
oncologists should recommend physical activity to their patients after treatment" (Irwin et 
al., 2008) (see paragraph 7.2.2). 
3.4 Other benefits of physical activity for cancer survivors 
Cancer survivors are not only at increased risk for progressive disease but also a host of 
comorbid conditions (other cancers, cardiovascular disease, obesity, diabetes and 
osteoporosis), functional decline and premature death (Demark-Wahnefried et al., 2006a). 
The impact of exercise is beyond the effects on cancer survival rate as exercise is also 
associated with other benefits for cancer survivors: exercise is consistently associated with 
improved quality of life, and also is effective in improving physical functioning (oxygen 
capacity, cardiorespiratory fitness, other fitness or strength measures, flexibility and global 
health), anthropometric measures (weight status, body fat, waist circumference) and health-
related biomarkers (blood pressure, heart rate, circulating hormonal levels) among cancer 
survivors (Demark-Wahnefried, 2006b). 
These effects are obtained with the levels of physical activity recommended for cancer 
survivors (Haskell et al., 2007) (Table 1). 
4. Physical activity recommendations for colon and breast cancer prevention 
and for cancer survivors  
Physical activity recommendations for colon and breast cancer prevention and after cancer 
treatment are summarized in table 1. 
5. Physical activity during cancer treatment  
More than 40 studies of randomised trials published since 1980 have evaluated the effects of 
physical activity during adjuvant cancer treatments. Despite methodological limitations and 
small samples sizes, all reported that physical activity (light to moderate intensity exercise 
using bicycle or walking program and/or structured exercise program using treadmill, 
various other forms aerobic equipment and strength training, at least 3 times a week for 20-
30 minutes) is safe and feasible during cancer treatment. Physical activity can improve 
functional capacities, cardio-respiratory fitness and decrease the treatment-related 
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symptoms (fatigue, nausea). Quality of life and sleep quality are also improved with 
physical activity (for a review see Kirshbaum, 2007 and Doyle et al., 2007).  
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Table 1. Recommendations of physical activity (PA: physical activity): 
There are few recommendations on the type, duration and intensity of physical activity to be 
practised during the cancer treatment (chemotherapy and/or radiotherapy). In most of the 
studies, the proposed physical activity was of light to moderate intensity, at the rate of 3 to 5 
times a week with a duration from 20 to 30 minutes by session. 
For people who were sedentary before diagnosis, low-intensity activities such as stretching 
and brief slow walks should be adopted and slowly advanced. 
6. What biological mechanisms explain the associations between physical 
activity and colon and breast cancer  
Evidence for the underlying mechanisms involved in the pathways between physical 
activity and cancer is emerging. Numerous biological mechanisms have been proposed and 
in some cases tested in randomized controlled trials (for a review see (Friedenreich et al., 
2010;Rogers et al., 2008; Chan & Giovannucci, 2010).  
In 2007 the World Cancer Research Fund examined associations for physical activity and 
several cancer types. They concluded that there is a statistical association between excess 
weight and some cancers including colon cancer and breast cancer in postmenopausal 
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women. These results were confirmed by a large standardized meta-analysis (Renehan et al., 
2008). The authors did a systematic review and meta-analysis to assess the strength of 
associations between BMI and different sites of cancer and to investigate differences in these 
associations between sex and ethnic groups. The objective was to determine the risk of 
cancer associated with a 5 kg/m² increase in BMI (which corresponds to weight gains of 
about 15 kg in men and 13 kg in women who have an average BMI of 23 kg/m²). They 
analyzed 141 articles, including 282 137 incident cases. In men, a 5 kg/m² increase in BMI 
was strongly associated with colon cancer (risk ratio [RR]=1.24, p<00001). In women, they 
recorded positive association between increased BMI and premenopausal (p=0.009) and 
postmenopausal (p=0.06) breast cancers. Associations were stronger in men than in women 
for colon (p<0.0001) cancer. Associations were generally similar in studies from North 
America, Europe and Australia, and the Asia–Pacific region.  
Mechanisms that link excess weight and cancer risk are not fully understood, though three 
hormonal systems -the insulin and insulin-like growth factor (IGF) axis, sex steroids, and 
adipokines - are the most studied candidates (Renehan et al., 2008). All three systems are 
interlinked through insulin (Figure 1).  
Obesity and a sedentary lifestyle induce insulin-resistance and a compensatory 
hyperinsulinism. Chronic hyperinsulinaemia decreases concentrations of IGF binding 
protein-1 and IGF binding protein-2, which increases bioavailable or free IGF-I with 
concomitant changes in the cellular environment (mitogenesis and anti-apoptosis) that favor 
tumour formation (Rogers et al., 2008). Circulating total IGF-1, which is a major determinant 
of free IGF-1 concentrations, is also associated with an increased risk of colorectal cancer, 
and with premenopausal rather than postmenopausal breast cancer (Renehan et al., 2008). 
For postmenopausal breast cancer, the increase in risk might be explained by the higher 
rates of conversion of androgenic precursors to oestradiol through increased aromatase 
enzyme activity in adipose tissue. Furthermore, chronic hyperinsulinaemia might promote 
tumorigenesis in oestrogen-sensitive tissues, since it reduces blood concentrations of sex-
hormone-binding globulin, and in turn, increases bioavailable oestrogen (Calle & Thun, 
2004).  
Beyond these mechanisms, other candidate systems include obesity-related inflammatory 
cytokines, altered immune response, oxidative stresses, the nuclear factor κB system. 
The beneficial effects of regular physical activity on the risk of cancer can be explained, 
among others, by their protective effect on weight gain and the reduction of abdominal 
adiposity. Independently of the variations of fat mass, regular physical activity decreases 
insulinemia by increasing peripheral insulin sensitivity (Dwyer et al., 2011). The direct 
effects of physical activity on IGF-1 are contradictory, some studies showing a decrease and 
others no variation of plasma IGF-1 levels with physical activity (Duclos et al., 2007). 
Regular physical activity can also reduce the risk of occurrence and/or recurrence of breast 
cancer by reducing the endogenous production of the estrogens but also by increasing the 
SHBG (Sex Hormone Binding Globulin) (Duclos 2001; Chatard et al., 2004). By binding to 
estradiol or testosterone, the SHBG therefore reduces their biologically active free fraction. 
The production of SHBG also depends on diet (normal or hypo-calorie intake, high-fibre 
diet, etc.), and the effects of physical activity are sometimes confused with the effects of diet 
(Longcope et al., 2000). Figure 1 presents an explanatory hypothesis of the pathways linking 
physical activity and insulin/IGF-1 /sex hormones to breast cancer development. physical 
activity could act by inverting these various pathways. 
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Fig. 1. Proposed mechanisms relating diet, physical activity and insulin to breast cancer  
For colon cancer, the protective effects of regular physical activity marshal systemic effects 
of physical activity and local effects (Chan & Giovannucci 2010). Physical activity could also 
increase colonic motility, although colonic motility has not been definitely linked to colon 
cancer risk.  
Other biological mechanisms of protective effects of physical activity have been suggested, 
such as the reduction of oxidative stress and effects on immunity. It is clear that the 
beneficial effects of physical activity depend on many inter-connected mechanisms. 
However, the level of scientific proof in each case is a matter of debate and further research 
is needed in order to determine the preventive mechanisms for each type of cancer. 
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In summary, exercise can alter biological processes that contribute to both anti-initiation and 
anti-progression events in the carcinogenesis process. However, more detailed studies are 
needed to examine each of the potential mechanisms contributing to an exercise-induced 
decrease in carcinogenesis in order to determine the minimum dose, duration and frequency 
of exercise needed to yield significant cancer-preventive effects, and whether exercise can be 
used prescriptively to reverse the sedentarity-induced and obesity-induced physiological 
changes that increase cancer risk (Rogers et al., 2008). 
Moreover, the mechanisms of the beneficial effects of regular physical activity on survival 
after cancer treatment, and most importantly on the quality of life (decreased post-treatment 
fatigue, improved symptoms secondary to treatment) have yet to be determined (not to 
mention the need to know when to begin physical activity in relation to treatment, and at 
what dose: duration and intensity). 
7. Barriers to physical activity in cancer survivor and in their physicians 
Cancer survivors are not only at increased risk for progressive disease but also a host of 
comorbid conditions (other cancers, cardiovascular disease, obesity, diabetes and 
osteoporosis), functional decline and premature death (Demark-Wahnefried et al., 2006a). 
The impact of exercise is beyond the effects on cancer survival rate as exercise is also 
associated with other benefits for cancer survivors: exercise is consistently associated with 
improved quality of life, and also is effective in improving physical functioning (oxygen 
capacity, cardiorespiratory fitness, other fitness or strength measures, flexibility and global 
health), anthropometric measures (weight status, body fat, waist circumference) and health-
related biomarkers (blood pressure, heart rate, circulating hormonal levels) among cancer 
survivors (Demark-Wahnefried et al., 2006a). 
Therefore initiating and maintaining an exercise regimen long term should be generalized in 
the growing population of cancer survivors. In other words, cancer survivors should be 
encouraged to initiate and maintain physical activity. 
However, adoption and maintenance of physical activity is a difficult challenge for healthy 
adults and is likely to be even more difficult after a cancer diagnosis. Concerning physical 
activity, cancer survivors are faced to two types of barriers: 
- their own barriers to adoption and maintenance of physical activity  
- barriers of their physicians to prescribe physical activity in cancer survivors. 
This suggests that interventions to increase physical activity in patients should be 
multifactorial and multidirectional, i.e. directed towards patients and their physicians. 
7.1 Cancer survivor barriers to adoption and maintenance of physical activity 
As a result of the cancer diagnosis, surgery and adjuvant treatments some cancer survivors 
experience fatigue, depression anxiety, reduced overall quality of life (Irwin, Smith, 
McTiernan, Ballard-Barbash, Cronin, Gilliland, Baumgartner, Baumgartner, & Bernstein 
2008). All these comorbid conditions favor sedentarity. 
Patients should be informed and educated on the role of physical activity, not only to aid in 
the prevention of cancer but also to improve survival rates following diagnosis.  
Thus, oncologists and physicians should discuss with their patients the benefits of physical 
activity after a diagnosis of cancer, reassure them that exercise is safe and associated with 
improved overall survival and quality of life, and to refer them to a certified cancer exercise 
trainer who will prescribe an exercise program that is tailored to them. The oncologist and 
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certified exercise trainer should also consider any preexisting conditions and adverse effects 
of treatment (Irwin et al., 2008).  
It is necessary to take into account the state of fatigue of the patients before prescribing a 
program of physical activity. In all cases, the prescription must be individualized and 
implemented very gradually.  
7.2 Barriers of physicians to prescribe physical activity in cancer survivors: What 
physicians should know, understand and explain to their patients 
There is a reluctance of oncologists and of physicians to prescribe physical activity. Many 
elements prevent them from providing exercise advice: lack of sufficient knowledge of the 
benefits of being physically active after a cancer diagnosis, fear of side-effects of exercise 
(cardiovascular risks, lymphedema). Finally most physicians do not have the training or 
resources to develop individualized exercise prescription for cancer survivors. 
7.2.1 Physician should know, understand and explain the wide spectrum of health 
benefits of physical activity 
In addition to the risk of recurrence of the cancer, cancer survivors are also at risk of chronic 
fatigue, loss of muscle mass, weight gain. It should be noticed that the average weight gain 
after breast cancer treatment is 3-5 kg, and that epidemiological studies have shown that 
weight gain after a cancer diagnosis is associated with an increased risk for recurrence and 
death compared with maintaining normal weight after diagnosis (Kroenke et al., 2005). 
Cancer survivors also have the same risks as the general population to develop 
cardiovascular diseases or metabolic diseases, or even they present an increased risk of 
developing these as obesity and a sedentary lifestyle are highly prevalent in cancer 
survivors. Specifically there is evidence that cancer survivors die of noncancer causes at a 
higher rate than persons in the general population (deaths being primarily from 
cardiovascular diseases and diabetes) (Carver et al., 2007). 
As detailed in paragraph 3.4, physical activity can reduce risk of other chronic diseases 
(cardiovascular diseases and diabetes) on one hand, and on the other hand, physical activity 
may help subjects with cancer avoid dying from their cancer. 
7.2.2 Physician should know, understand and explain that physical activity in cancer 
survivor is safe and well-tolerated 
The published work provides sufficient evidence to suggest that exercise is a safe and well-
tolerated supportive intervention that oncologists can recommend to their patients after the 
completion of primary treatment. 
In one of the largest studies to date, Courneya and colleagues examined the effects of 
aerobic exercise alone, resistance exercise alone, or usual care, on fitness, muscular strength, 
body composition, and quality of life in 242 breast cancer survivors initiating chemotherapy 
(Courneya et al., 2007). There were significant favorable effects of both aerobic and 
resistance exercise on multiple outcomes including self esteem, fitness, and body 
composition, as well as increased chemotherapy completion rates compared with usual care. 
Furthermore, no significant adverse events were reported; lymphedema did not increase or 
was not exacerbated by aerobic or resistance exercise. Recently, other clinical trials of 
women with breast cancer have shown no increased risk for or exacerbation of lymphedema 
from either aerobic and/or resistance exercise (Ahmed et al., 2006). 
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cardiovascular diseases or metabolic diseases, or even they present an increased risk of 
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may help subjects with cancer avoid dying from their cancer. 
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The published work provides sufficient evidence to suggest that exercise is a safe and well-
tolerated supportive intervention that oncologists can recommend to their patients after the 
completion of primary treatment. 
In one of the largest studies to date, Courneya and colleagues examined the effects of 
aerobic exercise alone, resistance exercise alone, or usual care, on fitness, muscular strength, 
body composition, and quality of life in 242 breast cancer survivors initiating chemotherapy 
(Courneya et al., 2007). There were significant favorable effects of both aerobic and 
resistance exercise on multiple outcomes including self esteem, fitness, and body 
composition, as well as increased chemotherapy completion rates compared with usual care. 
Furthermore, no significant adverse events were reported; lymphedema did not increase or 
was not exacerbated by aerobic or resistance exercise. Recently, other clinical trials of 
women with breast cancer have shown no increased risk for or exacerbation of lymphedema 
from either aerobic and/or resistance exercise (Ahmed et al., 2006). 
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Courneya and colleagues also completed a similar trial of aerobic exercise vs usual care in 
breast cancer survivors who had completed adjuvant treatment, and observed similar 
favorable effects of exercise on fitness and overall quality of life (Courneya et al., 2003). 
Overall, these, and other, studies have demonstrated that exercise is safe in cancer survivors 
and produces beneficial effects on quality of life and cancer-related symptoms with no 
adverse side effects. 
A long-term concern in breast-cancer survivors starting an exercise program is 
lymphoedema. The few studies that have assessed this issue clearly showed that upper 
body exercise does not induce or exacerbate lymphoedema, and on the contrary, it would 
seem that a suitable AP allow to limit this risk.  
7.2.3 Physician should know and understand the influence of their beliefs on physical 
activity on the beliefs and physical activity of their patients 
General practitioners (GP) are cited as the primary source of information influencing 
healthy lifestyle decisions, but few studies have evaluated whether GPs’ perceived barriers 
towards physical activity affect physical activity uptake in their patients. In type 2 diabetes 
patients, Duclos et al. (2011) have assessed the associations between GPs’ perceived barriers 
to prescribing physical activity and type 2 diabetes patients' perceived barriers to adopting 
physical activity. Their findings showed that GPs’ physical activity and GPs' perceived 
barriers, are associated with type 2 diabetes patients’ physical activity. An effect of GPs 
barriers on patients’ ones towards physical activity was depicted since the higher the GP’s 
barriers score, the higher the type 2 diabetes patient’s barriers score. Examining the nature 
of perceived barriers to physical activity in both type 2 diabetic patients (regarding physical 
activity practice) and their GPs (regarding physical activity prescription), common barriers 
emerged with a high score: "A low fitness level", "The fear of being tired", "Their actual 
physical health status, excluding diabetes", "The fear of suffering a heart attack". These 
common barriers are inconsistent with evidence-based medicine (Haskell et al., 2007). These 
results are consistent with the hypothesis that the beliefs of GPs might influence the beliefs 
of their type 2 diabetes patients. Finally, GPs' physical activity was positively correlated 
with their patients' physical activity. 
It has been shown that endorsement of physical activity is more credible coming from a 
professional who practices physical activity (Abramson et al., 2000). GPs should practise 
physical activity themselves, not only for their own benefit, but also as a stimulus for 
physical activity of their patients (Duclos et al., 2011).  
It remain to determine if this proves to be the case in cancer survivors. However this 
suggests that identifying and working on GPs’ barriers but also promoting physical activity 
in GPs may improve the uptake of physical activity in their patients. 
7.2.4 Recommendations for physicians 
As in other clinical and non-clinical populations, cancer survivors should obtain clearance 
from their physician or oncologist program. This clearance is especially important in cancer 
survivors who are at high risk for late-occurring toxic effects secondary to treatment that can 
increase their risk of cardiovascular disease. Thus, appropriate screening procedures for 
cardiac and cardiovascular disease are recommended before an exercise program is started.  
The prerequisite is that patients have obtained the prior agreement of their cancer specialist 
and that patients should be screened for osteoporosis, bone metastasis, cardiac toxicities, 
and lymphedema. 
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Oncologist and primary care physicians should not lose sight of the fact that a substantial 
body of research shows the benefit of a healthy diet and regular exercise for reducing risk 
for many of the comorbid conditions (ie, other cancers, cardiovascular disease, diabetes, and 
osteoporosis) and side-effects (ie, fatigue and depression) for which cancer survivors are 
especially prone. Thus, oncology care providers can assist their patients by endorsing 
existing health guidelines for their patients and for themselves and encouraging their 
patients to take active roles in pursuing general preventive health strategies (Jones & 
Demark-Wahnefried, 2006). 
8. Conclusion  
There is a large body of evidence that physical activity has an important role in prevention 
and management of cancer: physical activity reduces risk of breast and colon cancer, during 
and after cancer treatment physical activity ameliorate symptom experience, ameliorate 
treatment side effects, improve quality of life and reduce mortality and morbidity. As such, 
regular physical activity should be encouraged in all populations (general population, 
subjects at high risk of cancer, survivors of cancer… and in physicians) throughout all life. 
Now, the question is not: "why should I prescribe physical activity in my patients?" but 
"How initiating and maintaining physical activity in patients?". Initiating exercise is 
important; however, maintaining an exercise regimen long term is a significant challenge. 
Behavioural interventions are complex and involve multidisciplinary approach (patients, 
physicians, scientists, government, urbanists…). Whatever, it's time to get moving and it is 
never too late to get moving! 
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1. Introduction 
At the turn of the 20th century, the outlook was bleak for individuals diagnosed with cancer. 
The pathophysiology of cancer was not well understood, and the associated treatments were 
as dire as the disease itself. In 1971, President Nixon declared “war” on cancer (Haran & 
DeVita, 2005). Since then we have seen dramatic improvements in cancer prognoses. At 
present, more than 11.7 million men and women are living as cancer survivors in the US, 
primarily due to early detection and advances in treatment options (Centers for Disease 
Control, 2007). However, such treatments often result in long-term physical and psychological 
toxicities, which negatively impact the cancer survivor's quality of life (QOL). These sequelae 
include, but are not limited to, decreased muscle strength, reduced cardiorespiratory fitness, 
reduced lean body mass, bone loss, fatigue (Pihkala et al., 1995; Lucia et al., 2003), depression, 
emotional distress, and anxiety (Jones et al., 2010). Thus, cancer research has shifted from its 
initial focus on prevention, to one that is centered on controlling or eliminating treatment-
related toxicities with pharmacologic, physical, or social interventions. Now more than ever, 
healthy behavior choices are being promoted in attempt to limit this disease. In 2006, 42% of 
NIH-funded research projects contained an intervention component designed to improve the 
psychosocial well-being, physical status, and/or health behaviors of cancer survivors 
(National Institutes of Health, 2011). One such intervention, exercise rehabilitation, has been 
widely reported in the literature to benefit cancer patients. With more than two decades of 
literature examining this topic, research continues to support a link between a physically 
active lifestyle and improvements in mental and physical QOL in cancer survivors (Douglas, 
2005; Wiggins & Simonavice, 2009). Thus, the primary aim of this chapter will be to explore the 
role of physical activity and exercise in cancer recovery.  
2. Precautions during exercise 
Cancer survivors often have disease or treatment-specific limitations that affect the exercise 
response. The specific effects of cancer on the exercise response are determined by the 
tissues affected and their level of involvement. Treatment-specific limitations arise from the 
type and duration of anticancer therapy employed. Surgery, chemotherapy, and radiation 
are the most common forms of cancer treatment, and all are associated with both acute and 
chronic effects that may negatively impact the exercise response. Table 1 briefly lists some of 
the more common treatment-related effects. In addition, most people are treated with a 
combination of surgery, radiation, and chemotherapy, which may cause a host of treatment-
related problems. Pain, lymphedema, risk of infection, shortness of breath, neural deficits, 
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fatigue, nausea and vomiting, cachexia, dehydration, and emotional distress are all common 
effects of cancer and its associated treatments on the patient’s exercise tolerance.  
 
Cancer Treatment Potential Side Effects 
Surgery Pain 
Loss of flexibility 
Radiation Fatigue 
Skin changes 
Loss of flexibility 








Changes in body composition that influence 
gait and balance. 
Table 1. Potential Side Effects of Anticancer Therapy (Swartz, 2009). 
2.1 Pain 
Depending on the specific location of the cancer, patients may experience high levels of 
pain. A tumor often causes pain, particularly when it involves the musculoskeletal system, 
causing it to press on bones, nerves, or body organs. In addition, chronic pain is frequently 
reported following surgery, often when large amounts of healthy tissue are removed along 
with cancer tissue. Chemotherapy and radiation treatments may also cause pain resulting 
from such side effects as peripheral neuropathy, mucositis, and radiation injuries (American 
Cancer Society, 2011). In most situations, physicians can prescribe medications to alleviate 
pain; however the intensity, type, duration, and frequency of exercise may need to be 
adjusted until the pain is brought under control.  
2.2 Lymphedema 
Lymphedema is a swelling that results from a blockage of the lymph vessels that drain fluid 
from tissues. It is commonly caused by a mastectomy or the removal of underarm lymph 
nodes during breast cancer surgery, and is experienced by approximately 10-15% of breast 
cancer patients (Muss, 2007). It is characterized by a persistent swelling, typically of the arm 
or leg. Often, patients may be treated with compression bandages to limit swelling. It is 
advised that exercises be carefully designed, so as not to increase the swelling or cause 
infection (Kercher et al., 2008). 
2.3 Risk of infection 
Chemotherapy, radiation, and immunotherapy often have a substantial impact on white 
blood cell count. Consequently, immune function often weakens during cancer treatment. 
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Patients with very low blood counts are advised to avoid exercise all together, as they are at 
an increased risk for anemia. Frequent hand washing is advised, particularly in fitness 
centers, where germ count tends to be very high.  
2.4 Shortness of breath 
Shortness of breath is common when cancer has affected the lungs. It also may result when 
the bone marrow is affected, causing low red blood cell counts. Red blood cells carry oxygen 
throughout the body. Their ability to carry oxygen is measured by the amount of 
hemoglobin present in the blood. A low level of hemoglobin is indicative of anemia. With 
anemia, the body must work harder to supply oxygen to the tissues, causing the patient to 
feel fatigued and short of breath. Thus, anemic patients often have a limited aerobic 
performance because of the reduced oxygen-carrying capacity (Swartz, 2009). 
2.5 Neural deficits 
Neural deficits are common when tumors involve the central nervous system and brain. 
Problems with neural repair and decreased neurotransmitter activity may also arise as a side 
effect of anticancer therapy, related to the ability of chemotherapy to cross the blood-brain 
barrier and cause DNA damage and shortened telomere length (Klein, 2009). Neurological 
deficits can impact memory and emotion in cancer patients and may influence their 
motivation to adhere to an exercise program.  
2.6 Fatigue 
Fatigue is the most frequently reported symptom of cancer treatment (Schneider et al., 2003), 
affecting up to 96% of patients (Douglas, 2005). It is a whole-body tiredness that interferes 
with normal functioning and leaves the patient feeling irritable and unmotivated. Chronic 
fatigue has a negative impact on activities of daily life, social reintegration, and overall 
quality of life (Hartvig et al., 2006). In some patients, this fatigue is so debilitating to the 
individual that treatment must be discontinued or limited (Schneider et al., 2003). 
2.7 Nausea and vomiting 
Nausea, vomiting, and diarrhea are common effects of radiation and chemotherapy, leaving 
the patient feeling weak and at risk for electrolyte imbalances and dehydration. Cancer 
patients should avoid exercise for 24-hours after bouts of vomiting and diarrhea (Young-
McCaughan, 2006). As a result, it is important that exercise schedules be flexible to 
accommodate these bouts of irritation. Research indicates that in some instances, exercise 
will reduce feelings of nausea. However, if nausea persists upon initiation of exercise, 
activity should be stopped (Young-McCaughan, 2006). 
2.8 Cachexia 
Cachexia is a physical wasting syndrome accompanied by loss of muscle mass, fat mass, 
overall weight, and appetite. It affects up to 75% of cancer patients, especially those who are 
in the advanced stages of pancreas, esophagus, and stomach cancer. It is a metabolic 
disturbance that can result in electrolyte imbalances, weakness, fatigue, and reduced 
strength. Often, treatment with nutrient supplementation is ineffective (Martingnoni et al., 
2003). Patients suffering from cachexia often lack the energy to exercise, so little is known 
about the impact of exercise on this condition.  
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Dehydration is often experienced during chemotherapy, either as a side effect of frequent 
vomiting and diarrhea, or as a direct effect on the kidneys. Large quantities of water are 
necessary to help the kidneys filter chemotherapy medication. Fatigue and dizziness are 
symptoms of dehydration, both of which will impact the exercise response. It is important to 
ensure adequate fluid intake before, during, and after each exercise session.  
2.10 Emotional distress 
Cancer survivors will face a multitude of emotions as they battle cancer, creating a strain on 
interpersonal relationships. These emotions may include anger, depression, anxiety, and 
elation. This emotional distress can significantly impact a cancer patient’s desire to 
participate in an exercise program.  
3. Benefits of exercise 
3.1 Risk factors 
Not all risk factors that predispose an individual to cancer can be controlled (i.e., age, 
gender, race, genetic factors). However, healthy behaviors and lifestyle choices, along with 
environmental exposure risk reduction, can help reduce cancer development. Fifty to 75% of 
cancer deaths in the US are related to risk factors such as smoking, poor dietary choices, and 
physical inactivity (National Cancer Institute, 2009). Specifically, obesity and physical 
inactivity are associated with approximately 25-30% of colon, breast, endometrial, kidney, 
and esophageal cancers in the US (National Cancer Institute, 2009). The World Health 
Organization lists physical activity among the nine modifiable risk factors for cancer (World 
Health Organization, 2009). In addition, recent research supports the assertion that physical 
activity helps to prevent certain forms of cancer (Kruk, 2007; Miles, 2007), including cancer 
of the colon (Courneya & Friedenreich, 2007), breast (Courneya & Friedenreich, 2007), 
endometrium (Courneya & Friedenreich, 2007), prostate (Courneya & Friedenreich, 2007; 
Friedenreich & Orenstein, 2002), lung (Courneya & Friedenreich, 2007; Friedenreich & 
Orenstein, 2002), kidney (Friedenreich & Orenstein, 2002), rectus (Friedenreich & Orenstein, 
2002), and esophagus (Friedenreich & Orenstein, 2002) cancer. The average risk reduction 
for each of these cancers varies from approximately 10-40% (Wiggins & Simonavice, 2010). 
Moderate physical activity (>4.5 METs) appears to be associated with a greater protective 
effect than activities of lower intensity (Lee, 2003). 
3.1.1 Cancer survivorship 
In addition to reducing the risk of developing certain forms of cancer, physical activity has 
also been suggested to increase cancer survivorship by decreasing the risk of cancer 
recurrence, slowing the progression of cancer, and reducing the risk of secondary life-
threatening diseases (Courneya & Friedenreich, 2007; Holmes et al., 2005; Haydon et al., 
2005). One investigation (Holmes et al., 2005), revealed a reduction of 26-40% in the relative 
risk of breast cancer-related death and recurrence among the most active women compared 
with the least active. Similarly, higher levels of physical activity pre- and post-diagnosis of 
colon cancer and post-diagnosis of colorectal cancer were associated with a decrease in 
cancer-related mortality (Haydon et al., 2006; Meyerhardt et al., 2006a, 2006b). As such, the 
American Cancer Society recommends that exercise serve as an important part of an 
individual’s cancer care plan, asserting that exercise will decrease feelings of fatigue both 
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during and after treatment, and improve an individual’s feeling of control and hope 
(American Cancer Society, 2011). In addition, the 2008 US Department of Health and 
Human Services (US DHHS) Physical Activity Guidelines for Americans indicate that 
individuals with chronic conditions, such as cancer, should be “as physically active as their 
abilities and conditions allow” (Physical Activities Guidelines Advisory Committee, 2008). 
3.2 General health benefits of exercise 
The general health benefits associated with participating in an exercise program are 
numerous, and include: improved cardiac output, increased ventilation; improved flexibility 
and range of motion; increased muscular strength and endurance; decreased resting heart 
rate; improved stroke volume, vasodilation, perfusion; improved metabolic efficiency; and 
improved blood counts (Wilmore et al., 2008). Likewise, there are several positive 
physiological and psychological changes for cancer survivors associated with moderate 
levels of physical activity and structured exercise.  
3.2.1 Aerobic capacity 
Research indicates that individuals being treated for cancer have the potential to 
significantly increase their aerobic capacity by engaging both home-based and structured 
exercise programs. Young-McCaughan et al (2003) reported an increase in VO2max in cancer 
survivors following a 12-week exercise program. Thorsen et al (2005) found a significant 
increase in VO2max for cancer survivors following a 14-week home training program. 
Wiggins and Simonavice (2008) reported an increase in VO2max in breast cancer survivors 
after 3 months of resistance and aerobic training. Improvements in VO2max will enhance 
heart and lung functioning, thereby promoting healthy a blood pressure, blood volume, and 
gas exchange (Swartz, 2009). In addition, beneficial effects on energy balance, body mass, 
intestinal transit time, hormone concentrations, and antioxidant enzyme levels have been 
observed following improvements in aerobic capacity. Research also indicates an inverse 
relationship between fatigue and aerobic capacity, in that the higher an individual’s aerobic 
capacity, the lower their levels of fatigue, which translates into a positive influence on QOL 
(DeVita et al., 2008). 
3.2.2 Muscular strength and endurance 
Several studies report improvements in muscular strength and endurance as a result of 
participating in an exercise program. In one study, muscular strength increased by 
approximately 41% in patients who participated in a 6-week resistance training program 
(Quist et al., 2006). Likewise, a 12-month exercise program resulted in increases in upper 
body muscular strength and lower body endurance in breast cancer survivors (Wiggins & 
Simonavice, 2008). Finally, Cheema and Gual (2006) reported improvements in upper and 
lower body muscular endurance in previously trained breast cancer survivors following an 
8-week exercise program. Increased levels of muscular strength and endurance have a 
positive effect on body composition, and is therefore associated with lower cancer mortality 
risk (American Heart Association, 2011).  
3.2.3 Psychosocial measures 
A favorable link between exercise and fatigue, psychosocial measures, and QOL has been 
reported in the literature. Historically, rest was the most common medical advice given for 
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positive effect on body composition, and is therefore associated with lower cancer mortality 
risk (American Heart Association, 2011).  
3.2.3 Psychosocial measures 
A favorable link between exercise and fatigue, psychosocial measures, and QOL has been 
reported in the literature. Historically, rest was the most common medical advice given for 
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the treatment of fatigue (Courneya et al., 2000; Coon & Coleman, 2004; Meyerowitz et al., 
1983). Unfortunately, this can lead to even more fatigue (Schneider et al., 2003), as well as to 
aerobic de-conditioning and a lower functional capacity (Courneya et al., 2005). Conversely, 
several investigations have found that exercise is beneficial in reducing the fatigue 
experienced by individuals undergoing cancer treatment (Dimeo et al., 1996; Mock et al., 
2007; Schwartz et al., 2001; Segal et al., 2001). In general, fatigue tends to subside within the 
first 5-10 minutes of activity. In terms of long-term improvement, research indicates that 
regular aerobic exercise over a period of 6 months improved endurance in breast cancer 
survivors (Damush et al., 2005) and decreased fatigue in patients with prostate and Hodgkin 
Disease (Watson & Mock, 2004).  
Improvements in QOL (Wiggins & Simonavice, 2008, 2009; Courneya et al., 2009), anxiety 
(Courneya et al., 2003, 2000), depression (Courneya et al., 2003, 2000; Pirl & Roth, 1999), 
body image (Pinto et al., 2003), immune function (Galvo & Newton, 2005), and emotional 
well-being (Courneya et al., 2003) have also been reported following structured exercise 
programs. This holds true, even when cancer treatment has failed. It is believed that feelings 
of self-confidence and hope are directly related to the restored energy levels obtained 
through improved cardiorespiratory functioning. In addition, chronic exercise leads to a 
reduction in obesity and improved gastrointestinal functioning, both of which improve self-
image and overall outlook on life (Harriss et al., 2007).  
3.2.4 Cancer-specific benefits 
A concern with cancer survivors is that they often have comorbid conditions that will 
influence exercise prescription and management. More often than not, these comorbidities 
result from the very medications that are used to fight cancer. The good news, however, is 
that in most cases, exercise has been found to exert a positive effect on these toxicities. An 
outline of some of these conditions and the associated benefits of exercise is presented in 
Table 2. It should be noted that, for these adverse effects of cancer treatment, there may be 
predisposing factors which will influence the severity of the treatment effects. 
4. Components of an exercise program 
As demonstrated above, exercise is safe and effective both during and after most types of 
cancer treatment, and should therefore be included as an integral part of an individual’s cancer 
care plan. The American Cancer Society recommends that exercise be part of a continuum of 
cancer survival care, spanning from treatment to recovery, as well as after-recovery 
maintenance and living-with-advanced-cancer (Doyle et al., 2006). At present, exercise and 
cancer recovery programs specifically designed for survivors are being implemented all over 
the country. The following protocols for exercise training with cancer patients are those 
employed by the Maple Tree Cancer Alliance® (MTCA®), a cancer rehabilitation center in 
southwest Ohio dedicated to improving the quality of life of individuals afflicted with cancer 
by focusing on their physical and spiritual needs. All procedures used by MTCA® follow the 
guidelines set forth by the American College of Sports Medicine (ACSM). Typically, the 
training sessions resemble that of a general exercise program, in that they often involve an 
aerobic component, resistance training, and flexibility exercises. However, given the unique 
challenges imposed by working with cancer survivors, ACSM recommends that fitness 
professionals working with cancer patients obtain a specialized training certification prior to 
training this group of individuals (Schneider & Carter, 2003).  
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Cancer Treatment Toxicity Effect of Exercise 
Muscular Degeneration: 
Cancer treatments damage muscle tissue. Muscle 
damage may be severe enough to cause weakness and 
fatigue. 
 
Exercise increases the integrity of 
muscle tissue and protein 
synthesis, stimulates the release 
of numerous hormones that 
increase muscle cell growth and 
development, and improves 
metabolism (DeVita et al., 2001; 
Fischer et al., 2003). 
Neurotoxicity: 
 
Cancer treatments cause a decrease in motor function. 
 
Exercise can enhance motor unit 
recruitment and improve 
neurochemical availability at the 
cellular and tissue levels (Fischer 
et al., 2003; Snyder, 1986). 
Cardiotoxicity: 
Cancer treatments cause: decreased left ventricular 
dysfunction, reduced ejection fraction, diminished 
contractility, reduced cardiac output and stroke 
volume, decreased nutrient and oxygen delivery to 
tissues 
 
Exercise can improve 
cardiovascular efficiency by 
strengthening the myocardium, 
increasing cardiac output and 
stroke volume, and decreasing 
resting heart rate and lowering 
exercise heart rate (DeVita et al., 
2001; Fischer et al., 2003). 
Pulmonary Toxicity: 
Cancer treatments cause a disruption in the structural 
integrity of the airways 
 
Exercise can improve ventilation 
and transport of oxygen from the 
environment to the cellular level 
(Chabner & Longo 2010; Wilson, 
1978). 
Table 2. Persistent Effects of Cancer Treatments Relative to Exercise Training. 
4.1 Phase 1: Exercise during treatment 
The following procedures will assist the fitness trainer to design a safe and effective exercise 
program for patients who are currently undergoing cancer treatment. 
4.1.1 Prescreening 
Given that cancer survivors often have limitations that pose challenges to exercise, it is 
necessary that the exercise intervention be individualized according to the needs of each 
patient. Current health status, cancer treatments, and anticipated disease trajectory must all 
be taken into consideration by the fitness trainer before designing an exercise program 
(Schmitz et al., 2010). Therefore, it is important that fitness professionals work closely with 
physicians and understand the specifics of the cancer survivor’s diagnosis and treatments 
received, including existing health conditions and fitness level prior to cancer diagnosis. 
This is best obtained through comprehensive prescreening paperwork, which should 
include information regarding health history, cancer history, and psychological status, along 
with a medical examination and physician referral (Schneider et al., 2003). 
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patient. Current health status, cancer treatments, and anticipated disease trajectory must all 
be taken into consideration by the fitness trainer before designing an exercise program 
(Schmitz et al., 2010). Therefore, it is important that fitness professionals work closely with 
physicians and understand the specifics of the cancer survivor’s diagnosis and treatments 
received, including existing health conditions and fitness level prior to cancer diagnosis. 
This is best obtained through comprehensive prescreening paperwork, which should 
include information regarding health history, cancer history, and psychological status, along 
with a medical examination and physician referral (Schneider et al., 2003). 
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4.1.2 Fitness assessment 
Once the prescreening paperwork is completed and reviewed, the patient’s current level of 
fitness should be evaluated through a comprehensive fitness assessment. A comprehensive 
fitness assessment is one that measures body composition, cardiorespiratory fitness, 
muscular strength and endurance, flexibility, balance, and range of motion. Specifically, 
ACSM recommends a graded treadmill or bicycle ergometer test to assess cardiovascular 
function, a spirometer test for pulmonary function, dumbbells or resistance machines for 
muscular strength and endurance tests, and the modified sit and reach for flexibility 
assessment (Schneider & Carter, 2003). In most cases, cancer patients can tolerate the 
standardized assessment protocols (Swartz, 2009); however, adaptations for certain exercise 
tests may be necessary if the patient has limited mobility or impaired functioning. Pictures 





Fig. 1. Muscular Strength Assessment. 
 




Fig. 2. Muscular Endurance Assessment. 
 
 
Fig. 3. Flexibility Assessment. 
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Fig. 4. Body Composition Assessment. 
 
 
Fig. 5. Cardiovascular Endurance Assessment. 
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Fitness assessments are useful to quantitatively monitor progress during exercise training. 
Of note, however, is the fact that cancer-specific norms have not yet been developed. 
Therefore, the scores received by the cancer patient during his/her fitness assessment are 
compared to norm charts from a healthy population. This must be taken into consideration 
during goal setting, particularly for those individuals who are currently undergoing 
treatment. Typically, for these individuals, as well as patients with recurrent disease, the 
goal of the exercise program should be simply to preserve function. It is important to have 
realistic expectations for the exercise intervention so that the patient does not become 
discouraged, as research indicates that adherence to an exercise intervention is a challenging 
task (Markes et al., 2006).  
4.1.3 Exercise prescription 
Once the fitness assessment has been completed and reviewed, the fitness trainer may 
design an individualized exercise prescription for the patient. An exercise prescription is a 
plan of fitness-related activities designed for a specific purpose. In other words, an exercise 
prescription is a prescription for exercise. Recommendations pertaining to the frequency, 
intensity, duration, mode, and progression of exercise must be addressed. Ideally, for an 
individual undergoing cancer treatment, the prescription will include a whole-body 
workout that targets all the major muscle groups. The overall goal of the exercise program 
should be to minimize the general de-conditioning that often results from cancer treatment 
so that the cancer treatments are better tolerated. In general, the exercise prescription should 
include a slow progression and demonstrate adaptability to changes in the patient’s health 
status, which frequently will change from day-to-day during treatment. According to ACSM 
(Schmitz et al., 2010), the general objectives for exercise training among cancer survivors are 
as follows: 
1. To regain and improve physical function, aerobic capacity, strength, and flexibility. 
2. To improve body image and QOL. 
3. To improve body composition. 
4. To improve cardiorespiratory, endocrine, neurological, muscular, cognitive, and 
psychosocial outcomes. 
5. Potentially, to reduce or delay recurrence or a second primary tumor. 
6. To improve the ability to physically and psychologically withstand the ongoing anxiety 
regarding recurrence or a second primary cancer. 
7. To reduce, attenuate, and prevent long-term and late effects of cancer treatment. 
8. To improve the physiologic and psychological ability to withstand any current or future 
cancer treatments. 
At present, the optimal frequency, duration, and time course of adaptation to aerobic and 
resistance exercise training in cancer patients are not known, although research indicates 
that individuals undergoing cancer therapy benefit from low-to-moderate intensity aerobic 
and resistance exercise (Swartz, 2009). Based on available data, Table 3 presents some 
general guidelines a fitness professional may follow when designing an exercise program 
(Schmitz et al., 2010; Physical Activities Guidelines Advisory Committee, 2008; Haskell et 
al., 2007; Schneider & Carter, 2003).  
 Initially, intensity will depend on the patient’s functional status and exercise history prior to 
cancer diagnosis. Typically, previously active cancer patients may continue their exercise 
regimen, although intensity may need to be decreased during treatment. Progression should 
consist of increases in frequency and duration rather than in intensity (Physical Activities 
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Guidelines Committee, 2008; Schneider & Carter, 2003). To assist in progression, patients 
should be reassessed approximately every 6 months (Schneider & Carter, 2003). 
  
 Aerobic Training Strength Training Flexibility Training 
Frequency 3-5 days/wk 2-3 days/wk 2-7 days/wk 
Intensity 40-60% HRR* 40-60% HRR* Stretch to the point 
of mild discomfort 
Duration 20-60 min/session 1-3 sets, 8-12 reps 
per exercise 
10-30 seconds per 
stretch 







*HRR = Heart Rate Reserve 
HRR = [(Maximum Heart Rate – Resting Heart Rate) x % Intensity] + Resting Heart Rate 
Table 3. Guidelines for Designing an Exercise Prescription for Individuals Undergoing 
Cancer Treatment. 
4.1.4 Supervised exercise sessions 
Once the individualized exercise prescription has been created, the patient may begin 
supervised training sessions with the fitness professional. Prior to each exercise session, it is 
advisable to assess the patient’s readiness to exercise. Resting heart rate and blood pressure 
should be measured, and general information regarding the patient’s overall health status 
should be obtained. Contraindications to exercise are listed in Table 4. Depending on the 
information attained, the exercise intervention may need to be adjusted for that day.  
 
Onset of nausea following exercise initiation 
Vomiting within the last 24 hours 
Leg pain 
Decreased heart rate and blood pressure with increased workload 
Chest pain 
Difficult or shallow breathing 
Unusual muscle weakness 
Numbness in the extremities 
Chemotherapy treatment within the last 24-hours 
Irregular pulse during exertion 
Disorientation and confusion 
Dizziness 
Table 4. Contraindications to exercise in cancer patients. 
Each session should begin with a 5- to 10-minute warm-up that stimulates blood flow to the 
working muscles. The warm-up should involve some mild stretching and light aerobic 
activity. During the aerobic component of exercise, it is important to frequently monitor 
blood pressure and heart rate. If the patient is on a medication that affects heart rate, the 
Borg Scale of Exertion (Borg, 1973) (Figure 6) may be used to monitor intensity. Based on 
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this scale, a light-to-moderate intensity (RPE of 11 to 14) should be encouraged. If dizziness, 
nausea, or chest pain occurs, all exercise should be stopped. Frequent short breaks are 
sometimes encouraged to accommodate therapy-related fatigue. Aerobic exercise should be 
followed up by static stretching and range of motion exercises for all major muscle groups.  
 
 
Fig. 6. The Borg Scale Rating Perception of Effort (RPE).  
The type of resistance exercise performed will depend on the patient’s range of motion, 
tissue removal, and wound healing. ACSM recommends at least 48 hours of rest between 
each resistance training session (Schneider & Carter, 2003). Therefore, it may be advisable to 
plan a whole body approach to resistance training, where all major muscle groups are 
targeted in one day. If the patient is unwilling or unable to participate in traditional modes 
of strength training, Yoga or Pilates may serve as an alternative form of strength exercise. 
Sample exercises are shown in pictures below (Figures 7-10). 
At the conclusion of the exercise session, the patient should perform a 5-10 minute cool 
down along with some mild stretching. Sample stretches are shown in the pictures below 
(Figures 11 and 12). A proper cool down will reduce the potential for muscle soreness, 
decrease post-exercise dizziness, and allow the heart rate to return to its resting state.  
4.2 Phase 2: Exercise after cancer recovery 
For patients who have completed cancer therapy, exercise is important to maintain or 
improve function and prevent the development of diseases associated with inactivity (i.e. 
diabetes, cardiovascular disease, obesity) (Swartz, 2009). The objective of exercise training 
during cancer recovery should be to return the patient to their former level of physical 
function and make exercise an integral part of everyday life. Some side effects of anticancer 
medications do not appear for months or years after the discontinuation of treatment, 
therefore it is advised to maintain contact with the patient’s physician, in order to monitor 
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any changes in health status. The fitness professional should follow the same general 







Fig. 7. Lat Pull Down. 
 






Fig. 8. Lateral Chest Press. 
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Fig. 8. Lateral Chest Press. 
 






Fig. 9. Shoulder Press. 
 





Fig. 10. Leg Press. 
 
 
Fig. 11. Lower body stretch. 
 






Fig. 9. Shoulder Press. 
 





Fig. 10. Leg Press. 
 
 
Fig. 11. Lower body stretch. 
 




Fig. 12. Upper body stretch. 
5. Conclusion 
Two decades of research support the assertion that exercise is both safe and beneficial 
during cancer treatment. Most standard exercise protocols are well tolerated by patients. 
However, it is important that the fitness professional be aware of the specific effects of 
cancer and its treatments on the exercise response. Exercise prescriptions must be 
individualized according to the specific needs and health status of each patient. During each 
exercise session, modifications may need to be made to ensure patient safety, depending on 
the changing health of each patient. With the right program, remaining physically active 
during and after cancer treatment will improve the patient’s muscular strength and aerobic 
functioning, decrease fatigue, improve QOL and have a favorable effect on anxiety.  
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Fig. 12. Upper body stretch. 
5. Conclusion 
Two decades of research support the assertion that exercise is both safe and beneficial 
during cancer treatment. Most standard exercise protocols are well tolerated by patients. 
However, it is important that the fitness professional be aware of the specific effects of 
cancer and its treatments on the exercise response. Exercise prescriptions must be 
individualized according to the specific needs and health status of each patient. During each 
exercise session, modifications may need to be made to ensure patient safety, depending on 
the changing health of each patient. With the right program, remaining physically active 
during and after cancer treatment will improve the patient’s muscular strength and aerobic 
functioning, decrease fatigue, improve QOL and have a favorable effect on anxiety.  
6. References 
Activities Guidelines Advisory Committee. (2008). Physical Activity Guidelines Advisory 
Committee Report. US Department of Health and Human Services, Philadelphia, PA. 





The Role of Exercise in Cancer Survivorship 
 
143 
American Cancer Society. (2011). Stay Healthy. Healthy living information to help you stay 
well. Date of access: March 24, 2011. Available from: 
  http://www.cancer.org/Healthy/EatHealthyGetActive/GetActive/index 
American Heart Association. (2011). Physical Activity. Date of Access: April 14, 2011. 
Available from: 
 http://www.americanheart.org/presenter.jhtml?identifier=4563 
Borg, G.A.V. (1973). Rating Perception of Effort. Lippincott, Williams, & Wilkins, Philadelphia, 
PA. 
Cella, D., Lai, J.S., Chang, C.H., Peterman, A., & Slavin, M. (2002). Fatigue in cancer patients 
compared with fatigue in the general United States population. Cancer, 94, No. 2, 
pp. 528-38. 
Centers for Disease Control and Prevention. (2007). Cancer survivors—United States, 2007. 
MMWR. Recommendations and reports : Morbidity and mortality weekly report. 
Recommendations and reports / Centers for Disease Control, 60,9, pp. 269–272. 
Chabner, B.A., & Longo D.L. (2010). Cancer Chemotherapy and Biotherapy (5th ed.). Lippincott 
Williams & Wilkins, ISBN-10: 1605474312, Philadelphia, PA. 
Cheema, B.S.B, & Gual, C.A. (2006). Full-body exercise training improves fitness and quality 
of life in survivors of breast cancer. Journal of Strength and Conditioning Research, 20, 
No. 1, pp.14-21. 
Coon, S.K. & Coleman, E.A. (2004). Keep moving: Patients with myeloma talk about exercise 
and fatigue. Oncology Nursing Forum. 31, No. 6, pp. 1127-35. 
Courneya, K.S. & Friedenreich, C.M. (2007). Physical activity and cancer control. Seminars in 
Oncology Nursing, 23, pp. 242-52. 
Courneya, K.S., Friedenreich, C.M., Quinney, H.A., Fields, A.L.A, Jones, L.W., & Fairey A,S. 
(2003) A randomized trial of exercise and quality of life in colorectal cancer 
survivors. European Journal of Pharmacology, 12, 347-57. 
Courneya, K.S., Keats, M.R., & Turner, A.R. (2000). Physical exercise and quality of life in 
cancer patients following a high dose chemotherapy and autologous bone marrow 
transplatation. Psycho-oncology. 9, No. 2, pp. 127-36. 
Courneya, K.S., Stellar, C.M., Stevinson, C., McNeely, M.L., Peddle, C.J., Friedenreich, C.M., 
Tankel, K., Basi, S., Chua, N., & Mazurek, A. (2009). Randomized controlled trial of 
the effects of aerobic exercise on physical functioning and quality of life in 
lymphoma patients. Journal of Clinical Oncology, 27, No. 27, pp. 4605-12. 
Courneya, K.S., Vallance, J.K.H., Jones, L.W., & Reiman, T. (2005). Correlates of exercise 
interventions in non-Hodgkin’s lymphoma survivors: An application of the Theory 
of Planned Behavior. Journal of Sport and Exercise Psychology, 27, pp. 335-49. 
Damush, T., Perkins, A., & Miller, K. (2006). The implementation of an oncologist referred, 
exercise self-management program for older breast cancer survivors. Psycho-
oncology 15, No. 10, pp. 884-90. 
DeVita, V.T., Hellman, S., & Rosenberg, S.A. (2001). Cancer: Principles and Practice of Oncology 
(6th ed.). Vols. 1 and 2. Lippincott-Williams & Wilkins, ISBN-10: 0781722292, 
Philadelphia, PA. 
DeVita, V.T., Lawrence, T.S., & Rosenberg, S.A. (2008). Supportive Care and Quality of Life. 
In: Cancer: Principles & Practice of Oncology. Vol. 2. (8th ed.). pp. 2796. Lippincott 
Williams & Wilkins, ISBN-10: 9780781772075, Philadelphia, PA. 
 
Topics in Cancer Survivorship 
 
144 
Dimeo, F., Bertz, H., Finde, J., Fetscher, S., Mertelsmann, R., & Kuel, J. (1996). An aerobic 
exercise program for patients with haematological malignancies after bone marrow 
transplantation. Bone Marrow Transplantation, 18, No. 6, pp. 1157-60. 
Douglas, E. (2005). Exercise in cancer patients. The Physical Therapy Review, 10, pp. 71-88. 
Doyle, C., Kushi, L., Byers, T., Courneya, K.S., Denmark-Wahnefried, W., Grant, B., 
McTiernan, A., Rock, C.L., Thompson, C., Gansler, T., & Andrews, K.S. (2006). 
Nutrition and physical activity during and after cancer treatment: an American 
Cancer Society guide for informed choices. Cancer Journal for Clinicians, 56, No. 6, 
pp. 323-53. 
Fischer,D.S., Knobf, M.T., & Durivage, H.J. (2003). The Cancer Chemotherapy Handbook (6th 
ed.). Mosby, ISBN-10: 0323018904, St. Louis.  
Friedenreich, C.M. & Orenstein, M.R. (2002). Physical activity and cancer prevention: 
Etiologic evidence and biological mechanisms. The Journal of Nutrition, 132, pp. 
5456-64. 
Galvo, D.A. & Newton, R.U. (2005). Review of exercise intervention studies in cancer 
patients. Journal of Clinical Oncology, 23, No. 4, 899-909. 
Haran, C. & DeVita, V. (2005). The view from the top. Cancer World, 6 (June, 2005), pp. 38–43. 
Harriss, D., Cable, T., George, K., Reilly, T., Renenan, A.G., & Haboubi, N. (2007). Physical 
activity before and after diagnosis of colorectal cancer. Sports Medicine, 37, No. 11, 
pp. 947-60. 
Hartvig, P., Aulin, J., Hugerth, M., Wallenberg, S., & Wagenius, G. (2006). Fatigue in cancer 
patients treatedwith cytotoxic drugs. Journal of Oncology Pharmacy Practice, 12, No. 
3, pp. 155-164. 
Haskell, W.L., Lee, I.M., Pate, R.R., Powell, K.E., Blair, S.N., Franklin, B.A., Macera, C.A., 
Heath, G.W., Thompson, P.D., & Bauman, A. (2007). Physical activity and public 
health: Updated recommendation for adults from the American College of Sports 
Medicine and the American Heart Association. Medicine and Science in Sports and 
Exercise, 39, No. 8, pp. 1423-34. 
Haydon, A.M., Macinnis, R, English, D, & Giles G.G. (2006). The effect of physical activity 
and body size on survival after diagnosis with colorectal cancer. Gut, 55, No. 1, pp. 
62-7. 
Holmes, M.D., Chen, W.Y., Feskanich, D, Kroenke, C.H., & Colditz, G.A. (2005). Physical 
activity and survival after breast cancer diagnosis. JAMA, 293, No. 20, pp. 2479-86. 
Jones, J.M., Cheng, T., Jackman, M., Rodin, G., Walton, T., & Catton, P. (2010). Self-efficacy, 
perceived preparedness, and psychological distress in women completing primary 
treatment for breast cancer. Journal of Psychosocial Oncology, 28, No. 3, pp. 269-90. 
Kercher, K., Fleischer, A., & Yosipovitch, G. (2008). Lower extremity lymphedema update: 
pathophysiology, diagnosis, and treatment guidelines. Journal of the American 
Academy of Dermatology, 59, No. 2, 324-31. 
Klein, M. (2009). Immunobiological and neural substrates of cancer-related neurocognitive 
deficits. The Neuroimmunological Basis of Behavior and Mental Disorders, 3, pp. 327-40. 
Kruk, J. (2007). Physical activity in the prevention of the most frequent chronicdiseases: An 
analysis of the recent evidence. Asian Pacific Journal of Cancer Prevention, 8, pp.325-
38. 
Lee, I.M. (2003). Physical activity and cancer prevention – data from epidemiologic studies. 
Medicine and Science in Sports and Exercise, 35, No. 11, pp. 1823-7. 
 
The Role of Exercise in Cancer Survivorship 
 
145 
Lucia, A., Earnest, C., & Perez M. (2003). Cancer-related fatigue: Can exercise physiology 
assist oncologists? The Lancet Oncology, 4, No. 10, pp. 616-25. 
Markes, M., Brockow, T., & Resch, K.L. (2006). Exercise for women receiving adjuvant 
therapy for breast cancer. Cochrane Database of Systematic Reviews (Online), 18, No. 4, 
pp. CD005001. 
Martingnoni, M., Kunze, P., & Friess, H. (2003). Cancer Cachexia. Molecular Cancer, 2, pp. 36. 
Meyerhardt, J.A., Giovannucci, E.L., Holmes, M.D., Chan, A.T., Chan, J.A., Colditz, G.A., & 
Fuchs C.S. (2006). Physical activity and survival after colorectal cancer diagnosis. 
Journal of Clinical Oncology, 24, No. 22, pp. 3527-34. 
Meyerhardt, J.A., Heseltine, D., Niedzwiecki, D., Hollis, D., Saltz, L.B., Mayer, R.J., Thomas, 
J., Nelson, H., Whittom, R., Hantel, A., Schilsky, R.L., & Fuchs, C.S. (2006). Impact 
of physical activity on cancer recurrence and survival in patients with stage III 
colon cancer: Findings from CALGB 89803. Journal of Clinical Oncology, 24, No. 22, 
pp. 3535-41. 
Meyerowitz, B.E., Watkins, I.K., & Sparks, F.C. (1983). Quality of life for breast cancer 
patients receiving adjuvant chemotherapy. The American Journal of Nursing, 83, No. 
2, pp. 232-35. 
Miles, L. (2007). Physical activity and the prevention of cancer: A review of recent findings. 
Nutrition Bulletin, 32, pp. 250-82. 
Mock, V., Dow, K.H., Meares, C.J., Grimm, P.M., Dienemann, J.A., Haisfield-Wolfe, M.E., 
Quitasol, W.,  
Mitchell, S., Chakravorthy, A., & Gage, I. (2007). Effects of exercise on fatigue, physical 
functioning, and emotional distress during radiation therapy for breast cancer. 
Oncology Nursing Forum, 24, No. 6, pp. 991-1000. 
Muss, H.B. (2007) Breast cancer and differential diagnosis of benign lesions. In Cecil Medicine 
(23rd ed.), Goldman. L., Ausiello, D., eds. Pp. 1501-1509, Saunders Elsevier, ISBN-10: 
1416028056, Philadelphia, PA. 
National Cancer Institute. (2009) Cancer Trends Progress Report – 2007. Date of access: 
March 28, 2011. Available from 
  http://progressreport.cancer.gov/doc.asp?pid=1&did=2007&mid=vcol&chid=71  
National Institutes of Health. (2011). Estimates of Funding for Various Research,Condition, 
and Disease Categories. Date of access: March 24, 2011. Available from: 
 http://report.nih.gov/rcdc/categories/ 
Pihkala, J., Happonen, J.M., Virtanen, K., Souijarvi, A., Simes, M.A., Pesonen, E., & Saarinen 
U.M. (1995). Cardiopulmonary evaluation of exercise tolerance after chest 
irradiation and anticancer chemotherapy in children and adolescents. Pediatrics. 95, 
No. 5, pp. 722-26. 
Pinto, B., Clark, M., Maruyama, N., & Feder, F. (2003). Psychological and fitness changes 
associated with exercise participation among women with breast cancer. Psycho-
oncology. 12, No. 2, pp. 118-26. 
Pirl W.F. & Roth, A.J. (1999). Diagnosis and treatment of depression in cancer patients. 
Oncology 13, No. 9, pp. 1293-1301. 
Quist, M., Rorth, M., Zacho, M., Andersen, C., Moeller, T., Midtgaard, J., Adamsen, L. 
(2006). High-intensity resistance and cardiovascular training improve physical 
capacity in cancer patients undergoing chemotherapy. Scandinavian Journal of 
Medicine & Science in Sports, 16, No. 5, pp. 349-57. 
 
Topics in Cancer Survivorship 
 
144 
Dimeo, F., Bertz, H., Finde, J., Fetscher, S., Mertelsmann, R., & Kuel, J. (1996). An aerobic 
exercise program for patients with haematological malignancies after bone marrow 
transplantation. Bone Marrow Transplantation, 18, No. 6, pp. 1157-60. 
Douglas, E. (2005). Exercise in cancer patients. The Physical Therapy Review, 10, pp. 71-88. 
Doyle, C., Kushi, L., Byers, T., Courneya, K.S., Denmark-Wahnefried, W., Grant, B., 
McTiernan, A., Rock, C.L., Thompson, C., Gansler, T., & Andrews, K.S. (2006). 
Nutrition and physical activity during and after cancer treatment: an American 
Cancer Society guide for informed choices. Cancer Journal for Clinicians, 56, No. 6, 
pp. 323-53. 
Fischer,D.S., Knobf, M.T., & Durivage, H.J. (2003). The Cancer Chemotherapy Handbook (6th 
ed.). Mosby, ISBN-10: 0323018904, St. Louis.  
Friedenreich, C.M. & Orenstein, M.R. (2002). Physical activity and cancer prevention: 
Etiologic evidence and biological mechanisms. The Journal of Nutrition, 132, pp. 
5456-64. 
Galvo, D.A. & Newton, R.U. (2005). Review of exercise intervention studies in cancer 
patients. Journal of Clinical Oncology, 23, No. 4, 899-909. 
Haran, C. & DeVita, V. (2005). The view from the top. Cancer World, 6 (June, 2005), pp. 38–43. 
Harriss, D., Cable, T., George, K., Reilly, T., Renenan, A.G., & Haboubi, N. (2007). Physical 
activity before and after diagnosis of colorectal cancer. Sports Medicine, 37, No. 11, 
pp. 947-60. 
Hartvig, P., Aulin, J., Hugerth, M., Wallenberg, S., & Wagenius, G. (2006). Fatigue in cancer 
patients treatedwith cytotoxic drugs. Journal of Oncology Pharmacy Practice, 12, No. 
3, pp. 155-164. 
Haskell, W.L., Lee, I.M., Pate, R.R., Powell, K.E., Blair, S.N., Franklin, B.A., Macera, C.A., 
Heath, G.W., Thompson, P.D., & Bauman, A. (2007). Physical activity and public 
health: Updated recommendation for adults from the American College of Sports 
Medicine and the American Heart Association. Medicine and Science in Sports and 
Exercise, 39, No. 8, pp. 1423-34. 
Haydon, A.M., Macinnis, R, English, D, & Giles G.G. (2006). The effect of physical activity 
and body size on survival after diagnosis with colorectal cancer. Gut, 55, No. 1, pp. 
62-7. 
Holmes, M.D., Chen, W.Y., Feskanich, D, Kroenke, C.H., & Colditz, G.A. (2005). Physical 
activity and survival after breast cancer diagnosis. JAMA, 293, No. 20, pp. 2479-86. 
Jones, J.M., Cheng, T., Jackman, M., Rodin, G., Walton, T., & Catton, P. (2010). Self-efficacy, 
perceived preparedness, and psychological distress in women completing primary 
treatment for breast cancer. Journal of Psychosocial Oncology, 28, No. 3, pp. 269-90. 
Kercher, K., Fleischer, A., & Yosipovitch, G. (2008). Lower extremity lymphedema update: 
pathophysiology, diagnosis, and treatment guidelines. Journal of the American 
Academy of Dermatology, 59, No. 2, 324-31. 
Klein, M. (2009). Immunobiological and neural substrates of cancer-related neurocognitive 
deficits. The Neuroimmunological Basis of Behavior and Mental Disorders, 3, pp. 327-40. 
Kruk, J. (2007). Physical activity in the prevention of the most frequent chronicdiseases: An 
analysis of the recent evidence. Asian Pacific Journal of Cancer Prevention, 8, pp.325-
38. 
Lee, I.M. (2003). Physical activity and cancer prevention – data from epidemiologic studies. 
Medicine and Science in Sports and Exercise, 35, No. 11, pp. 1823-7. 
 
The Role of Exercise in Cancer Survivorship 
 
145 
Lucia, A., Earnest, C., & Perez M. (2003). Cancer-related fatigue: Can exercise physiology 
assist oncologists? The Lancet Oncology, 4, No. 10, pp. 616-25. 
Markes, M., Brockow, T., & Resch, K.L. (2006). Exercise for women receiving adjuvant 
therapy for breast cancer. Cochrane Database of Systematic Reviews (Online), 18, No. 4, 
pp. CD005001. 
Martingnoni, M., Kunze, P., & Friess, H. (2003). Cancer Cachexia. Molecular Cancer, 2, pp. 36. 
Meyerhardt, J.A., Giovannucci, E.L., Holmes, M.D., Chan, A.T., Chan, J.A., Colditz, G.A., & 
Fuchs C.S. (2006). Physical activity and survival after colorectal cancer diagnosis. 
Journal of Clinical Oncology, 24, No. 22, pp. 3527-34. 
Meyerhardt, J.A., Heseltine, D., Niedzwiecki, D., Hollis, D., Saltz, L.B., Mayer, R.J., Thomas, 
J., Nelson, H., Whittom, R., Hantel, A., Schilsky, R.L., & Fuchs, C.S. (2006). Impact 
of physical activity on cancer recurrence and survival in patients with stage III 
colon cancer: Findings from CALGB 89803. Journal of Clinical Oncology, 24, No. 22, 
pp. 3535-41. 
Meyerowitz, B.E., Watkins, I.K., & Sparks, F.C. (1983). Quality of life for breast cancer 
patients receiving adjuvant chemotherapy. The American Journal of Nursing, 83, No. 
2, pp. 232-35. 
Miles, L. (2007). Physical activity and the prevention of cancer: A review of recent findings. 
Nutrition Bulletin, 32, pp. 250-82. 
Mock, V., Dow, K.H., Meares, C.J., Grimm, P.M., Dienemann, J.A., Haisfield-Wolfe, M.E., 
Quitasol, W.,  
Mitchell, S., Chakravorthy, A., & Gage, I. (2007). Effects of exercise on fatigue, physical 
functioning, and emotional distress during radiation therapy for breast cancer. 
Oncology Nursing Forum, 24, No. 6, pp. 991-1000. 
Muss, H.B. (2007) Breast cancer and differential diagnosis of benign lesions. In Cecil Medicine 
(23rd ed.), Goldman. L., Ausiello, D., eds. Pp. 1501-1509, Saunders Elsevier, ISBN-10: 
1416028056, Philadelphia, PA. 
National Cancer Institute. (2009) Cancer Trends Progress Report – 2007. Date of access: 
March 28, 2011. Available from 
  http://progressreport.cancer.gov/doc.asp?pid=1&did=2007&mid=vcol&chid=71  
National Institutes of Health. (2011). Estimates of Funding for Various Research,Condition, 
and Disease Categories. Date of access: March 24, 2011. Available from: 
 http://report.nih.gov/rcdc/categories/ 
Pihkala, J., Happonen, J.M., Virtanen, K., Souijarvi, A., Simes, M.A., Pesonen, E., & Saarinen 
U.M. (1995). Cardiopulmonary evaluation of exercise tolerance after chest 
irradiation and anticancer chemotherapy in children and adolescents. Pediatrics. 95, 
No. 5, pp. 722-26. 
Pinto, B., Clark, M., Maruyama, N., & Feder, F. (2003). Psychological and fitness changes 
associated with exercise participation among women with breast cancer. Psycho-
oncology. 12, No. 2, pp. 118-26. 
Pirl W.F. & Roth, A.J. (1999). Diagnosis and treatment of depression in cancer patients. 
Oncology 13, No. 9, pp. 1293-1301. 
Quist, M., Rorth, M., Zacho, M., Andersen, C., Moeller, T., Midtgaard, J., Adamsen, L. 
(2006). High-intensity resistance and cardiovascular training improve physical 
capacity in cancer patients undergoing chemotherapy. Scandinavian Journal of 
Medicine & Science in Sports, 16, No. 5, pp. 349-57. 
 
Topics in Cancer Survivorship 
 
146 
Schneider, C.M., Carter, S. (2003). The role of exercise in recovery from cancer treatment. 
Rocky Mountain Cancer Rehabilitation Institute. ACSM Fit Society Page, 6, pp. 9. 
Schneider, C.M., Dennehy, C.A., & Carter, S.D. (2003). Exercise and Cancer Recovery. Human 
Kinetics, ISBN-10: 736036458, Champaign, IL. 
Schmitz, K.H., Courneya, K.S., Matthews, C., Demark-Wahnefried, W., Galval, D.A., Pinto, 
B.M., Irwin, M.L., Wolin, K.Y., Segal, R.J., Lucia, A., Schneider, C.M., von 
Gruenigen, V.E., & Schwartz, A.L. (2010). American College of Sports Medicine 
Roundtable on Exercise Guidelines for Cancer Survivors. Medicine and Science in Sports 
and Exercise, 42, No. 7, 1409-26. 
Schwartz, A.I., Mori, M., Gao, R., Nail, L.M., & King, M.E. (2001). Exercise reduced daily 
fatigue in women with breast cancer receiving chemotherapy. Medicine and Science 
in Sports and Exercise, 33, No. 5, pp. 718-23. 
Segal, R., Evans, W., Johnson, D., Smith, J., Colletta, S., Gayton, J., Woodard, S., Walls, G., & 
Reid, R. (2001). Structured exercise improves physical functioning in women with 
stages I and II breast cancer: Results of a randomized controlled trial. Journal of 
Clinical Oncology, 19, No. 3, pp. 657-65. 
Snyder, C.C. (1986). Oncology Nursing. Little Brown, Boston. 
Swartz, A.L. (2009). Cancer, In: ACSM’s Exercise Management for Persons with Chronic Diseases 
and Disabilities (3rd ed.). Durstine, J.L., Moore, G.E., Painter, P.L., Roberts, S.O., 
(Eds.). pp. 211-218, Human Kinetics, ISBN-10: 0736074333, Champaign, IL. 
Thorsen, L., Skovlund, E., Stromme, S.B., Hornslien, K., Dahl, A.A., & Fossa, S.D. (2005). 
Effectiveness of physical activity on cardiorespiratory fitness and health-Related 
quality of life in young and middle-aged cancer patients after chemotherapy. 
Journal of Clinical Oncology, 23, No. 10, pp. 2378-88. 
Watson, T. & Mock, V. (2004). Exercise as an intervention for cancer-related fatigue. Physical 
Therapy, 84, No. 8, pp. 736-43. 
Wiggins, M.S. & Simonavice, E.M. (2008). Quality of life benefits: A 12-month exercise 
cancer recovery casestudy. KAHPERD Journal. 44, pp.16-9. 
Wiggins, M.S. & Simonavice, E.M. (2009). Quality of life benefits in cancer survivorship with 
supervisedexercise. Physiological Reports, 104, No. 2, 421-24. 
Wiggins, M.S. & Simonavice, E.M. (2010). Cancer prevention, aerobic capacity, and physical 
functioning in survivors related to physical activity: A recent review. Cancer 
Management and Research, 2, pp. 157-64. 
Wilmore, J.H., Costill, D.L., & Kenney, W.L. (2008). Physiology of Sport and Exercise. (4th ed.). 
Human Kinetics. ISBN-10: 9780736055833, Champaign, IL.  
Wilson, J.K.V. (1978). Pulmonary toxicity of antineoplastic drugs. Cancer Treatment Reports, 
62, No. 12, pp. 2003-8. 
World Health Organization. (2009). Geneva: The Organization; 2009. Fact sheet no. 297: 
Cancer. Date of Access: March 28, 2011. Available from: 
 http://who.int/mediacentre/factsheets/fs297/en/index.html 
Young-McCaughan, S., Mays, M.Z., Arzola, S.M., Yoder, LH., Dramiga, S.A., Leclerc K.M., 
Caton, J.R., Sheffler, R.L., & Nowlin M.U. (2003). Change in exercise tolerance, 
activity and sleep patterns, and quality of life in patients with cancer participating 
in a structured exercise program. Oncology Nursing Forum, 30, No. 3, pp. 441-52. 
Young-McCaughan, S. (2006). Exercise in the rehabilitation from cancer. Medsurg Nursing, 
15, No. 6, pp. 384-88. 
10 
Nutritional Supplements for Cancer-Associated 
Fatigue and Cancer Therapy – A Molecular 
Basis for Restoring Mitochondrial Function 
Garth L. Nicolson 
Department of Molecular Pathology, 
The Institute for Molecular Medicine, Huntington Beach, California, 
USA  
1. Introduction  
Cancer patients routinely take multiple – dietary supplements to prevent recurrence or 
chronic disease, to improve quality of life and overall health, or to reduce the adverse effects 
of cancer therapy (Gansler et al., 2008; Miller et al., 2009; Ströhle et al., 2010; Velicer & 
Ulrich, 2008). In fact, one of the most common behavior changes among cancer patients is 
the use of dietary supplements (Miller et al., 2009). 
Although cancer patients routinely use dietary supplements, there is often little 
consideration as to their safety, efficacy and potential negative effects (Cassileth et al., 2009; 
Giovannucci & Chan, 2010). In fact, some data suggest that higher than recommended doses 
of some vitamins and minerals might result in enhancement of carcinogenesis, changes in 
survival in some cancers and interference with therapy or prescription medications 
(Cassileth et al., 2009; Giovannucci & Chan, 2010). Nonetheless, several potentially beneficial 
effects of dietary supplements have been recorded, including reductions in the risk of cancer 
carcinogenesis and tumor progression, enhancement of immune responses against cancers 
or immune systems in general, improvements in nutrition and general health, and 
reductions in the adverse effects of cancer therapy (Cassileth et al., 2009; Doyle et al., 2006; 
Isenring et all, 2010; Miller et al., 2009; Conklin, 2000; Nicolson & Conklin, 2008; Nicolson, 
2010; Ströhle et al., 2010),  
This review will concentrate on one particularly troublesome aspect of cancer and cancer 
therapy—cancer-associated fatigue. 
2. The importance of cancer-associated fatigue 
Cancer-associated fatigue adds considerably to cancer morbidity (Brown & Kroenke, 2009; 
Hofman et al., 2007). It exists in all types of cancers from the least to the most progressed 
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This review will concentrate on one particularly troublesome aspect of cancer and cancer 
therapy—cancer-associated fatigue. 
2. The importance of cancer-associated fatigue 
Cancer-associated fatigue adds considerably to cancer morbidity (Brown & Kroenke, 2009; 
Hofman et al., 2007). It exists in all types of cancers from the least to the most progressed 
cancers (Brown & Kroenke, 2009; Hofman et al., 2007). Along with pain and nausea, it is one 
of the most common and troublesome symptoms of cancer (Hofman et al., 2007; Prue et al., 
2006), especially in advanced cancers (Curt et al., 2000; Prue et al., 2006; Respini et al., 2003).  
In patients receiving adjuvant therapies the prevalence of cancer-associated fatigue is 
reported to be as high as 95% (Sood & Moynihan, 2005). Thus cancer-associated fatigue is a 
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problem before, during and after therapy and can continue to be a problem years after 
cancer treatment (Curt et al., 2000; Hofman et al., 2007). Cancer-associated fatigue has a very 
strong negative effect on quality of life; therefore, addressing and reducing cancer-
associated fatigue should be an important consideration in the treatment of cancer (Curt et 
al., 2000; Nicolson, 2010). 
Although not well understood, cancer-associated fatigue is thought to be a combination of 
the effects of having cancer plus the effects of cancer treatments (Curt et al., 2000; Hofman et 
al., 2007). Unfortunately, cancer-associated fatigue is rarely treated, and is often thought to 
be an unavoidable symptom (Brown & Kroenke, 2009; Hofman et al., 2007).  
Cancer-associated fatigue can be considered to be the product of a variety of contributing 
factors (Ahlberg et al., 2003). In addition to a decrease in the availability of cellular energy, 
there are psychological factors, such as the presence of depression, anxiety, sleep 
disturbances, among others, as well as anemia, endocrine changes, poor nutritional status, 
release of inflammatory cytokines and cancer therapy that can all contribute to cancer-
associated fatigue (Ahlberg et al., 2003; Gutstein, 2001; Manzullo & Escalante, 2002; Sood & 
Moynihan, 2005). Thus cancer-associated fatigue does not occur as an isolated symptom; 
rather, it occurs as one of multiple symptoms that are present in cancer patients. Similar to 
some other symptoms in cancer patients, the severity of cancer-associated fatigue correlates 
with decreased functional abilities (Given et al., 2001).  
Cancer therapy also contributes to cancer-associated fatigue (Sood & Moynihan, 2005). In 
fact, the most commonly found and disabling effect of cancer therapy is fatigue (Given et al., 
2001; Sood & Moynihan, 2005; Vogelzang et al., 1997). During cancer therapy fatigue 
problems can vary, from mild to severe, and excess fatigue during cancer therapy is a 
significant reason why patients discontinue therapy (Liu et al., 2005). Reviewing articles on 
the effects of cancer therapy on fatigue, it was noted that 80-96% of patients receiving 
chemotherapy and 60-93% receiving radiotherapy experienced moderate to severe fatigue, 
and fatigue continued for months to years after cancer therapy ended (Manzullo & 
Escalante, 2002). Therefore, in cancer patients controlling cancer-associated fatigue as well as 
therapy-induced fatigue are both important strategies (Marrow, 2007).  
There have been efforts at understanding and treating cancer-associated fatigue as well as 
developing ways to distinguish between depression and cancer-associated fatigue (Brown & 
Kroenke, 2009). Both cancer-associated fatigue and depression have multidimensional and 
heterogeneous qualities, possessing physical, cognitive and emotional dimensions and a 
certain degree of overlap across these dimensions (Brown & Kroenke, 2009; Sood & 
Moynihan, 2005). In cancer patients fatigue or loss of energy is a core aspect of diagnosing 
depression—thus both fatigue and depression are often diagnosed together. This is usually 
accomplished by self-assessment, where fatigue and depression are considered to be part of 
a clinical symptom cluster, co-morbitity or syndrome (Arnold, 2008; Bender et al., 2008). 
There are techniques, moreover, that can distinguish between these two different symptoms 
by removal of fatigue-associated assessments from an analysis of depression (Smets et al., 
1996; Stone et al., 2000). When assessing fatigue or cancer-associated fatigue, criteria have 
been established that take depression into consideration, and these two symptoms can thus 
be separated out by considering unshared properties (Cella et al., 2001). 
Chronic or intractable fatigue lasting more than 6 months that is not reversed by normal 
sleep is the most common complaint of patients seeking general medical care (Kroenke et 
al., 1988; Morrison, 1980). It occurs naturally during aging and is also an important 
secondary condition in many clinical diagnoses (Kroenke et al., 1988; McDonald et al., 1993). 
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Most fatigued patients understand fatigue as a loss of energy and inability to perform even 
simple tasks without exertion. Many medical conditions are associated with fatigue, 
including respiratory, coronary, musculoskeletal, and bowel conditions as well as infections 
(Kroenke et al., 1988; McDonald et al., 1993; Morrison, 1980). However, this symptom is 
especially important in the overwhelming majority of cancer patients (Ahlberg et al., 2003; 
Curt et al., 2000; Hofman et al., 2007; Sood, & Moynihan, 2005).  
3. Oxidative stress and damage to mitochondrial membranes – Relationship 
to fatigue 
Another phenomenon associated with cancer and its progression as well as aging and age-
related degenerative diseases is oxidative stress (Dreher & Junod,1996; Halliwell, 1996; 
Kehrer, 1993). Oxidative stress is caused by an intracellular excess of reactive oxygen (ROS) 
and nitrogen (RNS) free radical species over intracellular antioxidants. When this imbalance 
occurs, it results in oxidation of cellular structures, such as membrane lipids and proteins, 
and mutation of mitochondrial and nuclear DNA (Abidi & Ali, 1999; Bartsch & Nair, 2004; 
Marnett, 2000; Stadtman, 2002). ROS and RNS are naturally occurring cellular free radical 
oxidants that are usually present in low concentrations and are involved in gene expression, 
intracellular signaling, cell proliferation, antimicrobial defense and other normal cellular 
processes (Castro & Freeman, 2001; Ghaffari, 2008; Johnson et al., 1996). However, when 
ROS/RNS are in excess over cellular antioxidants, damage can occur to cellular structures 
(Abidi & Ali, 1999; Castro & Freeman, 2001; Ghaffari, 2008; Maes & Twisk, 2009). Recently 
Maes (2009) has proposed a link between excess oxidative stress (and activation of 
ROS/RNS pathways and fatigue and fatiguing illnesses. 
Under normal physiological conditions our cellular antioxidant defenses usually maintain 
ROS/RNS at appropriate concentrations that prevent excess oxidation of cellular structures 
(Barber & Harris, 1994; Fridovich,1995; Sun, 1990). Endogenous cellular antioxidant defenses 
include glutathione peroxidase, catalase and superoxide dismutase, among other enzymes 
(Jagetia et al., 2003; Seifried et al., 2003), and low molecular weight dietary antioxidants 
(Aeschbach et al., 1994; Schwartz,1996). Some of these dietary antioxidants have been used 
as natural chemopreventive agents to shift the excess concentrations of oxidative molecules 
towards more physiological levels (Prasad et al., 200; Tanaka, 1994). 
Excess oxidative stress (or primarily its mediators—excess ROS/RNS) within cancer cells 
has been linked to promotion and progression of malignancy of cancers (Brown & Bicknell, 
2001; Klaunig & Kamendulis, 2004; Ray et al., 2000; Tas et al., 2005; Toyokuni et al., 1995). 
Thus oxidative stress and antioxidant status have been examined in various malignant 
cancers, such as breast (Brown & Bicknell, 2001; Kang, 2002; Ray et al., 2000; Tas et al., 2005), 
prostate (Aydin et al., 2006; Sikka, 2003), colorectal (Otamiri & Sjodahl,1989; Oxdemirler et 
al., 1989), renal (Asal et al., 1990; Gago-Dominguez et al., 2002), and other malignancies 
(Batcioglu et al., 2006; Manoharan et al., 2005; Seril et al., 2003). In all of these cancers 
ROS/RNS were in excess of antioxidant concentrations, resulting in cellular oxidative stress. 
Thus these cancers could possibly have been induced as a consequence of excess ROS/RNS 
and oxidative damage to the genetic apparatus (Abidi & Ali, 1999; Dreher & Junod, 1996; 
Jaruga et al., 1992). Even more likely than carcinogenesis is the promotion of progression of 
tumors that might not evolve to malignancy in the absence of excess oxidative stress 
(Nicolson, 2010; Nicolson & Conklin, 2008). 
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4. Cancer therapy causes excess oxidative stress and severe fatigue  
The most common therapies used against cancers, such as chemotherapy, can result in the 
generation of excess ROS/RNS (Conklin, 2000; 2004). Thus cancer therapy and the resulting 
production of excess oxidative stress can damage biological systems other than tumors 
(Conklin, 2004; Nicolson, 2010; Nicolson & Conklin, 2008). During chemotherapy the highest 
known levels of oxidative stress are generated by anthracycline antibiotics, followed (in no 
particular order) by alkylating agents, platinum-coordination complexes, 
epipodophyllotoxins, and camptothecins (Conklin, 2004). The primary site of ROS/RNS 
generation during cancer chemotherapy is the cytochrome P450 monooxygenase system 
within liver microsomes. Enzyme systems such as the xanthine-xanthine oxidase system, and 
non-enzymatic mechanisms (Fenton and Haber-Weiss reactions) also play a role in creating 
excess oxidative stress during chemotherapy. The very high levels of oxidative stress caused 
by anthracyclines are also related to their ability to displace coenzyme Q10 (CoQ10) from the 
electron transport system of cardiac mitochondria, resulting in diversion of electrons directly 
to molecular oxygen with the formation of superoxide radicals (Conklin, 2000; 2004). 
Although anthracyclines and other chemotherapeutic agents cause generation of high levels 
of ROS/RNS, not all chemotherapeutic agents generate excess oxidative stress. Some agents 
generate only modest amounts of ROS/RNS. Examples of this are: platinum-coordination 
complexes and camptothecins, taxanes, vinca alkaloids, anti-metabolites, such as the 
antifolates, and nucleoside and nucleotide analogues (Conklin, 2000; 2004; Nicolson & 
Conklin, 2008). Most chemotherapeutic agents do, however, generate some oxidative stress, 
as do all anti-neoplastic agents when they induce apoptosis in cancer cells. Drug-induced 
apoptosis is usually triggered by the release of cytochrome c from the mitochondrial 
electron transport chain. When this occurs, electrons are diverted from NADH 
dehydrogenase and reduced CoQ10 to oxygen, resulting in the formation of superoxide 
radicals (Betteridge, 2000; Conklin, 2000). 
Use of chemotherapeutic agents to treat cancer causes oxidative stress that produces side 
effects, including fatigue. This can reduce the efficacy of therapy (Nicolson & Conklin, 2008; 
Nicolson, 2010). Many anti-neoplastic agents have clearly established mechanisms of action 
that are not dependent upon the generation of ROS/RNS; however, these drugs can only 
mediate their anticancer effects on cancer cells that exhibit unrestricted progression through 
the cell cycle and have intact apoptotic pathways. Oxidative stress interferes with cell cycle 
progression by inhibiting the transition of cells from the G0 to G1 phase, slowing progression 
through S phase by inhibition of DNA synthesis, inhibiting cell cycle progression of G1 to S 
phase, and by checkpoint arrest (Balin et al., 1978; Gonzalez, 1992; Hauptlorenz et al., 1985; 
Kurata, 2000; Schackelford et al., 2000). 
Chemotherapeutic agents can also activate DNA repair systems. DNA repair of damage 
caused by alkylating agents and platinum complexes results in resistance to these drugs, 
and checkpoint arrest during oxidative stress can enhance the repair processes and diminish 
the efficacy of treatment (Fojo, 2001; Wei et al., 2000; Zhen et al., 1992). Abolishing 
checkpoint arrest produces the opposite effect and enhances the cytotoxicity of 
antineoplastic agents. By reducing oxidative stress, antioxidants counteract the effects of 
chemotherapy-induced oxidative stress on the cell cycle and enhance the cytotoxicity of 
antineoplastic agents (Conklin, 2004). 
Oxidative stress can affect important intracellular signal transduction pathways that are 
necessary for the action of some antineoplastic agents (Conklin, 2004; Hampton et al., 1998; 
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Shacter et al., 2000). There are two major pathways of drug-induced apoptosis following 
cellular damage by antineoplastic agents: the mitochondrial pathway, initiated by release of 
cytochrome c, and the CD95 death receptor pathway, initiated by CD95L binding to its 
death receptor (Fojo, 2001). Oxidative stress during chemotherapy results in the generation 
of highly electrophilic aldehydes that have the ability to bind to the nucleophilic active sites 
of caspases as well as the extracellular domain of the CD95 death receptor. This inhibits 
caspase activity and the binding of CD96L ligand, and this results in the impairment of the 
ability of antineoplastic agents to initiate apoptosis (Chandra et al., 2000; Hampton et al., 
1998; Shacter et al., 2000). 
In addition to chemotherapy, radiotherapy also results in generation of oxidative stress and 
excess ROS/RNS (Feinendegen et al., 2007; Greenberger et al., 2001). The principal target of 
radiation is tumor cell DNA, and this can be directly damaged by radiation. However, 
genetic damage is also mediated by excess ROS/RNS (Epperly et al., 2003; Feinendegen et 
al., 2007). Recently the principal source of excess ROS/RNS during radiotherapy has been 
shown to be the mitochondria (Epperly et al., 2003; Sabbarova & Kanai, 2007). The initial 
cytotoxicity of radiation is now thought to be due to excess ROS/RNS triggering of 
apoptosis via alteration of mitochondrial metabolism. This causes transiently opening of 
mitochondrial permeability transition pores, which increases the influx of calcium ions into 
the matrix. The influx of calcium ions stimulates mitochondrial nitric oxide synthase and 
generation of nitric oxide, which inhibits the respiratory chain and eventually stimulates 
excess ROS/RNS free radicals that initiate apoptosis (Leach et al., 2002; Sabbarova & Kanai, 
2007). 
5. Cancer therapy and mitochondrial damage 
Cancer therapy is associated with several adverse side effects. One of the most difficult side 
effects is caused by chemotherapeutic drug damage to mitochondria (Conklin, 2000; 
Nicolson & Conklin, 2008). Cardiac mitochondria are especially sensitive to certain 
chemotherapy agents, such as anthracycline antibiotics (Conklin, 2004). Anthracycline-
induced cardiac toxicity is characterized by acute, reversible toxicity that causes 
electrocardiographic changes and depressed myocardial contractility and by chronic, 
irreversible, dose-related cardiomyopathy (Conklin, 2004; 2005). The selective anthracycline-
induced toxicity to cardiac cells is due to damage of cardiac mitochondria. The sensitivity of 
cardiac cells to anthracyclines, such as doxorubicin, has been found to be due to the unique 
properties of cardiac mitochondria in that they possess a Complex I-associated NADH 
dehydrogenase in the inner mitochondrial membrane facing the cytosol (Lehninger, 1951; 
Rasumssen & Rasmussen, 1985). 
Doxorubicin is a relatively small molecule, and because of this property it readily penetrates 
the outer mitochondrial membrane. However, because it is hydrophilic and cannot partition 
into the lipid membrane matrix, it cannot penetrate the inner mitochondrial membrane 
(Conklin, 2005; Nohl, 1987). Thus, it cannot participate in oxidation-reduction reactions with 
the type of inner matrix-facing, electron transport chain dehydrogenases found in most 
types of cells, including most tumor cells (Conklin, 2005; Nohl, 1987). But in heart cells 
doxorubicin can interact with the mitochondrial cytosolic-facing NADH dehydrogenase that 
is unique to this tissue (Davies & Doroshow, 1986; Doroshow & Davies, 1986). This 
interaction produces doxorubicin aglycones, which are highly lipid soluble and readily 
penetrate the inner mitochondrial membrane (Conklin, 2005; Gille & Nohl, 1997). At this 
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Shacter et al., 2000). There are two major pathways of drug-induced apoptosis following 
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the matrix. The influx of calcium ions stimulates mitochondrial nitric oxide synthase and 
generation of nitric oxide, which inhibits the respiratory chain and eventually stimulates 
excess ROS/RNS free radicals that initiate apoptosis (Leach et al., 2002; Sabbarova & Kanai, 
2007). 
5. Cancer therapy and mitochondrial damage 
Cancer therapy is associated with several adverse side effects. One of the most difficult side 
effects is caused by chemotherapeutic drug damage to mitochondria (Conklin, 2000; 
Nicolson & Conklin, 2008). Cardiac mitochondria are especially sensitive to certain 
chemotherapy agents, such as anthracycline antibiotics (Conklin, 2004). Anthracycline-
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induced toxicity to cardiac cells is due to damage of cardiac mitochondria. The sensitivity of 
cardiac cells to anthracyclines, such as doxorubicin, has been found to be due to the unique 
properties of cardiac mitochondria in that they possess a Complex I-associated NADH 
dehydrogenase in the inner mitochondrial membrane facing the cytosol (Lehninger, 1951; 
Rasumssen & Rasmussen, 1985). 
Doxorubicin is a relatively small molecule, and because of this property it readily penetrates 
the outer mitochondrial membrane. However, because it is hydrophilic and cannot partition 
into the lipid membrane matrix, it cannot penetrate the inner mitochondrial membrane 
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doxorubicin can interact with the mitochondrial cytosolic-facing NADH dehydrogenase that 
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location they can displace CoQ10 from the electron transport chain (Conklin, 2005; Davies & 
Doroshow, 1986).  
The displacement of CoQ10 from the electron transport chain during doxorubicin treatment 
results in decreases of CoQ10 in cardiac muscle (Karlsson et al., 1986) as the plasma 
concentration of CoQ10 increases (Eaton et al., 2000). CoQ10 normally accepts electrons from 
Complexes I and II and transfers them down the electron transport chain, resulting in the 
formation of water. However, the presence of aglycones in the inner mitochondrial 
membrane and inner matrix results in the transfer the electrons directly to molecular 
oxygen, resulting in the formation of superoxide radicals (Papadopoulou & Tsiftsoglou, 
1996). Thus, doxorubicin generates a high level of oxidative stress in cardiac mitochondria, 
causing acute cardiac toxicity and damage to mitochondrial DNA (Conklin, 2005; Doroshow 
& Davies, 1986; Palmeira et al., 1991). 
Anthracycline-damaged cardiac cell mitochondria cannot sustain their function, and 
changes in their structure results in disruption of mitochondria and eventually apoptosis 
(Serrano et al., 1999; Conklin, 2005; Gille & Nohl, 1997). This produces cardiac insufficiency 
and an inability to respond to pharmacological interventions, resulting ultimately in cardiac 
failure. However, if CoQ10 is administered during anthracycline chemotherapy, damage to 
the heart is prevented by decreasing anthracycline metabolism within cardiac mitochondria 
and by competing with aglycones for the CoQ10 sites within the electron transport chain 
(Conklin, 2005). Thus, CoQ10 administered concurrently with anthracyclines can maintain 
the integrity of cardiac mitochondria and prevent damage to the heart, and at the same time 
enhancing the anti-cancer activity of anthracyclines (Conklin, 2000; 2005). 
In addition to chemotherapy, radiotherapy also produces damage to tissues other than 
cancerous tissues. Agents that protect tissues against radiation effects have been used to 
reduce unwanted damage (Brizel, 2007; Sabbarova & Kanai, 2007).  
Radioprotective agents that have been used to decrease the adverse effects of radiotherapy 
are: antioxidants, free radical scavengers, inhibitors of nitric oxide synthase and anti-
inflammatory and immunomodulatory agents (Brizel, 2007; Sabbarova & Kanai, 2007). The 
most effective of these under development target mitochondria, such as proteins and 
peptides that can be transported into mitochondria and plasmids or nucleotide sequences, 
for example, agents that target and stimulate mitochondrial manganese superoxide 
dismutase genes to produce this important dismutase have been used as radioprotective 
agents (Sabbarova & Kanai, 2007). 
6. Molecular replacement of mitochondrial components during cancer 
therapy  
As discussed in Section 5, chemotherapy can displace important mitochondrial cofactors, 
such as CoQ10 (Conklin, 2000; 2005). During chemotherapy replacement of CoQ10 
dramatically prevents development of anthracycline-induced cardiomyopathy and 
histopathological changes. It can also prevent changes in electrocardiograms (EKG) 
characteristic of anthracycline-induced heart damage (Domae et al., 1981). Indeed, the 
administration of CoQ10 to animals resulted in increased survival, improvement in the EKG 
patterns, and reduced heart histopathological changes (Usui et al., 1982). These preclinical 
data, along with clinical data (discussed in Conklin, 2004 and Nicolson & Conklin, 2008) 
support the contention that CoQ10 protects the heart tssue from anthracycline-induced 
damage. 
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During chemotherapy of cancer, patients have received concurrent administration of CoQ10. 
This can affect both acute and chronic cardiotoxicity caused by anthracyclines (Conklin, 
2004; 2005; Nicolson & Conklin, 2008). For example, Judy et al. (1984) studied the 
importance of administering CoQ10 on the development of doxorubicin-induced 
cardiotoxicity in patients with lung cancer. Doxorubicin given alone without CoQ10 caused 
marked impairment of cardiac function with a significant increase in heart rate and a 
substantial decrease in ejection fraction, stroke index and cardiac index. In contrast, 
doxorubicin administered along with CoQ10, did not cause cardiotoxicity—cardiac function 
remained unchanged. Other studies have confirmed these results and have shown that 
CoQ10 can reduce the cardiac toxicity of doxorubicin in adults (Buckingham et al., 1997; 
Cortes et al., 1978) and children (Iarussi et al., 1994; Loke et al., 2006). 
Thus in preclinical and clinical studies the data indicate that CoQ10 protects the heart from 
the cardiotoxicity of anthracyclines. The impact of CoQ10 on the anti-neoplastic efficacy of 
anthracycline-based chemotherapy, however, was not studied in these reports (Buckingham 
et al., 1997; Cortes et al., 1978; Iarussi et al., 1994; Loke et al., 2006). 
7. Cancer-associated fatigue and other cancer-associated conditions  
The most common complaint of patients undergoing anti-neoplastic therapy is fatigue, but 
there are also other complaints that include: pain, nausea, vomiting, malaise, diarrhea, 
headaches, rashes and infections (Buckingham et al., 1997; Loke et al., 2006; Manzullo & 
Escalante, 2002). Other more serious problems can also occur, such as cardiomyopathy, 
peripheral neuropathy, hepatotoxicity, pulmonary fibrosis, mucositis and other effects 
(Buckingham et al., 1997; Liu et al., 2005; Loke et al., 2006; Manzullo & Escalante, 2002). Due 
to misconceptions among patients and their physicians, most patients feel that cancer 
therapy-associated fatigue is an untreatable symptom (Vogelzang et al., 1997). Although 
fatigue is usually the most commonly reported adverse symptom during cancer therapy, up 
until recently there was little effort directed at reducing fatigue before, during or after 
cancer therapy (Von Roenn & Paice, 2005). This has changed recently (Nicolson, 2010; 
Nicolson & Conklin, 2008). 
Reducing cancer-associated fatigue and fatigue associated with cancer therapy are now 
considered important therapeutic goals. Psychological, physical, pharmaceutical and 
nutraceutical methods have been undertaken to reduce fatigue and improve the quality of 
life of cancer patients (Borneman et al., 2007; Escalante et al., 2011; Nicolson, 2010). These 
treatments are based on suppressing fatigue but also on controlling co-morbid or related 
symptoms, such as pain, anemia, cachexia, sleep disorders, depression and other symptoms 
(Escalante et al., 2011; Mustian et al., 2007; Nicolson, 2010; Ryan et al., 2007; Watson & Mock, 
2004; Zee & Acoli-Isreal, 2009). 
Unfortunately, there is no standard protocol related to treating cancer-associated fatigue 
and related symptoms. In reviewing the types of supportive measures used to control 
fatigue and related symptoms, the data suggest that graded exercise, nutritional support, 
treatment of psychological problems (such as depression with certain anti-depressants or 
psycostimulants), treatment of anemia with hematopoetic growth factors and control of 
insomnia with cognitive behavioral therapy or pharmacological and nonpharmacological 
therapies all have a role to various degrees in controlling cancer-associated fatigue 
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enhancing the anti-cancer activity of anthracyclines (Conklin, 2000; 2005). 
In addition to chemotherapy, radiotherapy also produces damage to tissues other than 
cancerous tissues. Agents that protect tissues against radiation effects have been used to 
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dismutase genes to produce this important dismutase have been used as radioprotective 
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such as CoQ10 (Conklin, 2000; 2005). During chemotherapy replacement of CoQ10 
dramatically prevents development of anthracycline-induced cardiomyopathy and 
histopathological changes. It can also prevent changes in electrocardiograms (EKG) 
characteristic of anthracycline-induced heart damage (Domae et al., 1981). Indeed, the 
administration of CoQ10 to animals resulted in increased survival, improvement in the EKG 
patterns, and reduced heart histopathological changes (Usui et al., 1982). These preclinical 
data, along with clinical data (discussed in Conklin, 2004 and Nicolson & Conklin, 2008) 
support the contention that CoQ10 protects the heart tssue from anthracycline-induced 
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(Escalante et al., 2011; Mustian et al., 2007; Nicolson, 2010; Ryan et al., 2007; Watson & Mock, 
2004; Zee & Acoli-Isreal, 2009). Some of these approaches using pharmacological drugs and 
growth factors have been systematically analyzed in 27 studies (meta-analysis) by Milton et 
al. (2008). In this limited analysis, only a psycostimulant (methylphenidate) and 
hematopoetic growth factors (erythropoietin and darbopeitin) were more effective than 
placebo treatments. Other treatments were no better than placebo in the treatment of cancer-
related fatigue (Milton et al., 2008).  
8. Cancer-associated fatigue, aging and oxidative mitochondrial damage  
Cancer-associated fatigue has been defined as a multidimensional sensation (McDonald et 
al., 1993; Milton et al., 2008; Mustian et al., 2007; Ryan et al., 2007). Most patients understand 
fatigue as a loss of energy and inability to perform even simple tasks without exertion 
(Levy, 2008; Milton et al., 2008). Cancer-associated fatigue has been described as the 
dysregulation of several interrelated physiological, biochemical and psychological systems 
(Mustian et al., 2007; Ryan et al., 2007), but at the tissue and cellular levels fatigue is related 
to reductions in the efficiency of cellular energy systems, mainly found in mitochondria 
(Agadjanyan et al., 2003; Nicolson, 2003; 2005). Damage to mitochondrial components, 
mainly by ROS/RNS oxidation, can impair mitochondrial function, and this can also result 
in oxidative damage (reviewed in Bartsch & Nair, 2004; Castro & Freeman, 2001; Kehrer, 
1993). Mitochondrial membranes and DNA are major targets of oxidative stress, and with 
aging ROS/RNS mitochondrial damage can accumulate (Huang & Manton, 2004; Wei & 
Lee, 2002). 
During aging and in certain medical conditions oxidative damage to mitochondrial 
membranes impairs mitochondrial function (Huang & Manton, 2004; Logan & Wong, 2001; 
Wei & Lee, 2002). For example, in chronic fatigue syndrome patients there is evidence of 
oxidative damage to DNA and lipids (Logan & Wong, 2001; Manuel y Keenoy et al., 2001) as 
well as oxidized blood markers (Richards et al., 2000) and muscle membrane lipids (Felle et 
al., 2000) that are indicative of excess oxidative stress (Dianzani, 1993). In chronic fatigue 
syndrome patients also have sustained elevated levels of peroxynitrite due to excess nitric 
oxide, which can result in lipid peroxidation and loss of mitochondrial function as well as 
changes in cytokine levels that exert a positive feedback on nitric oxide production, 
increasing the rate of membrane damage (Pall, 2000).  
9. Molecular replacement of oxidized membrane components and its effect 
on fatigue  
In cancer patients mitochondrial membranes as well as other cellular membranes are 
especially sensitive to oxidative damage by ROS/RNS, which occurs at high rates in cancer 
(Batcioglu et al., 2006; Dianzani, 1993; Gago-Dominguez et al., 2002; Manoharan et al., 2005; 
Otamiri & Sjodahl, 1989; Oxdemirler et al., 1989; Seril et al., 2003). Oxidation of membrane 
phospholipids alters their structure, affecting lipid fluidity, permeability and membrane 
function (Dianzani, 1993; Nicolson et al., 1977; Subczynski & Wisniewska, 2000). One of the 
most important events caused by ROS/RNS damage is loss of electron transport function, 
and this appears to be related to mitochondrial membrane lipid peroxidation. Membrane 
oxidation induces permeability changes in mitochondria, and this can cause loss of 
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mitochondrial transmembrane potential, an essential requirement of oxidative 
phosphorylation (Kanno et al., 2004; Radi et al., 1994). 
Lipid Replacement Therapy (Nicolson, 2003; 2005; 2010) has been used to reverse the 
accumulation of damaged lipids in mitochondria and other cellular membranes. Lipid 
Replacement Therapy plus antioxidants can reverse ROS/RNS damage and increase 
mitochondrial function in certain fatiguing disorders, such as chronic fatigue, chronic 
fatigue syndrome and fibromyalgia syndrome. Lipid Replacement Therapy has been 
found to be effective in preventing ROS/RNS-associated changes and reversing 
mitochondrial damage and loss of function (reviewed in Nicolson, 2010; Nicolson & 
Ellithrope, 2006). 
Lipid Replacement Therapy with unoxidized lipid and antioxidant supplements has been 
effective in replacement of damaged cellular and mitochondrial membrane phospholipids 
and other lipids that are essential structural and functional components of all biological 
membranes (reviewed in Nicolson, 2010; Nicolson & Ellithrope, 2003). NTFactor, a Lipid 
Replacement oral supplement containing phospholipids, phosphoglycolipids, cardiolipid 
precursors and other membrane lipids, has been used successfully in animal and clinical 
lipid replacement studies (Agadjanyan et al., 2003; Ellithorpe et al., 2003; Nicolson & 
Ellithorpe, 2006; Nicolson et al., 2010). NTFactor's encapsulated lipids are protected from 
oxidation in the gut and can be absorbed and transported into tissues via lipid carriers 
without oxidation. Once inside cells the membrane lipids naturally replace oxidized, 
damaged membrane lipids by natural diffusion, and carrier proteins pick up the damaged 
lipids for degradation, transport and excretion (Mansbach & Dowell, 2000). 
In preclinical studies NTFactor has been used to reduce age-related functional damage. 
Using rodents Seidman et al. (2002) found that NTFactor prevented hearing loss associated 
with aging and shifted the threshold hearing from 35-40 dB in control, aged rodents to 13-17 
dB. They also found that NTFactor preserved cochlear mitochondrial function and 
prevented aging-related mitochondrial DNA deletions found in the cochlear. Thus NTFactor 
was successful in preventing age-associated hearing loss and reducing mitochondrial 
damage and DNA deletions in rodents (Seidman et al. 2002). 
In clinical studies Lipid Replacement Therapy has been used to reduce fatigue and protect 
cellular and mitochondrial membranes from oxidative damage by ROS/RNS (reviewed in 
Nicolson, 2003; 2005; 2010). A vitamin supplement mixture containing NTFactor was by 
used by Ellithorpe et al. (2003) in a study of patients with severe chronic fatigue and was 
found to reduce their fatigue by approximately 40.5% in 8 weeks. In these studies fatigue 
was monitored by use of the Piper Fatigue Scale to measure clinical fatigue and quality of 
life (Piper et al., 1987). In addition, in a subsequent study we examined the effects of 
NTFactor on fatigue and mitochondrial function in patients with chronic fatigue 
(Agadjanyan et al., 2003). Oral administration of NTFactor for 12 weeks resulted in a 35.5% 
reduction in fatigue and 26.8% increase in mitochondrial function; whereas after a 12-week 
wash-out period fatigue increased and mitochondrial function decreased back towards 
control levels (Agadjanyan et al., 2003). Thus in fatigued subjects dietary Lipid Replacement 
Therapy can significantly improve and even restore mitochondrial function and 
significantly decrease fatigue. Similar findings were observed in chronic fatigue syndrome 
and fibromyalgia syndrome patients (Nicolson & Ellithorpe, 2003). Recently a new 
formulation of NTFactor plus vitamins, minerals and other supplements resulted in a 36.8% 
reduction in fatigue within one week (Nicolson et al., 2010) (Table 1). 
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mitochondrial transmembrane potential, an essential requirement of oxidative 
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found to be effective in preventing ROS/RNS-associated changes and reversing 
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membranes (reviewed in Nicolson, 2010; Nicolson & Ellithrope, 2003). NTFactor, a Lipid 
Replacement oral supplement containing phospholipids, phosphoglycolipids, cardiolipid 
precursors and other membrane lipids, has been used successfully in animal and clinical 
lipid replacement studies (Agadjanyan et al., 2003; Ellithorpe et al., 2003; Nicolson & 
Ellithorpe, 2006; Nicolson et al., 2010). NTFactor's encapsulated lipids are protected from 
oxidation in the gut and can be absorbed and transported into tissues via lipid carriers 
without oxidation. Once inside cells the membrane lipids naturally replace oxidized, 
damaged membrane lipids by natural diffusion, and carrier proteins pick up the damaged 
lipids for degradation, transport and excretion (Mansbach & Dowell, 2000). 
In preclinical studies NTFactor has been used to reduce age-related functional damage. 
Using rodents Seidman et al. (2002) found that NTFactor prevented hearing loss associated 
with aging and shifted the threshold hearing from 35-40 dB in control, aged rodents to 13-17 
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prevented aging-related mitochondrial DNA deletions found in the cochlear. Thus NTFactor 
was successful in preventing age-associated hearing loss and reducing mitochondrial 
damage and DNA deletions in rodents (Seidman et al. 2002). 
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used by Ellithorpe et al. (2003) in a study of patients with severe chronic fatigue and was 
found to reduce their fatigue by approximately 40.5% in 8 weeks. In these studies fatigue 
was monitored by use of the Piper Fatigue Scale to measure clinical fatigue and quality of 
life (Piper et al., 1987). In addition, in a subsequent study we examined the effects of 
NTFactor on fatigue and mitochondrial function in patients with chronic fatigue 
(Agadjanyan et al., 2003). Oral administration of NTFactor for 12 weeks resulted in a 35.5% 
reduction in fatigue and 26.8% increase in mitochondrial function; whereas after a 12-week 
wash-out period fatigue increased and mitochondrial function decreased back towards 
control levels (Agadjanyan et al., 2003). Thus in fatigued subjects dietary Lipid Replacement 
Therapy can significantly improve and even restore mitochondrial function and 
significantly decrease fatigue. Similar findings were observed in chronic fatigue syndrome 
and fibromyalgia syndrome patients (Nicolson & Ellithorpe, 2003). Recently a new 
formulation of NTFactor plus vitamins, minerals and other supplements resulted in a 36.8% 
reduction in fatigue within one week (Nicolson et al., 2010) (Table 1). 
 




Table 1. Effects of dietary Lipid Replacement supplement NTFactor on Piper Fatigue Scale 
scores. 
10. Lipid replacement therapy in conjunction with cancer therapy 
Lipid Replacement Therapy has been used to reduce the adverse effects of chemotherapy in 
cancer patients (Nicolson, 2010). For example, a vitamin-mineral mixture with NTFactor has 
been used in cancer patients to reduce some of most common adverse effects of cancer 
therapy, such as chemotherapy-induced fatigue, nausea, vomiting, malaise, diarrhea, 
headaches and other side effects (Colodny et al., 2000). In two studies on patients with 
advanced metastatic colon, pancreatic or rectal cancers receiving a 12-week chemotherapy 
treatment schedule of 5-florouracil/methotrexate/leukovorin Lipid Replacement Therapy 
was used to reduce adverse effects of chemotherapy.  
In the first unblinded part of the clinical study the effectiveness of NTFactor in a vitamin-
mineral mixture administered before and during chemotherapy was determined by examining 
signs and symptoms, and in particular, the side effects of therapy. A quality of life evaluation 
was conducted by a research nurse, and it was determined that patients on NTFactor 
supplementation experienced significantly fewer episodes of fatigue, nausea, diarrhea, 
constipation, skin changes, insomnia and other side effects (Colodny et al., 2000). In this open 
label trial 81% of patients demonstrated an overall improvement in quality of life parameters 
while on chemotherapy with Lipid Replacement Therapy (Colodny et al., 2000).  
In the double-blinded, cross-over, placebo-controlled, randomized part of the study on 
advanced cancers the patients on chemotherapy plus Lipid Replacement Therapy showed 
improvements in signs/symptoms associated with the adverse effects of chemotherapy 
(Colodny et al., 2000). Adding Lipid Replacement resulted in improvements in the incidence 
of fatigue, nausea, diarrhea, impaired taste, constipation, insomnia and other quality of life 
indicators. Following cross-over from the placebo arm to the Lipid Replacement Therapy 
arm, 57-70% of patients on chemotherapy reported improvements in nausea, impaired taste, 
tiredness, appetite, sick feeling and other quality of life indicators (Colodny et al., 2000) 
(Table 2). This clinical trial and other data clearly demonstrated the usefulness of Lipid 
Replacement Therapy given during chemotherapy to reduce the adverse effects of cancer 
therapy (Nicolson, 2010).  
Nutritional Supplements for Cancer-Associated Fatigue and 




     Average % patients on test arm# 
First arm   Second arm improvement no change  worsening 
_________________________________________________________________________________ 
placebo      Propax(+NTFactor)  57      22     21 
 
Propax(+NTFactor) placebo   70       6      24 
_________________________________________________________________________________ 
Table modified from Nicolson (2010). 
* The same regimen of 5-flurouracil/methotrexate/leukovoran was used for colon, pancreatic or rectal 
cancers. 
#The percent of patients’ self-reporting adverse effects was averaged with the percent of patients with 
adverse effects reported by a research nurse. 
_________________________________________________________________________________ 
Table 2. Effects of Propax with NTFactor on the adverse effects of chemotherapy in a cross-
over trial. 
11. Summary – Cancer-sssociated fatigue and its treatment 
Nutritional supplements have been used in a variety of diseases to provide patients with a 
natural, safe alternative to pharmacological drugs. In patients with cancer nutritional 
supplements are often used for specific purposes or to improve quality of life. For example, 
cancer-associated fatigue is one of the most common symptoms in all forms and stages of 
cancer, but few patients receive assistance for their fatigue. Cancer-associated fatigue is 
associated with cellular oxidative stress, and during cancer therapy excess drug-induced 
oxidative stress can cause a number of adverse effects, including: fatigue, nausea, vomiting 
and more serious effects. Cancer-associated fatigue and the adverse effects of cancer therapy 
can be reduced with Lipid Replacement Therapy, a natural lipid supplement formulation 
that replaces damaged membrane lipids along with providing antioxidants and enzymatic 
cofactors. Administering dietary Lipid Replacement Therapy can reduce oxidative 
membrane damage and restore mitochondrial and other cellular functions. Recent clinical 
trials using cancer and non-cancer patients with chronic fatigue have shown the benefits of 
specific Lipid Replacement Therapy nutritional lipid supplements in reducing fatigue and 
restoring mitochondrial function. 
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1. Introduction 
Patients receiving anti-cancer treatment experience physical problems such as pain, fatigue 
and nausea, and psychological problems such as anxiety, depression, distress (Speca, et al., 
2006) and spiritual pain. A mindfulness approach is one of the most effective interventions 
to alleviate these problems. The Mindfulness-Based Stress Reduction (MBSR) program was 
modeled on the work of Kabat-Zinn (Kabat-Zin, 1990; Kat-Zinn, et al., 1998) and colleagues 
at the Center for Mindfulness-Massachusetts Medical Center. The program is based on the 
principal of mindfulness, defined as moment-to-moment, present-centered, purposive non-
judgmental awareness. The goal of the MBSR program is to guide participants to achieve 
greater awareness of themselves, their thoughts, and their bodies through class discussion, 
meditation, and yoga exercises (Garland, et al., 2007).  
For cancer patients, the MBSR have effects on mood disturbance stress symptoms (Speca, et 
al. 2000), or on QOL and the immune profile (Carlson, et al., 2004). The Mindfulness-Based 
Art-Therapy (MBAT), which includes mindfulness and art therapy, also produces a 
significant decrease in symptoms of distress and improvements in key aspects of health-
related QOL (Monti, et al., 2006). Moreover, the MBSR affects stress symptoms, mood, post-
trauma growth, and spirituality (Garland, et al., 2007; Matchim, et al., 2011). 
However, since the duration of the program in these studies are from at least 4 weeks to 
8 weeks, patients were sometimes hard to continue to participate. And they were easily 
to be tired because of chemotherapy or radiation therapy. Then we developed a 
mindfulness cyclic meditation program, in which participants could participate in the 
program even sitting on chair. After this program, anxiety and depression improved 
(Ando, et al., 2009).  
However, some of patients with advanced cancer stage were hard to participate, because 
their physical strength was very low and they could not sit or walk. Thus we needed to 
develop a new program for cancer patient with advanced cancer stage, and we developed a 
novel mindfulness program, a Bedside Mindfulness program (Figure 1). A yoga instructor 
and a clinical psychologist discussed about program, and made the leaflet with drawing by 
an illustrator.   
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Fig. 1. The Bed-side Mindfulness Program  
2. Study 1 – Efficacy of Bedside Mindfulness Program on mood related with 
mental health status 
Firstly, we examined the efficacy of this program for college students, because we could 
obtained both subjective and objective data. Some previous studies examined efficacy of 
mindfulness including objective data.  
Participants with alcohol use disorders received mindfulness program or cognitive behavior 
therapy. Psychological and physiological indices like Galvanic Skin Response of stress 
reduced in mindfulness program much more than cognitive behavior therapy (Brewer, et 
al., 2009). Or through mindfulness program, psychological distress like anxiety or 
depression reduced and also skin conductance level of women with chronic pain of 
fibromyalgia reduced (Lush, et al., 2009). These studies show that mindfulness reduced the 
skin conductance level which shows the stress level. Oppositely, healthy adults assigned a 
mindfulness group or a no mindfulness group. All participants viewed positive or negative 
films. Participants in the mindfulness group reported significantly greater positive affect in 
response to the positive film than those in the no mindfulness group. However, there was 
no significance between conditions on Galvanic Skin Response (GSR) or heart rate (Erisman 
& Roemer, 2010). That is, results of efficacy of mindfulness on skin conductance level are 
inconsistence. 
About salivary cortisol as an indicator, for breast cancer outpatients MBSR program 
participants was associated with enhanced quality of life and decreased stress symptoms 
(Matchimy, et al., 2011), altered cortisol and immune patterns consistented with less stress 
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and mood disturbance (Carlson, et al., 2007). In the above studies, skin conductance or 
salivary level was used as indicators. Moreover, we thought that effects of a mindfulness 
program might be different by a level of mental health states, and we predicted that the 
Bedside Mindfulness Program might be more effective for people or patients with mental 
problems.  
Thus, in this study, we examined mental health and mood as psychological indicator. Mood 
consists of the tense arousal and the energetic arousal (Matthews, et al., 1990). Tense 
arousals show a level of tension and it is uncomfortable. Energetic arousal shows a level of 
activity. As physiological indicator, we used Galvanic Skin Response and the salivary level 
of amylase which measure level of stress.  
Participants and methods  
The participants were Japanese college students in Western Japan consist of 4 males and 16 
females; mean age 22.7±4.8. As questionnaires, we used the Japanese UWIST Mood 
Adjective Check List : JUMACLE (Shirasawa, et al. 1999). There are 20 items (10 each for 
Tense Arousal and Energetic Arousal). Items for Tense Arousal were [I am] “tense,”  
“jittery,” “nervous,” and so on. Items about Energetic Arousal were [I am] “active,” 
“vigorous,” “energetic,” and so on. Participants answered on a 4-point Likert scale ranging 
from 1= not at all to 4=exactly so. The range of scores for Tense Arousal and Energetic 
Arousal was from 10 to 40. To measure mental state, we used the Japanese version of the 
General Health Questionnare-30 (Goldberg & Hillier, 1979) which was developed from the 
original one by Nakagawa and Daibo (1985). We separated participants into a non-risk 
group and a high-risk group by the cut-off point. The Bedside Mindful Program BMP 
included meditation, moving their hands or legs to focus their attention on bed (Figure 1). 
The BMP takes about 30 to 60 minutes per session and was conducted by nurses or a clinical 
psychologist who received training for at least 3 hours. The training included basic 
communication skills and Yoga skills learned directly from a Yoga specialist or using a CD. 
In the class, students received this program and complete questionnaires pre- and post-
intervention. The study was approved by the appropriate institutional ethics committees 
and was performed in accordance with the ethical standards laid down in the Declaration of 
Helsinki. Statistical analysis, we separated participants into two groups, high risk group and 
non-risk group by cut off points of General Health Questionnaire. The t-test and the effects 
size test were performed on the scores of JUMACL, GSR, and salivary level of amylase.   
Results 
The Tense Arousal of the non-risk group significantly decreased from 18.4±21.6 to 14.5 
±22.3 (t=3.1, p<0.01) (Figure 2) . The effect size was large (Table 1). The Tense Arousal of 
the high risk group also significantly decreased from 20.0±29.1 to 14±26 (t=4.68, 
p<0.001)(Figure 3) and the effect size was large. The Energetic Arousal of the non-risk group 
significantly decreased from 29.7±39.1 to 26.6±43.6 (t=3.31, p<0.01) (Figure 4) and the 
effect size was large. However, that of the high risk group increased from 27.9±37.4 to 
28.5±52.7 (t=-0.27, p=0.79) (Figure 5), though it was not significant and there was no effect. 
The salivary level of amylase of the non-risk group decreased from 99.8 to 73.9 (t=1.01, 
p=0.34) and the effects size was medium (Table 2). The salivary level of amylase of the high 
risk group significantly decreased from 71.7 to 45.2 (t=2.27, p=0.05) and the effect size was 
large.  
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 TA  EA  
 Effect size r Level Effect size r Level 
Non-risk group 0.72 Large 0.74 Large 
High-risk group 0.84 Large 0.09 None 









































Fig. 3. Changes of Energetic Arousal scores  
Times 
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The GSR of the non risk group decreased a very little from 241.9 to 240 and there was no 
effect. Oppositely the GSR of the risk group increased from 301 to 386.2 (t=-1.21, p=0.26) and 
the effect size was medium.  
 
 GSR  Amylase  
 Effect size r Level Effect size r Level 
Non-risk group 0.02 None 0.32 Medium 
High-risk group 0.38 Medium 0.60 Large 
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The Tense Arousal significantly decreased both in the non-risk group and the hight-risk 
group. The effects size was large in both groups. These results show that the BMP decrease 
tension or anxiety, regardless the mental health status. It is because that breathing  
and meditation leads people to focus attention on themselves, and attention moves from 
things with tension or anxiety to themselves. The effects of decrease of tension  
by mindfulness agree with the previous studies (Garland, et al., 2007; Matchim & Armer, 
2007).  
The Energetic Arousal of the non-risk group significantly decreased after the therapy and 
showed middle effect size. It shows that BMP decrease of activity and sedate their feelings 
for good mental health. This result is different from Ogasawara, et al. (2006) in which the 
Energetic Arousal of college healthy students did not significantly change by relaxation of 
aroma hand massage. Ditto, et al. (2006) shows that mindfulness meditation produced 
different cardiovasucular and autonomic effects that relaxation, giving weight to the 
criticism against the conceptualization of mindfulness practice as a mere relaxation 
technique (Bishop, 2002).  
In the high-risk group, the score did not change, showing no effect size. This result suggests 
that the BMP did not decrease  activities for non- risk persons. The reasons of this 
phenomenon were that this therapy is useful to maintain energy for high-risk persons.    
As for the salivary level of amylase, the high score demonstrates high level of negative 
stress. The scores of amylase significantly decreased in the high-risk group, but it did not 
change in non-risk group. It means that the BMP is more effective to reduce stress for high 
risk persons than non risk persons to reduce negative stress. In the previous study, the 
efficacy of mindfulness like decrease cortisol level which shows stress level as the 
physiological indicator (Carlson, et al., 2007) agreed with the present study for high risk 
persons. Carlson et al. (2007) demonstrated that breast cancer patients felt much 
psychological stress than healthy women, but the level of the salivary cortisol as the 
physiological indicator did not differ between patients and healthy women. Their studies 
suggest that physiological level was the same between patients and healthy women. 
However, from the present study, the effects of mindfulness program may be different by 
mental health level. 
About GSR scores, a low score means high tension or stress. The GSR scores did not change 
in no-risk group, however, those of the high-risk group increased with middle effects size. It 
shows that the BMP has much more effects to reduce tension or stress for high risk persons 
than non-risk persons. Erisman & Roemer (2010) showed that the level of skin conductance 
was not differ between the mindfulness group and the non-mindfulness group. Though the 
present study design is different from Erisman & Roemer, contents of program or health 
level might affect people differently. The effects of mindfulness to physiological aspect will 
be needed to examine further more.  
2.1 The efficacy of the Bedside Mindfulness Program on mood of cancer patients 
We investigated the effects of the Bedside Mindfulness Program on mood by a level of 
mental status of cancer patients. We hypothesized that effects of the program on tension 
arousal may be the same regardless of mental status, however, effects of the program on 
energetic arousal may be differently.  
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Participants and methods 
Four cancer patients participated in the study. Table 3 shows patients’ back ground. We 
used the same questionnaire to patients as college students. The primary physician selected 
participants. A pastoral care worker conducted the BMP, in which she conducted the 
program about from 30 to 60 minutes. Before the program, patients completed the General 
Health Questionnare-30 and the Japanese UWIST Mood Adjective Check List (JUMACL), 
and after the program, they completed the JUMACL.   
 
 Age Gender Disease Stage 
Patient A 64 Female Breast Ⅳ 
Patient B 45 Female Lung Ⅳ 
Patient C 50 Female Breast Ⅳ 
Patient D 34 Female Breast Ⅳ 
Table 3. Back ground of cancer patients. 
Results 
Table 4 shows the results. We reviewed each patient, patient A, Patient B, Patient C, and 
patient D. The score of GHQ was low and under the cut-off point. The scores of Patient A 
and Patient D was 1 and they had no mental problems. The scores of Patient B and Patient C 
show a little mental problem. The score 10 of TA was the lowest in the JUMACL, thus, 
patients had   originally low tense arousal except patient C. As for EA, the score of Patient A 
and patient D who had no mental problems decreased (from 39 to 36, from 39 to 31), 
however, those of patient B and Patient C who had a little mental problem increased (from 
30 to 40, from 34 to 39). 
 










  Pre post change Pre post changes 
Patient A 1 10 10  39 36  
Patient B 3 10 10  37 40  
Patient C 6 14 10  34 39  
Patient D 1 10 10  39 31  
Table 4. Score of GHQ (pre), Tense Arousal (TA) and Energetic Arousal (EA)  
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physiological indicator did not differ between patients and healthy women. Their studies 
suggest that physiological level was the same between patients and healthy women. 
However, from the present study, the effects of mindfulness program may be different by 
mental health level. 
About GSR scores, a low score means high tension or stress. The GSR scores did not change 
in no-risk group, however, those of the high-risk group increased with middle effects size. It 
shows that the BMP has much more effects to reduce tension or stress for high risk persons 
than non-risk persons. Erisman & Roemer (2010) showed that the level of skin conductance 
was not differ between the mindfulness group and the non-mindfulness group. Though the 
present study design is different from Erisman & Roemer, contents of program or health 
level might affect people differently. The effects of mindfulness to physiological aspect will 
be needed to examine further more.  
2.1 The efficacy of the Bedside Mindfulness Program on mood of cancer patients 
We investigated the effects of the Bedside Mindfulness Program on mood by a level of 
mental status of cancer patients. We hypothesized that effects of the program on tension 
arousal may be the same regardless of mental status, however, effects of the program on 
energetic arousal may be differently.  
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Participants and methods 
Four cancer patients participated in the study. Table 3 shows patients’ back ground. We 
used the same questionnaire to patients as college students. The primary physician selected 
participants. A pastoral care worker conducted the BMP, in which she conducted the 
program about from 30 to 60 minutes. Before the program, patients completed the General 
Health Questionnare-30 and the Japanese UWIST Mood Adjective Check List (JUMACL), 
and after the program, they completed the JUMACL.   
 
 Age Gender Disease Stage 
Patient A 64 Female Breast Ⅳ 
Patient B 45 Female Lung Ⅳ 
Patient C 50 Female Breast Ⅳ 
Patient D 34 Female Breast Ⅳ 
Table 3. Back ground of cancer patients. 
Results 
Table 4 shows the results. We reviewed each patient, patient A, Patient B, Patient C, and 
patient D. The score of GHQ was low and under the cut-off point. The scores of Patient A 
and Patient D was 1 and they had no mental problems. The scores of Patient B and Patient C 
show a little mental problem. The score 10 of TA was the lowest in the JUMACL, thus, 
patients had   originally low tense arousal except patient C. As for EA, the score of Patient A 
and patient D who had no mental problems decreased (from 39 to 36, from 39 to 31), 
however, those of patient B and Patient C who had a little mental problem increased (from 
30 to 40, from 34 to 39). 
 










  Pre post change Pre post changes 
Patient A 1 10 10  39 36  
Patient B 3 10 10  37 40  
Patient C 6 14 10  34 39  
Patient D 1 10 10  39 31  
Table 4. Score of GHQ (pre), Tense Arousal (TA) and Energetic Arousal (EA)  
 




Although patients in this study felt no mental problems originally, the decrease of TA of 
patient C suggests that BMP affects to decrease tense arousal. This facts support the results 
of college students. As for EA, the scores of Patient B and Patient C with a little mental 
problems increased, oppositely patient A and Patient C with no mental problem decreased. 
This facts also are the same of those of college students who received the same progrm, such 
that the EA score of the high-risk group increased, but that of the non-risk group decreased. 
Patients reflected the process of the program.  
There were 2 patters. Some patients reflected that they were very calm before the program 
and they felt much more calm after the program. Other patients reflected that they had some 
problems before the program and they felt some energy to active something after the 
program. That is, this program affects on energy to elevate, particular for persons with some 
mental problems. In near future, we need to investigate further more.  
2.2 The efficacy of the Bedside Mindfulness Program on anxiety or depression  
We assess the efficacy of the Bedside Mindfulness Program (BMP) on anxiety or depression 
of cancer patients, because most of cancer patients feel anxiety or depression about 
treatments, future, works, economy, or recurrence. It seemed to be important for us to 
examine the efficacy of the Bedside Mindfulness Program on anxiety or depression. 
Purpose 
The aim of this study was to examine the efficacy of the BMP on anxiety of depression of 
cancer patients.  
Participants and methods  
Participants were cancer patients who received treatments like chemotherapy or radiation. 
The primary physicians selected patients. Table 5 shows the background of patients. The 
interviewer was a pastoral care worker. There were two sessions. In the first session, a 
patient received the BMP. The duration was about 60 minutes. Patients completed the 
questionnaires pre and post the intervention. Participants completed the Hospital Anxiety 
and Depression Scale. 
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Table 5. Basic data of participants. 
The Relationships Between Stress 




The scores of HADS decreased from 9.57±7.1 to 6.86±6.9 after the program (t=1.49, 
p=0.161). The score of Anderson symptoms increased from 18.4±18.3 to 21.3±26.4 (t=-0.43, 














Fig. 6. Changes of HADS score 
Discussion 
The HADS score decreased in 10 % significance. It suggests that the BMP affects to 
decrease patients’ anxiety or depression. Like the cyclic meditation therapy which 
alleviated patients’ anxiety or depression (Ando, Morita, Akechi, et al., 2009), our 
mindfulness program for cancer patient affects on anxiety or depression. Since the cut-off 
points of the HADS score was 19/20, the patients in the present study did not have 
serious problems. It might be because the primary physician in the present study 
supported patients’ mental aspect.  
The Anderson symptom score increased a little, though it was not significant. It might be 
because patients under treatments were easily affected by the treatment process and the 
physical states were changeable. Since anxiety or depression of patients decreased 
regardless of the increase of symptom, this program may be useful to alleviate anxiety or 
depression, even though patients have symptoms. 
As the co-relation coefficient between HADS score and Anderson scores was significantly 
high (r=0.84), patients who had much physical symptoms feel much more anxiety or 
depression. In the present study, since the duration was only one week, and session times 
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were only two times, we could not assess the efficacy of this program in details. In future, 
we need to investigate much more. 
3. Conclusion 
The Bedside Mindfulness Program decreases tension and maintains energy of mood, and it 
is supported by the results of Galvanic Skin Response level and amylase. For cancer 
patients, this program may be useful to reduce anxiety and depression. Since anxiety and 
depression related with physical symptoms, we assess the efficacy of this program from 
long term perspective.  
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1. Introduction 
1.1 Physical activity, body composition and cancer 
Cancer is not a new disease, there are findings of neoplasia in the mummies of ancient 
Egypt, there are descriptions of the Romans and the Greeks and even remains in the fossil of 
dinosaurs. The study of the epidemiology of cancer, however, demonstrates an increasing 
incidence with an alarming progression, which is also involving countries which were 
considered "protected" or otherwise at low risk until last century. 
 The progressive industrialization has led to an increase of environmental pollution with 
newly synthesized toxic substances, unknown by biological systems during the 
evolutionary process. Technological innovation has also increased the yield in 
agriculture, which has resulted in an increased food availability and a profound change 
in eating habits both for the type and for the amount of introduced nutrients. 
Technological development has also radically changed lifestyle with a progressive 
increase in sedentariness, a reduction to the sun exposure, causing a vitamin D 
deficiency also in children, by altering the circadianicity of circadian rhythms which 
regulate, depending on sunlight, the correct functioning of our body, including cell 
proliferation. 
In general, the standard of living has increased in many countries, it has lengthened the life 
expectancy and, with it has increased cancer. 
The improvement of recovery rates and survival with the progressive increase in the 
average age, in association with a greater focus on the quality of life, has led to basic 
definitions for cancer rehabilitation. This aims to help both to minimize the effects induced 
by the disease and the treatment (surgery, chemotherapy, radiotherapy, hormone therapy) 
and to regain control of many aspects of life in order to become an effective means of 
prevention for recurrences and comorbidity (Carver, JR.; Shapiro, CL 2007 ). 
The rehabilitative intervention, therefore, shouldn’t aim only to control physical pain but 
also to relieve the mental, social and spiritual pain, with all the other symptoms ( Mikkelsen 
T .2009) (Fialka-Moser, V Crevenna, R.. 2003 ). 
Since the 80’s, scientific literature has stressed the link between sedentariness and certain 
types of cancer (Garabrant 1984). 
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Physical activity is one of the modulators of the cancer risk and survival factors that 
awakens our attention to the possibility of implementing a strategy within our operational 
capabilities. 
In the history of scientific analysis of data related to physical activity, the capability to 
monitor it has come up against many methodological difficulties which have prevented to 
gather uncontaminated data, due to poor sensitivity and specificity of the used methods. 
In particular, seven are the highlighted weak points: 
1. most of the studies used questionnaires, often in retrospective and self-administration 
situations , giving many problems related both to their poor reliability of self 
assessment, typical of overweight people (as they often are physically inactive people) 
and to the inconsistencies sometimes found between the body mass and the energy 
expenditure calculation; 
2. The quantification considered the so-called occupational (work-related activities) and / 
or recreational activities. Monitoring involved long periods of time in which the 
introduced technologies in the workplace have often increased sedentary lifestyle.  
3. Most of our literature hasn’t revealed the composition of each person’s diet both under 
a calorie and under a composition point of view, right now when we are focusing our 
attention to glycemic index of food for their capability to induce abnormal insulin 
elevations, an anabolic hormone but with powerful proliferative activities. 
4. We can’t very often have reported data on the qualitative composition of lipids or their 
quantitative distribution during the day: the intake of dietary fat with a "cafeteria" diet 
(often connected with the type of job) shows the capability to induce inflammation and 
to trigger a chain of pro-cancerous events. 
5. We can’t always find reliably identified the duration and intensity of each physical 
activity and not always the used algorithms are normalized for the mass of each 
individual. 
6. The daily activities are not located in the light and dark temporal space. Furthermore 
we don’t have any idea, even indirect, of the situation of the vitamin D connected with 
the sun exposure and whose lack, especially in over 60 year people, can be a risk factor 
for different types of neoplasia.  
7. We do not always have signs of body composition, being the BMI (Body Mass Index) 
the parameter for measuring the individual’s structure, but it does not give an idea of 
body fat (especially in Asian people). This is an important piece of information as body 
fat is a good parameter to consider the relationship between energy intake and energy 
expenditure in physical activity. Fat is also an active organ under an inflammatory and 
hormonal point of view for carcinogenesis processes and tumor progression, but it is 
also a sensitive tissue in its plasticity in physical activity.  
1.2 As regards the management of physical activity after the patient's diagnosis, it 
should be noted that 
1. the American College of Sports Medicine has recommended to everybody, healthy and 
tumor-bearing, to do physical activity, even if of moderate intensity, for at least 30 
minutes for 5 days a week (Haskell 2007, Schmitz 2010); 
2. the American Institute for Cancer Research and the Word Cancer Fund recommends to 
practise physical activity at least 60 minutes a day, even if of moderate intensity, or 30 
minutes of intense activity (World 2007) in order to reduce cancer risk. 
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1.3 As regards the creation of a proper physical exercise for the individual it should 
be noted that 
the relationship between the mass of our body and the height has always been a guide for 
trainers to do their job. Older clinicians spoke about constitutional types, such as brachytype 
to mean short people in stature or those who appeared long-limbed, basically thin and tall. 
Today the relationship between weight in kilograms and height in squared meters, called 
BMI (Body Mass Index), has become a useful indicator of easy calculation to define the 
population in terms of normal-weight (BMI between 19 and 25), underweight (BMI <19), 
overweight (BMI between 25 and 30) or obese (between 30 to 35) or super-obese (> 35).   The 
BMI correlates with the amount of fat, with the production of inflammatory proteins, with 
blood pressure, with the risk of many disabling diseases or life-threatening conditions such 
as diabetes, dementia, arthritis, depression, cardiovascular diseases and, with increasing 
evidence, cancer. The World Health Organization estimates that worldwide there are at least 
1.6 billion overweight people (WHO 2006). Obese people exceed 400 millions whose 
incidence in Western countries has now reached and in some cases exceed 20% of the entire 
population (CDC 2006). 
 The link between the weight gain and the incidence of cancer has been linked to 
biochemical factors that characterize the increase of fat mass like the increase of insulin, 
of IGF (Insulin Like Growth Factor), of Adipokine, Steroids, but also hypoxia linked to 
obesity and the entering into circulation of stromal fat cells (IARC 2002, World Cancer 
Research 2007, Renehan 2006, 2008, 2009). 
 Today there are a lot evidences of a strong correlation between obesity and cancer, with 
specificity for each sex, with the involvement of a growing type of cancer in different 
populations. 
 The obesity is linked to 20% of all cancer deaths in women and 14% in men (Calle 2003) 
 It is evident that in case of obesity, exercise becomes an important moment to fight 
what described above. 
 Tumors associated with increased BMI are cancer of breast in post-menopausal women, 
of prostate, of kidney, of esophagus, of endometrium, and it was determined that there 
is an increased risk for each increment of 5 Kg/m2 at the BMI (Roberts 2010) 
 There is a direct correlation between BMI and plasma insulin levels (McKeown-Eyssen 
1994, Giovannucci 1995) 
 High levels of insulin are associated with insulin resistance and low plasma levels of 
Insulin like Growth Factor Binding Protein 1 and 2 (IGFBP1/2), proteins which bind 
IGF-1 (Insulin-like Growth Factor 1) which in turn has an activity to promote cell 
proliferation. The reduction of IGFBP1 and IGFBP2 increases the levels of free IGF-1. 
 Many epidemiological studies have shown that high plasma levels of insulin before 
eating, C peptide (an insulin secretion indicator of the pancreas), are related to risk of 
endometrial, pancreatic, colorectal, postmenopausal breast cancer (Goodwin 2002, 
Pisani 2008; Wolpin 2009) 
 Obese individuals usually have high plasma levels of IGF-1 (Frystyk 2004), and high 
plasma levels of IGF-1 have been linked to high risk for cancer of the colon and the 
rectum, the prostate and the premenopausal breast (Renehan 2004) and, with less 
evidence, in the postmenopausal phase (Renehan, 2006). The IGF-1 elevation in adipose 
tissue results in an increase of aromatase, an enzyme involved in the conversion of 
androgen hormones into estradiol hormone at high mitogenic activity on the epithelium 
of the mammary gland (Travis 2003). 
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Physical activity is one of the modulators of the cancer risk and survival factors that 
awakens our attention to the possibility of implementing a strategy within our operational 
capabilities. 
In the history of scientific analysis of data related to physical activity, the capability to 
monitor it has come up against many methodological difficulties which have prevented to 
gather uncontaminated data, due to poor sensitivity and specificity of the used methods. 
In particular, seven are the highlighted weak points: 
1. most of the studies used questionnaires, often in retrospective and self-administration 
situations , giving many problems related both to their poor reliability of self 
assessment, typical of overweight people (as they often are physically inactive people) 
and to the inconsistencies sometimes found between the body mass and the energy 
expenditure calculation; 
2. The quantification considered the so-called occupational (work-related activities) and / 
or recreational activities. Monitoring involved long periods of time in which the 
introduced technologies in the workplace have often increased sedentary lifestyle.  
3. Most of our literature hasn’t revealed the composition of each person’s diet both under 
a calorie and under a composition point of view, right now when we are focusing our 
attention to glycemic index of food for their capability to induce abnormal insulin 
elevations, an anabolic hormone but with powerful proliferative activities. 
4. We can’t very often have reported data on the qualitative composition of lipids or their 
quantitative distribution during the day: the intake of dietary fat with a "cafeteria" diet 
(often connected with the type of job) shows the capability to induce inflammation and 
to trigger a chain of pro-cancerous events. 
5. We can’t always find reliably identified the duration and intensity of each physical 
activity and not always the used algorithms are normalized for the mass of each 
individual. 
6. The daily activities are not located in the light and dark temporal space. Furthermore 
we don’t have any idea, even indirect, of the situation of the vitamin D connected with 
the sun exposure and whose lack, especially in over 60 year people, can be a risk factor 
for different types of neoplasia.  
7. We do not always have signs of body composition, being the BMI (Body Mass Index) 
the parameter for measuring the individual’s structure, but it does not give an idea of 
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fat is a good parameter to consider the relationship between energy intake and energy 
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also a sensitive tissue in its plasticity in physical activity.  
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should be noted that 
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2. the American Institute for Cancer Research and the Word Cancer Fund recommends to 
practise physical activity at least 60 minutes a day, even if of moderate intensity, or 30 
minutes of intense activity (World 2007) in order to reduce cancer risk. 
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1.4 Breast cancer and the management of physical exercise 
Breast cancer is the most common female cancer in many countries. 
1.4.1 As regards risk factors for breast cancer it should be noted that 
these have been identified in the: 
 Excess weight 
 Excess body fat 
 High insulin on an empty stomach 
 Insulin resistance 
 Increased plasma levels, Insulin Like Growth Factor 
 Increased plasma levels of hormones at estrogen and androgen activity 
All the listed factors above are involved in the proliferative in vitro and in vivo cancer 
processes (Stephenson, 2003; Del Giudice 1998; Bruning 1995; Sachdev 2001; IARC 2002). 
In literature there are few data about the effects of physical activity on women related to the 
parameters listed above (Schmitz 2005) 
 There is evidence that obesity is a risk factor for breast cancer (Stephenson 2003, World 
Cancer Research Fund 2007) 
 The high caloric intake in relation to the energy needs has been indicated as a possible 
cause of increased risk of breast cancer, but studies have given conflicting results. A 
positive relationship was described by 7 out of 15 case control studies (Franceschi 1996; 
Iscovitch 2004; Katsouyanni 1994, Levi 1993; Toniolo 1989; vant'Veer 1990, Yu 1990), 2 
out of 10 prospective studies (Gaard 1995; Barrett -Connor 1993), with a relative risk 
between 1.3 and 3.5. Instead, no relationship was found by other authors (Malin 2005; 
Graham 1991.1992; Holmberg 1994, Ingram 1991; Katsoiyanni 1988, Miller 1978, Rohan 
1995, Yuan 1995, Holmes 1999, Howe 1991, Jones 1999; Kushi Velie 1992 2000; van der 
Brandt 1993) and an author found an inverse relationship (Knekt 1990). 
 In a latest prospective study, 38.660 women aged from 55 to 74 years were monitored in 
the U.S.A. between 1993-2003. In that period of time, 764 new cases of breast cancer 
were diagnosed. The use of questionnaires allowed us to quantify the contribution of 
energy, the amount of physical activity, the weight, the height and the BMI of the 
population. The relative risk (RR) of breast cancer for patients with the highest quartile 
of caloric intake compared with women with the lowest quartile was equal to 1.25 BMI 
> 30Kg/m2 compared with BMI < 22.5 kg/m2 and led to a risk equal to 1.35. Women 
with intense physical activity > 4 hours weekly reduced their RR to 0.78% compared to 
less active ones. Patients with the highest energy intake, with a higher BMI, doing less 
physical activity than the others, have a RR of 2.10 (Chang, 2006). 
 Obesity, at the moment of diagnosis, is an unfavorable prognostic factor both for 
recurrence and for survival (Chlebowsky 2002, Boyd 1981, Goodwin 2002, Kumar 2000, 
Newman 1986) 
 The weight gain after the diagnosis is a common phenomenon (Rock 1999; Demark-
Wahnefried 1997, 2001; McInnes 2001; Goodwin 1999; Asiani 1999; Harvie 2004; 
Freedman 2004; xxDonegan 1978; Donegan 1978; Dixon 1978; Hernandez 1983; Bonomi 
1984; Foltz 1985; Heasman 1985; Hunington 1989; Chlebowski 1986, 1993, Goodwin 
1988, 1998, Gordon 1990; Levine 1991; Demark-Wahnefried 1983,1997; Faber-
Langendoen 1996, Cheney 1997). 
 In the Health Eating and Lifestyle Study (HEAL), 514 women with breast cancer, stage 
0-IIIA, were monitored for body composition by DEXA for a period of 2 years. At the 
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end of the first year after diagnosis, 68% showed a weight gain between 1.7 and 4.7 kg 
and 74% increased their fat mass between 2.1 and 3.9%. Three years after diagnosis, the 
patients with greater weight gain were those with the higher stage, post-menopausal, 
younger, with greater reductions in physical activity after diagnosis (Irwin 2005). 
 The chemotherapy has an important role in weight gain. The role of Tamoxifen would 
seem poor, instead, more important is the effect of other drugs such as 
Cyclophosphamide, Metrotexate, Epirubicin, Fluorouracil (Demark-Wahnefried 1993, 
Goodwin 1999, Cheney 1998 Fisher 1997; Ascani 1999, Shepherd 2001, Faber-
Lanhendoen 1996; Camora 1990 ) 
 Weight gain after diagnosis is a negative prognostic factor for survival (Chlebowsky 
1987; Camora 1990; Bonomi, 1985), however, it was denied by other authors (Levine 
1991; Heasman 1985, Goodwin 1988, Costa 2002) 
 Women with breast cancer have an increased risk for hypertension and diabetes (Aziz 
2002; Ganz 1998) 
1.5 Weight and physical exercise 
 Excess weight and reduced physical activity are included in a proportion between one-
quarter to one-third of breast cancer carriers (IARC 2002) 
 Physical activity is considered a reliable factor for breast cancer risk reduction in 
postmenopausal women (IARK 2002, World Cancer Research Fund in 2007, 
Monninkhof 2007; Friedenreich 2008), regular physical activity in itself can reduce the 
risk up to 20% (Warburton 2007) 
 Case-control studies (Vanio 2002, Bernstein 1994, Carpenter 1999, Carpenter 2003; Yang 
Bernstein 2005) and cohort studies (McTiernan, 2003; Patel 2003; Dallal 2007; Lahmann 
2007) demonstrated that the risk of invasive cancer of the breast is reduced by a 
percentage varying from 15 to 50% in women who do physical activity. Furthermore, a 
reduction of 50% has been reported in women of childbearing age with 4 hours of 
physical activity per week or post-menopausal women with the habit of regular and 
intense physical activity (Carpenter 1999, 2003). The results were confirmed in 
geographically different populations. They involved Asian and African-American 
women (Yang) Bernstein 2005). The risk of carcinoma in situ is reduced in women with 
regular physical activity as well (Patel 2003) 
 The California Teachers Study (CTS), a prospective study on 133.000 women, showed 
that both the invasive breast cancer and the carcinoma in situ show a level of risk 
inversely correlated with the amount of physical activity as long as women were 
involved at least 5 hours per week during all their fertile life. 
 However, it should be noted that moderate or intense protracted physical activity for a 
long period of life has demonstrated protection only for the risk of invasive cancer, 
compared with positive neoplasia for estrogen receptors, but not for invasive cancers 
which are negative for these receptors (Dallal 2007) 
 The EPIC (European Prospective Investigation into Cancer and Nutrition) showed that 
women with higher recreational or occupational physical activity have a lower risk than 
those with the lowest quartile of physical activities, both in pre and post menopause. In 
an absolute sense neither recreational nor occupational activity show a  relation with 
the risk. (Lahmann 2007). 
 With regard to breast cancer in postmenopausal women in a meta-analysis of 19 cohort 
studies and 29 case-control studies showed an inverse relationship between risk and 
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amount of physical activity (Monninkhof 2007). The evidence is weaker for 
premenopausal women in which a risk reduction of 6% per weekly additional hour of 
physical activity, but only in half of the studies considered of the "highest quality". 
 In particular, women with breast cancer, who exercise more than 9 MET per week, 
show a reduction in recurrence between 40 and 67% (McTiernan, 2008; Ibrahim 2010, 
Irwin 2007) compared with sedentary individuals. 
1.6 The management of physical exercise in case of prostate cancer 
 There are a lot of studies in literature which suggest a low risk reduction. (Vanio 2002). 
Instead, physical activity reduces the risk of the prostatic adenoma (Platz 1998) 
 There is, however, some evidence that, in the groups, the most active men show a 
reduced risk of 10-30%, compared with the less active ones, and that the benefit is much 
more evident when high-intensity physical activity has started early in life 
(Friedenreich 2002) 
  In a case control study of patients with grade 2 or more of prostate cancer, physical 
activity, which they had started in adolescence and which they had continued at high 
intensity for the rest of life, showed no substantial risk reduction (Friedenreich 2004) 
 Cohort studies didn’t demonstrate significant risk reduction, but they reduced the 
incidence of more severe forms or the ones with a fatal outcome (Friedereich 2004, 
Giovannucci 2005, Patel 2005) 
 The prostate cancer survivors have a reduced mortality of 61% if they do high-intensity 
physical activity for at least 3 hours per week (Kenfield 2011) 
1.7 Cancer of the colon-rectum and the management of physical exercise during 
cancer disease 
Colon cancer is one of the forms of neoplasia with increasing incidence, with a prevalence in 
some countries, reaching 10% of the population suffering from cancer (Jemal 2010, Bhatia 
2008). 
The improvement of diagnostics and treatments has led to a substantial improvement in 
survival at 5 years that has passed through the most severe not localized forms (Altekruse 
2010), from 51% in 1975 to 69.5% in 2006. 
Survivors are at risk of developing a second cancer of the colon or of other organs, mainly 
breast, prostate, skin and lungs (Green 2002, Andre 2009, Birgisson 2005). 
Most of the survivors of colon cancer are at risk of developing other diseases, mainly 
cardiovascular, pulmonary and psychiatric (Phipps, 2008, Jansen 2010; Yabroff 2004, 
Trentham-Dietz, 2003; Brown 1993; Denlinger 2011). 
Often the survivors suffer from the consequences of therapies such as ostomy, neuropathies, 
chemotherapy, asthenia and depression. These may represent important limitations to the 
use of physical exercise as a therapeutic tool (Phipps 2008, Rauch 2004, Schneider 2007). 
Physical activity has been proposed as a therapeutic but non- pharmacological tool to 
improve the quality of life and prognosis of patients suffering from colorectal cancer as well 
as a primary prevention means. 
 The National Comprehensive Cancer Network recommends, during and at the end of 
anticancer treatment, a program of lasting and resistance physical activity to reduce 
asthenia. 
 The American Cancer Society wishes a physical activity program to improve the quality 
of life, preventing recurrences or the incidence of concomitant diseases (Brown 2003) 
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 The American College of Sports Medicine, through a consensus, hopes for neoplastic 
patients a moderate-intensity physical activity of at least 150 minutes per week or 75 
minutes per week of intense activity, combined with two/three weekly stretching 
sessions for the most important muscle groups (Schmitz 2010). 
Studies on the role of physical activity in reducing the colon cancer risk are those which 
oncologists recognize as the most convincing (Vainio 2002). Literature provides numerous 
prospective studies (Lee 1995; Gerhardsson 1988, Martinez 1997, Wu 1987; Thun 1992; 
Dancing 1990-Barbash, Albanian 1989, Severson 1989; Lynge 1988, Paffembarger 1987, 
Giovannucci 1995), and retrospective (Fraser 1983 , Longnecker 1995, Wittemore 1990, Kuna 
199 °, Markowitz 1992, Peters 1989, Brownson 1989, Kato 1990, Fredriksson 1989). 
A meta-analysis of 19 cohort studies showed a reduction in the incidence of cancer in 22% of 
males and in 29% of women with physical activity (Samad 2005). 
Another meta-analysis of 52 observational studies showed that physical activity reduces the 
development of colon cancer (Wolin 2009). 
However: 
 data are more convincing in men than in women (Cheblowski 2004); 
 the use of hormone replacement therapy alone tends to reduce the risk of cancer and 
this gives serious problems of interpretation when the examined women were older ; 
 the combination of moderate physical activity all life long with high-intensity 
recreational physical activity has for women little impact on cancer risk (Mai 2007); 
 women, who did physical activity in the fertile age at least 4 hours a week, have a 25% 
lower risk than those whose activities did not exceed 30 minutes per week (Mai 2007) 
 post-menopausal women, who didn’t do any hormone treatment, have a 46% risk 
reduction, if they did physical activity for at least 4 hours a week ; 
 women with hormone therapy do not have further risk reductions with the regular 
practice of physical activity ; 
 physical activity doesn’t give any risk reduction of the rectum cancer. 
In a study of 680 patients with colon cancer, who belong to a population of 51.500 subjects, 
recruited by the Health Professional Follow-up Study, the survivors in the period 1986-2004 
were monitored every 2 years with a specific questionnaire for assessing physical activity in 
MET, the results showed that subjects with an energy expenditure higher than 18 MET per 
week had a 50% risk reduction of recurrence. An activity over 
27 MET per week, compared with patients with MET <3, showed a reduction in mortality 
risk equal to 0.47. Free from cancer patients were 82.2% with activity <3 MET, 87.4%, those 
between 3 and 27 MET, 92.1% those with > 27 MET in 5 years. Free of cancer patients were, 
for 3 MET levels, were respectively 79.4%, 81.2%, 88.3% in 10 years. Mortality in patients 
with activities <27 MET had a death rate of 50% lower than the sedentary ones; this result 
was not related to age, disease stage, BMI, tumor location and physical activity before the 
diagnosis. (Meyerhardt 2009). 
 From an observational prospective cohort study, the Nurses' Health Study, conducted 
among 121.700 subjects in the period 1986-2002, 573 women with a diagnosis of colon 
cancer, stage I-III, were enrolled. All participants were monitored with a questionnaire 
and a scale which was able to measure the activity in MET hours/week. If no response 
was given, they did a research aimed at establishing the evolution of the illness or the 
death. The level of physical activity before the diagnosis had no effect on the mortality 
rate.The physical activity after diagnosis reduced, in subjects with <18 MET hours / 
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 The American College of Sports Medicine, through a consensus, hopes for neoplastic 
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week had a 50% risk reduction of recurrence. An activity over 
27 MET per week, compared with patients with MET <3, showed a reduction in mortality 
risk equal to 0.47. Free from cancer patients were 82.2% with activity <3 MET, 87.4%, those 
between 3 and 27 MET, 92.1% those with > 27 MET in 5 years. Free of cancer patients were, 
for 3 MET levels, were respectively 79.4%, 81.2%, 88.3% in 10 years. Mortality in patients 
with activities <27 MET had a death rate of 50% lower than the sedentary ones; this result 
was not related to age, disease stage, BMI, tumor location and physical activity before the 
diagnosis. (Meyerhardt 2009). 
 From an observational prospective cohort study, the Nurses' Health Study, conducted 
among 121.700 subjects in the period 1986-2002, 573 women with a diagnosis of colon 
cancer, stage I-III, were enrolled. All participants were monitored with a questionnaire 
and a scale which was able to measure the activity in MET hours/week. If no response 
was given, they did a research aimed at establishing the evolution of the illness or the 
death. The level of physical activity before the diagnosis had no effect on the mortality 
rate.The physical activity after diagnosis reduced, in subjects with <18 MET hours / 
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week energy expenditure, the index of mortality risk to 0.39 compared with women 
with <3 MET activity. Mortality in 5 years gave the following percentages: 14.1% for 
patients with <3 MET activity, 14.4% for those whose activity was between 3 and 17.9 
MET hours per week, 62% for the > 18 MET group. Those women who increased their 
physical activity compared with the pre diagnosis period reduced by 50% their risk of 
mortality. 
 Physical activity, before the diagnosis, indirectly correlates with the reduced incidence 
of recurrence (Haydon 2006). 
 The amount of physical activity, before the diagnosis, does not affect mortality 
(Meyerhardt in 2006, 2009). 
 The amount of physical activity after diagnosis reduces the risk of recurrence and 
mortality (Meyerhardt 2006a, 2006 b). 
1.8 As regards risk factors for colon cancer it should be noted that 
 many studies have shown a relationship between BMI and risk of colorectal cancer 
(Potter, 1993, Manson 1995, Murphy 1998). 
 Fat has an important role, especially in its topographic distribution (Giovannucci 1995). 
 High levels of visceral adiposity are related to high levels of insulin on an empty 
stomach (kissenbach 1982; Bjorntorp 1990; Krotkiewsky 1983). 
 The Health Professionals Follow-up Cohort Study conducted on a population of 31.400 
men, highlighted that waist-thigh circumference ratio, which is a surrogate of the 
visceral fat measure, correlated with the risk of colon cancer in the rectum; individuals 
with the highest quartile showed a 3.4 RR, compared with the ones who had the lowest 
quartile, (Giovannucci 1995). 
 The insulin and the Insulin Like Growth Factor 1 (IGF-1) have a mitogenic activity and 
induce cell proliferation of colon mucosa cells, in vivo and in vitro (Giovannucci 1995, 
Singh 1993, Tran 1996). 
 Patients with type 2 diabetes have a high incidence of colon adenomas (Hu 1999, Will 
1998, Nishi 2001). 
 High levels of plasma insulin have been linked to higher risk of colon cancer 
(McKeown-Eyssen 1994, Shoen 1999, Yamada 1998). 
 The observational Cardiovascular Health Study showed the onset of the colorectal 
cancer in 102 subjects. It was carried out in 5.849 subjects, who were monitored for 3 
years. The relative risk was twice for those who belonged to the quartile with the 
highest glucose on an empty stomach (also insulin on an empty stomach should be 
tested), compared with the ones with the lowest quartile of blood glucose levels. High 
levels of plasma glucose and insulin, after the glucose tolerance test were related to a 
colorectal cancer risk of 2.4. (Shoen 1999). 
 High plasma levels of C-peptide in patients with colorectal cancer are related to an 
unfavorable prognosis for survival (Wolpin 2009). 
 High IGF-1 levels in non-cancer subjects have been associated with high risk of 
colorectal cancer in two important, prospective studies, the Nurses Health Study and 
the Physicians Health Study. This association was not confirmed by the European 
prospective study, EPIC (European Prospective Investigation into Cancer) (Giovannucci 
2000; McPollack 1999, Rinaldi 2010) 
 Two meta-analyses did not confirm the relationship between risk and pre-disease IGF-1 
levels (Rinaldi, 2010; Renehan 2004). 
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 The IGF-1 levels during the disease are not related to the prognosis of the survivors 
(Haydon 2006). 
 The IGFBP-3 (Insulin like Growth Factor Binding Protein-3) levels, a protein whose 
deficiency increases the percentage of circulating free IGF-1, correlate inversely with 
mortality. In subjects with higher IGFBP-3 levels, the mortality risk was reduced by 
50%. 
2. Our point of view with regard to an ideal physical activity in oncological 
patients to survive 
The development of exercise in cancer rehabilitation context has as its primary goal the 
promotion of a better quality of life, especially in terms of individual perception. 
The rehabilitation outcome has to be measured in terms of an individual perception of well-
being, and it is also expressed in a collective form, involving all the interested subjects to 
this topic in its definition. 
The outcome, in general, has to do with the return to society of people who experienced the 
disease, as it happens for other important but not lethal diseases. 
After having expressed, in the international review, what is believed to induce positive 
effects in the body system which survived cancer, through the use of physical exercise, we 
find useful to propose a rehabilitative treatment which is not limited to recommend regular 
metabolic activity but aims to recover the remaining capacity of the subject, through a 
specific approach to the patient and the pathology but, at the same time, it aims to increase 
his/her residual performance with progressive metabolic load by METs . 
Therefore, we divided our therapeutic intervention in 3 phases: 
Phase 1 Recovery of Residual Capacity. 
Phase 2 Recovery sensory-motor and functional capacity. 
Phase 3 Recovery of the quality of Life. 
2.1 Phase 1: Recovery of residual capacity 
The rehabilitation strategy is aimed at: 
1. recovering joint mobility and elasticity of muscle tissue, according to the existing 
damage and to the diseases;  
2. increasing the uninjured muscle tone; 
3. rebalancing the muscle synergies of the body system, by reprogramming the body static 
and dynamic scheme. 
Our rehabilitation method uses instrumental and not instrumental techniques. 
The aim of the therapy is to: 
 induce the gradual recovery of joint mobility through passive and active exercises; 
 induce a sensory stimulus for body perception in the space. This is realized by us by using 
tools such as PANCAFIT or similar and the postural bench system (TecnoBody, Bergamo, 
Italy), equipped with six independent sensors, each one positioned at the dorsal, lumbar 
and sacroiliac level. It allows real-time to assess the load that the patient places on each of 
the sensors. This feedback visual system allows the operator to assess and to work on 
deficient areas of the body from the proprioceptive and muscle point of view. It also 
allows the patient to modify, to learn and to increase his/her perception of the body in the 
space, inducing the acquisition of a suitable elastic posture for the two hemisomas; 
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 induce muscular adaptations in the recovery of muscle tone, in this regard we use a 
focused vibratory acoustic stimulation at high intensity (VISS, VISSMAN, Rome, Italy). 
Vibrations stimulate bone marrow function and the upper motor centers in order to 
obtain a better performance of controls, responsible for muscle recruitment; they 
activate the aerobic metabolism; they have an analgesic effect; they increase local 
circulation and bone density; they cause an increase in contractile capacity and elasticity 
of the skeletal muscle tissue; 
 recover muscle synergies and elasticity of muscle tissue. 
Rehabilitation protocol 
2 sessions per week for at least 2 months with a metabolic cost of 18-21 METs. 
Physical Therapies: 
focused high intensity vibratory stimulation (VISS, VISSMAN, Rome, Italy).  
Position: supine in the absence of muscle contraction; frequency: 300Hz; duration: 30 min. 
Motor Rehabilitation: 
 passive mobilization; 
 passive muscle stretching exercises; 
 Postural motor training using postural bench (TecnoBody, Bergamo, Italy). Position: 
supine; duration: 30 min.; 
 isometric force exercises. 
2.2 Phase 2: Sensory-motor and functional recovery 
The rehabilitation strategy aims to: 
replan the balance system to ensure that the brain (CNS) can use the sensory systems which 
are still working; 
increase the tone of postural muscles, looking for an enhancement of the lower limbs and 
trunk muscles.  
In our rehabilitation method, we use instrumental or not instrumental techniques. 
The aim of therapy is to : 
 induce adaptation to the pathological condition; 
 induce a sensory readaptation (e.g. placing the patient on a tilting platform demanding 
stabilization motor tasks in closed and open kinetic chain (I-Moove Allcare Innovations 
Chabeuil, France); 
 support a sensory substitution (e.g. trying to strengthen the role of vestibulo-spinal 
control by strengthening the ability to use proprioceptive afferents in a patient with 
sensory and/or motor neuropathy); 
 induce a tone recovery and proprioception of the muscle skeletal kinetic chains by 
creating an unstable environment where the patient has to relate to rebalance the 
relationship between the kinetic chains, enhancing inter-and paravertebral muscles and 
searching for a core stability increase with the I -Move system or similar; 
 induce a muscle strength increase, especially in the lower limbs. 
Rehabilitation protocol 
3 sessions per week for at least three months with a metabolic cost of 21-24 METs. 
 




Focused high intensity vibratory stimulation (VISS, VISSMAN, Rome, Italy)  
Position: orthostatic; frequency: 300Hz; duration: 10 min 
Motor Rehabilitation: 
 20 min of aerobic cycle ergometer, 80-95 bpm. 
 Passive muscle stretching exercises. 
 Global proprioceptive training (I-Moove Allcare Innovations Chabeuil, France). 
Position: orthostatic; duration: 30 min. 
 Postural motor sense training using postural bench (TecnoBody, Bergamo, Italy). 
Position: orthostatic; duration: 10 min. 
 Isometric force exercises. 
2.3 Phase 3: Recovery of quality of life 
The rehabilitation strategy is aimed at strengthening of the recovered sensorimotor capacity to 
allow the patient a gradual return to society, improving his/her quality of life    Increasing the 
muscle strength needed for walking and for the orthostatic position, developing 
proprioception and requiring motor tasks more and more difficult and functional in daily life. 
In our rehabilitation method, we use instrumental or not instrumental techniques. 
The aim of therapy is to: 
 induce a proprioceptive increase using instruments for monitoring the performance 
which is achieved by biofeedback (e.g. I-Moove allows you to balance the muscle 
synergies through its helical movement, taking the natural, spiral course of the muscle 
fascia. The special movement of the platform can be expanded and strengthened 
specifically for the patient by increasing and improving proprioception, mobility and 
strength. (I-Moove Allcare Innovations Chabeuil, France); 
 increase selectively the muscle strength (e.g. isotonic and isokinetic exercises, load of 
60% RM for 12 repetitions for 4 series); 
 stimulate motor learning; 
 create a cardio circulatory metabolic adaptation. 
Rehabilitation protocol 
3 sessions per week for three months with a metabolic cost of 25-29 METs. 
Physical Therapy: 
Focused high intensity vibratory stimulation (VISS, VISSMAN, Rome, Italy). Position: 
supine in the absence of muscle contraction; frequency: 300Hz; duration: 30 min. 
Global vibratory stimulation (PhysioPlate FIT, Globus Italy srl, Codognè (TV), Italy). 
Position: orthostatic; frequency: 50Hz; duration: 10 minMotor Rehabilitation: 
 40 min of aerobic cycle ergometer, 100-110 bpm; 
 active and passive stretching; 
 global proprioceptive training (I-Moove Allcare Innovations Chabeuil, France). 
Position: orthostatic; duration: 30 min; 
 coordination exercises and complex motion; 
 isokinetic and / or isotonic strength exercises. Our protocol is repeated after 3 months 
from the end of the entire project, by repeating phase 2 and 3 with a duration of 1 
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month per each phase in 24 months from the end of the specific medical or surgical 
oncology treatment. 
3. Conclusions  
Cancer patients suffer from persistent emotional and social distress, because of functional 
deficits, all that results in a reduced quality of life (QOL). The QOL assessment should 
include at least four functional dimensions: physical, the emotional, the social and the 
cognitive function. These dimensions are positively influenced by a proper rehabilitation 
program which includes physical exercise. It is well known that phyisical activity is an 
important means to prevent and to fight the problems of inactivity and disuse, and to 
reduce fatigue. 
The information about the role of physical activity in oncology has been increasing over the 
years, and now is possible to confirm that ” the physical activity decreases the risk of 
disease; in patients who suffer from cancer, it prolongs survival, reduces the occurrence 
of concomitant diseases and improves the life quality” in (U.S. Department of Health and 
Human Services, 2008). 
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month per each phase in 24 months from the end of the specific medical or surgical 
oncology treatment. 
3. Conclusions  
Cancer patients suffer from persistent emotional and social distress, because of functional 
deficits, all that results in a reduced quality of life (QOL). The QOL assessment should 
include at least four functional dimensions: physical, the emotional, the social and the 
cognitive function. These dimensions are positively influenced by a proper rehabilitation 
program which includes physical exercise. It is well known that phyisical activity is an 
important means to prevent and to fight the problems of inactivity and disuse, and to 
reduce fatigue. 
The information about the role of physical activity in oncology has been increasing over the 
years, and now is possible to confirm that ” the physical activity decreases the risk of 
disease; in patients who suffer from cancer, it prolongs survival, reduces the occurrence 
of concomitant diseases and improves the life quality” in (U.S. Department of Health and 
Human Services, 2008). 
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1. Introduction 
New protocols in the early diagnosis and treatment of cancer have led to major 
improvements in the long-term survival of patients. However, aggressive chemotherapy or 
radiotherapy of the pelvic region, often lead to infertility, due to the damage of the follicles 
and/or oocytes that are present in the ovaries. In women the probability of sterilization due 
to cancer therapy varies with age, the type of treatment, and the follicular reserve in the 
ovary. Safeguarding their reproductive potential is a very important issue for women that 
have not yet started or completed their family, and even more so in pre-pubertal girls. 
Several options, some of which are still in the experimental phase, can now be offered to 
these women to (partially) preserve their fertility.  
In this review, we will, after briefly describing the anatomy and physiology of an ovary, 
discuss the detrimental effects of chemotherapy and radiation on ovarian function. 
Subsequently, the various options that are currently available or are still in an experimental 
phase, for preserving fertility in women and pre-pubertal girls, will be discussed. These 
options (with the exception of option (i)), deal with cryopreserving either oocytes, embryos 
or ovarian tissue until the patient has been cured.  
i. Minimizing the effects of radiation of the inner pelvic region by transposing the ovaries 
from the radiation area. 
ii. Standard IVF procedures can be offered to women who are awaiting chemotherapy and 
radiotherapy for neoplastic disease. This procedure results in the generation of embryos 
that can be transferred after recovery of the disease. This option has its limitations, since 
it not only requires the presence of a male partner, but also delays cancer treatment 
during ovarian stimulation. In addition, the number of embryos that can be produced is 
restricted, and the chance of achieving a pregnancy after transfer of a cryo-preserved 
embryo is only 8-30%. Furthermore, the presence of estrogen-sensitive tumors is a 
contra-indication for this type of treatment, as high estradiol levels are induced during 
a normal IVF procedure, although alternative stimulation protocols with aromatase-
inhibitors are nowadays available for these specific patients. Most importantly, this 
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treatment is not an option for pre-pubertal girls, or for post-pubertal girls who are not 
yet involved in a stable relationship.  
iii. Aspiration of oocytes, followed by cryopreservation and IVF (if necessary preceded by 
in vitro maturation). This option has already been applied to a number of patients. 
Although the same drawbacks that apply to standard IVF are applicable, this procedure 
is mainly aimed at the treatment of post-pubertal girls/young women without a stable 
relationship. Only limited scientific data are currently available to substantiate its 
efficacy and long-term safety.  
iv. As an alternative, cryopreservation of small ovarian cortex strips containing primordial 
follicles can be offered. After the patient has been cured, these cortex strips can 
subsequently be retransplanted either heterotopically or orthotopically. This procedure 
has been successfully used to re-establish female fertility in humans in a limited 
number of cases. A major problem with these avascular implants however is their 
relative short life expectancy and follicular loss due to long term ischemic injury 
directly after reimplantation. 
v. Cryopreservation and subsequent reimplantation of intact ovaries may be a valuable 
addition to the existing array of options, especially for pre-pubertal girls and post-
pubertal girls/women without a stable relationship. An important safety issue of this 
procedure is obviously the chance of reintroduction of malignant cells that may be 
present in the cryopreserved intact ovary. For this reason, patients with solid types of 
tumor and diffuse types of cancer such as leukemia that have a high chance of 
metastasizing to the ovaries, will have to be excluded from this kind of therapy. The 
cryobiological and surgical aspects of the preservation and retransplantation of an 
organ in toto, is technically clearly more challenging than the cryopreservation and 
transfer of isolated cells or tissue strips. The advantages of this approach are obvious; 
immediate revascularization of the transplanted ovary ensures that less ischemic 
damage is inflicted to the ovarian tissue post-thawing, and that more follicles will 
survive. In addition menses, normal long term reproductive functions, and normal 
hormonal status will be restored. 
Finally, we will go into the safety of the procedure. Inevitably the autotransplantation of 
cortical strips or intact ovaries carries the risk of reintroducing malignant cells from the graft 
into the recipient. 
The increase in knowledge of the biology and treatment of cancer has been accompanied by 
an increase in the efficacy of cancer therapies. Long term survival rates for many cancer 
types have therefore increased accordingly (Gatta et al., 2009). Consequently, the quality of 
life of cancer survivors is becoming an important issue. 
The possibility to have genetically concordant progeny is for many people an event that is 
essential for an unrestricted quality of life as an adult (Schover, 2009). The loss of fertility 
that may result from cancer therapy, is therefore an additional complication on top of an 
already difficult period spent on conquering a devastating disease. 
With this in mind, it is of the utmost importance to explore the possibilities for fertility 
preservation in patients that are to be treated with a gonado-toxic therapy. For post-pubertal 
boys and men, this can be achieved relatively easy via the cryopreservation of their semen 
prior to start of the therapy. For pre-pubertal boys this is not an option, as semen production 
is initiated during puberty. Also for this group of patients options for fertility preservation 
are being developed. 
 




In this paper we confine ourselves to fertility preservation for female patients. We discuss 
the causes of anti-cancer therapy-related infertility, and review the current options for 
fertility preservation. We illustrate this matter with two case reports from our own clinical 
practice. In addition we discuss some as yet experimental procedures, that may in the future 
be offered to patients requiring fertility preservation. 
2. Ovaries, oocytes and female reproduction 
The human ovary is spherical structure with a mean volume of 7 cm3 (range 2-15 cm3; Munn 
et al., 1986). The inner ovarian mass, the medulla, consists mainly of stromal cells and 
contains the larger blood vessels. The outer layer of the ovary consists of the cortical tissue, 
spanning 2-3 mm. This tissue is rich in extra-cellular matrix proteins and poor in capillaries , 
and contains the vast majority of the follicles containing oocytes that comprise the ovarian 
reserve. The most important role of the follicle is to protect the oocyte, and support its 
development. Follicles are comprised of layer(s) of theca cells and granulosa cells. Different 
stages of follicles can be distinguished, ranging from primordial follicles to primary follicles, 
and via secondary finally to tertiary (antral) follicles. 
In contrast to males in whom spermatogenesis is a continuous process resulting in the 
uninterrupted generation of fresh spermatozoa, in women a fixed number of oocytes is formed 
during embryogenesis from 1000-2000 germ cells. These germ cells are present in the human 
embryo at 30 days after conception. After 9-10 weeks, these cells transform to oogonia (Baker, 
1972), that degenerate for the greater part between 10 and 20 weeks of gestation. After 5 
months of gestation, the first meiotic division is initiated in the remaining oogonia, resulting in 
the differentiation to primary oocytes. At this stage the meiotic division process is arrested, 
and the oocytes enter a stage of dormancy (Wandji, 1996). At birth only 300.000 to 400.000 
oocytes remain in the ovaries. From birth, the number of oocytes gradually decreases, and at 
the beginning of puberty around 200.000 oocytes remain. Under the influence of pituitary 
gonadotropic hormones (Gougeon, 1996; Oktay, 1997), each month a cohort of primary oocytes 
is recruited, and resumes development. Usually only one primary oocyt completes the first 
meiotic division. This secondary oocyt again enters a stage of dormancy, and is ovulated. The 
second dormant stage is only lifted after fertilization by a sperm cell. Around the age of 50 
years, the total oocyte reserve is almost depleted and the woman enters menopause. In 
addition to age, several factors may affect the follicular reserve, leading to an early exhaustion 
and to premature ovarian insufficiency (POI). These factors include fertility-threatening 
therapies that are discussed in more detail in the next section. 
3. Effects of radio- and chemotherapy on female fertility  
3.1 Chemotherapy 
Cytotoxic therapy may affect all components of the follicle, including granulosa cells, theca 
cells, and of course the oocyt itself (Sobrinho et al., 1971; Blumenfeld et al., 1999). In 
addition, interactions between these cell types that are required for oocyt development may 
be disturbed, resulting in the demise of the oocyt. Damage may become manifest by reduced 
ovarian weight, stromal fibrosis and in a reduction in the number of oocytes and ovarian 
follicles (Warne et al., 1973; Meirow et al., 1999; Oktem & Oktay, 2007). 
The effect of chemotherapy on fertility is dependent on the type of the cytotoxic agent, the 
dose, and the duration of the therapy. Alkylating agents such as cyclophosphamide, L-
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yet involved in a stable relationship.  
iii. Aspiration of oocytes, followed by cryopreservation and IVF (if necessary preceded by 
in vitro maturation). This option has already been applied to a number of patients. 
Although the same drawbacks that apply to standard IVF are applicable, this procedure 
is mainly aimed at the treatment of post-pubertal girls/young women without a stable 
relationship. Only limited scientific data are currently available to substantiate its 
efficacy and long-term safety.  
iv. As an alternative, cryopreservation of small ovarian cortex strips containing primordial 
follicles can be offered. After the patient has been cured, these cortex strips can 
subsequently be retransplanted either heterotopically or orthotopically. This procedure 
has been successfully used to re-establish female fertility in humans in a limited 
number of cases. A major problem with these avascular implants however is their 
relative short life expectancy and follicular loss due to long term ischemic injury 
directly after reimplantation. 
v. Cryopreservation and subsequent reimplantation of intact ovaries may be a valuable 
addition to the existing array of options, especially for pre-pubertal girls and post-
pubertal girls/women without a stable relationship. An important safety issue of this 
procedure is obviously the chance of reintroduction of malignant cells that may be 
present in the cryopreserved intact ovary. For this reason, patients with solid types of 
tumor and diffuse types of cancer such as leukemia that have a high chance of 
metastasizing to the ovaries, will have to be excluded from this kind of therapy. The 
cryobiological and surgical aspects of the preservation and retransplantation of an 
organ in toto, is technically clearly more challenging than the cryopreservation and 
transfer of isolated cells or tissue strips. The advantages of this approach are obvious; 
immediate revascularization of the transplanted ovary ensures that less ischemic 
damage is inflicted to the ovarian tissue post-thawing, and that more follicles will 
survive. In addition menses, normal long term reproductive functions, and normal 
hormonal status will be restored. 
Finally, we will go into the safety of the procedure. Inevitably the autotransplantation of 
cortical strips or intact ovaries carries the risk of reintroducing malignant cells from the graft 
into the recipient. 
The increase in knowledge of the biology and treatment of cancer has been accompanied by 
an increase in the efficacy of cancer therapies. Long term survival rates for many cancer 
types have therefore increased accordingly (Gatta et al., 2009). Consequently, the quality of 
life of cancer survivors is becoming an important issue. 
The possibility to have genetically concordant progeny is for many people an event that is 
essential for an unrestricted quality of life as an adult (Schover, 2009). The loss of fertility 
that may result from cancer therapy, is therefore an additional complication on top of an 
already difficult period spent on conquering a devastating disease. 
With this in mind, it is of the utmost importance to explore the possibilities for fertility 
preservation in patients that are to be treated with a gonado-toxic therapy. For post-pubertal 
boys and men, this can be achieved relatively easy via the cryopreservation of their semen 
prior to start of the therapy. For pre-pubertal boys this is not an option, as semen production 
is initiated during puberty. Also for this group of patients options for fertility preservation 
are being developed. 
 




In this paper we confine ourselves to fertility preservation for female patients. We discuss 
the causes of anti-cancer therapy-related infertility, and review the current options for 
fertility preservation. We illustrate this matter with two case reports from our own clinical 
practice. In addition we discuss some as yet experimental procedures, that may in the future 
be offered to patients requiring fertility preservation. 
2. Ovaries, oocytes and female reproduction 
The human ovary is spherical structure with a mean volume of 7 cm3 (range 2-15 cm3; Munn 
et al., 1986). The inner ovarian mass, the medulla, consists mainly of stromal cells and 
contains the larger blood vessels. The outer layer of the ovary consists of the cortical tissue, 
spanning 2-3 mm. This tissue is rich in extra-cellular matrix proteins and poor in capillaries , 
and contains the vast majority of the follicles containing oocytes that comprise the ovarian 
reserve. The most important role of the follicle is to protect the oocyte, and support its 
development. Follicles are comprised of layer(s) of theca cells and granulosa cells. Different 
stages of follicles can be distinguished, ranging from primordial follicles to primary follicles, 
and via secondary finally to tertiary (antral) follicles. 
In contrast to males in whom spermatogenesis is a continuous process resulting in the 
uninterrupted generation of fresh spermatozoa, in women a fixed number of oocytes is formed 
during embryogenesis from 1000-2000 germ cells. These germ cells are present in the human 
embryo at 30 days after conception. After 9-10 weeks, these cells transform to oogonia (Baker, 
1972), that degenerate for the greater part between 10 and 20 weeks of gestation. After 5 
months of gestation, the first meiotic division is initiated in the remaining oogonia, resulting in 
the differentiation to primary oocytes. At this stage the meiotic division process is arrested, 
and the oocytes enter a stage of dormancy (Wandji, 1996). At birth only 300.000 to 400.000 
oocytes remain in the ovaries. From birth, the number of oocytes gradually decreases, and at 
the beginning of puberty around 200.000 oocytes remain. Under the influence of pituitary 
gonadotropic hormones (Gougeon, 1996; Oktay, 1997), each month a cohort of primary oocytes 
is recruited, and resumes development. Usually only one primary oocyt completes the first 
meiotic division. This secondary oocyt again enters a stage of dormancy, and is ovulated. The 
second dormant stage is only lifted after fertilization by a sperm cell. Around the age of 50 
years, the total oocyte reserve is almost depleted and the woman enters menopause. In 
addition to age, several factors may affect the follicular reserve, leading to an early exhaustion 
and to premature ovarian insufficiency (POI). These factors include fertility-threatening 
therapies that are discussed in more detail in the next section. 
3. Effects of radio- and chemotherapy on female fertility  
3.1 Chemotherapy 
Cytotoxic therapy may affect all components of the follicle, including granulosa cells, theca 
cells, and of course the oocyt itself (Sobrinho et al., 1971; Blumenfeld et al., 1999). In 
addition, interactions between these cell types that are required for oocyt development may 
be disturbed, resulting in the demise of the oocyt. Damage may become manifest by reduced 
ovarian weight, stromal fibrosis and in a reduction in the number of oocytes and ovarian 
follicles (Warne et al., 1973; Meirow et al., 1999; Oktem & Oktay, 2007). 
The effect of chemotherapy on fertility is dependent on the type of the cytotoxic agent, the 
dose, and the duration of the therapy. Alkylating agents such as cyclophosphamide, L-
 




phenyalanine mustard, and chlorambucil permanently damage ovarian tissue by interacting 
with DNA (Meirow et al., 1999; Manger et al., 2006; Oktem & Oktay, 2007). Analysis of a group 
of 138 young females receiving the alkylating agent busulfan as a preparative regimen for 
indicated that 83% of these women showed signs of fertility impairment, demonstrating the 
potentially very severe effects of this type of compounds (Borgmann-Staudt et al., 2011). 
Mertens et al. (1998) showed an even higher percentage of 99% in gonadal dysfunction for 
women receiving allogeneic haematopoietic stem cell transplantation. The cumulative dose of 
the cytotoxic drug being administered is an important factor in determining the level of 
ovarian insufficiency (Goldhirsch et al., 1990). Permanent ovarian insufficiency was more often 
induced when high dosages of drugs were administered during a short period of time, 
compared to low doses given over a longer time (Koyama et al., 1977).  
In addition the age of the patient is pivotal in determining the amount of damage that is 
inflicted to the ovary. Older women, with an already decreased number of primordial 
follicles, have a higher risk of developing acute complete POI, compared with young 
women who still possess numerous primordial follicles (Schilsky et al., 1981; Sanders et al., 
1996; Tauchmanova et al., 2002). Prepubertal girls seem less vulnerable to cytotoxic drugs 
than adults (Chiarelli et al., 1990). This may be explained by the fact that several 
chemotherapeutical drugs affect DNA replication and/or RNA and protein synthesis, and 
are therefore targeted at metabolically active cells. In prepubertal ovaries all follicles are in a 
dormant, metabolically quiescent state, and therefore less prone to chemotherapy induced 
damage. In contrast, in adult ovaries a number of follicles will be in an active state, and 
therefore more prone to chemotherapy induced damage. Nicosia et al. (1985) actually 
showed in ovarian autopsy material derived from patients having received chemotherapy, 
that the number of growing follicles was reduced, whereas the number of primordial 
follicles remained the same.  
3.2 Radiotherapy 
Similar to the effects of chemotherapeutical agents on DNA integrity, ionizing radiation, 
amongst other effects, also interferes with DNA function. As a consequence, also 
radiotherapy may negatively affect the ovarian reserve. Analogous to chemotherapy, the 
(cumulative) dose and the fractionation schedule determine the degree of damage to the 
ovary (Gosden et al., 1997). The human oocyte is exceptionally sensitive to radiation (Howell 
& Shalet, 1998) and the estimate of the LD50 ( the lethal dose need to kill half the total 
number of oocytes) seems to be less than 2 Gy (Wallace et al., 2003). Also for radiation 
therapy, the age of the patient is an important factor in determining the level of damage. A 
dose of 4 Gy leads to sterility in 30% of young women, and in 100% of women over 40.  
Not surprisingly, the combination of radiotherapy with chemotherapy increases the risk of 
POI (Williams et al., 1999; Wallace et al., 2005; Chemaitilly et al., 2006). Abdominal 
radiotherapy in combination with alkylating agents increased the risk of POI 27-fold (Byrne 
et al., 1992). By the age of 31, 42% of patients treated with this combination therapy, was 
postmenopausal, compared with 5% of women in the normal population.  
3.3 Effects on pregnancy and health of newborns 
In addition to their effects on oocytes and follicles, chemotherapy and radiotherapy may 
also influence uterine function. Radiation may lead to impaired uterine growth in 
premenarchal girls and failure of uterine development during pregnancy, leading to 
 




miscarriages, premature births and intrauterine growth retardation (Ogilvy-Stuart et al., 
1997; Critchley, 1999; Critchley et al., 1992; 2002; Wallace et al., 2005). Comparable results 
were described by Salooja et al. (2001), who showed that in women that had received total 
body irradiation prior to autologous or allogeneic stem cell transplantation, are at high risk 
for maternal and fetal complications. These problems are probably a consequence of uterine 
vascular damage and reduced elasticity of the uterine musculature. 
4. Current options for fertility preservation 
4.1 Ovarian transposition 
An way to prevent damage to the ovaries caused by ionizing radiation therapy applied to 
the pelvic region, is to surgically move the ovary temporarily to a location outside the field 
of radiation (Hadar et al., 1994; Howard, 1997). This procedure, referred to as oophoropexy, 
can be performed laparoscopically. Potential ovarian insufficiency following transposition 
may occur if the ovaries are not entirely moved outside the field of radiation, or when they 
spontaneously migrate back to their original position. Ovarian failure can also occur when 
the ovarian vascular pedicle has been compromised by the surgical procedure (Feeney et al., 
1995). Oophoropexy is a safe and effective procedure, allowing preservation of ovarian 
function in 80% of cases (Bisharah & Tulandi, 2003). 
4.2 Vitrification of oocytes 
Cryopreservation of mature or immature oocytes is an obvious approach to preserve 
fertility. As no fertilization of the oocytes is yet required, this is option is especially suitable 
for women without a partner. The collection of mature oocytes requires stimulation with 
follicle stimulating hormone (FSH). This procedure, that may have to be repeated to obtain a 
sufficient number of oocytes, takes at least two weeks, and is therefore only suitable for 
women for whom it is safe to postpone their cancer treatment. The use of high doses of FSH 
makes this option unsuited for women with oestradiol-sensitive breast tumors, as high 
levels of oestradiol are induced by the FSH treatment (Sonmezer & Oktay, 2006) This caveat 
may be circumvented by the simultaneous use of aromatase inhibitors /anti oestrogens such 
as letrozole or tamoxifen (Oktay et al., 2005b; Sonmezer & Oktay, 2006). Alternatively, 
immature oocytes can be collected without prior stimulation. This procedure may also be 
used for young (prepubertal girls). Evidently, these immature oocytes must be matured in 
vitro (IVM) before they can be fertilised (Gosden, 2005).  
After collection of the oocytes, they have to be cryopreserved in liquid nitrogen for long 
term storage. The formation of ice crystals during the freezing process may severely damage 
the oocyte, rendering it useless for further use. This is especially the case for mature oocytes, 
as they possess a fragile and sensitive meiotic spindle. Immature oocytes are in this respect 
less sensitive. Cryodamage can be prevented by freezing the oocytes in the presence of 
cryoprotective agents via specific protocols, either by slow freezing, or via vitrification (Cao 
et al., 2009; Chian et al., 2009; Kuwayama et al., 2005). During the latter procedure, that 
appears to result in more oocytes surviving the process undamaged, the oocytes are frozen 
extremely rapidly (> 12.000 °C/minute), in the presence of high concentrations of 
cryoprotectant, resulting in the prevention of ice crystal formation.  
A consequence of the cryopreservation procedure (either slow freezing or vitrification) is 
hardening of the zona pellucida. Therefore, cryopreserved oocytes can only be fertilized via 
 




phenyalanine mustard, and chlorambucil permanently damage ovarian tissue by interacting 
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makes this option unsuited for women with oestradiol-sensitive breast tumors, as high 
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may be circumvented by the simultaneous use of aromatase inhibitors /anti oestrogens such 
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immature oocytes can be collected without prior stimulation. This procedure may also be 
used for young (prepubertal girls). Evidently, these immature oocytes must be matured in 
vitro (IVM) before they can be fertilised (Gosden, 2005).  
After collection of the oocytes, they have to be cryopreserved in liquid nitrogen for long 
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the oocyte, rendering it useless for further use. This is especially the case for mature oocytes, 
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intracytoplasmatic sperm injection (ICSI). As the pregnancy rate per cryopreserved oocyte is 
approximately 3% (Kuwayama et al., 2005; Cobo et al., 2007; Homburg et al., 2009), a large 
number of oocytes, equivalent to several stimulation cycles and/or oocyte retrieval 
procedures, are required to achieve a reasonable chance of progeny. The exact number of 
children conceived with cryopreserved oocytes is unknown, but it is estimated to be over 
500 worldwide. Postnatal parameters such as birth weight and incidence of congenital 
anomalies, were comparable with the reference population, indicating the safety of this 
procedure (Borini et al., 2007; Chian et al., 2008). 
4.3 Cryopreservation of embryos 
For women with a partner, the generation and cryopreservation of embryos is a suitable 
option. Obviously, this option will generally require ovarian stimulation, and is therefore 
subject to the same limitations as mentioned previously for the collection and 
cryopreservation of mature oocytes – the cancer treatment has to be postponed to allow for 
one or more ovarian stimulation(s), and extreme caution has to be taken when stimulating 
women with hormone sensitive tumors. The factor time may be circumvented by skipping 
the stimulation with FSH and collect immature oocytes instead. Evidently, in that case IVM 
has to be performed prior to fertilisation of the oocytes. Employing tamoxifen or letrozole 
based stimulation regimes may be used in the case of hormone sensitive tumors (see 
previous paragraph) (Oktay et al., 2005a, 2005b; Sonmezer & Oktay, 2006). Oktay et al. 
(2005b) has shown that in cancer patients who had been stimulated with this compound, 
recurrence rates were not elevated compared to cancer patients who had not been receiving 
any ovarian stimulation. Although we should keep in time that the follow up period was 
confined to only a limited number of years.  
Theoretically, in women with hormone sensitive tumors oocytes can also be collected in a 
spontaneous (non-stimulated) cycle. However, the very limited number of oocytes that can 
be collected this way (one or two per cycle) makes this a very inefficient option and is 
therefore not advisable (Brown et al., 1996). 
Embryo cryopreservation is an established and efficient technique, with reported implantation 
rates per thawed embryo between 8 and 30% (Frederick et al., 1995; Selick et al., 1995; Wang et 
al., 2001; Son et al., 2002; Senn et al., 2006), that has resulted in the birth of tens of thousands of 
children worldwide. In the future, new cryopreservation techniques such as vitrification may 
further improve the efficiency of this technique (Kuwayame et al., 2005). 
4.3.1 Case report A: Emergency IVF in a patient with breast cancer 
Mrs. X was diagnosed 3 years ago with breast cancer. She then underwent a lumpectomy of the right 
breast, and received radiotherapy. Shortly thereafter a unilateral recurrence was found, and a 
mastectomy with lymph node dissection was performed. Pathologic examination revealed an invasive 
ductal carcinoma, positive for estrogen and progesterone receptors. No tumor cells were found in the 
lymph nodes, and no other indications for metastatic disease were found. Additional chemotherapy 
courses were planned. 
At this stage the patient, now 35 years of age, and her partner visited the Centre for Reproductive 
Medicine of our hospital, and expressed their interest in fertility preservation. After establishing that 
the current reproductive status of herself as well as of her partner showed no abnormalities, the 
possibilities for fertility preservation were discussed. Although oocyte vitrification and ovarian tissue 
banking were in theory viable options, the couple was counseled to proceed with an emergency IVF-
 




ICSI attempt, followed by cryopreservation of the embryos, as this would probably give the highest 
chance of progeny within the time limit set by the oncologist. 
The ovarian stimulation protocol was started one month after the mastectomy. Regarding the 
hormone receptor positive status of the tumor, a regimen combining FSH and letrozol was selected in 
order to avoid the high oestradiol levels associated with ovarian hyperstimulation. The treatment 
eventually resulted in the retrieval of 13 oocytes, 12 of which could be inseminated via ICSI. Of the 7 
resulting embryos, 3 were eligible for cryopreservation. The efficacy of the letrozol treatment was 
demonstrated by the finding that during the stimulation with FSH, oestradiol levels did not rise 
beyond 1000 pmol/L.  
The patient than completed 5 cycles of chemotherapy. In addition, she received adjuvant hormonal 
therapy. Menses had stopped and the patient suffered from hot flushes. Two years later at age 37, the 
patient wanted to achieve pregnancy. After discontinuation of medication, the hot flushes diminished 
and menses did resume. Five months later the patient conceived spontaneously, but unfortunately the 
pregnancy ended in an abortion. As further spontaneous conceptions did not occur, two cycles of 
fresh IVF were performed. Although the second cycle resulted in a pregnancy, this again ended in an 
abortion. The patient is now being prepared to receive the embryos that were cryopreserved prior to 
the start of her chemotherapy. 
4.4 Cryopreservation of ovarian cortical tissue strips 
As mentioned previously, each fertility preservation option is aimed at a specific group of 
patients. When the patient is prepubertal, when there is no partner is available for the 
generation of embryos, or when the cancer treatment cannot be postponed in order to 
perform ovarian stimulation, cryopreservation of ovarian tissue strips may be an alternative 
approach. Silber et al. (2005) showed previously that transplantation of fresh (non 
cryopreserved) ovarian cortex strips between identical twin sisters was actually feasible. The 
development of efficient freezing and thawing protocols for cortex strips has rendered this 
technique applicable for fertility preservation purposes and has recently led to the thirteenth 
live birth (Donnez et al., 2011).  
Although still experimental, this option is nowadays being performed on an increasing 
scale. Cortical fragments can be obtained laparoscopically, and slow frozen using DMSO as 
a cryoprotectant. Care should be taken to minimize the thickness of the cortical strips to 1 
mm, to facilitate diffusion of the cryoprotectant into the tissue. In addition, thin fragments 
will suffer less from ischemic damage, which is a serious problem after retransplantation. A 
significant proportion (60-95%) of (growing) follicles that survive the freezing and thawing 
process, is actually lost due to warm posttransplantation ischemia (Baird et al., 1999; Nisolle 
et al., 2000; Candy et al., 2000; Aubard et al., 1999, Aubard, 2003; Liu et al., 2002). Cortical 
strips can be autotransplanted heterotopically (for instance subcutaneous in the forearm), or 
orthotopically. Thus far, only orthotopic transplantation has led to the birth of a number of 
healthy offspring (Donnez et al.,2004; Meirow et al.,2005, 2007; Demeestere et al., 2006; 2007; 
2010; Andersen et al.,2008; Schmidt et al., 2011; Ernst et al., 2010).  
Cryopreservation of ovarian cortical strips is applicable for a wide range of different 
patients. Conception may require artificial reproductive techniques like IVF or ICSI, but may 
occur spontaneously as well. An additional advantage of this technique is resumption of the 
regular hormonal processes, leading to the reversal of the postmenopausal status that many 
patients experience after their cancer therapy. Follicular development and restoration of 
ovarian function usually occur 4-5 months after a transplantation procedure ( Donnez et al., 
2006a; 2008), as more than 120 days are required to initiate follicular growth and 
 




intracytoplasmatic sperm injection (ICSI). As the pregnancy rate per cryopreserved oocyte is 
approximately 3% (Kuwayama et al., 2005; Cobo et al., 2007; Homburg et al., 2009), a large 
number of oocytes, equivalent to several stimulation cycles and/or oocyte retrieval 
procedures, are required to achieve a reasonable chance of progeny. The exact number of 
children conceived with cryopreserved oocytes is unknown, but it is estimated to be over 
500 worldwide. Postnatal parameters such as birth weight and incidence of congenital 
anomalies, were comparable with the reference population, indicating the safety of this 
procedure (Borini et al., 2007; Chian et al., 2008). 
4.3 Cryopreservation of embryos 
For women with a partner, the generation and cryopreservation of embryos is a suitable 
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ICSI attempt, followed by cryopreservation of the embryos, as this would probably give the highest 
chance of progeny within the time limit set by the oncologist. 
The ovarian stimulation protocol was started one month after the mastectomy. Regarding the 
hormone receptor positive status of the tumor, a regimen combining FSH and letrozol was selected in 
order to avoid the high oestradiol levels associated with ovarian hyperstimulation. The treatment 
eventually resulted in the retrieval of 13 oocytes, 12 of which could be inseminated via ICSI. Of the 7 
resulting embryos, 3 were eligible for cryopreservation. The efficacy of the letrozol treatment was 
demonstrated by the finding that during the stimulation with FSH, oestradiol levels did not rise 
beyond 1000 pmol/L.  
The patient than completed 5 cycles of chemotherapy. In addition, she received adjuvant hormonal 
therapy. Menses had stopped and the patient suffered from hot flushes. Two years later at age 37, the 
patient wanted to achieve pregnancy. After discontinuation of medication, the hot flushes diminished 
and menses did resume. Five months later the patient conceived spontaneously, but unfortunately the 
pregnancy ended in an abortion. As further spontaneous conceptions did not occur, two cycles of 
fresh IVF were performed. Although the second cycle resulted in a pregnancy, this again ended in an 
abortion. The patient is now being prepared to receive the embryos that were cryopreserved prior to 
the start of her chemotherapy. 
4.4 Cryopreservation of ovarian cortical tissue strips 
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cryopreserved) ovarian cortex strips between identical twin sisters was actually feasible. The 
development of efficient freezing and thawing protocols for cortex strips has rendered this 
technique applicable for fertility preservation purposes and has recently led to the thirteenth 
live birth (Donnez et al., 2011).  
Although still experimental, this option is nowadays being performed on an increasing 
scale. Cortical fragments can be obtained laparoscopically, and slow frozen using DMSO as 
a cryoprotectant. Care should be taken to minimize the thickness of the cortical strips to 1 
mm, to facilitate diffusion of the cryoprotectant into the tissue. In addition, thin fragments 
will suffer less from ischemic damage, which is a serious problem after retransplantation. A 
significant proportion (60-95%) of (growing) follicles that survive the freezing and thawing 
process, is actually lost due to warm posttransplantation ischemia (Baird et al., 1999; Nisolle 
et al., 2000; Candy et al., 2000; Aubard et al., 1999, Aubard, 2003; Liu et al., 2002). Cortical 
strips can be autotransplanted heterotopically (for instance subcutaneous in the forearm), or 
orthotopically. Thus far, only orthotopic transplantation has led to the birth of a number of 
healthy offspring (Donnez et al.,2004; Meirow et al.,2005, 2007; Demeestere et al., 2006; 2007; 
2010; Andersen et al.,2008; Schmidt et al., 2011; Ernst et al., 2010).  
Cryopreservation of ovarian cortical strips is applicable for a wide range of different 
patients. Conception may require artificial reproductive techniques like IVF or ICSI, but may 
occur spontaneously as well. An additional advantage of this technique is resumption of the 
regular hormonal processes, leading to the reversal of the postmenopausal status that many 
patients experience after their cancer therapy. Follicular development and restoration of 
ovarian function usually occur 4-5 months after a transplantation procedure ( Donnez et al., 
2006a; 2008), as more than 120 days are required to initiate follicular growth and 
 




approximately 85 days to the reach final maturation stage from a pre-antral follicle 
(Gougeon, 1985, Oktem & Oktay, 2008). Unfortunately, the survival time of a single 
autotransplanted number of strips is usually limited to a few months, with exceptions of 
survival up to approximately 3 years (Kim et al., 2009; Meirow et al., 2007; Silber et al., 
2008a), requiring another surgical intervention to transplant a new set of cortex strips.  
4.4.1 Case report B: Ovarian tissue cryopreservation in a patient with Hodgkin’s 
lymphoma 
Mrs. Y was diagnosed with Hodgkin’s lymphoma at the age of twenty. As she was to start with six 
cycles of chemotherapy the next month, she visited our fertility Centre to discuss the options for 
fertility preservation.  
Although the patient was at the time in a steady relationship, she regarded herself to young to start 
emergency IVF, as this would confront both herself and her partner with the definitive choice of 
having children together in the future. Ovarian hyper stimulation followed by cryopreservation of the 
retrieved oocytes was not considered an optimal option, as the time to the start of her chemotherapy 
was relatively short, allowing for only one cycle of hyperstimulation. As a consequence, only a limited 
number of oocytes would be obtained. 
Eventually the choice was made for cryopreservation of ovarian cortical strips. At that time we could 
not offer her this procedure ourselves so we referred her to another centre. Biopsies of both ovaries 
were taken via a laparoscopic procedure, and 13 strips were cryopreserved. She then started with the 
chemotherapy. Since then, she has had two relapses, that were treated with chemotherapy, 
radiotherapy, and stem cell transplantation.  
At the age of 27, the patient and her partner visited our Centre as she wished to conceive. She had 
now been in complete remission for 3 years. Hormonal examination showed that she was 
postmenopausal, indicating that both spontaneous conception as well as IVF treatments were no 
options to achieve pregnancy. The couple was referred back to the clinic where her ovarian tissue was 
cryopreserved, and is now considering autotransplantation of the ovarian cortical strips. 
5. Future options for fertility preservation 
Several alternative procedures are being evaluated to expand the current array of fertility 
preservation options. These include the isolation and cryopreservation of follicles from 
ovarian tissue that is harvested laparoscopically (Bedaiwy & Falcone, 2007; Feigin et al., 
2007). However, isolation of follicles by either mechanical or enzymatic means is difficult, 
especially from human ovaries (Dolmans et al., 2006). In addition, this approach requires 
different cryopreservation techniques then for oocytes and embryos, and sophisticated in 
vitro maturation protocols to obtain oocytes that can be fertilized in vitro by IVF or ICSI. 
A more promising future option may comprise the cryopreservation of an intact ovary, 
including its vascular pedicle. The vascular pedicle can be used to reconnect the thawed 
ovary to the circulation, thereby preventing the devastating effects of warm ischemia that is 
known to deplete the follicles in ovarian tissue transplanted without vascular anastomosis 
(Newton et al., 1996; Nisolle et al., 2000; Candy et al., 1997; Aubard et al., 1999; Baird et al., 
1999; Aubard, 2003; Liu et al., 2008 ). However, the successful cryopreservation of an intact 
organ represents an immense technical challenge. Pioneering work by Parrot (1960) on 
murine ovaries provided proof of principle. Later reports showed that also in other 
mammalian species this proved to be a viable approach. Freezing and autologous grafting of 
whole ovaries has now been performed in rabbits (Chen et al., 2005), pigs (Imhof et al., 
 




2004), and sheep (Bedaiwy et al., 2003; Arav et al., 2005; Imhof et al., 2006), yielding 
promising results. In rats (Wang et al., 2002) and sheep (Imhof et al., 2006), this procedure 
has actually resulted in live offspring. In humans, transplantation of fresh (non-
cryopreserved) intact ovaries has also been performed successfully. Ovarian 
autotransplantation in the upper arm was performed before pelvic irradiation (Leporrier 
1987, Hilders et al., 2004). Over a period of 16 years, the ovary remained functional 
(Leporrier et al., 2002). A first full-term pregnancy was obtained using orthotopic fresh 
whole ovary transplantation between identical twin sisters (Silber et al., 2008b). 
Cryopreservation of an intact human ovary with its vascular pedicle has been described 
previously (Martinez-Madrid et al., 2004, 2007; Bedaiwy et al., 2006). These authors showed 
that perfusion of the ovary with cryoprotectants led to a certain degree of protection from 
cryodamage. The subsequent autotransplantation of frozen and thawed human ovaries, 
however, has thus far not been performed. Major obstacle in this respect is the much larger 
volume of human ovaries compared to murine and ovine ovaries (Gerritse et al., 2008). This 
larger volumes hampers the sufficient diffusion of cryoprotectant into the tissue (Donnez et 
al., 2006b). In addition, the freezing kinetics in a bulky organ are bound to be completely 
different from those in a small volume organ (Pegg, 2005). Finally, all components of the 
organ, including the vascular pedicle, the inner vasculature, the stromal tissue and of course 
the follicles, should be verifiably protected before retransplantation to human subjects can 
be even considered. This requires the development of biologically relevant assays that are 
able to quantify cryodamage in a reliable fashion. Understandably, efforts have focused 
mainly on the survival of the follicles within the intact cryopreserved ovary. This has been 
done by conventional histology (Bedaiwy et al., 2003, Arav et al., 2005 Courbiere et al., 2005, 
2006; Martinez-Madrid et al., 2004; Imhof et al., 2006; Baudot 2007), immunohistochemistry 
(Arav et al., 2005; Bedaiwy et al., 2006), determining the frequency of apoptosis (Bedaiwy et 
al., 2003, 2006; Martinez-Madrid et al., 2007), using survival/viability/proliferation assays 
(Bedaiwy et al., 2003, 2006; Martinez-Madrid et al., 2004, Arav et al., 2005, Courbiere et al., 
2005, 2006; Imhof et al., 2004; Baudot et al., 2007, Onions et al., 2008), transmission electron 
microscopy (Martinez-Madrid et al., 2007) and estradiol assays (Huang et al., 2008; 
Isachenko et al., 2007; Gerritse et al., 2010). These studies have produced relevant 
information on the prevention of cryodamage in follicles, but have largely left out the main 
component of the ovary, namely the stromal cell compartment that constitutes over 95% of 
the ovarian mass. An additional reason to focus also on survival of stromal cells is the 
observation that these cells are vital for optimal follicular development (McLaughlin and 
McIver, 2009). Finally, the metabolically active stromal cells have been described to be more 
sensitive to cryodamage than the quiescent primordial oocytes (Kim et al., 2004). These 
observations emphasize the need for a cryopreservation protocol that not only efficiently 
preserves the follicles/oocytes, but the stromal cell compartment as well.  
We therefore decided to develop an assay that is capable of quantifying the basal 
metabolism of the bulk of the tissue as a measure of cryodamage. For this purpose we 
measured the uptake of glucose and the release of lacate by cultured ovarian tissue 
fragments. We used bovine ovaries as a model system, as they are comparable to human 
ovaries with respect to size, monthly cycle, and number of follicles that mature per cycle 
(Gerritse et al., 2008). In this model system we were able to test different cryopreservation 
protocols. Our results show that both immersion of the bovine ovary in cryoprotectant, 
combined with perfusing it for a prolonged period of time, resulted in a nearly complete 
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protection of the ovarian metabolism. This procedure did not affect the endothelium of the 
vascular pedicle and the inner vasculature (Gerritse et al., submitted). We plan to 
xenotransplant optimally cryopreserved bovine ovaries into immune deficient rats, in order 
to test the ability of the follicles to develop in vivo and produce mature oocytes. 
6. Safety aspects of ovarian tissue autotransplantation 
A major point of concern when autotransplanting ovarian tissue to cured cancer patients, is 
the possibility that (metastasized) tumor cells are present in the ovarian graft and are 
reintroduced to the patient (Shaw et al., 1996). Thus far a limited number of patients has 
received an autransplantation, and up to now no relapses have been reported. It should be 
noted, however, that most patients receiving an autotransplantation suffered from early 
stage cancer when their tissue was harvested. In addition, the follow up period after the 
transplantation has been relatively short. As a consequence, the experience with this matter 
is only limited, and retransplantation of the malignancy can never be ruled out completely. 
Shaw et al. (1996) actually showed that lymphoma could be transmitted via cryopreserved 
ovarian tissue in a mouse model. The physician therefore has the responsibility to counsel 
the patient comprehensively on the risk of malignant cells being present in the ovarian 
tissue, and the possible consequences after autotransplantation. Two different approaches 
can be used to draft an advice.First, one can extrapolate on statistical data describing the 
frequency with which a certain tumor in a certain stage will metastasize to the ovary. For a 
number of solid tumor types, ovarian metastases have been described for advanced stages 
but not for early stage tumors (Rosendahl et al., 2011). These include Hodgkin’s disease 
(Khan et al., 1986), renal cell carcinoma (Insabato et al., 2003) and breast cancer (Horvath et 
al., 1977). It should be noted, however, that systematically collected data are missing for 
most tumor types, giving only a limited idea of the risk of tumor dissemination to the ovary. 
In contrast to solid tumors, diffuse malignancies such as leukemia are likely to be present in 
all blood-filled organs, including the ovary. Therefore, patients suffering from these kind of 
diseases should probably be excluded from using (cryopreserved) ovarian tissue as a means 
for fertility preservation. The second, and probably preferable, option, is to tailor a patient 
specific approach, i.e. analyzing (part of) the tissue that is to be autotransplanted in the 
future for the presence of (residual) disease. In an ideal situation, sensitive and specific tests 
would be available for the detection of each tumor type in a tissue. Techniques that have 
been used to asses the presence of malignant cells in ovarian tissue include conventional 
histology (Azem et al., 2010; Donnez et al., 2011), immunohistochemistry (Rosendahl et al., 
2011), PCR amplification of tumor specific RNA/DNA (Rosendahl et al., 2010), and 
xenotransplantation of ovarian tissue fragments to immune deficient mice (Dolmans et al., 
2010). In real life, however, these approaches encounter several obstacles. Histology is 
relatively non-sensitive as individual tumor cells can be missed, and usually only a limited 
number of sections is analyzed. Whereas immunohistochemistry is generally more sensitive 
than histology, it requires specific tumor cell markers that are not available for most type of 
cancers. While PCR in itself is a very sensitive technique, the ratio between the few 
malignant cells that are potentially present in the graft and the large number of normal 
ovarian cells impairs the reliability and sensitivity of this test. PCR results that indicate the 
presence of residual tumor cells are therefore mostly qualitative and not quantitative. 
Furthermore, PCR detects only the presence of relatively short stretches of specific 
RNA/DNA sequences and not viable cells. Xenotransplantation experiments may provide 
 




biologically relevant information, but are expensive and cumbersome and probablyl not 
routinely applicable. Apart from these practical issues, positive tests results raise some more 
questions. First, we do not know when a positive signal becomes biologically significant,. i.e. 
predictive of relapse after transplantation. Examples of this notion are a positive PCR signal 
that may be derived from a number of deceased cells and may therefore not be of clinical 
relevance. We currently we do not know exactly how many malignant cells are required for 
reintroduction of the tumor. In animal models as few as 200 lymphoblasts were sufficient to 
introduce leukemia (Hou et al., 2007), but the same may not apply to the human situation. 
Next, the ovarian tissue fragment that is being analyzed for residual disease, is evidently no 
longer available for transplantation. The outcome of the analysis will therefore not 
necessarily be applicable to the cortical fragments that are actually transplanted. The 
importance of this notion was substantiated by the finding that malignant cell DNA was 
found in an ovarian cortex fragment by PCR analysis, whereas the adjacent cortex fragment 
from the same ovary was found to be PCR-negative (Rosendahl, 2010).  Finally, the 
autotransplantation of small volume cortex fragments is much less likely to reintroduce the 
malignancy then the autotransplantation of an intact ovary.  
7. Concluding remarks 
The last decade has seen the development of a number of options for fertility preservation for 
cancer patients. All the options that are currently available have their own specific indications 
and contraindications. The choice for the appropriate option will be a shared decision of both 
the patient and her physician, requiring a careful evaluation and counseling. Increasing the 
awareness of physicians to address the issue of fertility preservation before starting 
gonadotoxic therapy should be an integral part of medical education. 
Current research, including intact ovary cryopreservation, may lead to several exciting new 
options for fertility preservation. It should be noted that this option is not intended to 
replace the current possibilities, but will rather have its own specific patient population that 
may benefit most from this procedure. The obvious risk of intact ovary autotransplantation 
is reintroduction of the malignancy. Evidently, more research into the development of valid 
and biologically relevant tumor detection methods in ovarian tissue, as well as in the 
prevalence of ovarian metastases in cancer patients with different types of primary tumors, 
is urgently needed.  
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1. Introduction 
Oocytes designed for reproductive function in women are the largest cell in the human 
body. They are surrounded by granulosa cells to form the follicles that in various stages of 
development are present in the ovarian cortex (Fig. 1).  
 
 
Fig. 1. Primary follicle in frozen/thawed human ovarian cortex (20X magnification) 
The ovary of a healthy woman contains a finite number of follicles that decreases over time. 
The peak number is reached in the fifth month of gestation with approximately 7 million 
follicles. This number reduces progressively due to atresia, so at birth there are only 1-2 
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1. Introduction 
Oocytes designed for reproductive function in women are the largest cell in the human 
body. They are surrounded by granulosa cells to form the follicles that in various stages of 
development are present in the ovarian cortex (Fig. 1).  
 
 
Fig. 1. Primary follicle in frozen/thawed human ovarian cortex (20X magnification) 
The ovary of a healthy woman contains a finite number of follicles that decreases over time. 
The peak number is reached in the fifth month of gestation with approximately 7 million 
follicles. This number reduces progressively due to atresia, so at birth there are only 1-2 
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million follicles that, at puberty, become 300.000. Approximately, 400 of these follicles 
become mature oocytes and ovulate during the fertile life of the female.  
At the age of 37, there is usually an acceleration of follicular loss, which is correlated with an 
increase in follicle-stimulating hormone (FSH) level.  
Last year Wallace reported with a mathematical model combined with histological evidence, 
the establishment and decline of non-growing follicles (NGFs) in the human ovary.  Wallace 
shows for the first time that the rate of NGF  recruitment increases from birth to age 14 years 
and then declines with age until menopause (Fig. 2) (Wallace & Kelsey, 2010).  
 
 
Fig. 2. The best histological model for the establishment of the NGF population after 
conception and the subsequent decline until menopause (Kindly provided by Professor 
Wallace).  
However, the central dogma of ovarian biology has been questioned by new discoveries. 
Johnson in 2004 reported that germline stem cells (GSCs) are present in the mouse ovary, 
and could become new follicles (Johnson et al., 2004). It seems that female germline stem cell 
reside in an extragonadal location, the bone marrow, and reach the ovary through the 
circulatory system (Johnson et al., 2005; Lee et al., 2007). De Felici reported that germline 
stem cells exist in adult mouse ovaries but are quiescent under physiological conditions, 
contributing to the oocyte reserve only in response to ovotoxic damage (De Felici, 2010). 
Recently, Bukovsky showed  the production of new eggs in cultures derived from 
premenopausal and postmenopausal human ovaries (Bukovsky et al., 2009).  
Despite these exciting new prospects to indicate that oocytes are continuously formed in the 
female adult, at the present it is known that the pool of follicles is limited, so in case of toxic 
ovarian events that may affect the ovary, opportune measures should be considered to 
preserve the fertility of young women. According to the law in different countries regulating 
assisted reproductive technologies, approaches to fertility preservation include embryo, 
oocyte cryopreservation, or ovarian tissue banking followed by ovarian tissue transplant or 
in in-vitro culture. 
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However, cryopreservation of ovarian tissue may be the only acceptable method to preserve 
fertility for prepubertal girls, for women who cannot delay the start of cancer treatment for 
ovarian stimulation, and probably for women with hormone-sensitive malignancies. All 
these situations make ovarian tissue freezing the only option for female fertility 
preservation.  
Therefore, an entire ovary or part of it, is removed laparoscopically, frozen and stored in 
liquid nitrogen at -196°C.  After complete recovery of the patient, the tissue can be used to 
restore gametogenic and/or steroidogenic function.  
Potential indications for ovarian tissue cryopreservation are patients diagnosed with 
malignant (extra-pelvic diseases: bone cancer, thyroid cancer, kidney cancer, breast cancer, 
melanoma, neuroblastoma; pelvic diseases: non-gynecological malignancy, gynaecological 
malignancy; systemic diseases: Hodkin’s disease, non-Hodgkin’s lymphoma, leukaemia, 
melanoblastoma) or benign diseases (recurrent ovarian cysts, etc), or with non malignant 
autoimmune diseases (systemic lupus erythematosus, rheumatoid arthritis, autoimmune 
thrombocytopenia or other haematological diseases).  These patients are being treated 
successfully with chemotherapy and/or radiotherapy or repeated surgery, greatly improved 
in recent years, but all these therapies can be toxic to the ovary.   So, it is important to focus 
attention on the quality of life, including fertility preservation, as well as on survival of these 
young women. 
2. Effect of radiotherapy, chemotherapy, or other toxic drugs on female 
reproduction 
The risk of ovarian failure after anticancer treatments is assessed in relation to patient’s age, 
treatment protocol and type of cancer as reported by Meirow  (Meirow and Nugent, 2001).  
High-dose ionizing radiation is used to treat many types of cancer and hematologic 
malignancies. Ovarian transposition is not possible in case of total irradiation as is required 
for bone marrow transplantation (Meirow et al., 2010). The estimated dose at which half of 
the follicles are lost in humans (LD50) is 4 Gy (Wallace et al., 1989), but is age-dependent. 
Lashbaugh reported that the toxic ovarian dose, which leads to permanent loss of fertility is 
higher in young women (20 Gy) than older (6 Gy) (Lushbaugh & Casarett, 1976).  
Chemoterapic agents can be grouped into five classes of drugs based on their mode of action 
(alkylating agents, aneuploidy inducers, topoisomerase II inhibitors, antimetabolites and 
radiomimetics) as summarized by Meirow. It was found that alkylating agents imposed the 
highest risk in causing ovarian failure with an odd ratio (OR) of 3,98, followed by cisplatin 
with an OR of 1.77 (Meirow and Nugent, 2001).  
Schmidt, reported that the ovaries of healthy young girls contain a higher number of 
follicles than ovaries from older women, meaning young girls are more resistant to 
chemotherapy.  Even if chemotherapeutic agents differ in their ovarian toxicity (Schmidt et 
al., 2010), they are often used in combination, so their adverse effects are increased and 
cannot always be easily evaluated.  
In 2007, Oktem and Oktay, published an interesting paper on ovarian damage from 
chemotherapy. They present the first quantitative evidence in humans, by histological 
evaluation, that alkylating agents can significantly reduce ovarian reserve, and may affect 
stromal cell function (Oktem & Oktay, 2007). Meirow also reported that injury from 
chemotherapy is in stromal cells as well as in follicles and blood vessels (Meirow, 2010). 
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3. Ovarian tissue cryopreservation 
To preserve ovarian tissue for a lengthy period of time, it should be stored in liquid nitrogen 
at a temperature of -196°C. However, ovarian tissue cryopreservation is complex and 
requires preservation of multiple cell types, thus the ability to successfully cryopreserve 
would be a powerful clinical tool in an assisted reproductive laboratory.  
As reported by Bakhach in 2009, is easy to imagine the cell damage when temperatures fall 
from +37°C to -196°C. There is a loss of about 95% of intracellular water, an increase of 
electrolyte concentrations in both intra and extracellular media, and ice formation in the 
intracellular spaces that deform cells and destroy intracellular structures (Bakhach, 2009).  
Hovatta in 2005 published an interesting work on the different methods of ovarian tissue 
freezing which emphasizes the importance of trying to preserve most of the cellular tissue 
components, including even the small proportion of ovarian medulla which contain blood 
vessels and nerves so important for ovarian tissue function recovery after reimplantation 
(Hovatta, 2005). Recently, Donnez reported that revascularization of grafts depends also on 
the preservation of vessels  in grafted tissue, and not only on neoangiogenesis from the host 
(Donnez et al., 2011-b).   
It should be stressed that the protocol of ovarian tissue freezing is still not standardized. So, 
there are several freezing procedures that range from slow freezing/rapid thawing, 
vitrification or ultrarapid-freezing. Freezing protocols differ also depending on the 
cryoprotectants used, dehydration/rehydration time and temperature, different protein 
support, and on the containers used for storage such us cryovials, strips or other tubes.  
Approaches to human ovarian tissue cryopreservation are currently characterised by the use 
of slow freezing/rapid thawing methods using dimethylsulphoxide (DMSO) or propanediol 
(PROH) as a cryoprotectant. The slow freezing requires the use of a machine that slowly 
decreases the temperature, so the freezing programme so takes a few hours. This procedure 
has the disadvantage that it can lead to the formation of ice crystals, affecting correct tissue 
preservation. This disadvantage is avoided by using the protocol of vitrification, where high 
concentrations of cryopotectants are used, which increased ovarian toxicity too. Ultra-rapid 
freezing should be a method somewhere between the previous two using the advantages 
given by vitrification with a lower concentration of cryoprotectant to act on increasing the 
cooling rate.  
In 2003 Shaw published an interesting paper on the terminology associated with 
equilibrium cooling procedures or ‘slow cooling’ and non-equilibrium protocols such as 
‘vitrification’, ‘rapid cooling’ and ‘ultrarapid cooling’ that is helpful in clarifying the terms 
often used inappropriately (Shaw & Jones, 2003).  
The positive results achieved by oocyte vitrification, has been discussed in recent years, but 
at the present time this procedure applied to ovarian tissue has given conflicting results.  
Isachenko has worked extensively on the ovarian tissue vitrification. Her paper of 2007 
showed a better preservation of ovarian tissue by slow freezing in which the quality of 
follicles was higher compared to the rapid freezing (Isachenko et al., 2007; Isachenko et al., 
2009).  
In 2007 Li  demonstrated that the vitrification method for cryopreservation of human 
ovarian tissue is effective and simple (Li et al., 2007). Kagawa in 2009 found no difference in 
oocyte viability between fresh and vitrified human ovarian cortical tissue (kagawa, 2009). In 
another paper ovarian stroma was shown to be significantly better preserved by vitrification 
compared to slow freezing (Keros et al., 2009). 
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However, data on cryopreservation of human ovarian tissues by vitrification are still modest 
and controversial. This may be due to the fact that the same cryopreservation procedure is 
often used, such as slow freezing or vitrification, but different freezing protocol (types of 
cryoprotectant, concentration used and time of diffusion, etc.), this creates significant bias 
that must be considered.  
In addition vitrification presupposes direct contact with liquid nitrogen, which is a potential 
source of microbial contamination, as reported by Isachenko (Isachenko et al., 2009). 
In conclusion, an ideal ovarian cryopreservation method has not yet been established. 
4. How to use 
After 4 or 5 years when the patient is considered oncologically cured, the ovarian tissue 
stored in liquid nitrogen can be used. There are several ways to use tissue after thawing, 
such us reimplantation in various anatomic sites in the same patient or in a host animal or in 
vitro culture to grow primordial follicles present in large number (Fig. 3). 
 
 
Fig. 3. Techniques using human cryopreserved ovarian tissue. 
4.1 Ovarian tissue culture 
When dealing with tumours that can metastasize to the ovary, ovarian tissue reimplantation 
should be avoided due  to the risk of retransmitting cancer cells. In these cases the only 
option is to develop other methods in which the primordial follicles are matured in vitro 
within ovarian tissue pieces. Only in mice was the full maturation of primordial follicles 
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In 2008 Picton published an interesting review on in vitro growth and maturation of 
follicles, which showed a number of different culture systems. It showed that culture of thin 
cortical strips has many advantages such as avoiding the damage caused by mechanical or 
enzymatic recovery of follicle present in the cortex, and provides a complex support system 
that resembles the ovary in vivo as the follicles also remain in contact with the surrounding 
stromal cells. This contact is very important at least until development of secondary follicles, 
when the follicles from the surrounding stroma should be left to facilitate further 
development. Thus, a multi-step strategy for the complete in vitro growth and maturation of 
follicles is promoted (Picton et al., 2008). 
Recently another interesting review was published by Fabbri which summarizes the most 
relevant literature of the last ten years on in vitro cultures of ovarian cortical pieces. The 
conclusion was that the current optimal method for growing and maturing human follicles 
remains whole tissue culture. The authors underline the difficult of graduating nutrient 
concentration and especially what is best to add to the culture media and when (Fabbri et 
al., 2009). 
In conclusion the culture of ovarian cortex strips is under development and currently not 
applicable to the human species, owing to the long period necessary for the follicle to 
complete development, almost six months compared to the couple of weeks in mice.  
However, as suggested by Picton before these strategies can be utilised therapeutically, 
extensive testing is required to confirm the epigenetic health and genetic normality of in 
vitro growth derived oocytes (Picton et al., 2008). 
We must not forget that oocytes are matured in vitro, after full development of follicles in 
vitro for a period exceeding 90 days, with the addition of nutrients that are not exactly what 
you get in their natural anatomic site, both as concentration and as timing of administration. 
So, even if complete follicle development in vitro is far from being clinically applicable, this 
does not mean that patients with malignancies that metastasize to the ovary should be 
excluded from the eventuality of cryopreserved tissue. We cannot know whether the study 
of in vitro cultures will make progress in a few years time. 
4.2 Ovarian tissue reimplantation 
The main option of this strategy is to transplant cortical ovarian tissue into the pelvic cavity, 
into its original location (orthotopic site) or in a different site, such as forearm, arm, 
abdominal wall, etc. (heterotopic site) when anticancer treatment is completed and the 
patient is disease-free.  
Human transplantation history begins in the heterotopic site, such as the arm or the 
forearm. First studies on heterotopic reimplantation of an organ date back to 1975 and were 
applied to parathyroid gland. Several authors demonstrated that parathyroid autografts 
secret hormone and maintain normal serum calcium in the host (Wells et al., 1975; Hickey & 
Samaan, 1975). Oktay was the first to begin reimplanting of heterotopic tissue in the 
forearm, paving the way to human reimplantation history. In 2004 Oktay published a paper 
on the first embryo development after heterotopic transplantation of cryopreserved ovarian 
tissue (Oktay et el., 2004).  
Successful orthotopic transplantation of ewe cryopreserved ovarian tissue was first 
performed by Gosden in 1994 (Gosden et al., 1994). The orthotopic transplantation is the site 
most suitable compared to the heterotopic site, because it is the natural environment, with 
comfortable temperatures and pressures for proper follicular development.  
After several animal studies, ten years later, the first live human birth after frozen-thawed 
ovarian cortex orthotopic reimplantation was achieved by the Belgian group led by Donnez 
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(Donnez et al., 2004), followed recently by other live births (Donnez et al., 2011-a; Donnez et 
al., 2011-b; Meirow & Levron, 2005; Meirow et al., 2007; Demeestere et al., 2007; Demeestere 
et al., 2009; Anderson et al., 2008; Ernst  et al., 2010;  Silber et al., 2010; Piver et al., 2009; 
Sanchez-Serrano et al., 2010; Revel et al., 2011; Roux et al., 2010), as shown in table 1.  
The major disadvantage of transplanting ovarian cortical strips is that revascularization of 
the graft needs several days, according to the species. So, revascularization occurrs within 
48h after transplantation in rats and within 1 week of grafting in sheep. This leads to great 
loss of follicles from the grafts in transplantation due to ischemic injury, which can however 
be avoided by performing a whole ovarian transplantation thus providing immediate 
revascularization of the transplant (Onions et al., 2009; Bedaiwy & Falcone, 2004; Bedaiwy et 
al., 2006; Bromer & Patrizio, 2009). However, whole ovarian transplantations have a high 
rate of vascular complication, such as risk of thrombosis. Therefore, further work is needed 
before whole ovarian tissue transplantation can be considered a viable option for fertility 
preservation.  
Exogenous factors such as antioxidants, growth factors or hormones have been tested to 
improve follicular survival in ovarian grafts by reducing ischaemia-reperfusion injury 
(Nugent et al., 1998; Torrents et al., 2003;  Demeestere et al., 2009). 
Until now, slow programmed ovarian tissue freezing is the only procedure that has resulted 
live births following orthotopic transplantation of frozen/thawed human ovarian tissue 
slices, but it is unknown or difficult to quantify how many women have attempted ovarian 
tissue reimplant.  
The risk of ovarian tissue reimplantation includes transplantation of the primary tumour.  
However, most malignant diseases encountered during the reproductive years do not 
metastasize to the ovaries, except blood-borne malignancies such as leukemias, neuroblastoma 
and Burkitt’s lymphoma.  In the 1996 Shaw reported the transmission of lymphoma from a 
donor to a graft recipient (Shaw et al., 1996). Recently, Dolmans demonstrated, by quantitative 
RT-PCR, ovarian contamination by malignant cells by reimplant cryopreserved ovarian tissue 
in acute and chronic leukaemia patients (Dolmans et al., 2011).  
So, it is highly recommended to use the best assessment to detect micro-metastases on a 
small portion of the harvested tissue before cryopreservation, it is also useful to freeze a less 
valuable part of the cortex, such as ovarian medulla.   
As suggested by Von Wolff, sophisticated techniques are required to exclude first 
macroscopic ovarian pathology, such as ovarian metastasis, using imaging (sonography, CT 
scan, etc.). Then immunohistochemistry and polymerase chain reaction (PCR) to exclude 
single malignant cells, and identified minimal residual disease (MRD) by highly sensitive 
RT-PCR. Another effective method  is xenotransplant  small sample  of ovarian tissue in a 
immunodeficient animal host (Von Wolff et al., 2009). 
4.3 Xenotransplantation 
Xenotransplantation falls between reimplantation and in vitro culture, so the follicles within 
the tissue are growing in vivo in an animal host (T-and B-cell-deficient SCID mice). It has 
been applied to assess the risk of reimplanting malignant cells after human ovarian tissue 
reimplantation, and to observe follicle development.   
Last year Dath compared four grafting (intraperitoneal, ovarian bursa, sub-cutaneous, and 
intramuscular) sites for xenotransplantation of human ovarian tissue to nude mice, 
concluding that all four sites equally supported early follicular growth and preserved some 
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In 2008 Picton published an interesting review on in vitro growth and maturation of 
follicles, which showed a number of different culture systems. It showed that culture of thin 
cortical strips has many advantages such as avoiding the damage caused by mechanical or 
enzymatic recovery of follicle present in the cortex, and provides a complex support system 
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follicles is promoted (Picton et al., 2008). 
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quiescent follicles (Dath et al., 2010). However, Sonmezer reported an asynchrony between 
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Table 1. Live births after frozen/thawed orthotopic transplantation of human ovarian tissue.  
In conclusion, xenotransplantation should be carefully considered in its human clinical 
application because of the risk of cross-species retroviral infection.  
 




As reported by Maltaris it is important to assess the ‘ovarian reserve’ that is the available 
pool of primordial follicles in the ovary and is a major determinant of female fertility 
potential. This information is important for a correct strategy of fertility preservation before 
cancer treatment. In general, ovarian reserve tests are either biochemical or biophysical 
(Maltaris et al., 2006), but new methods are required. 
In conclusion, a common goal of life-saving methods must be to protect the fertility of 
young women to this aim it is important to form a closely collaborative team comprising 
gynaecologists, surgeons, oncologists, haematologists, biologists and psychologists. 
Specifically, it is important that the oncologist gives an assessment of the degree of ovarian 
damage in order to decide how much ovarian tissue to retrieve and store.  
It is known that for each malignant disease only few protocols are commonly used, so it is 
possible to analyse the risk of ovarian failure. Meirow reported that the ovarian failure rate 
was 50% for breast cancer, 44% for non-Hodgkin’s lymphoma, and 32% for Hodgkin’s 
disease (Meirow & Nugent, 2001). 
Before proceeding to cryopreserve ovarian tissue, it is important to identify a series of tests 
for morphological analyses (such as staining with hematoxylin and eosin for observation by 
an optical microscope, or a more thorough evaluation of cell components by electron 
microscopy), for functional analyses (such as immunohistochemistry), or for viability 
analyses (such as trypan blue); in order to assess the degree of overall tissue preservation 
with the procedure adopted in the laboratory.  
In addition, it is also important to put an age limit to the preservation of ovarian tissue. The 
patient can use it only after cancer remission, therefore not before few years, so the  
cryopreservation of ovarian tissue of a patient older than 38 years old may be a useless 
procedure but could give psychological support to women. In any case, patients should be 
properly informed about the real possibility of recovering fertility and be able to get 
pregnant.  
In conclusion, we agree with Donnez that ovarian tissue cryopreservation should be offered 
before anticancer treatments in all cases where there is a high risk of  premature ovarian 
failure and where emergency in vitro fertilization is not possible (Donnez et al., 2011-c). 
If the dogma of reproductive biology is that of a finite number of follicles in the ovary 
which, moreover, undergo atresia during reproductive life, all procedures to preserve 
fertility should be carried out before acting on the ovary with drugs, therapies, surgery or 
potentially toxic treatments. Therefore, live births after cryoprserved ovarian tissue 
trasnplantation opened up new chapter in the field of infertility preservation.  
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1. Introduction 
Lung cancer is one of the leading causes of cancer in the population. The aging population is 
a reality. More and more, in oncology, we are facing challenges about management of cancer 
in this important population. In this chapter, we will review data on lung cancer and aging. 
We will explore how to evaluate this particular population to offer them the best treatment 
possible, bearing in mind that some adjustment may be necessary compared to younger 
population. 
2. Definition of the elderly 
2.1 Chronologic aging 
The cut-off point for an adult to be considered “elder” is not well defined. According to 
most of the literature, age 70 years is used as a chronologic marker for definition of elderly 
population. This is also the age most commonly used in the clinical trials in oncology as a 
limit for recruitment (Balducci, 2000). 
2.2 Physiologic aging 
In fact, elderly should be referring to a state either than a chronological age. It is well known 
that with time, especially at or around 70 years of age, a number of age-related physiologic 
changes occur affecting the physiologic reserve of the person. Many of these changes may 
affect the tolerance to cancer treatment as; decreased renal and liver functions, decreased 
volume of distribution, immune response and intestinal absorption (Avery et al., 2009). 
Talking more specifically about lung function, age-related pulmonary changes include a 
decreased response to hypoxemia or hypercapnia, decreased elasticity of the lung tissue, 
increased ventilation-perfusion mismatch, and decreased forced expiratory volume 
(Gonzalez-Aragoneses et al., 2009).  
3. The aging population 
Population age is increasing in developed country. In the United States, in 2000, there were 
35 million persons aged over 65 years old. This proportion is expected to continue to 
increase from 40 million in 2010 to 81 million in 2040 (U.S. Census Bureau). In Canada, the 
situation is similar. In 2036, Statistics Canada estimates the population of persons aged 70 
years and older to be situated between 10 and 10.8 million. 
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The National institute of Aging has characterised the aging of the American Society as a 
“silver tsunami for which we are unprepared” (Fried & Hall, 2008). 
4. Cancer as an aging problem 
Is is recognized that the risk of cancer increases with age. In Canada, 43% of all new cancer 
cases and 61% of cancer deaths will occur among those who are at least 70 years old.  
Figure 1 represents the number of new cases of cancer for Canadian males together with the 
corresponding age-standardized rates for 1981-2006 and estimates to the year 2010. It shows 
that despite the relative stability in age-standardized rates, the number of new cancer cases 
continue to rise steadily as the Canadian population grows and ages. The figure shows the 
major contribution of the population’s growth and the aging population to the rising 
numbers of new cases from cancer. 
 
 
Fig. 1. Incidence of cancer for Canadian males with age-standardized rates (1981-2006) (from 
Canadian Cancer Statistics 2010). 
The lowest line represents the total number of new cancer cases that would have occurred 
each year if the population size and age structure had remained in the same as it was in 
1981, reflecting the impact of changing risk. The middle line represents the number of new 
cases that would have occurred if the age structure had remained the same as it was in 1981, 
reflecting the impact of changing risk and population growth. The top line, the actually 
occurring number of new cancer cases, represents the combined impact of changes in risk, 
population growth and the aging of population. This figure is similar for new cancer cases 
ial of adjuvant chemotherapaths rates in male and female. It indicates the importance of the 
impact of the aging population on the growth in the number of cancer cases that has 
occurred over the last 30 years (Canadian Cancer Statistics 2010). 
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5. Lung cancer in elderly 
In Canada, both in men and women, lung cancer is the second most common cancer (13.9%) 
after prostate cancer in men and breast cancer in women. In 2010, it represents 24,200 new 
cases. More than half of all newly diagnosed cases will occur among people aged 70 years 
and older. More importantly, lung cancer is the leading cause of cancer death in both sex 
representing 20,600 deaths. Lung cancer deaths peak at age 70-79 years for both male and 
female in Canada.  
In United States, median age for diagnosis for lung cancer was 71 years of age from 2004 to 
2008 according to SEER data. 29% of cases were in persons aged between 75 and 84 and 8.3% 
were older than 85 years old. In the same period, the median age at death for cancer of the 
lung and bronchus was 72 years of age, with 30.7% between ages 75 and 84 and 9.6% in 
persons older than 85 years. 
6. Evaluation of the elderly cancer patient 
6.1 Oncologic evaluation 
On the oncologic point of view, evaluation of an elderly patient should be exactly the same 
as for a younger one. Clinical and pathological stage of disease should be determined with 
the same accuracy. The complete workup for lung cancer includes at least a complete 
history and physical examination, a bronchoscopy, a CT scan of the chest and upper 
abdomen and blood tests for assessment of liver and renal function. CT scan of the head 
should be done if there are any suspicions of metastasis, or in advanced cases, as well as a 
complete bone scan. Ideally, patients must have a Pet-Scan to complete the workup. As for 
younger patients, biopsy of the tumour for histology is always mandatory.  
When surgery or radiation therapy treatment are anticipate, pulmonary function test are 
essential to determine the capacity of the patient to tolerate those procedure. 
Unfortunately, in the elderly population, lung cancers are less susceptible to be diagnosed at 
an early stage and the evaluation is more often incomplete. More than 20% of cancers in 
patients aged more than 85 years of age are diagnosed on a clinical or radiologic basis 
without pathologic confirmation (Goddwin & Osborne, 2004). 
6.2 Geriatric evaluation 
The geriatric assessment of a patient is also a diagnostic process. It may be done by an 
individual clinician, but more often, the geriatric evaluation involve a more intensive 
multidisplinary program. This is often referred to a comprehensive geriatric assessment 
(CGA). The optimal goal is to evaluate the patients’ global and functional status, in order to 
improve treatment decisions and outcomes. His use is now recommended by the 
International Society of Geriatric Oncology (SIOG) for all cancer patient aged more than 70 
years old. This recommendation is based on the evidence that the incidence of geriatric 
problems increases sharply after 70 in cancer patients (Extermann et al., 2005, as cited in 
Balducci et al., 1990). The CGA permits to detect unaddressed problems, improve older 
cancer patients functional status and possibly their survival. The SIOG was not able to 
recommend any specific tool or approach above others for this assessment (Extermann et al., 
2005). 
Whatever the approach or the tools used to complete a CGA, different aspects should be 
included as; functional status, comorbid medical conditions, cognitive and nutritional 
status, psychological state, social support and review of the medication. 
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6.3 Components of a comprehensive geriatric assessment 
6.3.1 Functional status 
Functional status represents the patient’s ability to perform daily activities. The more 
commonly used performance status score are the Karnofsky or Eastern Cooperative 
Oncology Group (ECOG) scales. In older patients, these scores were showed to under-
represent the degree of functional impairment (Repetto et al., 2002). For that reason, it is 
important to include the autonomy for Activities of Daily Living (ADL), such as feeding, 
grooming, transferring and toileting and for the Instrumental Activities of Daily Living 
(IADL) such as shopping, housekeeping, managing finances, preparing meals and taking 
medications in the evaluation of functional status for these patients.  
A study of 566 patients with advanced non-small cell lung cancer age ≥ 70 years receiving 
chemotherapy explores the impact of functional status on the overall survival. Improved 
overall survival was associated with independence in IADLs and higher quality of life 
scores. Limitations in basic ADLs and the presence of comorbidity were not predictors of a 
decrease in overall survival (Maione et al. 2005). However, limitation in basic ADLs was 
previously shown to predict chemotherapy toxicity and postoperative survival and 
morbidity (Extermann & Huria, 2007). 
6.3.2 Comorbidities 
In cancer patients, comorbidity can be seen as a competitive cause of death. It is well known 
that with increasing age, the number or comorbid medical conditions increases. It is 
important to consider these comorbid conditions in life expectancy and potential treatment 
tolerance when balancing the risks and benefits of them. Charlson Comorbidity Index (CCI) 
is a way to assess the number and severity of comorbid condition (Charlson et al., 1987). 
Additional issues regarding the treatment of elderly cancer patients are the presence of 
geriatric syndromes as; dementia, delirium, depression, falls, neglect and abuse, failure to 
thrive, incontinence and spontaneous bone fracture. 
A review of the National Cancer Institute of Canada (NCI) Clinical Trials Group in 2008 
analyzed 1,255 patients enrolled in two large, prospectively randomized trials of systemic 
chemotherapy for NSCLC. Patients aged 65 and older were more likely to have a CCI score 
of ≥ 1 (42 % versus 26%). Age did not influence overall survival, but the Charlson 
Comorbidy Index ≥ 1 appeared prognostic for poorer survival (Asmis et al., 2008). The 
impact of comorbidity was recently studied in a population of 83 untreated lung cancer 
patients over the age of 70. It was shown that they have a high prevalence of comorbidity 
but these may not cause patient’s death (Gironés et al., 2011).  
6.3.3 Cognitive status 
Cognitive deficits are associated in the geriatric population with an increase in mortality of 
over 150% at 5 years. They are also associated with an increase risk of complications, 
depression, and functional decline. 
Cognitive deficits and dementia in oncology patient is often unrecognized. However, it was 
demonstrated that 25-50% of older patients with cancer had abnormalities in screening 
cognitive exam that warranted further evaluation. Cognitive dysfunction can have 
significant impact in the pathway of cancer treatment; dysfunction on the ability to weigh 
the risks and benefits of cancer therapy, compliance with treatment, and recognition of the 
signs of toxicity that require medical attention (Extermann & Hurria, 2007). It was 
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previously demonstrated than even when treated in a specialized geriatric oncology 
program, cognitively impaired patients had a survival of cancer one third of that of 
nonimpaired patients in various tumor type and stages, even if they received similar 
treatments (Extermann & Hurria, 2007, as cited in Callen et al. 2004). Therefore, screening 
for cognition should be part of the evaluation in the elderly patient afflicted with lung 
cancer. 
6.3.4 Nutritional status 
The importance of malnutrition on overall survival and morbidity is well known in the 
general cancer population. It is also demonstrated that aging is a factor for an increase risk 
of malnutrition. Other than mortality, poor nutritional status can have an impact on the 
quality of life, response to chemotherapy, and any other medical complications. 
6.3.5 Psychological state 
Many reports have shown that the incidence of psychological distress is approximately one-
third of older patient with cancer. Studies of geriatric assessment show that 14% to 40% of 
older patients have depressive symptoms (Extermann & Hurria, 2007). A large 
epidemiologic studies of 24,696 older breast cancer in the SEER database (ages 67 to 90 
years) revealed that a recent diagnosis of depression put them at risk for receiving less-than-
definitive treatment for their cancer, and they also experienced shorter survival (Extermann 
& Hurria, 2007 as cited in Goddwin et al, 2004). In addition, depressive symptoms have 
impact on quality of life, increased utilization of healthcare resources and can affect 
treatment compliance. 
6.3.6 Social support 
Social support is a major factor that puts patients at risk for psychological distress. Even 
monthly telephone call was shown to reduce depression in older patients with cancer. This 
method was demonstrated to reduce significantly anxiety (p<0.0001), depression (p=0.0004), 
and overall distress (p<0.0001) compare to no similar support (Extermann & Hurria, 2007 as 
cited in Kornblith et al., 2006).  
6.3.7 Review of the medication 
Polypharmacy is a significant problem in the geriatric population. Many physiologic 
changes in the elderly may have impact on pharmacokinetic; a decrease in total body water, 
an increase in body fat, a decrease in renal function, decrease in hepatic mass and blood 
flow, and decrease in bone marrow reserve. The combination of those changes and 
polypharmacy is associated with an increase risk of drug interactions, adverse drug events 
and problem with compliance. Therefore, it is essential to regularly review the medication 
list to discontinue any unnecessary medications and avoid potential drug interactions. 
6.4 Impact of the CGA 
Many trials have studied the impact of a CGA on outcome of elderly patients with cancer. A 
meta-analysis of 28 controlled trials had demonstrated that CGA if linked to geriatric 
interventions reduced early re-hospitalisation and mortality in older patients through early 
identification and treatment of problems (Pallis et al. 2010, as cited in Stuck et al., 1993). In a 
 
Topics in Cancer Survivorship 
 
228 
6.3 Components of a comprehensive geriatric assessment 
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previously demonstrated than even when treated in a specialized geriatric oncology 
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flow, and decrease in bone marrow reserve. The combination of those changes and 
polypharmacy is associated with an increase risk of drug interactions, adverse drug events 
and problem with compliance. Therefore, it is essential to regularly review the medication 
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interventions reduced early re-hospitalisation and mortality in older patients through early 
identification and treatment of problems (Pallis et al. 2010, as cited in Stuck et al., 1993). In a 
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recent French study it was shown that comprehensive geriatric evaluation did significantly 
influence treatment decisions in 82% of the older cancer patients. In this 161 patients group, 
with a median age of 82.4 years, cancer treatment was change in 79 patients (49%), including 
delayed therapy in 5 patients, less intensive therapy in 18% and more intensive therapy in 
28% of patients (Chaïbi et al. 2010).  
It is interesting to notice that even a simplified geriatric assessment, adapted to cancer and 
quicker to perform than a CGA was recently demonstrated effective in patients with 
thoracic cancer. It is an important aid to decision-making in the management of elderly 
patients with bronchial cancer (Cudennec et al., 2010). 
 
Aim Method 
Social evaluation Place of residence: home, type of residence for 
an elderly, dependent patient Helpers, aids 
around the home 
Iatrogenic risk Number and classes of drugs 
Existence of ≥3 co-morbidities significant 
in geriatrics 
Dementia, confusion, depression, incontinence, 
falls, malnutrition, progressive heart failure, 
other cancer 
Nutritional status Loss of weight over the previous 3 months 
(≥5%), albuminemia levels 
Cognitive functions Mini Mental State Examination (MMSE), Clock 
drawing task  
State of mind Mini-Geriatric Depression Scale (mini-GDS) 
Risk of fall Timed “Get up and go” test 
Sense organs Vision and hearing 
Autonomy Instrumental Activities of Daily Living (IADL) 
Table 1. Simplified Geriatric Assessment of patients with bronchial cancer (Cudennec et al., 
2010). 
7. Surgery 
Surgery remains the mainstay of treatment for early stage NSCLC. Unfortunately, according 
to most published reports, elderly have a significant lower resection rates compared to 
younger patients and age is one of the factor influencing the decision for surgical treatment. 
Sigel retrospectively analyzed 27 850 patients with stage I lung cancer. The rate of lung 
surgery was 95% for patients less than 60 years and 79% in patients > 80 years (Sigel et al., 
2009). An analysis of Riquet showed that patients older than 70 years of age represents 
21.7% of patients who had surgery for lung cancer, patients of 75 years and older represents 
8.8% and older than 80 years old are only 1.9% in proportion (Riquet et al., 2001).  
These observations are still true, even considering the significant improvement in 
anesthesia, in technical procedures of lung resection and post-operative care that greatly 
enhanced the security of the surgery, even in a frail population. In patients with stage I and 
II, surgical option is still the prefer treatment option. The 5-year overall survival rates for 
pathological stage I range between 67% for pT1pN0 and 57% for pT2pN0 tumors. The 
corresponding values based on clinical stage are 61% for cT1cN0 and 37% for cT2cN0. 
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7.1 Evaluation and selection of patients 
Patients must have a very good evaluation and adequate scrutiny is necessary to evaluate 
those who will really benefit from surgery. Preoperative assessment of cancer in the elderly 
(PACE) incorporates validated instruments including the CGA, an assessment of fatigue 
and performance status and an anaesthesiologist’s evaluation of operative risk. It is 
considered to be a valuable tool in enhancing the decision process concerning the candidacy 
of elderly patients for surgical intervention. It also reduce inappropriate age-related inequity 
in access to surgical intervention (PACE, 2008). 
7.2 Different types of surgery are used for the elderly. But which one is better? 
Survival data from the SEER database with patient of all ages shown that survival for lung 
cancer stage I and II were 56 and 34% respectively (Chang et al., 2007). The most important 
question regarding surgical resection for lung cancer is how aggressive should it be? The 
choice of the type of surgery is particularly important in the elderly. Right pneumonectomy 
is likely to be avoided in octogenarians (Broks et al., 2007; Port et al., 2004; Van Meerbeeck et 
al., 2002), but low rate of pneumonectomy in different series make this difficult to assess. As 
an indication, the British Thoracic Society Guidelines indicates that pneumonectomy is 
associated with higher risk of mortality.  
The sublobar pulmonary resection remains controversial in patients of any age. In a SEER 
analysis of 14,555 patients with stage I or II NSCLC, it was showed that benefit of a 
lobectomy was not evident for patients older than 71 years compared with limited resection 
(Meryet al., 2005). Okami did a non-randomized study to evaluate the different types of 
surgery in the elderly patients. A total of 764 patients, including 133 elderly and 631 
younger patients had lobectomy or sublobar resection. The survival after sublobar resection 
was significantly lower than that after standard lobectomy in the younger group (64% vs 
90.9%). Comparatively, no difference was seen in the elderly (67.6% vs 74.3%). However, 
locoregional recurrences were higher in patients with sublobar resection than lobectomy in 
young and older patients (Okami et al., 2009). A phase III study regarding this specific topic 
would be necessary to confirm this information. 
Another study done in Pittsburg has compared lobectomy to the segmentectomy for stage I 
lung cancer. In a subgroup of 99 octogenarian patients, the segmentectomy was associated 
with an improvement of the 3-year survival (p=0.02) (Schuchert et al., 2009). 
7.3 The impact of comorbidities on surgical outcomes 
A review of 10,761 patients with lung cancer stage IA showed the age of 67 years or more as 
an independent factor associated with long-term survival worse after surgery. One of the 
major criticisms of this study is that patients were not stratified based on their functional 
status or their comorbidities. It is known that these two factors are associated with advanced 
age and are predictors of mortality in elderly patients suffering from lung cancer (Maione et 
al., 2005; Frasci et al., 2000; Asmis et al., 2008; Schuchert et al., 2009).  
In another study of 126 patients 70 years of age or older with lung cancer, the Charlson 
Comorbidity Index has been performed in patients for lung surgery. A low score was a 
predictor of major complications after surgery (Birim et al., 2003). Some studies in patients 
older than 80 years of age were also conducted (Brokx et al., 2007; Okami et al., 2009; Wada 
et al., 1998). At the Mayo Clinic, 294 patients aged between 80 and 94 years underwent 
pulmonary resection and their 1-year survival was 80% and 2-year survival was 62% 
(Dominguez-Ventura et al., 2007). 
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recent French study it was shown that comprehensive geriatric evaluation did significantly 
influence treatment decisions in 82% of the older cancer patients. In this 161 patients group, 
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7. Surgery 
Surgery remains the mainstay of treatment for early stage NSCLC. Unfortunately, according 
to most published reports, elderly have a significant lower resection rates compared to 
younger patients and age is one of the factor influencing the decision for surgical treatment. 
Sigel retrospectively analyzed 27 850 patients with stage I lung cancer. The rate of lung 
surgery was 95% for patients less than 60 years and 79% in patients > 80 years (Sigel et al., 
2009). An analysis of Riquet showed that patients older than 70 years of age represents 
21.7% of patients who had surgery for lung cancer, patients of 75 years and older represents 
8.8% and older than 80 years old are only 1.9% in proportion (Riquet et al., 2001).  
These observations are still true, even considering the significant improvement in 
anesthesia, in technical procedures of lung resection and post-operative care that greatly 
enhanced the security of the surgery, even in a frail population. In patients with stage I and 
II, surgical option is still the prefer treatment option. The 5-year overall survival rates for 
pathological stage I range between 67% for pT1pN0 and 57% for pT2pN0 tumors. The 
corresponding values based on clinical stage are 61% for cT1cN0 and 37% for cT2cN0. 
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Patients must have a very good evaluation and adequate scrutiny is necessary to evaluate 
those who will really benefit from surgery. Preoperative assessment of cancer in the elderly 
(PACE) incorporates validated instruments including the CGA, an assessment of fatigue 
and performance status and an anaesthesiologist’s evaluation of operative risk. It is 
considered to be a valuable tool in enhancing the decision process concerning the candidacy 
of elderly patients for surgical intervention. It also reduce inappropriate age-related inequity 
in access to surgical intervention (PACE, 2008). 
7.2 Different types of surgery are used for the elderly. But which one is better? 
Survival data from the SEER database with patient of all ages shown that survival for lung 
cancer stage I and II were 56 and 34% respectively (Chang et al., 2007). The most important 
question regarding surgical resection for lung cancer is how aggressive should it be? The 
choice of the type of surgery is particularly important in the elderly. Right pneumonectomy 
is likely to be avoided in octogenarians (Broks et al., 2007; Port et al., 2004; Van Meerbeeck et 
al., 2002), but low rate of pneumonectomy in different series make this difficult to assess. As 
an indication, the British Thoracic Society Guidelines indicates that pneumonectomy is 
associated with higher risk of mortality.  
The sublobar pulmonary resection remains controversial in patients of any age. In a SEER 
analysis of 14,555 patients with stage I or II NSCLC, it was showed that benefit of a 
lobectomy was not evident for patients older than 71 years compared with limited resection 
(Meryet al., 2005). Okami did a non-randomized study to evaluate the different types of 
surgery in the elderly patients. A total of 764 patients, including 133 elderly and 631 
younger patients had lobectomy or sublobar resection. The survival after sublobar resection 
was significantly lower than that after standard lobectomy in the younger group (64% vs 
90.9%). Comparatively, no difference was seen in the elderly (67.6% vs 74.3%). However, 
locoregional recurrences were higher in patients with sublobar resection than lobectomy in 
young and older patients (Okami et al., 2009). A phase III study regarding this specific topic 
would be necessary to confirm this information. 
Another study done in Pittsburg has compared lobectomy to the segmentectomy for stage I 
lung cancer. In a subgroup of 99 octogenarian patients, the segmentectomy was associated 
with an improvement of the 3-year survival (p=0.02) (Schuchert et al., 2009). 
7.3 The impact of comorbidities on surgical outcomes 
A review of 10,761 patients with lung cancer stage IA showed the age of 67 years or more as 
an independent factor associated with long-term survival worse after surgery. One of the 
major criticisms of this study is that patients were not stratified based on their functional 
status or their comorbidities. It is known that these two factors are associated with advanced 
age and are predictors of mortality in elderly patients suffering from lung cancer (Maione et 
al., 2005; Frasci et al., 2000; Asmis et al., 2008; Schuchert et al., 2009).  
In another study of 126 patients 70 years of age or older with lung cancer, the Charlson 
Comorbidity Index has been performed in patients for lung surgery. A low score was a 
predictor of major complications after surgery (Birim et al., 2003). Some studies in patients 
older than 80 years of age were also conducted (Brokx et al., 2007; Okami et al., 2009; Wada 
et al., 1998). At the Mayo Clinic, 294 patients aged between 80 and 94 years underwent 
pulmonary resection and their 1-year survival was 80% and 2-year survival was 62% 
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A review of 297 articles was done by Chambers (2010) to consider the impact of lung 
resection on morbidity, mortality and postoperative quality of life for patients aged over 70 
years. They found twelve articles to answer this question. The collective analysis of these 12 
articles showed a five-year survival following surgery for early stages in those under age 70 
between 69 and 77%, for those over 70 years, the five-year survival ranges from 59 to 78%. 
The 30-day mortality rate was 5.7% in patients younger than 70 years against 1.3 to 3.3% in 
those over 70 years, length of hospital stay after thoracoscopy was respectively 4.6 and 4.9 to 
5.2 days. The post-operative lung functions were also equivalent between the two groups. 
FEV1 decreased 13% compared to 18% in patients older than 70 years (p=0.34) comparing 
the functional vital capacity decrease were equivalent between both groups (9% vs 14%).  
Lung function was also compared among young and elderly patients after lobectomy for 
early stage NSCLC. Changes in FEV1 and functional vital capacity were not significant 
although postoperative complications occurred in 32% of younger patients and 48% in the 
elderly (Sullivan et al., 2005). 
8. Adjuvant chemotherapy 
The use of adjuvant chemotherapy in the elderly is increasingly popular (Wang et al., 2008). 
In a SEER database, 25.8% of patients aged between 66 and 69 years received adjuvant 
treatment compared to 19.8% for those aged 70 to 74, 13.7% for those of 75 to 79 and only 9% 
for patients older than 80 years old. In the LACE meta-analysis of 4,584 patients with 
adjuvant chemotherapy, the hazard ratio for mortality was 0.89 and favored chemotherapy, 
with a 5-year absolute survival benefit of 5.4%. The authors concluded that the benefit of 
chemotherapy is similar between the elderly and their younger counterpart (Pignon et al., 
2006). Another meta-analysis of the impact of adjuvant chemotherapy done by the Non-
Small Cell Lung Cancer Collaborative Group and regrouping 52 trials with 9,387 patients 
between 1963 and 1992 has showed the same absolute benefice on survival of 5% at 5 years. 
The odds ratio for survival is similar between the different groups of age (Cochrane review, 
2000). 
Pepe et al. at ASCO meeting in 2006 presented an age-specific evaluation of BR10 study, a 
phase III trial with patients with stage Ib and II NSCLC and comparing four cycles of 
cisplatin and vinorelbine with observation. 155 patients of the 482 enrolled in this study 
were aged 65 years and older. Baseline characteristics were similar between age cohorts 
except for the histology with more elderly patients with squamous cell cancer. In general, 
elderly received a lower mean dose intensity of chemotherapy. Overall survival was in favor 
of the younger patients, but chemotherapy led still to a benefit effect compared with 
standard observation in elderly. There were few patients aged over 75 and without regard to 
treatment, survival was still poor at 26% at 5 years (Pepe et al., 2007).  
Other studies have been conducted on adjuvant chemotherapy, but the elderly subgroup 
was either absent, very little or without subgroup analysis as in the IALT study (Arriagada 
et al., 2004), Anita study (Douillard et al., 2006), Italian study Alpi (Scagliotti et al., 2003), Big 
Lung Trial (Waller et al., 2004) and CALGB (Strauss et al., 2004, 2006). 
Because studies on this subject are retrospective, it is still difficult to conclude on the exact 
role of surgery in elderly patients with lung cancer. However, surgery should be considered 
for patients in good condition. Lobectomy is preferable to the limited resections if patients 
are medically fit (Alberts et al., 2007). Pneumonectomy is associated with greater morbidity 
and mortality and should only be performed in a highly selected group of patients. With 
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few conclusive results available from studies of adjuvant chemotherapy in elderly, it is 
difficult to conclude that it should be a standard treatment for older people. However, we 
can possibly extrapolate from studies done with younger patients and use it in selected 
patients aged less than 75 years of age.  
9. Radiotherapy  
It was demonstrated that nearly 25% of patients with disease stage I or II did not have 
surgery, most often because of significant comorbidities, patient preferences or poor lung 
functions (Bach et al., 1999; Spiro et al., 2002). For elderly who are not candidates for 
surgery, radiation therapy is possible. Unfortunately, it usually gives poor results with a 5-
year survival estimated at between 6 to 14% (Razet al., 2007; Wisnivesky et al., 2005). In this 
section, the curative as well as palliative indication for radiation will be discussed. 
Radiation therapy has been shown to improve outcomes compared to best supportive care 
alone (Raz et al., 2007). A subgroup analysis, in the study of Morita, assessed the impact of 
age in relation with survival in irradiated patients. One hundred and forty-nine patients 
older than 80 years with stage I lung cancer were included in this analysis. The survival was 
lower in older patients compared with younger. The 3- and 5-years actuarial survival was 
15.4% and 7.7% in octogenarians versus respectively 38.2% and 25.2% in younger (p=0.035) 
(Morita et al., 1997). Similar results were found by Sibley (Sibley et al., 1998). However, a 
retrospective study from 6 studies of EORTC with 1,208 patients has shown no difference in 
overall survival between patients older or younger of 70 years (Pignon et al., 1998). Other 
retrospective studies compared treatment outcomes in younger and older patients. The 
North Central Cancer Treatment Group studied the impact of age (≥ 70 years versus 
younger) with two different schedules of radiation, either daily or twice per day, combined 
with concurrent chemotherapy. The 2-year survival rates were 39% in younger and 36% in 
the elderly and at 5-year, it was 18% versus 13% in patients ≥ 70 years (p=0.4). Toxicity of 
grade 4 or more were significantly higher in older patients (81%) than in younger ones 
(62%). The conclusion of this study was that toxicity is higher in elderly, but the survival is 
similar. Thus for fit patients this treatment can be proposed (Schild et al., 2003). 
In the treatment of locally advanced NCSLC, the standard of care is radiation with 
chemotherapy based on cisplatin. Two major trials demonstrated a survival advantage for 
the use of induction chemotherapy prior to radiation therapy (Dillman et al., 1990; Sause et 
al., 2000). After the publication of these results, studies have been done to test the combined 
treatment. These studies shown that combined chemoradiotherapy is more effective 
compared to radiation alone (Dillman et al., 1990; Furuse et al., 1999). Elderly were in 
general excluded from these studies and few trials have been done about the role of 
combined chemoradiation in this particular population. A phase II study in 40 elderly 
patients with unresectable stage III or medically inoperable stage I and II lung cancer treated 
with concurrent carboplatin and radiation was done. For stage IIIA/IIIB patients, the 
median survival time was 15.1 months and 1-and 2-year actuarial survival rates were 52.6% 
and 20.5%, respectively. For stage I/II patients, 1- and 3-year actuarial survival rates were 
90.9% and 69.3%, respectively (Atagi et al., 2000). 
A phase III trial was performed by Atagi in 2005 with patients older than 70 years with stage 
III NSCLC. Patients were randomly assigned to either radiation therapy (dose of 60 Gy) 
with concurrent carboplatin or radiation therapy alone. 4 patient’s death may have resulted 
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A review of 297 articles was done by Chambers (2010) to consider the impact of lung 
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except for the histology with more elderly patients with squamous cell cancer. In general, 
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few conclusive results available from studies of adjuvant chemotherapy in elderly, it is 
difficult to conclude that it should be a standard treatment for older people. However, we 
can possibly extrapolate from studies done with younger patients and use it in selected 
patients aged less than 75 years of age.  
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It was demonstrated that nearly 25% of patients with disease stage I or II did not have 
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general excluded from these studies and few trials have been done about the role of 
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and 20.5%, respectively. For stage I/II patients, 1- and 3-year actuarial survival rates were 
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A phase III trial was performed by Atagi in 2005 with patients older than 70 years with stage 
III NSCLC. Patients were randomly assigned to either radiation therapy (dose of 60 Gy) 
with concurrent carboplatin or radiation therapy alone. 4 patient’s death may have resulted 
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from poor compliance in the design of the radiation fields. This trial was closed early with 
only 46 randomised patients. 
A retrospective study of Langer (2002b) examined 104 patients older than 70 years with 
good performance status and minor weight loss receiving either sequential chemotherapy 
followed by daily radiotherapy, concomitant chemotherapy with daily radiotherapy or 
concomitant chemotherapy with twice daily radiation in phase III RTOG protocol 94-10. 
Concurrent treatment was proved to be favourable in the elderly, but toxicities were 
increased in this group. Median survival was 22.4 months for concurrent therapy with daily 
radiation, 16.4 months for concurrent chemotherapy with twice daily radiation treatment 
and 10.8 months for sequential treatment (p=0.069). 
Patients over 70 years of prospective studies performed by CALGB were retrospectively 
analyzed by Rocha Lima (2002). In CALGB 9130, patients were randomised between 
vinblastine and cisplatin followed by radiation alone at dose of 60 Gy or neoadjuvant 
vinblastine and cisplatin followed by concurrent radiation with carboplatin. 22% of the 
patients enrolled in this study had between 70-79 years and no patients had more than 80 
years of age. Age was not found to be a factor in survival or response rate, but elderly had 
more neutropenia and renal toxicity of grade 3 or more. 
Hayakawa (2001) showed an alteration of performance index in only 5% of patients between 
75-79 years and 8% in those more than 80 years when they are treated with radiation alone 
of 60 Gy. Another study presenting results about toxicity in 51 patients older than 65 years 
shows no augmentation of the toxicity in these patients in function with age, but survival 
was significantly correlated with performance status and importance of comorbidities 
(Fiorica et al., 2010). 
Retrospective case series of older patients treated with curative radiation alone have 
demonstrated a median survival of up to 37 months for stage I-II and 8 months pour stage 
III (Bonfili et al., 2009; Lonardi et al., 2000; San José et al., 2006 & Tombolini et al., 2000).  
It is recommended to provide elderly patients with advanced lung cancer disease in good 
general condition radiotherapy combined with chemotherapy. Concomitant treatment gives 
better results, but it is also more toxic to patients. For those that concomitant treatment is not 
possible, chemotherapy may be given before sequential radiotherapy. If the general 
condition of the patient or his comorbidities do not allow use of chemotherapy, he should 
receive radiation therapy alone either for curative or palliative purpose. 
9.1 Radiotherapy planning  
9.1.1 Treatment volume 
There would be an increase of interruption of radiation treatment with the increased volume 
of the radiation field in patients over 80 years (Zachariah et al., 1997). For patients over 90 
years, Ikeda (1999) showed that radiotherapy is better tolerated if treatment is limited to the 
macroscopic volume. In Pergolizzi (2002), 40 patients with stage IIIA, aged older than 75 
years, were treated with involved field with median dose of 60 Gy. The overall survival was 
18% at 3-years and 12% at 5 years.  
9.1.2 Radiation technique 
Technique of radiation could also influence the response to treatment in elderly population. 
Thus, Park’s study evaluate whether complex radiotherapy planning with 3D techniques 
was associated with improvement outcomes in elderly compared with intermediate analysis 
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with 2D planning. They found a better survival in patients treated with a more complex 
planning (Park et al., 2010). 
In 2008, Yu conducted a multicenter prospective study in older patients with Intensity 
Modulated Radiotherapy (IMRT), an inverse planning technique. 80 patients had stage I and 
II disease and were medically inoperable or refused surgery. Patients received 66 Gy to 
involved field including primary tumor and clinical enlarged nodes. Objective response rate 
was 88.6%, with 1-, 2- and 5-year overall survival rates of 65.8%, 55.7% and 25.3% 
respectively and local progression-free survival was 84.8%. Toxicity was minimal. This 
study confirms that involved field radiation is a reasonable treatment for elderly patients.  
9.2 Stereotactic radiation 
Stereotactic body irradiation (SBRT) is a technique that utilizes precisely targeted radiation 
to tumor while minimizing radiation to adjacent normal tissue. This is accomplished by 
using multiple beams (typically 10 to 12) or large angle arc rotations. This technique is 
promising in the elderly. SBRT accurately delivers highly hypofractionated doses of 
radiation. High biologically effective radiation doses are generally of advantage with regard 
to tumor cell kill and local tumor control. SBRT is in general well tolerated and local control 
is similar than for patients treated with surgery. 
In Zimmermann study, 68 patients were treated with a mean dose of 37.5 Gy in 3-5 fractions. 
The mean age was 76 years. Actuarial local tumor control at 1, 2 and 3 years was 96%, 88% 
and 88%. Disease-specific survival was 96%, 82% and 73% at 1, 2, and 3 year follow-up. 2 
patients died by local tumor progression and a total of 8 patients died from their lung cancer 
disease. 55% of patients had mild acute and subacute toxicities (Zimmerman 2006). In 
Indiana University study, patients received in a phase I trial 66 Gy in 3 fractions for T2 
tumors. The maximum tolerated dose was not reached for T1 tumors at 60 Gy in 3 fractions 
(McGarry et al., 2005; Timmerman et al., 2003). A RTOG multicenter study treated 59 
patients with T1-T2N0 tumor with 54 Gy in 3 fractions. Three-year local control of the tumor 
was 98%. The three-year disease-free and overall survivals were 48% and 56% respectively 
(Timmerman, 2010). 
In general, the results for stereotactic radiotherapy appear better than those of standard 
radiotherapy. Local control at 3 years vary from 86-95% (Baumann et al., 2006, 2009; Onishi 
et al., 2007; Xia et al., 2006; Zimmermann et al., 2006) for patients treated with SBRT while 
for external radiotherapy, local recurrences are more than 50% (Rowell et al., 2001 & Qiao et 
al., 2003) with 5-years survival around 10 to 30%. 
Moreover a Palma analysis on 875 elderly patients shown that SBRT introduction was 
associated with an improvement of 16% in the use of radiation, and a decline in the number 
of untreated elderly patients (Palma et al., 2010).  
9.3 Palliative radiation 
The main goal of palliative radiation is to decrease the pulmonary symptoms of the patients. 
The number of treatment may vary according to the general functional status of the patients. 
According to a review of 13 randomized trials, no significant difference was observed for 
specific symptom control end points, but there is an improvement in survival favoured with 
high dose radiotherapy. For good functional status patients, it is recommended to use a 
palliative dose of radiation with a biological effective dose (BED) of at least 35 Gy10 
(Fairchild et al., 2008). Another review of 12 randomized controlled studies recommends a 
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from poor compliance in the design of the radiation fields. This trial was closed early with 
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vinblastine and cisplatin followed by concurrent radiation with carboplatin. 22% of the 
patients enrolled in this study had between 70-79 years and no patients had more than 80 
years of age. Age was not found to be a factor in survival or response rate, but elderly had 
more neutropenia and renal toxicity of grade 3 or more. 
Hayakawa (2001) showed an alteration of performance index in only 5% of patients between 
75-79 years and 8% in those more than 80 years when they are treated with radiation alone 
of 60 Gy. Another study presenting results about toxicity in 51 patients older than 65 years 
shows no augmentation of the toxicity in these patients in function with age, but survival 
was significantly correlated with performance status and importance of comorbidities 
(Fiorica et al., 2010). 
Retrospective case series of older patients treated with curative radiation alone have 
demonstrated a median survival of up to 37 months for stage I-II and 8 months pour stage 
III (Bonfili et al., 2009; Lonardi et al., 2000; San José et al., 2006 & Tombolini et al., 2000).  
It is recommended to provide elderly patients with advanced lung cancer disease in good 
general condition radiotherapy combined with chemotherapy. Concomitant treatment gives 
better results, but it is also more toxic to patients. For those that concomitant treatment is not 
possible, chemotherapy may be given before sequential radiotherapy. If the general 
condition of the patient or his comorbidities do not allow use of chemotherapy, he should 
receive radiation therapy alone either for curative or palliative purpose. 
9.1 Radiotherapy planning  
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There would be an increase of interruption of radiation treatment with the increased volume 
of the radiation field in patients over 80 years (Zachariah et al., 1997). For patients over 90 
years, Ikeda (1999) showed that radiotherapy is better tolerated if treatment is limited to the 
macroscopic volume. In Pergolizzi (2002), 40 patients with stage IIIA, aged older than 75 
years, were treated with involved field with median dose of 60 Gy. The overall survival was 
18% at 3-years and 12% at 5 years.  
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Technique of radiation could also influence the response to treatment in elderly population. 
Thus, Park’s study evaluate whether complex radiotherapy planning with 3D techniques 
was associated with improvement outcomes in elderly compared with intermediate analysis 
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with 2D planning. They found a better survival in patients treated with a more complex 
planning (Park et al., 2010). 
In 2008, Yu conducted a multicenter prospective study in older patients with Intensity 
Modulated Radiotherapy (IMRT), an inverse planning technique. 80 patients had stage I and 
II disease and were medically inoperable or refused surgery. Patients received 66 Gy to 
involved field including primary tumor and clinical enlarged nodes. Objective response rate 
was 88.6%, with 1-, 2- and 5-year overall survival rates of 65.8%, 55.7% and 25.3% 
respectively and local progression-free survival was 84.8%. Toxicity was minimal. This 
study confirms that involved field radiation is a reasonable treatment for elderly patients.  
9.2 Stereotactic radiation 
Stereotactic body irradiation (SBRT) is a technique that utilizes precisely targeted radiation 
to tumor while minimizing radiation to adjacent normal tissue. This is accomplished by 
using multiple beams (typically 10 to 12) or large angle arc rotations. This technique is 
promising in the elderly. SBRT accurately delivers highly hypofractionated doses of 
radiation. High biologically effective radiation doses are generally of advantage with regard 
to tumor cell kill and local tumor control. SBRT is in general well tolerated and local control 
is similar than for patients treated with surgery. 
In Zimmermann study, 68 patients were treated with a mean dose of 37.5 Gy in 3-5 fractions. 
The mean age was 76 years. Actuarial local tumor control at 1, 2 and 3 years was 96%, 88% 
and 88%. Disease-specific survival was 96%, 82% and 73% at 1, 2, and 3 year follow-up. 2 
patients died by local tumor progression and a total of 8 patients died from their lung cancer 
disease. 55% of patients had mild acute and subacute toxicities (Zimmerman 2006). In 
Indiana University study, patients received in a phase I trial 66 Gy in 3 fractions for T2 
tumors. The maximum tolerated dose was not reached for T1 tumors at 60 Gy in 3 fractions 
(McGarry et al., 2005; Timmerman et al., 2003). A RTOG multicenter study treated 59 
patients with T1-T2N0 tumor with 54 Gy in 3 fractions. Three-year local control of the tumor 
was 98%. The three-year disease-free and overall survivals were 48% and 56% respectively 
(Timmerman, 2010). 
In general, the results for stereotactic radiotherapy appear better than those of standard 
radiotherapy. Local control at 3 years vary from 86-95% (Baumann et al., 2006, 2009; Onishi 
et al., 2007; Xia et al., 2006; Zimmermann et al., 2006) for patients treated with SBRT while 
for external radiotherapy, local recurrences are more than 50% (Rowell et al., 2001 & Qiao et 
al., 2003) with 5-years survival around 10 to 30%. 
Moreover a Palma analysis on 875 elderly patients shown that SBRT introduction was 
associated with an improvement of 16% in the use of radiation, and a decline in the number 
of untreated elderly patients (Palma et al., 2010).  
9.3 Palliative radiation 
The main goal of palliative radiation is to decrease the pulmonary symptoms of the patients. 
The number of treatment may vary according to the general functional status of the patients. 
According to a review of 13 randomized trials, no significant difference was observed for 
specific symptom control end points, but there is an improvement in survival favoured with 
high dose radiotherapy. For good functional status patients, it is recommended to use a 
palliative dose of radiation with a biological effective dose (BED) of at least 35 Gy10 
(Fairchild et al., 2008). Another review of 12 randomized controlled studies recommends a 
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short course (one or two fraction) of hypofractioned radiotherapy for the majority of the 
patients. Selected patients with good performance status should be considered for higher 
dose regimens as this could increase their survival (Toy et al., 2003). 
9.3.1 Brachytherapy as palliation 
Another way to treat lung cancer disease is using palliative brachytherapy. This treatment is 
effective to treat endobronchial disease. This often causes cough, hemoptysis and dyspnea. 
Stout compared external beam radiation therapy (EBRT) with endobronchial brachytherapy. 
He showed that EBRT offers a better palliation. Furthermore, there was slightly improved in 
survival (Stout et al., 2000). However, some patients cannot be treated with external beam 
radiation and brachytherapy could be offered to them. This approach seems to be more 
effective than other types of treatment, such as cryotherapy, cauterization or phototherapy, 
which only superficially destruct cancer cell (Hetzel et al., 1985; Sutedja et al., 1994; Walsh et 
al., 1990). High-dose rate brachytherapy is cost-effective and convenient owing to its short 
irradiation time and the fact that it can be provided on an outpatient basis. Endobronchial 
brachytherapy treats tumors up to 1-cm deep with 100% of prescribed dose and a decreasing 
dose can reach up to 2-cm deep.  
A retrospective study with inoperable endobronchial lung cancer or metastasis had shown a 
significant improvement of symptoms and a good survival. 85% of patients had an 
improvement of the dyspnea during or shortly after the end of the treatment. Hemoptysis 
was stopped in all 23 patients of the study and 77% of them had an improvement of their 
cough. Patients had received 4 weekly fractions of 5 Gy each time. The complication rate 
during treatment was low (Dagnault et al., 2010).  
Thus, for palliation, hypofractionated external beam radiation therapy and brachytherapy 
are alternatives to proper treatment for the relief of symptoms. 
10. Chemotherapy 
The treatment of advanced lung cancer requires chemotherapy. The standard combination is 
based on a combination of platinum and either vinorelbine, gemcitabine, paclitaxel or 
docetaxel. Few studies have yet been made to assess the best chemotherapy agents in 
elderly people. Many of the available data are from analysis of subgroups. The American 
College of Chest Physician guidelines recommends chemotherapy for stage IV NSCLC for 
selected patients older than 70 years. They caution that the benefits of chemotherapy in 
patients over 80 years of age are unknown and recommend instead a case by case 
assessment (Socinski et al., 2007).  
The first important question is to determine if older people tolerates chemotherapy as well 
as younger patients and if the outcome of the treatments is the same. Some studies have 
been done in this direction. Nguyen (1999) compared cisplatin and gemcitabine to cisplatin 
alone and showed that tolerance to treatment and outcome of patients were identical for 
patients aged more or less than 70 years. In a subset analysis of an Eastern Cooperative 
Oncology Group study (ECOG 5592) patients received cisplatin and etoposide or paclitaxel. 
A total of 574 patients were included in this trial, which 15% were 70 or older. The response 
rate, the time to progression and the survival rate did not differ across groups but there was 
higher hematological and neuropsychiatric toxicities in the elders. There was no difference 
in the quality of life (Langer et al., 2002a). In the CALGB 7730 trial, 561 patients received 
paclitaxel compared to paclitaxel and carboplatin. The total of patients aged more than 70 
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years included in this trial was 27% or 155 patients. In that study, there was no formal 
subgroup analysis based on age, but the general data revealed no obvious difference 
between age groups (Lilenbaum et al., 2005). Further studies with subgroup analysis 
showed similar results (Belani et al., 2005; Earle et al., 2001; Hensinget al., 2003; Iberti et al., 
1995; Langer et al., 2003; Rocha Lima et al., 2002). We can then conclude that the survival 
benefit is similar in elderly as in younger patients. 
10.1 Importance of patient evaluation for chemotherapy treatment 
As previously discussed, age by itself should not be a factor to decide if a patient will 
received or not chemotherapy treatment. That decision should be taken considering the 
global functional status of the patients and his comorbidities, particularly cardiovascular 
and pulmonary ones. Aging is associated with several physiologic changes in organ 
function. Those changes could alter drug pharmacokinetics and they could have an impact 
on cytotoxic chemotherapy toxicity and tolerability (Wildiers et al., 2003). Thus, it is always 
mandatory to know the serum creatinine, but also the creatinine clearance to assess renal 
function, particularly for chemotherapy agents whose main route of elimination is by the 
kidney, as platinum derivatives and methotrexate. It is also important to evaluate the bone 
marrow reserve as this reserve may diminish with increasing age, and the risk of 
neutropenia increases with age (Langer et al., 2002; Rocha Lima et al., 2002). 
10.2 Single-agent chemotherapy versus best supportive care 
This question was evaluated in elderly patients with advanced/metastatic NSCLC in the 
Italian phase III trial, Elderly Lung Cancer Vinorelbine Italian Group Study (ELVIS) 
(Ardizzoni et al., 2005). Patients over 70 years of age were randomly assigned to either 
receive vinorelbine (30 mg/m2 on days 1 and 8) or to receive best supportive care (BSC). 
Even if the accrual of this study was poor, with only 161 evaluable patients, it demonstrated 
that there was a significant advantage of survival in the vinorelbine arm (p=0.03). The 
median survival was 21 weeks for BSC versus 28 weeks for vinorelbine. Survival rates were 
41% at 6 months for control arm compared to 55% in the vinorelbine arm. At 12 months, 
survival was respectively 14% for BSC and 32% with vinorelbine. This study also shown that 
patients receiving chemotherapy had a significant benefit in disease-related quality-of-life 
(QoL) measures (decreased pain p=0.02, decreased dyspnea p=0.05). Toxicity was 
acceptable. Only 5 of 71 older patients discontinued treatment secondary to severe toxic 
events (3 patients had constipation grade 3, 1 patient had constipation grade 4 and 1 patient 
had grade 2 heart toxicity). Even if 4 patients had a grade 4 leukopenia, treatment had not 
been interrupted. 
10.3 Type of single-agent chemotherapy 
Others chemotherapy were tested to find the best one in elderly patients. A phase III trial of 
West Japan Thoracic Oncology Group Trial (WJTOG 9904) randomized 182 patients older 
than 70 years between two agents: docetaxel (60 mg/m2 on day 1) or vinorelbine (25 mg/m2 
on days 1 and 8). Patients received 4 cycles every 21 days. Median survival was not 
significantly different between two arms with docetaxel group being 14.3 months compared 
to 9.9 months with vinorelbine (p=0.138). However, others outcomes were significantly in 
favour of docetaxel. Thus, the progression-free survival was 5.5 months versus 3.1 months 
(p<0.001) and the response rate was 22.7% compared to 9.9% (p=0.019). Even if no 
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short course (one or two fraction) of hypofractioned radiotherapy for the majority of the 
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patients over 80 years of age are unknown and recommend instead a case by case 
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as younger patients and if the outcome of the treatments is the same. Some studies have 
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years included in this trial was 27% or 155 patients. In that study, there was no formal 
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between age groups (Lilenbaum et al., 2005). Further studies with subgroup analysis 
showed similar results (Belani et al., 2005; Earle et al., 2001; Hensinget al., 2003; Iberti et al., 
1995; Langer et al., 2003; Rocha Lima et al., 2002). We can then conclude that the survival 
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received or not chemotherapy treatment. That decision should be taken considering the 
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function. Those changes could alter drug pharmacokinetics and they could have an impact 
on cytotoxic chemotherapy toxicity and tolerability (Wildiers et al., 2003). Thus, it is always 
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function, particularly for chemotherapy agents whose main route of elimination is by the 
kidney, as platinum derivatives and methotrexate. It is also important to evaluate the bone 
marrow reserve as this reserve may diminish with increasing age, and the risk of 
neutropenia increases with age (Langer et al., 2002; Rocha Lima et al., 2002). 
10.2 Single-agent chemotherapy versus best supportive care 
This question was evaluated in elderly patients with advanced/metastatic NSCLC in the 
Italian phase III trial, Elderly Lung Cancer Vinorelbine Italian Group Study (ELVIS) 
(Ardizzoni et al., 2005). Patients over 70 years of age were randomly assigned to either 
receive vinorelbine (30 mg/m2 on days 1 and 8) or to receive best supportive care (BSC). 
Even if the accrual of this study was poor, with only 161 evaluable patients, it demonstrated 
that there was a significant advantage of survival in the vinorelbine arm (p=0.03). The 
median survival was 21 weeks for BSC versus 28 weeks for vinorelbine. Survival rates were 
41% at 6 months for control arm compared to 55% in the vinorelbine arm. At 12 months, 
survival was respectively 14% for BSC and 32% with vinorelbine. This study also shown that 
patients receiving chemotherapy had a significant benefit in disease-related quality-of-life 
(QoL) measures (decreased pain p=0.02, decreased dyspnea p=0.05). Toxicity was 
acceptable. Only 5 of 71 older patients discontinued treatment secondary to severe toxic 
events (3 patients had constipation grade 3, 1 patient had constipation grade 4 and 1 patient 
had grade 2 heart toxicity). Even if 4 patients had a grade 4 leukopenia, treatment had not 
been interrupted. 
10.3 Type of single-agent chemotherapy 
Others chemotherapy were tested to find the best one in elderly patients. A phase III trial of 
West Japan Thoracic Oncology Group Trial (WJTOG 9904) randomized 182 patients older 
than 70 years between two agents: docetaxel (60 mg/m2 on day 1) or vinorelbine (25 mg/m2 
on days 1 and 8). Patients received 4 cycles every 21 days. Median survival was not 
significantly different between two arms with docetaxel group being 14.3 months compared 
to 9.9 months with vinorelbine (p=0.138). However, others outcomes were significantly in 
favour of docetaxel. Thus, the progression-free survival was 5.5 months versus 3.1 months 
(p<0.001) and the response rate was 22.7% compared to 9.9% (p=0.019). Even if no 
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significant differences in global QoL were observed between the two groups, it is interesting 
to notice that patients in the docetaxel group had a significant greater improvement in 
overall symptom score than those in vinorelbine group. One disadvantage of docetaxel is 
that it induces significantly severe neutropenia more frequently. To conclude, docetaxel in 
monotherapy can be considered as an option of treatment in older patients (Kudoh et al., 
2006). A phase 2 study performed in older patients compared gemcitabine and docetaxel 
and these agents had comparable efficacy and tolerability profiles (Leong et al., 2007). 
In 2010, a phase II trial was published on the role of single-agent vinorelbine in patient older 
than 70 years with poor performance status (ECOG 2 or more). Forty-three patients received 
oral vinorelbine at the dose of 60 mg/m2 on days 1 to 8 every 3 weeks. Overall response rate 
was 18.6%, median time to progression was 4.0 months and median overall survival was 8.0 
months. This treatment was safe, without grade 3 or 4 toxicity, exception of a single non-
febrile grade 3 neutropenia. Therefore, vinorelbine is safe for elderly patient, even in those 
with poor performance status (Camerini et al., 2010). Previously, another study with 
docetaxel in monotherapy, comparing weekly to 3-weekly administration, had also 
conclude that this treatment is effective and well tolerated in older patients, even with poor 
performance status (Lilenbaum et al., 2007). 
An international expert panel ruled in favour of the use of single-agent chemotherapy in the 
elderly cancer patient. A third-generation agent is recommended for patients with any 
performance status and a platinum-based chemotherapy is recommended for those with 
performance status 0 or 1 and no contre-indications for comorbidities (Gridelli et al., 2005).  
10.4 Combination versus single-agent chemotherapy 
When studies revealed that single-agent chemotherapy improved survival, the search for 
more effective treatment continued and studies with combinations of chemotherapy have 
been done. Few randomized trials compared a combination of chemotherapy to a single 
agent. A French Intergroup study randomly assigned 451 patients of 70-89 years with 
performance status 0-2 that previously had untreated stage III or IV disease. Patients 
received a combination of carboplatin (AUC 6 on day 1) plus paclitaxel (90 mg/m2, days 1, 8 
and 15) every 4 weeks for a total of four cycles or a single agent (gemcitabine or vinorelbine, 
as predetermined by each institution). Gemcitabine (1,150 mg/m2) or vinorelbine (30 
mg/m2) were given on days 1 and 8 for 5 cycles, every 3 weeks. At ASCO meeting in 2010, 
preliminary results were presented. For the first 313 patients, overall survival was 
significantly better in the combination arm with 10.4 months versus 6.2 months for single 
agent chemotherapy. Progression-free survival was significantly improved with 
combination chemotherapy (6.3 versus 3.2 months) and this difference was significant. The 
combined treatment was well tolerable even if neutropenia grade 3 and 4 were more 
frequent with the combination chemotherapy (Quoix et al., 2010). 
A phase III study done by The South Italian Cooperative Oncology Group (SICOG) 
randomized patients between vinorelbine (30 mg/m2 days 1 and 8 every 3 weeks), versus 
vinorelbine/gemcitabine (vinorelbine 30 mg/m2 and gemcitabine 1,200 mg/m2, days 1 and 
8 every 3 weeks). In this study an interim analysis of survival with the first 60 patients was 
done. This analysis showed a significant survival advantage for the combination arm, with 
median survival of 29 weeks versus 18 weeks for the single arm. Following these results, the 
study was closed prematurely. The estimated 6-months and 1-year survival were 56% and 
30% for the combination group and 32% and 13% in the single-agent arm (p<0.01). Patients 
receiving monotherapy treatment had more symptoms and deterioration of quality of life. 
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Toxicity for the combination arm resulted in grade 3-4 neutropenia and thrombocytopenia 
in 38% and 13% respectively, and it was more prevalent than in the vinorelbine arm (Frasci 
et al., 2000). 
The Cancer and Leukemia Group B reported results of a phase III trial (CALGB-9730) that 
compared a combination of carboplatin and paclitaxel with paclitaxel in monotherapy. In 
this study, in which 155 patients had over 70 years, the response rate was 36% versus 21% 
respectively. The median survival was better in patients treated with the combination 
compared with monotherapy (8.0 vs 5.8 months respectively- non significant) (Lilenbaum et 
al., 2005).  
Docetaxel and cisplatin doublet was compared with docetaxel in monotherapy in a phase III 
trial for elderly patient with NSCLC (Ansari et al., 2007). The planned sample size was 115 
patients per arm, but the study was closed when the planned interim analysis showed that 
the doublet may be beneficial for patient aged 70 to 74 years.  
However, results remain conflicting about the impact of a combination of chemotherapy. 
Multicenter Italian Lung cancer in the elderly Study (MILES) is another randomized study 
that involves patients aged 70 years or older. 698 patients were randomly assigned to 
gemcitabine alone (1,200 mg/m2 days 1 and 8, every 3 weeks), vinorelbine alone (30 mg/m2 
on days 1 and 8, every 3 weeks) or gemcitabine (1,000 mg/m2) plus vinorelbine (25 mg/m2) 
both administrated on days 1 and 8 every 3 weeks (Gridelli et al., 2003). In this study, there 
was no difference between each single-agent and the combination arm for progression-free 
survival and overall survival. The estimated 1-year survival was 38% and 28% for patients 
respectively with vinorelbine and gemcitabine alone. In the combination arm, the overall 
survival was 30%. Median survival was 36 weeks for vinorelbine, 28 weeks for gemcitabine 
alone and 30 weeks for the combination. Toxicities were more frequent in the patients 
receiving combination chemotherapy. Thus, the combination of vinorelbine and gemcitabine 
was not shown to be more effective than single agent vinorelbine or gemcitabine in elderly 
patients with NSCLC (Gridelli et al., 2003). 
A study analysed the baseline assessment of functional status, comorbidity and quality of 
life in elderly patients randomised in MILES trial. The presence of comorbidity was assessed 
with a checklist of 33 items, items 29 and 30 of the European Organisation for research and 
Treatment of Cancer (EORTC) core questionnaire QLQ-C30 were used for the quality of life 
and the Charlson scale was used to summarize cormorbidity. Better values of activities of 
instrumental activities of daily living (IADL) (p=0.04) and of baseline quality of life 
(p=0.0003) were significantly associated with better prognosis. Two others factors, either 
activities of daily living (ADL) and the Charlson scale score had no prognostic value 
(Maione et al., 2005). 
An analysis from SEER data on patients with NSCLC over 65 years old evaluated the role of 
chemotherapy. Of over 21,000 patients evaluated, only 25.8% received first-line chemotherapy. 
After adjusting for comorbidities, age and performance status, patients with chemotherapy 
had an increased adjusted 1-year survival rate of 27% when compared to those without 
chemotherapy (11%) and a reduction of the adjusted risk of death, with a hazard ratio of 0.558. 
In this study, the use of combination of platinum agents was associated with an increase 
survival at 30.1% compared with single-agent at 19.4% (Davidoff et al., 2010). 
A meta-analysis involving 2,867 patients of randomized controlled trial had shown superior 
results for efficacy and tolerability of docetaxel compared with vinorelbine or vindesine 
(Douillard et al., 2007; Laporte et al., 2007). The overall survival was 11% greater in patients 
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with doxetaxel compared with vinca alkaloid-based regimen (HR 0.89). This benefit was 
observed when docetaxel was used with or without a platinum agent as part of the regimen. 
In this meta-analysis, the benefit of docetaxel was at least as much important in older 
patients than in younger (Laporte et al., 2007). 
In conclusion, for fit elderly patients, combination chemotherapy with a platinum-based 
regimen can improve survival without much toxicity. For patients without a good 
performance status a single-agent may be proposed. 
10.5 Second-line therapy 
No definitive studies have been conducted in the second-line setting in older patients with 
NSCLC. A phase II study has shown utility of docetaxel as second-line therapy. Tibaldi's 
trial demonstrated an objective response rate of 21% (Tibaldi et al., 2006). A subset analysis 
of a phase III trial compared docetaxel with pemetrexed, in 86 patients older than 70 years. 
This study demonstrated an objective response rate of 6% and a median overall survival of 
9.5 months in the pemetrexed group and 7.7 months in docetaxel (not statistically 
significant) (Weiss et al., 2006). 
10.6 EGFR-thyrosin kinase inhibitors 
Over the last years, many biologic and targeted therapies have been approved. Molecules 
which target epidermal growth factor receptor (EGFR) include erlotinib and gefitinib. Some 
monoclonal antibodies are also now approved for the use in lung cancer like cetuximab 
which targets EGFR and bevacizumab which targets the vascular endothelial growth factor 
(VEGF). 
Thanks to their oral administration and their toxicity profile, the EGFR may be alternative 
treatments in chemotherapy-naïve elderly. In a phase II trial, chemotherapy-naïve patients 
older than 75 years with advanced NSCLC received gefitinib in monotherapy. The primary 
objective of this study was the objective response rate. 49 patients were eligible. The 
response rate was 25% with median survival of 10 months and 1-year survival of 50%. Skin 
disorders were the most frequent adverse side effects, in 76% of patients (Ebi et al., 2008). 
A phase II trial, INVITE, compared gefitinib versus vinorelbine in chemotherapy-naïve 
elderly patients with advanced non-small-cell lung cancer. 97 patients were randomly 
assigned to gefitinib and received 250 mg/d orally and 99 patients received vinorelbine (30 
mg/m2 infusion on days 1 and 8 of a 21–day cycle). The primary endpoint was progression-
free survival and the hazard ratio was 1.19 (gefitinib versus vinorelbine). Overall survival 
was 2.7 months for gefitinib versus 2.9 months for vinorelbine and hazard ratio was 0.98. 
Disease control rates were 43.3% for gefitinib and 53.5% for vinorelbine. The quality of life 
(QoL) was also analysed in this study. There was no statistical difference between gefitinib 
and vinorelbine for pulmonary symptom improvement (PSI) and QoL. The improvement of 
overall QoL and PSI were 24.3% and 36.6% for gefitinib and 10.9% and 31.0% for vinorelbine 
respectively. 54 patients had EGFR FISH-positive and the hazard ratio were 3.13 for PFS and 
2.88 for OS (Crinò et al., 2008). 
A phase III trial, TOPICAL, compared erlotinib versus placebo in chemotherapy-naïve 
patients with poor performance status who were not candidate for first line chemotherapy. 
Overall survival was not significantly different between both groups (Lee et al., 2010). 
For elderly patients whose tumor contains an EGFR mutation, it is recommend to treat with 
an EGFR TK inhibitor, as erlotinib or gefitinib, rather than chemotherapy. 
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Regarding the use of bevacizumab, few subsets analyses were done. In ECOG 4599, patients 
over 70 years were randomized to carboplatin and paclitaxel, with or without the addition 
of bevacizumab. The overall incidence of severe or fatal (grade 3 to 5) toxicity was 
significantly higher (87% versus 61%) in those receiving bevacizumab and treatment-related 
deaths were more frequent (6.3% versus 2.6%). This trial revealed a trend toward 
improvement in disease response (29% versus 17 %) and progression-free survival (5.9 
versus 4.9 months), without benefit in overall survival (Ramalingam et al., 2008). 
11. Conclusion 
Lung cancer is already a significant problem in our population. It is one of the major causes 
for cancer mortality in the younger population, even more in the elderly. The aging 
population will continue to grow and the proportion of elderly with lung cancer will 
increase in coming decades. Oncologist will have to develop their abilities to better evaluate 
them and to give them the appropriate treatment for their condition. Actually, no specific 
assessment tool is proved to be better than other, but we demonstrated the importance of a 
form of CGA and all his components in the evaluation of these persons.  
Many treatment options are available and proved to be effective in the elderly. It can vary 
from standard treatment, as for younger patient, to more adapted treatment, in regard to the 
general functional status of the person and his comorbidities.  
For patients with early stage disease, surgery remains the treatment of choice with or 
without adjuvant chemotherapy. When it is not possible, radiation therapy is an excellent 
alternative, well tolerated with limited side effects. In case of advanced disease, radiation 
combined or not to chemotherapy is the option, according to the general functional status of 
the patient. Palliative treatment, either radiation or chemotherapy can also be offered to the 
elderly patient, according to their symptoms and wishes.  
A good evaluation of the patient and realistic goal for treatment remain essential in this 
population, but treatment decisions based solely on chronological age is no longer 
acceptable at this time. 
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1. Introduction 
Lung cancer is the leading cause of cancer death in many counties. Despite significant 
improvement in chemotherapy and radiotherapy, surgery is still the cornerstone of non-
small cell lung cancer treatment. The lung cancer is categorized into non-small cell lung 
cancer or small cell lung cancer according to the histology. The patients with stage IA-IIB 
non-small cell lung cancer and stage I small cell lung cancer are good candidates for lung 
resection which can offer the best chance for cure. In a series of 407 individuals with 
resectable cancer, the 346 who went to thoracotomy had a median survival of 30.9 months 
compared with 15.6 months in the 57 who did not go to surgery (Loewen, et al. 2007). A part 
of individuals with stage IIIA non-small cell stage may also be the surgical candidates if 
they are adequately treated with chemotherapy and/or radiotherapy before and/or after 
surgery. The long term goals of lung cancer surgery include cancer control improving 
survival and quality of life of the patients. 
Smoking is the important risk factor not only for lung cancer but also for other comorbid 
diseases such as chronic obstructive pulmonary disease (COPD) and coronary heart disease. 
The patients with lung cancer and COPD have reduced ability to tolerate further losses in 
lung function. Because of relatively high incidence of postoperative complications, the 
hospital mortality, as well as disappointing long-term survival after surgical resection of 
lung cancer, the appropriate selection of patients for pulmonary resection is a continuing 
challenge. It was reported that only about 30% of individuals with lung cancer were 
determined to be candidates for lung resection because of the advanced stage (Damhuis & 
Schutte 1996). In addition, a report showed that 37% of individuals who present with 
anatomically resectable disease deemed not to be surgical candidates based on poor lung 
function alone (Baser, et al. 2006). If a patient is deemed a candidate for surgery, it must be 
realized that pulmonary function will be affected by the resection. The decline in lung 
function varies with the extent of the resection. Accordingly, it is important to be informed 
about the risk factors and how they affect postoperative morbidity, mortality, and long-term 
survival. 
Pulmonary function measures such as the forced expiratory volume in one second (FEV1) 
and the diffusing capacity for carbon monoxide (DLco) are useful predictors of 
postoperative outcome (Bousamra, et al. 1996; Ferguson, et al. 1988; Markos, et al. 1989). 
Postoperative value of FEV1 is certainly the most widely used parameter for preoperative 
risk stratification. It has been shown to be an independent predictor of complications 
including mortality (Kearney, et al. 1994; Mitsudomi, et al. 1996; Ribas, et al. 1998). The 
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assessment of regional lung function to predict postoperative function is integral to 
preoperative evaluation of pulmonary resection candidates who have impaired lung 
function. There are four validated ways to predict postoperative FEV1. However, all of them 
tend to underestimate the predicted value compared with the actual postoperative lung 
function. Although predicted postoperative FEV1 (ppoFEV1) somewhat exactly correlates 
with actual postoperative FEV1 (apoFEV1), the correlation can be affected by several clinical 
factors. If actual postoperative lung function quite differs from predicted value, it may be a 
cause of serious clinical outcome especially in the patients with marginal postoperative lung 
function; someone may undergo life-threatening lung resection, and someone may lose the 
opportunity to be cured by surgery. Therefore, we need to know clinical factors as many as 
possible which can affect the discrepancy between apoFEV1 and ppoFEV1. The aim of the 
chapter is to review the accuracy of the prediction methods for postoperative lung function, 
especially FEV1, and the clinical factors affecting the prediction accuracy. This will confer 
the ideas about the appropriate selection of patients for pulmonary resection and 
perioperative management for risk reduction. 
2. The physiologic evaluation for the decision about operability 
2.1 Lung function test 
Among lung function measures, FEV1 and DLco are the most useful predictors of 
postoperative outcomes. Both absolute values and percent predicted normal values have 
been studied and proved as a predictors of postoperative complications including mortality 
(Licker, et al. 2006). The generally accepted lung function for minimal postoperative 
mortality is preoperative FEV1 > 1.5 L for a lobectomy, and > 2L for a pneumonectomy. 
Those who have lung function above this level can undergo surgery without further 
evaluation. There is little evidence that one cutoff absolute value of FEV1 should be used to 
permit resection of varying extent. Although the absolute value for ppoFEV1 that would 
allow resection has not been found, the previous studies suggested the values greater than 
0.8-1 L for acceptable postoperative mortality (Boysen, et al. 1981; Wernly, et al. 1980). The 
values of pulmonary function expressed as percentage of normal are more convenient and 
useful because they are affected by individual's age, sex, height, and race. In terms of 
percentage of normal, ppoFEV1 less than 30% predicted would be very highly risky for 
perioperative death and ppoFEV1 greater than 40% has been suggested for tolerable 
resection up to calculated extent of resection (Beckles, et al. 2003; Colice, et al. 2007; Markos, 
et al. 1989). If ppoFEV1 is between 30% and 40%, the decision had better to incorporate the 
result of maximal oxygen consumptions (VO2max). 
Cardiopulmonary exercise testing has been used as a means to access a patient's fitness for 
lung resection. Several studies have identified exercise capacity (VO2max) as a predictor of 
postoperative complications as well as of postoperative long term mortality (Bolliger, et al. 
1995; Brutsche, et al. 2000). Risk for perioperative complications can generally be stratified 
by VO2max. Several studies demonstrated that preoperative VO2max > 20 mL/kg/min was 
not associated with increased risk of complications or death (Bolliger, et al. 1994; Richter 
Larsen, et al. 1997). Patients with VO2max of 15 to 20 mL/kg/min can undergo curative 
lung cancer surgery with an acceptably low mortality rate (Richter Larsen, et al. 1997; Win, 
et al. 2005). On the contrary, the risk of perioperative death sharply increases below the level 
of VO2max < 15 mL/kg/min (Bolliger, et al. 1995; Win, et al. 2005). VO2max < 10 
mL/kg/min has been reported as a very high risk of postoperative death (Holden, et al. 
1992; Olsen, et al. 1989). 
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Algorithmic approaches for the candidate selection have been developed in an effort to 
improve decision making (Colice, et al. 2007; Wyser, et al. 1999). Wyser et al. showed that 
algorithmic decision reduced the complications in half compared with the author's prior 
series. In summary, individuals with VO2max < 10 mL/kg/min, or < 15 mL/kg/min with 
both ppoFEV1 and ppoDLco < 40% predicted, are at high risk for perioperative death and 
complications. Both preoperative FEV1 and DLco ≥ 80% predicted normal or VO2max ≥ 20 
mL/kg/min allow lobectomy or pneumonectomy without any further evaluation. 
2.2 Stair climbing and walking test 
If cardiopulmonary exercise test were not available, another simple exercise test could 
replace the test. Stair climbing has been investigated, and it was proven to correlate with 
FEV1 and VO2max very well (Bolton, et al. 1987; Pollock, et al. 1993). It is generally accepted 
that patient who can climb five flights of stairs has VO2max > 20 mL/kg/min, and 
conversely, patient who cannot climb one flight of stairs has VO2max < 10 mL/kg/min 
(Beckles, et al. 2003). The data about the shuttle walking or 6-minute walking test are 
limited, but they can also surrogate cardiopulmonary exercise test. 
2.3 Arterial blood gas analysis 
The results of arterial blood gas analysis reflect the cardiopulmonary functional status. 
Historically, hypercapnea (PaCO2 > 45 mmHg) has been regarded as an exclusion criterion 
for lung resection (Celli 1993). However, a few clinical studies suggested that hypercapnea 
did not increase perioperative complications (Harpole, et al. 1996; Kearney, et al. 1994). 
Hypercapnea is not an independent risk factor for increased perioperative complications, 
and the operability should be decided after further physiologic testing. 
3. The methods for prediction of postoperative lung function 
The surgical procedure depends on the stage of lung cancer and on the cardiopulmonary 
reserve of the patients. A prospective randomized trial comparing limited resection to 
lobectomy in patients with peripheral stage I lung cancers reported that the patients treated 
with limited resection had a three-fold increase in local recurrence, a 75% increase in 
combined local and distant recurrence, and a 50% increase in death with cancer  (Ginsberg & 
Rubinstein 1995). Therefore, anatomic resection such as lobectomy or pneumonectomy 
should be done if physiologically feasible. Lung sparing anatomic resection like sleeve 
lobectomy is preferred over pneumonectomy, if anatomically appropriate and if margin-
negative resection can be achieved. A study compared clinical outcomes of the elderly 
patients undergoing sleeve lobectomy or pneumonectomy due to non-small-cell lung cancer 
(Bolukbas, et al. 2011). The loss of FEV1 was 12.0% vs. 27.3% (p = 0.001), and 5 year survival 
rate was 59% vs. 0% favoring sleeve lobectomy although there was no statistical difference 
in postoperative mortality (6.5% in sleeve lobectomy vs. 10.3% in pneumonectomy). 
Sublobar resection, either segmentectomy (preferred) or wedge resection, is appropriate in 
selected patients if margin-negative resection can be achieved. The limited resection is 
appropriate especially for the patients with poor pulmonary reserve or other major co-
morbidity that contraindicates lobectomy. 
For the prediction of postoperative remnant lung function, the anatomy of the lung 
should be understood. The right lung consists of three lobes; upper, middle and lower 
lobe. The right upper lobe consists of 3 segments, the right middle lobe 2 segments, and 
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the right lower lobe 5 segments. The left lung consists of two lobes; upper and lower lobe. 
The left upper lobe consists of 4 segments, the left lower lobe 4 segments. The 
anteromediobasal segment of the left lower lobe is the counterpart of anterobasal segment 
and mediobasal segment of the right lower lobe, but it has a common bronchial orifice. 
Although it is anatomically one segment, it contains two segments in volume. Therefore, 
the left lung is regarded to have 9 segments in terms of volume; 4 segments in the left 
upper lobe and 5 segments in the left lower lobe. Each segment is assumed to have same 
volume (1/19 of the lung function). The four validated methods to predict postoperative 
lung function are: 1) anatomic calculation, 2) split radionuclide perfusion scanning, 3) 
quantitative computed tomography (CT) scanning, and 4) dynamic perfusion magnetic 
resonance imaging (MRI). Using these techniques, the actual lung function was 
consistently underestimated, particularly if the starting value was lower (Giordano, et al. 
1997; Zeiher, et al. 1995). The accuracy of prediction of anatomic calculation is slightly 
lower than the other methods, but the other methods effectively predict postoperative 
FEV1 with similar accuracy. Medical cost, local expertise and availability of equipments 
should be considered for the choice. 
3.1 Anatomic calculation 
Estimation of predicted postoperative lung function based on anatomical calculation is the 
simplest, but the accuracy is slightly lower than other methods. Predicted postoperative 
FEV1 can be calculated by simple subtraction of the FEV1 proportion of resected lung 
segments from the total preoperative FEV1 (Juhl & Frost 1975; Zeiher, et al. 1995). 
ppoFEV1 = preoperative FEV1 x [1 - (number of segments to be resected  19)] 
For example, if a patient will undergo right upper lobectomy, the predicted postoperative 
FEV1 will be calculated to remain 16/19 (84.2%) of preoperative FEV1. This method is also 
applied to the other methods as a basic concept. 
3.2 Split radionuclide perfusion scanning 
In most clinical cases, the extent of pulmonary disease may be different in each side of the 
lung, which is leading cause of different regional lung function according to the disease 
status. This is a major violation of the assumption that each lung segment represents the 
same lung function. The general principle of the radionuclide scanning technique is same for 
the anatomic calculation method. The prediction of postoperative lung function can be 
calculated by the following two steps. The first step is determining the functional 
contribution of resected (right or left) lung by quantitative perfusion lung scan, and the 
second step is applying the principle of anatomical calculation to the resected lung. 
Postoperative lung function is then estimated to be the product of the preoperative function 
and the portion of lung function that will remain after resection as estimated by the scan. 
ppoFEV1 = preoperative FEV1 x [1 – functional fraction of the resected lung 
 (number of segments to be resected/total segments of that lung)] 
The accuracy of these techniques has been questioned. A recent study using technetium 
scanning calculated values of imprecision from 18%-21% despite showing reasonable 
correlation (Giordano, et al. 1997). 
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3.3 Quantitative CT scanning 
Quantitative computed tomography scanning has been studied as a technique to estimate 
postresection lung function. The basic concept is similar to radionuclide perfusion scanning 
method. This measures the split lung function using the CT attenuation density instead of 
radionuclide signal intensity. The volume of lung with attenuation between -500 and -910 
Hounsfield units was used to estimate functional lung volume. The portion of the lung 
remaining postresection was predicted by calculating lung volume in the area to be resected 
as a portion of total lung volume. With this, predicted postoperative function correlated as 
well as the method using radionuclide quantitative perfusion imaging (Wu, et al. 2002). 
3.4 Dynamic perfusion magnetic resonance imaging (MRI) 
A study showed that magnetic resonance (MR) perfusion imaging had almost the same 
sensitivity and specificity for diagnosis of pulmonary perfusion defects as conventional 
perfusion scintigraphy (Berthezene, et al. 1999). The regional lung function is calculated from 
the subtraction images for normal lung parenchyma using image analysis software. The 
accuracy of MR perfusion for the prediction of ppoFEV1 was validated in a study (Iwasawa, et 
al. 2002). This study demonstrated that the correlation between perfusion ratios derived from 
MR perfusion image and radionuclide perfusion scanning was excellent (R = 0.92). The 
correlation between ppoFEV1 and actual postoperative FEV1 was similar when the two 
methods were compared (R = 0.682 in MR perfusion and R = 0.667 in radionuclide perfusion). 
4. Clinical parameters affecting prediction accuracy of postoperative lung 
function 
Prediction accuracy of postoperative lung function is affected not only by the calculation 
technique, but also the clinical factors associated with the actual postoperative lung 
function. The actual lung function closely relates to the physiology of lung volume 
reduction, reversibility of airway obstruction, pharmacotherapy, and postoperative 
respiratory rehabilitation. 
4.1 Chronic obstructive pulmonary sisease 
Pulmonary function is affected by lung resection and the decline in lung function varies 
with the extent of the resection. The degree of functional loss appears to be less in 
individuals with poor baseline lung function uniformly across the studies (Bobbio, et al. 
2005; Boushy, et al. 1971; Edwards, et al. 2001). In patients with severe emphysema, surgery 
performed to remove the most emphysematous portion of the lung may lead to 
improvements in lung function (Fishman, et al. 2003). A case-matched study demonstrated 
that the patients with COPD had a three-fold higher rate of cardiopulmonary morbidity 
(28% versus 10%, p=0.04), but lower reduction in FEV1 (6% versus 13%, p=0.0002) compared 
with non-COPD patients after lobectomy for lung cancer (Pompili, et al. 2010). Importantly, 
although the postoperative quality of life in both groups was reduced, there were no 
significant differences in quality of life between the groups. This suggests that the patients 
with lung cancer and COPD may be unexpectedly tolerable with the curative lung resection 
if the candidates are carefully selected. This is attributed to lung volume reduction effect 
which takes place very early. The risk-benefit should be balanced based on the negative 
physiologic effects of thoracotomy versus positive effects of lung volume reduction in the 
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the right lower lobe 5 segments. The left lung consists of two lobes; upper and lower lobe. 
The left upper lobe consists of 4 segments, the left lower lobe 4 segments. The 
anteromediobasal segment of the left lower lobe is the counterpart of anterobasal segment 
and mediobasal segment of the right lower lobe, but it has a common bronchial orifice. 
Although it is anatomically one segment, it contains two segments in volume. Therefore, 
the left lung is regarded to have 9 segments in terms of volume; 4 segments in the left 
upper lobe and 5 segments in the left lower lobe. Each segment is assumed to have same 
volume (1/19 of the lung function). The four validated methods to predict postoperative 
lung function are: 1) anatomic calculation, 2) split radionuclide perfusion scanning, 3) 
quantitative computed tomography (CT) scanning, and 4) dynamic perfusion magnetic 
resonance imaging (MRI). Using these techniques, the actual lung function was 
consistently underestimated, particularly if the starting value was lower (Giordano, et al. 
1997; Zeiher, et al. 1995). The accuracy of prediction of anatomic calculation is slightly 
lower than the other methods, but the other methods effectively predict postoperative 
FEV1 with similar accuracy. Medical cost, local expertise and availability of equipments 
should be considered for the choice. 
3.1 Anatomic calculation 
Estimation of predicted postoperative lung function based on anatomical calculation is the 
simplest, but the accuracy is slightly lower than other methods. Predicted postoperative 
FEV1 can be calculated by simple subtraction of the FEV1 proportion of resected lung 
segments from the total preoperative FEV1 (Juhl & Frost 1975; Zeiher, et al. 1995). 
ppoFEV1 = preoperative FEV1 x [1 - (number of segments to be resected  19)] 
For example, if a patient will undergo right upper lobectomy, the predicted postoperative 
FEV1 will be calculated to remain 16/19 (84.2%) of preoperative FEV1. This method is also 
applied to the other methods as a basic concept. 
3.2 Split radionuclide perfusion scanning 
In most clinical cases, the extent of pulmonary disease may be different in each side of the 
lung, which is leading cause of different regional lung function according to the disease 
status. This is a major violation of the assumption that each lung segment represents the 
same lung function. The general principle of the radionuclide scanning technique is same for 
the anatomic calculation method. The prediction of postoperative lung function can be 
calculated by the following two steps. The first step is determining the functional 
contribution of resected (right or left) lung by quantitative perfusion lung scan, and the 
second step is applying the principle of anatomical calculation to the resected lung. 
Postoperative lung function is then estimated to be the product of the preoperative function 
and the portion of lung function that will remain after resection as estimated by the scan. 
ppoFEV1 = preoperative FEV1 x [1 – functional fraction of the resected lung 
 (number of segments to be resected/total segments of that lung)] 
The accuracy of these techniques has been questioned. A recent study using technetium 
scanning calculated values of imprecision from 18%-21% despite showing reasonable 
correlation (Giordano, et al. 1997). 
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3.3 Quantitative CT scanning 
Quantitative computed tomography scanning has been studied as a technique to estimate 
postresection lung function. The basic concept is similar to radionuclide perfusion scanning 
method. This measures the split lung function using the CT attenuation density instead of 
radionuclide signal intensity. The volume of lung with attenuation between -500 and -910 
Hounsfield units was used to estimate functional lung volume. The portion of the lung 
remaining postresection was predicted by calculating lung volume in the area to be resected 
as a portion of total lung volume. With this, predicted postoperative function correlated as 
well as the method using radionuclide quantitative perfusion imaging (Wu, et al. 2002). 
3.4 Dynamic perfusion magnetic resonance imaging (MRI) 
A study showed that magnetic resonance (MR) perfusion imaging had almost the same 
sensitivity and specificity for diagnosis of pulmonary perfusion defects as conventional 
perfusion scintigraphy (Berthezene, et al. 1999). The regional lung function is calculated from 
the subtraction images for normal lung parenchyma using image analysis software. The 
accuracy of MR perfusion for the prediction of ppoFEV1 was validated in a study (Iwasawa, et 
al. 2002). This study demonstrated that the correlation between perfusion ratios derived from 
MR perfusion image and radionuclide perfusion scanning was excellent (R = 0.92). The 
correlation between ppoFEV1 and actual postoperative FEV1 was similar when the two 
methods were compared (R = 0.682 in MR perfusion and R = 0.667 in radionuclide perfusion). 
4. Clinical parameters affecting prediction accuracy of postoperative lung 
function 
Prediction accuracy of postoperative lung function is affected not only by the calculation 
technique, but also the clinical factors associated with the actual postoperative lung 
function. The actual lung function closely relates to the physiology of lung volume 
reduction, reversibility of airway obstruction, pharmacotherapy, and postoperative 
respiratory rehabilitation. 
4.1 Chronic obstructive pulmonary sisease 
Pulmonary function is affected by lung resection and the decline in lung function varies 
with the extent of the resection. The degree of functional loss appears to be less in 
individuals with poor baseline lung function uniformly across the studies (Bobbio, et al. 
2005; Boushy, et al. 1971; Edwards, et al. 2001). In patients with severe emphysema, surgery 
performed to remove the most emphysematous portion of the lung may lead to 
improvements in lung function (Fishman, et al. 2003). A case-matched study demonstrated 
that the patients with COPD had a three-fold higher rate of cardiopulmonary morbidity 
(28% versus 10%, p=0.04), but lower reduction in FEV1 (6% versus 13%, p=0.0002) compared 
with non-COPD patients after lobectomy for lung cancer (Pompili, et al. 2010). Importantly, 
although the postoperative quality of life in both groups was reduced, there were no 
significant differences in quality of life between the groups. This suggests that the patients 
with lung cancer and COPD may be unexpectedly tolerable with the curative lung resection 
if the candidates are carefully selected. This is attributed to lung volume reduction effect 
which takes place very early. The risk-benefit should be balanced based on the negative 
physiologic effects of thoracotomy versus positive effects of lung volume reduction in the 
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surgical decision for the patients with lung cancer and COPD. As most lung cancer patients 
have more or less emphysematous changes, adequate volume reduction may open small 
airways, expand or overinflate functional alveoli, improve diaphragmatic movement and 
consequently increase postoperative FEV1 than the expected. This is consistent with the 
basic principle of volume reduction surgery for severe emphysema that postoperative lung 
function can be improved by resection of relatively functionless emphysematous lung. 
4.2 Resected lung portion 
Besides preoperative lung function, a study has suggested that the prediction accuracy of 
postoperative lung function could be influenced by other clinical factor such as resected 
lung portion (Sekine, et al. 2003). Sekine et al. reported that the presence of COPD and 
resection of the lower lung portion (lower lobectomy or middle-lower bilobectomy) were 
significantly associated with minimal deterioration of pulmonary function after lobectomy. 
The authors retrospectively analyzed 521 patients who had undergone lobectomy for lung 
cancer. The ppoFEV1 was calculated by modified anatomic calculation by multiplying a 
specific coefficient according to the baseline FEV1 categories. The apoFEV1 was measured at 
1 month after operation. Minimal alteration of postoperative lung function, defined as 
apoFEV1 ≥ 1.15  ppoFEV1, was confirmed to be associated with COPD (vs. non-COPD) 
and resection of the lower lung portion (vs. upper lung portion) in multivariate analysis. 
Lung volume reduction theory can explain minimal alteration of apoFEV1 in the patients 
with COPD. The authors speculated that occasional anatomic repositioning after upper 
lobectomy, which causes narrowing of the orifice of lower or middle lobe bronchus, and 
different movement and elevation of diaphragm between upper lobectomy and lower 
lobectomy might be the potential causes the minimal alteration in the cases of resection of 
the lower lung portion (Nonaka, et al. 2000; Van Leuven, et al. 1999). 
4.3 Number of resected lung segment and bronchodilator response 
The writer of this chapter and his colleagues (Kim, et al. 2008) investigated another clinical 
factors affecting prediction accuracy. Some of the findings would like to be introduced in 
detail, because those may help for the selection of candidates for surgery and perioperative 
management of the patients.  
A total of 82 patients with non-small-cell lung cancer undergoing pulmonary resection were 
retrospectively analyzed in this study. Forty eight patients underwent lobectomy, 11 
patients underwent bilobectomy, and the remaining 23 patients underwent 
pneumonectomy. The ppoFEV1 was dually estimated by anatomical calculation and split 
radionuclide perfusion scanning method. The mean time interval between surgery and 
apoFEV1 was 24 ± 7 days. The ppoFEV1 calculated by split radionuclide perfusion scanning 
method was more accurate than that by anatomic calculation method (apoFEV1/ppoFEV1 = 
1.00 ± 0.19 vs. 1.07 ± 0.23, p < 0.001). Multivariate linear regression analysis was performed 
to identify clinical parameters affecting the prediction accuracy with the covariates of age, 
gender, preoperative FEV1, time interval between surgery and the day of measuring 
apoFEV1, preoperative bronchodilator response (% increase in FEV1 after inhalation of short 
acting beta-2 agonist), resected lung portion, and the number of resected lung segments. 
Among these clinical factors, the number of resected lung segments and preoperative FEV1 
were significant clinical factors affecting the prediction accuracy (p = 0.026 and 0.002, 
respectively). As the preoperative FEV1 became smaller and the more lung segments were 
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resected, apoFEV1 tended to be larger than ppoFEV1. It is noteworthy that the 
corresponding means of apoFEV1/ppoFEV1 for each number of resected lung segments 
gathered on a straight line of a constant slope. The apoFEV1 was closest to ppoFEV1 when 
four segments were resected. Contrary to the previous report, resected lung portion (upper 
or lower portion resection) was not related to the prediction accuracy (p = 0.10). However, 
more number of segments was resected in lower portion resection compared with upper 
portion resection (5.6 ± 1.1 vs. 3.7 ± 1.0, p = 0.001), which might be a confounding factor. 
Lung functions of 46/82 patients were followed at 106 ± 30 days after surgery, which was 
reflecting plateau lung function of the patients undergoing lung resection. As expected, 
plateau apoFEV1 was increased by 13% compared with apoFEV1 measured at 24 days after 
surgery. In predicting plateau lung function, split radionuclide perfusion scanning method 
was also superior to anatomic calculation (plateau apoFEV1/ppoFEV1 = 1.11 ± 0.24 vs. 1.18 ± 
0.30, p < 0.001). These data also indicate that the prediction methods are fitter for short-term 
postoperative value rather than long-term value. In general, postoperative lung function 
gradually improves with time (Brunelli, et al. 2007). However, the plateau apoFEV1 was lower 
than the apoFEV1 measured at 24 days in 9/46 (19%) patients. Their preoperative 
bronchodilator response values were higher than those of the others although it did not reach 
statistical significance (11.2 ± 8.4% vs. 7.0 ± 6.8%, p = 0.11). The study did not investigate 
prescription status of bronchodilator or the patients' adherence to the drugs. However, this 
finding suggests that adequate perioperative bronchodilator therapy is necessary for the 
patients with high bronchodilator response, especially for the patients with poor lung 
function. Bronchodilator response is a well known predictor of pulmonary function 
improvement after long term treatment with long acting beta-2 agonist. A study demonstrated 
that bronchodilator response, wheezing history positively correlated with improvement in 
FEV1 after three months inhalation treatment with salmeterol/fluticasone combination, 
conversely negative correlation with emphysema extent (Lee, et al. 2011). COPD is a complex 
and heterogeneous disorder of mixed chronic bronchitis and emphysema. Another study 
showed that three months inhalation treatment with long-acting beta-agonist and 
corticosteroid significantly improved the FEV1 of obstruction-dominant patients compared 
with the emphysema-dominant subgroup. Again, baseline bronchodilator response and DLco 
were the meaningful predictors associated with improvement of FEV1 after the treatment (Lee, 
et al. 2010). If the patients with high bronchodilator response do not receive regular 
bronchodilator treatment after surgery, the FEV1 should decrease and the prediction accuracy 
of postoperative lung function would be affected as a matter of course. 
Preoperative FEV1 was significantly lower in the COPD group than in the non-COPD group 
(67.1 ± 8.3% vs. 101.6 ± 15.2%, p < 0.001). The apoFEV1 was about 14% larger than ppoFEV1 
in the COPD group while apoFEV1 was very similar to ppoFEV1 in the non-COPD group 
(apoFEV1/ppoFEV1 = 1.1 ± 0.2 in COPD group and 1.0 ± 0.1 in non-COPD group, p < 
0.001). These are the same results with the previous studies indicating that the prediction of 
postoperative lung function is more accurate in the non-COPD group than in the COPD 
group, and postoperative lung function of the COPD group may be less deteriorated than 
that of the non-COPD group. 
5. Physiologic changes in the lung volume reduction surgery 
Actual postoperative FEV1 is better than the predicted value in the patients with COPD, 
which is universally observed in many clinical studies. This phenomenon is explained by 
the physiology of lung volume reduction. In patients with COPD, inhaled air is trapped in 
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surgical decision for the patients with lung cancer and COPD. As most lung cancer patients 
have more or less emphysematous changes, adequate volume reduction may open small 
airways, expand or overinflate functional alveoli, improve diaphragmatic movement and 
consequently increase postoperative FEV1 than the expected. This is consistent with the 
basic principle of volume reduction surgery for severe emphysema that postoperative lung 
function can be improved by resection of relatively functionless emphysematous lung. 
4.2 Resected lung portion 
Besides preoperative lung function, a study has suggested that the prediction accuracy of 
postoperative lung function could be influenced by other clinical factor such as resected 
lung portion (Sekine, et al. 2003). Sekine et al. reported that the presence of COPD and 
resection of the lower lung portion (lower lobectomy or middle-lower bilobectomy) were 
significantly associated with minimal deterioration of pulmonary function after lobectomy. 
The authors retrospectively analyzed 521 patients who had undergone lobectomy for lung 
cancer. The ppoFEV1 was calculated by modified anatomic calculation by multiplying a 
specific coefficient according to the baseline FEV1 categories. The apoFEV1 was measured at 
1 month after operation. Minimal alteration of postoperative lung function, defined as 
apoFEV1 ≥ 1.15  ppoFEV1, was confirmed to be associated with COPD (vs. non-COPD) 
and resection of the lower lung portion (vs. upper lung portion) in multivariate analysis. 
Lung volume reduction theory can explain minimal alteration of apoFEV1 in the patients 
with COPD. The authors speculated that occasional anatomic repositioning after upper 
lobectomy, which causes narrowing of the orifice of lower or middle lobe bronchus, and 
different movement and elevation of diaphragm between upper lobectomy and lower 
lobectomy might be the potential causes the minimal alteration in the cases of resection of 
the lower lung portion (Nonaka, et al. 2000; Van Leuven, et al. 1999). 
4.3 Number of resected lung segment and bronchodilator response 
The writer of this chapter and his colleagues (Kim, et al. 2008) investigated another clinical 
factors affecting prediction accuracy. Some of the findings would like to be introduced in 
detail, because those may help for the selection of candidates for surgery and perioperative 
management of the patients.  
A total of 82 patients with non-small-cell lung cancer undergoing pulmonary resection were 
retrospectively analyzed in this study. Forty eight patients underwent lobectomy, 11 
patients underwent bilobectomy, and the remaining 23 patients underwent 
pneumonectomy. The ppoFEV1 was dually estimated by anatomical calculation and split 
radionuclide perfusion scanning method. The mean time interval between surgery and 
apoFEV1 was 24 ± 7 days. The ppoFEV1 calculated by split radionuclide perfusion scanning 
method was more accurate than that by anatomic calculation method (apoFEV1/ppoFEV1 = 
1.00 ± 0.19 vs. 1.07 ± 0.23, p < 0.001). Multivariate linear regression analysis was performed 
to identify clinical parameters affecting the prediction accuracy with the covariates of age, 
gender, preoperative FEV1, time interval between surgery and the day of measuring 
apoFEV1, preoperative bronchodilator response (% increase in FEV1 after inhalation of short 
acting beta-2 agonist), resected lung portion, and the number of resected lung segments. 
Among these clinical factors, the number of resected lung segments and preoperative FEV1 
were significant clinical factors affecting the prediction accuracy (p = 0.026 and 0.002, 
respectively). As the preoperative FEV1 became smaller and the more lung segments were 
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resected, apoFEV1 tended to be larger than ppoFEV1. It is noteworthy that the 
corresponding means of apoFEV1/ppoFEV1 for each number of resected lung segments 
gathered on a straight line of a constant slope. The apoFEV1 was closest to ppoFEV1 when 
four segments were resected. Contrary to the previous report, resected lung portion (upper 
or lower portion resection) was not related to the prediction accuracy (p = 0.10). However, 
more number of segments was resected in lower portion resection compared with upper 
portion resection (5.6 ± 1.1 vs. 3.7 ± 1.0, p = 0.001), which might be a confounding factor. 
Lung functions of 46/82 patients were followed at 106 ± 30 days after surgery, which was 
reflecting plateau lung function of the patients undergoing lung resection. As expected, 
plateau apoFEV1 was increased by 13% compared with apoFEV1 measured at 24 days after 
surgery. In predicting plateau lung function, split radionuclide perfusion scanning method 
was also superior to anatomic calculation (plateau apoFEV1/ppoFEV1 = 1.11 ± 0.24 vs. 1.18 ± 
0.30, p < 0.001). These data also indicate that the prediction methods are fitter for short-term 
postoperative value rather than long-term value. In general, postoperative lung function 
gradually improves with time (Brunelli, et al. 2007). However, the plateau apoFEV1 was lower 
than the apoFEV1 measured at 24 days in 9/46 (19%) patients. Their preoperative 
bronchodilator response values were higher than those of the others although it did not reach 
statistical significance (11.2 ± 8.4% vs. 7.0 ± 6.8%, p = 0.11). The study did not investigate 
prescription status of bronchodilator or the patients' adherence to the drugs. However, this 
finding suggests that adequate perioperative bronchodilator therapy is necessary for the 
patients with high bronchodilator response, especially for the patients with poor lung 
function. Bronchodilator response is a well known predictor of pulmonary function 
improvement after long term treatment with long acting beta-2 agonist. A study demonstrated 
that bronchodilator response, wheezing history positively correlated with improvement in 
FEV1 after three months inhalation treatment with salmeterol/fluticasone combination, 
conversely negative correlation with emphysema extent (Lee, et al. 2011). COPD is a complex 
and heterogeneous disorder of mixed chronic bronchitis and emphysema. Another study 
showed that three months inhalation treatment with long-acting beta-agonist and 
corticosteroid significantly improved the FEV1 of obstruction-dominant patients compared 
with the emphysema-dominant subgroup. Again, baseline bronchodilator response and DLco 
were the meaningful predictors associated with improvement of FEV1 after the treatment (Lee, 
et al. 2010). If the patients with high bronchodilator response do not receive regular 
bronchodilator treatment after surgery, the FEV1 should decrease and the prediction accuracy 
of postoperative lung function would be affected as a matter of course. 
Preoperative FEV1 was significantly lower in the COPD group than in the non-COPD group 
(67.1 ± 8.3% vs. 101.6 ± 15.2%, p < 0.001). The apoFEV1 was about 14% larger than ppoFEV1 
in the COPD group while apoFEV1 was very similar to ppoFEV1 in the non-COPD group 
(apoFEV1/ppoFEV1 = 1.1 ± 0.2 in COPD group and 1.0 ± 0.1 in non-COPD group, p < 
0.001). These are the same results with the previous studies indicating that the prediction of 
postoperative lung function is more accurate in the non-COPD group than in the COPD 
group, and postoperative lung function of the COPD group may be less deteriorated than 
that of the non-COPD group. 
5. Physiologic changes in the lung volume reduction surgery 
Actual postoperative FEV1 is better than the predicted value in the patients with COPD, 
which is universally observed in many clinical studies. This phenomenon is explained by 
the physiology of lung volume reduction. In patients with COPD, inhaled air is trapped in 
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the thorax as a result of decreased elastic recoil of the lung and early closure of the small 
airways during exhalation. This is manifested as hyperinflation of the chest, flattening of the 
diaphragm, increased intra-thoracic pressure, and reduced inspiratory capacity. These 
worsen during exercise and result in dyspnea and limitation of exercise capacity. After 
surgical volume reduction, there is expansion of the remaining lung in addition to reduction 
of the overall thoracic volume and pressure, and it is probable that some areas of relative 
compression have been reexpanded. Lung volume reduction surgery is associated with 
improvement in exercise capacity, lung function, quality of life, and dyspnea, but the 
changes after surgery are variable according to the individuals (Gelb, et al. 2001). The 
improvement of FEV1 and reduction in hyperinflation has been explained by the increase of 
lung parenchymal elastic recoil (Sciurba, et al. 1996). It is accompanied with subsequent 
repositioning of the diaphragm, recruitment of inspiratory muscles, and improvement of 
respiratory mechanics (Benditt, et al. 1997; Criner, et al. 1998). 
Surgical treatment of emphysema had been tried with multiple wedge resections and 
plications technique which is no longer used (Brantigan & Mueller 1957), and then Cooper et 
al. reintroduced lung volume reduction surgery as a possible surgical therapy for selected 
patients with a heterogeneous form of emphysema (Cooper, et al. 1995). The most affected 
portions are excised about 20% to 35% of the volume of each lung for lung volume 
reduction. The surgical mortality rate ranges  4-15% and one-year mortality rates are as high 
as 17% (Argenziano, et al. 1996; Flaherty, et al. 2001; Gelb, et al. 2001). A large randomized 
controlled trial was conducted to compare lung volume reduction surgery with medical 
therapy for severe emphysema (Fishman, et al. 2003). The FEV1 of surgery arm was 
significantly better than that of medical treatment group after 6, 12, and 24 months follow-
up. The rates of improvement versus deterioration of FEV1 compared with the baseline 
were 65% : 35% at 6 months follow-up, 56% : 44% at 12 months, and 43% : 57% at 24 months 
in the lung volume reduction surgery group. It is also observed in the bullectomy case series 
that FEV1 is initially improved after lung volume reduction surgery and then returns to the 
baseline lung function with time. The 90-day mortality was 7.9% (95% confidence interval, 
5.9-10.3%) in surgery group, and 1.3% (95% confidence interval, 0.6-2.6%) in medical 
treatment group. The functional benefits of lung volume reduction surgery came at the price 
of increased short-term mortality. Overall mortality was similar in both treatment groups, 
but subgroup analysis showed that the survival benefit was observed in the patients with 
predominantly upper lobe emphysema and a low baseline exercise capacity. Patients with 
non–upper lobe emphysema and high baseline exercise capacity are poor candidates for 
lung volume reduction surgery, because of increased mortality and negligible functional 
gain. 
The similar physiologic changes can be also expected in the giant bullae. If a giant bulla 
compresses the adjacent normal lung parenchyma and it is causing incapacitating dyspnea, 
it should be resected for the reexpansion of the normal lung. Bullectomy can produce 
immediate lung function improvement, but the benefit usually decline with time (Laros, et 
al. 1986; Schipper, et al. 2004). Giant bullae are frequently combined with emphysema. 
6. COPD and lung cancer 
COPD is characterized by chronic airflow limitation that is not fully reversible and usually 
progressive with time. The airflow limitation is usually associated with an abnormal 
inflammatory response of the lung to noxious particles or gases. COPD refers to patients 
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with emphysema or chronic bronchitis, though these two disease entities are frequently 
mixed up to a varying ratio. It is accompanied with some significant extrapulmonary effects 
and comorbidities (Agusti 2005). COPD has been defined in several ways, and the 
differences in definitions and diagnosis affect the estimates of the burden of the disease. The 
Global Initiative for Chronic Obstructive Lung Disease (GOLD) defines the disease in stages 
of clinical severity based on FEV1 and FEV1/FVC (forced vital capacity) from post-
bronchodilator spirometry (Rabe, et al. 2007). The statement recommends to use the fixed 
ratio post-bronchodilator FEV1/FVC < 0.7 for definition of airflow limitation despite a 
problematic issue of overdiagnosis. 
COPD are at risk for lung cancer due to common risk factors like aging, smoking, reactive 
oxygen species (Azad, et al. 2008; Soriano, et al. 2005; Young, et al. 2009). Tobacco smoking 
is considered to be the leading cause both of lung cancer and COPD. Smokers have a higher 
prevalence of respiratory symptoms and lung function abnormalities, a greater annual 
decline rate in FEV1 and a greater COPD mortality rate than nonsmokers. Smoking accounts 
for more than 85-90% of all lung cancer related deaths (Doll & Peto 1976). Cancer cells 
proliferate in reactive oxygen species rich inflammatory environment which is promoting 
DNA damage, inactivation of apoptosis, upregulation of growth factors, cytokines, and 
activating growth supporting genes (Cook, et al. 2004). Reactive oxygen species and chronic 
inflammation are also important pathologic mechanisms of COPD. A meta-analysis 
demonstrated that overall relative risk of lung cancer for subjects with COPD was 2.22 (95% 
confidence interval, 1.66-2.97%). Besides COPD, previous history of pneumonia or 
tuberculosis also increased the lung cancer risk even in never-smoker population (Brenner, 
et al. 2011).  Chronic inflammation has been proposed as a cause of cancer development. 
An effective COPD management includes severity assessment, regular monitoring, risk 
factor elimination, pharmacotherapy, and rehabilitation. This multidimensional approach 
includes patient education, health advice, counseling about smoking cessation, instruction 
in exercise and nutrition. Almost all the same therapeutic approach and monitoring should 
be also applied to the patients with the patients undergoing lung resection. 
Pharmacotherapy is helpful to prevent and control respiratory symptoms, reduce the 
frequency and severity of exacerbation, and improve exercise capacity and quality of life. 
The existing medications for COPD do not modify the long-term decline in lung function, 
but regular treatment with long-acting anticholinergic bronchodilator (Tiotropium 
bromide), long-acting beta-2 agonists, inhaled glucocorticoid, and its combination can 
decrease the rate of decline of lung function (Celli, et al. 2008; Tashkin, et al. 2008). 
Bronchodilators acting on peripheral airways reduce air trapping, thereby reducing residual 
lung volume and improving respiratory symptoms and exercise capacity. Patient education 
is essential in COPD like any other chronic diseases. The component of education should 
include smoking cessation, disease information about pathophysiology and natural course, 
general approach to the therapy, and self management skill. The poor adherence of the 
patients with COPD to the inhaler medication has been pointed out (Bender, et al. 2006). 
However, it is essential to remind the patients of regular using inhaler medication, because 
adherence to inhaled medication has been shown to be significantly associated with reduced 
risk of death and admission to hospital due to exacerbation in COPD (Vestbo, et al. 2009). 
COPD doubles the risk of postoperative pulmonary complications (Kroenke, et al. 1993). 
Strategies for reducing pulmonary complications are needed. Preoperatively, inhaled 
bronchodilators such as long-acting anticholinergics or beta-2 agonists are indicated for the 
patients with COPD. Adequate drug therapies can maximize the potential to tolerate lung 
 
Topics in Cancer Survivorship 
 
258 
the thorax as a result of decreased elastic recoil of the lung and early closure of the small 
airways during exhalation. This is manifested as hyperinflation of the chest, flattening of the 
diaphragm, increased intra-thoracic pressure, and reduced inspiratory capacity. These 
worsen during exercise and result in dyspnea and limitation of exercise capacity. After 
surgical volume reduction, there is expansion of the remaining lung in addition to reduction 
of the overall thoracic volume and pressure, and it is probable that some areas of relative 
compression have been reexpanded. Lung volume reduction surgery is associated with 
improvement in exercise capacity, lung function, quality of life, and dyspnea, but the 
changes after surgery are variable according to the individuals (Gelb, et al. 2001). The 
improvement of FEV1 and reduction in hyperinflation has been explained by the increase of 
lung parenchymal elastic recoil (Sciurba, et al. 1996). It is accompanied with subsequent 
repositioning of the diaphragm, recruitment of inspiratory muscles, and improvement of 
respiratory mechanics (Benditt, et al. 1997; Criner, et al. 1998). 
Surgical treatment of emphysema had been tried with multiple wedge resections and 
plications technique which is no longer used (Brantigan & Mueller 1957), and then Cooper et 
al. reintroduced lung volume reduction surgery as a possible surgical therapy for selected 
patients with a heterogeneous form of emphysema (Cooper, et al. 1995). The most affected 
portions are excised about 20% to 35% of the volume of each lung for lung volume 
reduction. The surgical mortality rate ranges  4-15% and one-year mortality rates are as high 
as 17% (Argenziano, et al. 1996; Flaherty, et al. 2001; Gelb, et al. 2001). A large randomized 
controlled trial was conducted to compare lung volume reduction surgery with medical 
therapy for severe emphysema (Fishman, et al. 2003). The FEV1 of surgery arm was 
significantly better than that of medical treatment group after 6, 12, and 24 months follow-
up. The rates of improvement versus deterioration of FEV1 compared with the baseline 
were 65% : 35% at 6 months follow-up, 56% : 44% at 12 months, and 43% : 57% at 24 months 
in the lung volume reduction surgery group. It is also observed in the bullectomy case series 
that FEV1 is initially improved after lung volume reduction surgery and then returns to the 
baseline lung function with time. The 90-day mortality was 7.9% (95% confidence interval, 
5.9-10.3%) in surgery group, and 1.3% (95% confidence interval, 0.6-2.6%) in medical 
treatment group. The functional benefits of lung volume reduction surgery came at the price 
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predominantly upper lobe emphysema and a low baseline exercise capacity. Patients with 
non–upper lobe emphysema and high baseline exercise capacity are poor candidates for 
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inflammatory response of the lung to noxious particles or gases. COPD refers to patients 
 
Prediction of Postoperative Lung Function 
 
259 
with emphysema or chronic bronchitis, though these two disease entities are frequently 
mixed up to a varying ratio. It is accompanied with some significant extrapulmonary effects 
and comorbidities (Agusti 2005). COPD has been defined in several ways, and the 
differences in definitions and diagnosis affect the estimates of the burden of the disease. The 
Global Initiative for Chronic Obstructive Lung Disease (GOLD) defines the disease in stages 
of clinical severity based on FEV1 and FEV1/FVC (forced vital capacity) from post-
bronchodilator spirometry (Rabe, et al. 2007). The statement recommends to use the fixed 
ratio post-bronchodilator FEV1/FVC < 0.7 for definition of airflow limitation despite a 
problematic issue of overdiagnosis. 
COPD are at risk for lung cancer due to common risk factors like aging, smoking, reactive 
oxygen species (Azad, et al. 2008; Soriano, et al. 2005; Young, et al. 2009). Tobacco smoking 
is considered to be the leading cause both of lung cancer and COPD. Smokers have a higher 
prevalence of respiratory symptoms and lung function abnormalities, a greater annual 
decline rate in FEV1 and a greater COPD mortality rate than nonsmokers. Smoking accounts 
for more than 85-90% of all lung cancer related deaths (Doll & Peto 1976). Cancer cells 
proliferate in reactive oxygen species rich inflammatory environment which is promoting 
DNA damage, inactivation of apoptosis, upregulation of growth factors, cytokines, and 
activating growth supporting genes (Cook, et al. 2004). Reactive oxygen species and chronic 
inflammation are also important pathologic mechanisms of COPD. A meta-analysis 
demonstrated that overall relative risk of lung cancer for subjects with COPD was 2.22 (95% 
confidence interval, 1.66-2.97%). Besides COPD, previous history of pneumonia or 
tuberculosis also increased the lung cancer risk even in never-smoker population (Brenner, 
et al. 2011).  Chronic inflammation has been proposed as a cause of cancer development. 
An effective COPD management includes severity assessment, regular monitoring, risk 
factor elimination, pharmacotherapy, and rehabilitation. This multidimensional approach 
includes patient education, health advice, counseling about smoking cessation, instruction 
in exercise and nutrition. Almost all the same therapeutic approach and monitoring should 
be also applied to the patients with the patients undergoing lung resection. 
Pharmacotherapy is helpful to prevent and control respiratory symptoms, reduce the 
frequency and severity of exacerbation, and improve exercise capacity and quality of life. 
The existing medications for COPD do not modify the long-term decline in lung function, 
but regular treatment with long-acting anticholinergic bronchodilator (Tiotropium 
bromide), long-acting beta-2 agonists, inhaled glucocorticoid, and its combination can 
decrease the rate of decline of lung function (Celli, et al. 2008; Tashkin, et al. 2008). 
Bronchodilators acting on peripheral airways reduce air trapping, thereby reducing residual 
lung volume and improving respiratory symptoms and exercise capacity. Patient education 
is essential in COPD like any other chronic diseases. The component of education should 
include smoking cessation, disease information about pathophysiology and natural course, 
general approach to the therapy, and self management skill. The poor adherence of the 
patients with COPD to the inhaler medication has been pointed out (Bender, et al. 2006). 
However, it is essential to remind the patients of regular using inhaler medication, because 
adherence to inhaled medication has been shown to be significantly associated with reduced 
risk of death and admission to hospital due to exacerbation in COPD (Vestbo, et al. 2009). 
COPD doubles the risk of postoperative pulmonary complications (Kroenke, et al. 1993). 
Strategies for reducing pulmonary complications are needed. Preoperatively, inhaled 
bronchodilators such as long-acting anticholinergics or beta-2 agonists are indicated for the 
patients with COPD. Adequate drug therapies can maximize the potential to tolerate lung 
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resection, help us to offer potentially curative treatment to the patients as many as possible. 
Postoperatively, lung expansion maneuvers and pain control are the two most important 
methods for reducing the risk of pulmonary complications. Both the incentive spirometry 
and deep breathing exercise are proved to be effective for lung expansion and reducing 
pulmonary complications (Thomas & McIntosh 1994). A meta-analysis of randomized 
controlled trials of postoperative pain control and pulmonary complications demonstrated 
that epidural local anesthetics significantly reduce the risk of pneumonia and all 
postoperative pulmonary complications (Ballantyne, et al. 1998). Pulmonary function 
recovers up to 6 months after a lobectomy, and up to 3 months after a pneumonectomy 
(Bolliger, et al. 1996; Nezu, et al. 1998). There has been little research on long term 
postoperative optimized outcome in terms of lung function and quality of life. There is no 
direct evidence supporting an additional role of bronchodilators in the lung resection 
candidate beyond what would be standard use for COPD or asthma. A study showed that 
post-operative respiratory rehabilitation after lung resection for lung cancer was beneficial 
for the Borg dyspnea scale, exercise capacity represented by 6-minute walk distance, and 
maintenance of lung function (Cesario, et al. 2007). The inpatient rehabilitation program 
included supervised incremental exercise and educational sessions covering such topics as 
pulmonary physiopathology, pharmacology of patients’ medications, dietary counseling, 
relaxation and stress management techniques, energy conservation principles, and 
breathing retraining. The individuals joining the rehabilitation program had the 
significantly improved exercise capacity and maintained FEV1, whereas the control group 
had the significantly decreased exercise capacity and decreased FEV1 compared with 
baseline values. Although the rehabilitation is not confined to pharmacotherapy, it should 
be kept in mind that multidimensional efforts to maintain exercise capacity and lung 
function should be required because they could be labile after lung resection. 
7. Conclusion 
Medical operability of lung cancer has been frequently determined based on preoperative 
FEV1, DLCO, and VO2max. Predicted postoperative FEV1 is still the most helpful indicator 
for the safe operation as it provides fundamental information about underlying lung 
function and disease status. As the concept of regional lung function is introduced to 
anatomic calculation, the prediction accuracy of postoperative lung function is improved. 
However, substantial gap is still present between ppoFEV1 and apoFEV1, which tends to be 
greater in COPD and large lung volume resection. This inaccuracy may be critical in the 
patients with marginal lung function after lung resection. We should consider that the the 
accuracy can be affected not only by the technique to measure the regional lung function, 
but also several clinical factors such as the presence of obstructive lung disease, resected 
lung portion, extent of lung volume resection, preoperative bronchodilator response, 
adherence to bronchodilator therapy, physical exercise, nutrition, postoperative pain 
control, patient education and so on. 
The moderate to severe COPD should not hinder the curative resection of lung cancer which 
could increase the chance of cure, if the candidates of surgery would be properly selected, 
because the surgery could partly work as lung volume reduction, thereby minimizing the 
loss of pulmonary function in patients with COPD. Proper perioperative management 
regarding the aforementioned clinical factors is mandatory to improve lung function and 
reduce postoperative complication despite remarkable advances in anesthesia, surgery. 
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1. Introduction 
Although around 80% of men aged 80 years and older and 15% to 30% of men aged 50 years 
and older have microscopic undiagnosed prostate cancer found at autopsy, only 3% men die 
because of prostate cancer.1 Increasing prostate-specific antigen (PSA) screening at younger 
ages has increased overdiagnosis2 and overtreatment3 of localized prostate cancer (LPC). More 
than 90% of US patients currently diagnosed with prostate cancer have LPC and 
approximately 94% of patients with LPC choose treatment.4 Based on data from leading 
studies, a model had recently projected only a 0% to 2% 15-year mortality from low-grade 
(Gleason score <7) screen-detected LPC in men aged 55 to 74 years if they chose observation 
instead oftreatment.5 By consensus, urologists and radiation oncologists recommend treatment 
for LPC if a patient has a further 10-year life expectancy 6 (the10-year rule7) regardless of 
cancer grade, even though no randomized trials have shown that treatment can improve 
survival in patients in whom the cancer was screen-detected. National guidelines by the 
American Cancer Society and the National Comprehensive Cancer Network (NCCN) also 
recommend treatment for most patients.8 However, in the review by Zeliadt et al,9 different 
studies had found that patients rate the sexual, urinary, and bowel side effects of treatment to 
be just as important as the potential benefit in survival; that if risks and benefits of treatment 
were explained with-out bias, 75% of patients chose a lower radiation dose despite a lower 
predicted survival; that 90% of physicians but fewer than 20% of patients ranked the effect of 
treatment on survival as one of their top 4 concerns; and that patients who chose treatment 
believed that treatment was guaranteed to improve survival. At a median of 6 years after 
treatment, health-related quality of life (HRQOL) of treated patients was worse than that of 
controlpatients.10 Many patients regretted that they chosetreatment.11 
To our knowledge, no studies of patient-physician communication have examined patients’ 
anticipated survival benefit of treatment. Without data from randomized trials in screen-
detected patients, it is difficult to counsel patients regarding their survival with and without 
treatment. Even with the use of multi-factorial models, accuracy of predicted survival is 75% 
or lower.12 Physicians are also poor at estimating baseline co-morbidity adjusted life 
expectancy (CALE), which is critical in making an informed decision.13 Thus, patients may 
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approximately 94% of patients with LPC choose treatment.4 Based on data from leading 
studies, a model had recently projected only a 0% to 2% 15-year mortality from low-grade 
(Gleason score <7) screen-detected LPC in men aged 55 to 74 years if they chose observation 
instead oftreatment.5 By consensus, urologists and radiation oncologists recommend treatment 
for LPC if a patient has a further 10-year life expectancy 6 (the10-year rule7) regardless of 
cancer grade, even though no randomized trials have shown that treatment can improve 
survival in patients in whom the cancer was screen-detected. National guidelines by the 
American Cancer Society and the National Comprehensive Cancer Network (NCCN) also 
recommend treatment for most patients.8 However, in the review by Zeliadt et al,9 different 
studies had found that patients rate the sexual, urinary, and bowel side effects of treatment to 
be just as important as the potential benefit in survival; that if risks and benefits of treatment 
were explained with-out bias, 75% of patients chose a lower radiation dose despite a lower 
predicted survival; that 90% of physicians but fewer than 20% of patients ranked the effect of 
treatment on survival as one of their top 4 concerns; and that patients who chose treatment 
believed that treatment was guaranteed to improve survival. At a median of 6 years after 
treatment, health-related quality of life (HRQOL) of treated patients was worse than that of 
controlpatients.10 Many patients regretted that they chosetreatment.11 
To our knowledge, no studies of patient-physician communication have examined patients’ 
anticipated survival benefit of treatment. Without data from randomized trials in screen-
detected patients, it is difficult to counsel patients regarding their survival with and without 
treatment. Even with the use of multi-factorial models, accuracy of predicted survival is 75% 
or lower.12 Physicians are also poor at estimating baseline co-morbidity adjusted life 
expectancy (CALE), which is critical in making an informed decision.13 Thus, patients may 
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accept a treatment recommendation not knowing what their baseline CALE is, how much 
the newly diagnosed cancer could reduce it, or how effectively treatment could minimize 
that reduction. Current over-treatment of LPC might be because patients do not understand 
the pros and cons of treatment.  
In this study we surveyed newly diagnosed patients about their anticipation of survival with 
and without treatment. By estimating their baseline CALE without considering the newly 
diagnosed cancer, we calculated their perceived decrease in longevity with observation 
(PDLO), and their perceived increase in longevity with treatment (PILT) for the cancer. 
2. Methods 
We surveyed patients who had been newly diagnosed with LPC (stages T1a to T2c) in the 
preceding 6 months, had met with their urologist after the diagnosis, were scheduled to 
receive treatment or observation, and had not yet been treated with surgery or radiation. 
Patients with dementia, or those who could not read, write, or understand English, were 
excluded. All patients were recruited from a large, private urology practice in Norfolk, 
Virginia. Staff at this practice systematically contacted patients newly diagnosed with LPC 
between March 2005 and November 2007 regarding their interest in participation in a self-
administered mailed survey. Two concomitant pretreatment self-administered surveys were 
used. The first survey asked patients about expectations of survival with and without 
treatment, co-morbid diseases, mood, social support, satisfaction with life, health, and 
education by physicians about treatment options. A list of health-related words in a closed 
envelope was mailed with the survey. Patients were requested to open the envelope and 
read these words on the telephone to a research assistant. This was done to estimate patient 
health literacy by using a brief version of the Rapid Estimation of Health Literacy in 
Medicine scale.14 Patients were given a $10 stipend for completing this survey. A second 
pretreatment survey was a part of a longitudinal follow-up by urologists to evaluate generic 
HRQOL, prostate cancer related symptoms, and fear of cancer recurrence. The study 
methods were reviewed and approved by an Institutional Review Board. 
3. Measures 
The Charlson Comorbidity Index (CCI) is a validated measure of co-morbidity. We used a 
patient self-reported CCI scale that asked about the presence and severity of 12 chronic 
conditions; the Prostate Cancer Outcomes Study used this CCI version.15 Score categories 
are 0, 1, 2, and 3 or more diseases.  
The NCCN practice guidelines had recommended, for the first time in 2007,8 that the health 
adjusted life expectancy of LPC patients can be estimated by weighting age-based life 
expectancy by 1.5 for patients in the highest health quartile, using no weighting for patients 
in the middle 2 health quartiles, and weighting by 0.5 for patients in the lowest health 
quartile. We used co-morbidity scores as surrogate markers of health status because co-
morbidity is the main determinant of life expectancy in older patients, 16 and the most 
important prognostic factor for patients with LPC who are <75 years old is the co-morbidity 
score. 17 We categorized patients into health quartiles by using their CCI score (0 disease 
score = highest health quartile; 1 or 2 disease score = middle 2 health quartiles; 3 or higher 
disease score = lowest health quartile). Our basis of equating a 1 or 2 disease score with the 
middle 2 health quartiles was that almost half (49%) of the 3173 patients newly diagnosed 
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with LPC in a Prostate Cancer Outcomes Study15 had a disease score of 1 or 2, and almost 
half (55.5%) of our patients had a disease score of 1 or 2. Both studies used the same version 
and scoring of the CCI. Patients were placed in 4 CALE categories: <5 years, 5 to 10 years, 10 
to 20 years, and 20 years. These 4 categories were scored, respectively, from 1 to 4.  
Patients were asked the following 2 questions: “How long do you expect you will live without 
any treatment for prostate cancer?” (Q1) and “How long do you expect you will live after 
treatment for prostate cancer?” (Q2). The possible responses to both questions were grouped 
into 4 categories (similar to the CALE categories): <5 years, 5 to 10 years, 10 to 20 years, and 
>20 years. These 4 categories were also scored from 1 to 4, respectively. Based on Q1, Q2, and 
CALE scores, we calculated the patient’s PDLO (which is CALE category score minus Q1 
category score) and the patient’s PILT (which is Q2 category score minus Q1 category score). A 
PDLO of 10 or more years is at least a 2-category difference between the CALE category and 
the Q1 category; this is only possible if the CALE was >20 years and the Q1 response was 5 to 
10 years or if the CALE was 10 to 20 years and the Q1 response was <5 years. Similarly, a PILT 
of 10 or more years indicates that the response to Q2 was 10 years or more than the response to 
Q1. We conducted ordinal logistic regression analyses to identify the main socio-demographic, 
health, and cancer characteristics that could predict PDLO and PILT of 10 or more years.  
The following validated self-administered scales were used. (1) The Short-Form 36 (SF-36, 
version 2) measures generic HRQOL; we calculated physical component summary and 
mental component summary scores from SF-36 data.18 (2) The Prostate Cancer Index 
measures urinary, sexual, and bowel symptoms and how much they bother the patient.19 (3) 
The Duke Activity Status Index20 measures functional capacity in metabolic equivalents; this 
scale asks patients whether they could perform 12 activities which have different levels of 
exertion. (4) The Hospital Anxiety and Depression Scale measures the presence and severity 
of anxiety and depression.21 (5) The Fear of Cancer Recurrence Scale measures the fear of 
possible cancer recurrence.22 (6) The Medical Outcomes Study Social Support Survey 
measures social support in an overall score that includes multidimensional sub-scores. 23 (7) 
The Delighted-Terrible Seven Faces Scale24 was used to measure patient satisfaction with 
life, health, and with education given by physicians about treatment options for LPC. (8) 
The Rapid Estimation of Health Literacy in Medicine scale, discussed earlier, measures 
health literacy; this was the only scale administered by telephone.14 
4. Statistical analyses 
Frequencies and relative frequencies were used to describe categorical variables. 
Continuous variables were described using the mean, median, and SD. Chi-square tests, 
Fisher’s exact test, and independent sample t tests were used to examine bivariate 
associations. Unadjusted and adjusted odds ratios (ORs) and their 95% CIs were estimated 
using ordinal logistic regression analysis. Socio-demographic and health factors that were 
found to be associated with PDLO and PILT in the bivariate analysis at an alpha level of 0.20 
were kept in the multivariate models. All analyses were performed using SAS software 
(version 9.1, SAS Institute, Inc., Cary, NC). 
5. Results 
Surveys were mailed to 430 patients newly diagnosed with LPC, but 69 patients had already 
started treatment by the time the patients received the surveys, 3 patients never received the 
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surveys, and 2 patients were found to be ineligible to participate because their cancer was not 
localized to the prostate. Of the 356 remaining patients, 104 patients did not return the survey 
because they were “not interested” in participating and 68 patients who did not return the 
surveys did not give a reason for not participating or could not be contacted. One hundred 
eighty-four of 356 patients (survey response rate of 52%) completed and returned the first 
pretreatment survey; 23 of these 184 patients (12.5%) patients chose observation. Table 1 shows 
a demographic comparison of patients who chose treatment or observation. Mean patient age 
was 61.5 years, and most patients reported college education and a family income of >$50,000.  
 
Overall  Treatment Observation 
Characteristic  (n [%]) (n [%]) (n [%]) P‡  
Age (years)  n = 184 n = 161 n = 23  
<60  71 (38.6) 68 (42.2) 3 (13.0)  
60–70  91 (49.5) 81 (50.3) 10 (43.5)  
>70  22 (11.9) 12 (7.5) 10 (43.5) <.0001  
Mean +/- SD  61.5 +/- 7.9 60.6 +/- 7.6 68.2 +/- 5.9 <.0001  
Race  n = 184 n = 161 n = 23  
African American  26 (14.1) 26 (16.2) 0 (0.0)  
White  158 (85.9) 135 (83.9) 23 (100) .05§  
Education  n = 180 n = 157 n = 23  
<High school  7 (3.9) 7 (4.5) 0 (0.0)  
High school  65 (36.1) 56 (35.7) 9 (39.1)  
College  108 (60.0) 94 (59.9) 14 (60.9) .58  
Health literacy  n = 173 n = 150 n = 23  
Below 6th grade  1 (0.6) 1 (0.7) 0 (0.0)  
6th-9th grade  16 (9.3) 15 (10.0) 1 (4.4)  
>9th grade  156 (90.2) 134 (89.3) 22 (95.7) .63  
Family income  n = 179 n = 156 n = 23  
Low (>$50,000)  57 (31.8) 50 (32.0) 7 (30.4)  
High (=>$50,000)  122 (68.2) 106 (67.9) 16 (69.6) .88  
*Treatment patients had either surgery or radiotherapy. 
†Observation patients had neither surgery nor radiotherapy. 
‡Unless otherwise specified, statistical significance is for chi-square test (categorical variables) or 
independent samples t test (continuous variables). 
§Fischer’s exact test. 
Table 1. Comparison of Socio-demographic Characteristics of Patients with Localized 
Prostate Cancer who Chose Treatment* and Observation†  
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Table 2 shows a comparison of patients who chose treatment or observation by cancer grade, 
PSA, life expectancy by age, and co-morbidity scores. Mean Gleason grade was 6.6. Table 2 
also includes a comparison of these patient groups by SF-36 scores (Physical Component and 
Mental Component Scores), as well as the urinary, sexual, and bowel function scores of the 144 
of 184 patients who had also returned the second pretreatment survey. Table 3 shows a 
comparison of patients who chose treatment or observation by CALE, anxiety and depression, 
function capacity, social support, and satisfaction. Mean CALE was 22.9 years. Table 4 shows 
the baseline CALE for the 184 patients and the responses of 170 of the 184 patients who had 
answered questions about their perceived life expectancy without treatment (Q1) and with 
treatment (Q2) of the cancer. Without treatment, perceived life expectancy was <5 years in 
15.2%, 5 to 10 years in 48.8%, 11 to 19 years in 33.5% and 20 or more years in 2.4% of the 
patients. With treatment, it was <5 years in 0.6%, 5 to 10 years in 6.5%, 11 to 19 years in 30.0%, 
and 20 or more years in 62.9% of the patients. By contrast, baseline CALE was <5 years in 0.5%, 
5 to 10 years in 2.2%, 11 to 19 years in 36.4%, and 20 or more years in 60.9%. A total of 170 
patients had data on CALE, Q1, and Q2. As compared with CALE, 65 (38.2%) of these 170 
patients expected their survival to decrease by 10 or more years without treatment. As 
compared with their perceived survival without treatment, 81 (47.6%) of 170 patients expected 
their survival to increase by 10 or more years with treatment. Of the 108 patients with a 
baseline CALE of >20 years, only 2 (1.9%) expected to live beyond 20 years without treatment 
whereas 84 (77.8%) expected to live beyond 20 years with treatment (data not shown). Neither 
of these perceptions was significantly related to whether the patients chose treatment or 
observation. However, to a statistically insignificant extent, patients who chose treatment were 
more likely than observation patients to expect a 10 or more years reduction in survival 
without treatment (50% vs. 33.3%, _2 test; P = .26) and a 10 or more year increase in survival 
with treatment (39.9% vs. 16.7%, Fisher’s exact test; P =.13). 
 
Overall  Treatment  Observation  
Factors  (n [%])  (n [%])  (n [%])  P*  
Gleason Grade  n = 184  n = 161  N = 23   
2–4  0 (0.0)  0 (0.0)  0 (0.0)   
5–6  103 (55.9)  84 (52.1)  19 (82.6)   
7  62 (33.7)  60 (37.3)  2 (8.7)   
8–10  19 (10.3)  17 (10.6)  2 (8.7)  0.02  
Mean +/- SD  6.6 +/- 0.7  6.6 +/- 0.7  6.2 +/- 0.7  0.02  
Prostate-specic antigen  n = 183  n = 161  n = 23   
=<10  159 (86.9)  139 (86.3)  21 (91.3)   
>10  24 (13.1)  22 (13.7)  2 (8.7)  0.74  
Mean +/- SD  6.7 +/- 5.3  6.8 +/- 5.5  5.6 +/- 3.4  0.14  
Life expectancy by age 
(years)  
n = 183  n = 160  N = 23   
<10  4 (2.2)  2 (1.3)  2 (8.7)   
10–20  104 (56.8)  86 (53.8)  18 (78.3)   
>=20  75 (40.9)  72 (45.0)  3 (13.0)  0.002*  
Comorbidity score  n = 184  n = 161  N = 23   
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0  74 (40.2)  66 (40.9)  8 (34.8)   
1  75 (40.8)  67 (41.6)  8 (34.8)   
2  27 (14.7)  23 (14.3)  4 (17.4)   
>=3  8 (4.4)  5 (3.1)  3 (13.0)  0.16  
Mean +/- SD  0.9 +/- 1.0  0.83 +/- 0.96  1.26 +/- 1.5  0.18  
Short Form-36 subscales      
Physical component 
summary  
n = 142  n = 134  n = 8   
Mean +/- SD  54.5 +/- 7.6  54.5 +/- 7.2  52.6 +/- 12.3  0.66  
Mental component 
summary  
n = 142  n = 134  n = 8   
Mean+/- SD  44.1 +/-6.8  43.9 +/- 6.9  46.4 +/- 4.5  0.29  
Prostate cancer index      
Urinary  n = 141  n = 132  n = 9   
Mean +/- SD  90.2 +/- 16.9  90.1 +/- 17.4  91.3 +/- 9.3  0.83  
Bowel  n = 142  n = 133  n = 9   
Mean +/- SD  88.8 +/- 12.5  88.5 +/- 12.8  92.9 +/- 4.5  0.03  
Sexual  n = 137  n = 128  n = 9   
Mean +/- SD  57.7 +/- 29.9  57.8 +/-30.4  55.4 +/- 23.8  0.82  
Urinary Bother  n = 144  n = 135  n = 9   
Mean +/- SD  86.1 +/- 23.0  85.9 +/- 23.4  88.9 +/- 18.2  0.71  
Bowel Bother  n = 144  n = 135  n = 9   
Mean +/- SD  92.5 +/- 17.5  92.0 +/- 17.9  100 +/- 0.0  0.0001  
Sexual Bother  n = 142  n = 133  n = 9   
Mean +/- SD  65.8 +/- 36.8  65.4 +/- 36.8  72.2 +/- 38.4  0.59  
Fear of cancer recurrence  n = 141  n = 133  n = 8   
Mean +/- SD  10.7 +/- 3.8  10.7 +/- 3.7  10.9 +/- 4.5  0.92  
Table 2. Comparison of Patients who Chose Treatment and Observation by Prostate Cancer-
Related and Health Factors  
 
Overall  Treatment  Observation  
Characteristic  (n [%] (n [%]* **  (n [%]† ***  P‡ *  
Comorbidity-adjusted life 
expectancy 
    
All ages 184 (100)  161 (100)  23 (100)   
<5 years 1 (0.5)  0 (0)  1 (4.3)   
5–10 years 4 (2.2)  2 (1.2)  2 (8.7)   
11–19 years 67 (36.4)  52 (32.3)  15 (65.2)   
>=20 years 112 (60.9)  107 (66.5)  5 (21.7)  <.0001  
Mean +/- SD 22.9 +/- 7.6  23.9 +/- 7.3  < .0001  
Anxiety score  n = 183  n = 160  n = 23   
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None/normal (0–7) 145 (79.2)  123 (76.9)  22 (95.7)   
Mild anxiety (8–10) 23 (12.6)  23 (14.4)  0 (0.0)   
Moderate anxiety (11–14) 12 (6.6)  11 (6.9)  1 (4.4)   
Clinical (15–21) 3 (1.6)  3 (1.9)  0 (0.0)  .18  
Mean +/- SD 5.1 +/- 3.5  5.4 +/- 3.5  2.8 +/- 2.9  .0008  
Depression score  n = 178  n = 156  n = 22   
None/normal (0–7) 172 (96.6)  150 (96.2)  22 (100)   
Mild depression (8–10) 4 (2.3)  4 (2.6)  0 (0.0)   
Moderate (11–14) 1 (0.6)  1 (0.6)  0 (0.0)   
Clinical (15–21) 1 (0.6)  1 (0.6)  0 (0.0)  .83  
Mean +/- SD 1.7 +/- 2.3  1.7 +/- 2.4  1.4 +/- 1.7  .49  
Functional capacity  n = 184  n = 160  n = 23   
Mild activities (<3 METs) 1 (0.5)  1 (0.6)  0 (0.0)   
Moderate activities (3–6 METs) 20 (10.9)  15 (9.3)  5 (21.7)   
Vigorous activities (>=6 METs) 163 (88.6)  145 (90.1)  18 (78.3)  .19  
Social support  n = 183  n = 160  n = 23   
<50 7 (3.8)  6 (3.8)  1 (4.4)   
50–75 33 (18.0)  29 (18.1)  4 (17.4)   
75–100 143 (78.1)  125 (78.1)  18 (78.3)  .98  
Satisfaction with Life  n = 178  n = 156  n = 22   
Delighted or highly satised 138 (77.5)  121 (77.6)  17 (77.3)   
Satised or lower 40 (22.5)  35 (22.4)  5 (22.7)  .97  
Mean +/- SD 6.0 +/- 0.9  5.9 +/- 0.9  6.1 +/- 1.0  .64  
Satisfaction with health  n = 178  n = 156  n = 22   
Delighted or highly satised 85 (47.8)  72 (46.1)  13 (59.1)   
Satised or lower 93 (52.3)  84 (53.9)  9 (40.9)  .26  
Mean +/- SD 5.0 +/- 1.3  5.0 +/- 1.3  5.4 +/- 1.4  .19  
Satisfaction with education by 
physician in treatment choices 
n = 178  n = 156  n = 22   
Delighted or highly satised 141 (79.2)  126 (80.8)  15 (68.2)   
Satised or lower 37 (20.8)  30 (19.2)  7 (31.8)  .17  
Mean +/- SD 6.1 +/- 0.9  6.1 +/- 0.9  5.9 +/- 1.1  .1  
*Treatment patients had either surgery or radiotherapy. 
†Observation patients had neither surgery nor radiotherapy. 
‡Unless otherwise specified, statistical significance is for chi-square test (categorical variables) or 
independent samples t test (continuous variables). 
MET, metabolic equivalent. 
Table 3. Distribution of Men by Prostate Cancer-Related and Health Characteristics  
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Baseline CALE Score Q1 Q2 
(n = 184) (n = 170) (n = 170) 
<5 1 (0.5) 26 (15.2) 1 (0.6) 
5–10 4 (2.2) 83 (48.8) 11 (6.5) 
11–19 67 (36.4) 57 (33.5) 51 (30.0) 
>=20 112 (60.9) 4 (2.4) 107 (62.9) 
Data provided as n (%). 
CALE, co-morbidity adjusted life expectancy; Q1, How long do you expect you will live without any 
treatment for prostate cancer?; Q2, How long do you expect you will live after the treatment of your 
choice for prostate cancer? 
Table 4. Distribution of Men with Localized Prostate Cancer by Calculated Co-morbidity 
Adjusted Life Expectancy  
Tables 5 and 6 present ordinal logistic regression models for PDLO and PILT. Age, CALE, 
depression, and anxiety scores predicted both PDLO and PILT. Furthermore, PSA level 
predicted PDLO, whereas social support predicted PILT. 
 
 Unadjusted Effects 
Adjusted Effects (OR 




OR (95% CI) 
Age 25 62 83 1.08 (1.04–1.13) 1.01 (0.92–1.10) 
PSA level 25 62 82 0.94 (0.88–1.00) 0.93 (0.86–1.00) 
CALE 25 62 83 0.92 (0.88–0.96) 0.93 (0.84–1.02) 
Anxiety score 25 62 83 0.88 (0.81–0.96) 0.96 (0.85–1.08) 
Depression score 25 58 82 0.79 (0.67–0.93) 0.85 (0.69–1.04) 
*A (PDLO) =<0 (reference group) indicates that CALE and self-reported survival expectation without 
treatment are within the same range or CALE is less.  
†A (PDLO) = 1 suggests that CALE exceeds self-reported survival expectation without treatment by one 
response category. 
‡A (PDLO) >=2 suggests that CALE exceeds self-reported survival expectation without treatment by at 
least 2 response categories (ie., 
about 10 years). All covariates in the ordinal logistic regression model are dened as continuous 
variables. 
PDLO, perceived decrease in longevity with observation (categorized); PSA, prostate-specic antigen; 
CALE, comorbidity adjusted life expectancy; OR, odds ratio. 
Table 5. Ordinal Logistic Regression Modeling for Perceived Decrease in Longevity with 
Observation (PDLO) among Men with Localized Prostate Cancer  
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 Unadjusted Effects 
Adjusted Effects (OR 
95% CI)  PILT =<0* PILT = 1† 
PILT 
=>2‡ 
OR (95% CI) 
Age 18 87 65 1.08 (1.04–1.13) 1.09 (0.99–1.19) 
CALE 18 87 65 0.93 (0.89–0.97) 1.02 (0.93–1.12) 
Anxiety Score 18 87 65 0.89 (0.82–0.98) 0.91 (0.81–1.02) 
Depression score 18 83 64 0.93 (0.82–1.05) 1.06 (0.89–1.26) 
Social Support 18 87 65 1.01 (0.99–1.03) 1.00 (0.98–1.02) 
*PILT <=0 (reference group) indicates that CALE and self-reported survival expectation with treatment 
are within the same range or CALE is less.  
†A (PILT) = 1 suggests that CALE exceeds self-reported survival expectation with treatment by one 
response category. 
‡A (PILT) >=2 suggests that CALE exceeds self-reported survival expectation with treatment by at least 
2 response categories (ie., 
about 10 years). All covariates in the ordinal logistic regression model are dened as continuous 
variables. 
PILT, perceived increase in longevity with treatment (categorized); CALE, comorbidity adjusted life 
expectancy; OR, odds ratio.  
Table 6. Ordinal Logistic Regression Modeling for Perceived Increase in Longevity with 
Treatment (PILT) among Men with Localized Prostate Cancer  
6. Discussion 
Prostate cancer is the most common solid cancer in men. Younger patients make up a fast 
growing population that is being screen-detected and treated for low-risk LPC.25 To our 
knowledge, this is the first study to report the perceptions of newly diagnosed patients 
about how the cancer or its treatment could affect their survival. The mean age of our 
patients (61.5 years) was similar to the range of 58 to 64 years of US patients currently 
undergoing radical prostatectomy.26 The mean Gleason grade was 6.6 in our patients, 
similar to other series in which almost half of screen-detected cancers were   
“insignificant.”27 By choosing treatment, these low-risk patients had accepted the treatment 
side effects in exchange for longer anticipated survival. Our questions were designed to find 
how much longer these patients expected to live by choosing treatment. These expectations 
were evaluated after the patients had discussed their treatment options with their urologists. 
Despite their mean baseline CALE of 22.9 years, without treatment, 26 of 170 patients 
expected to live <5 years and only 4 expected to live >20 years; with treatment, only 1 
expected to live <5 years and 107 patients expected to live >20 years.   
What should these patients really be expecting? Nearly 86% of all patients diagnosed 
through PSA screening are not expected to die because of prostate cancer.28 The Connecticut 
Tumor Registry found that almost 20% of patients with Gleason grade 6 or higher who 
chose observation died as a result of LPC during a period of 20 years.29 However, all the 
Registry’s patients had been clinically diagnosed; in contrast, patients diagnosed with 
screen-detected LPC are expected to have a longer survival because of a gain in lead time. 
Patients in another commonly cited natural history study30 were also not diagnosed by PSA 
screening. A review31 found that only one randomized, high-quality trial32 could find a 
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 Unadjusted Effects 
Adjusted Effects (OR 
95% CI)  PILT =<0* PILT = 1† 
PILT 
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Social Support 18 87 65 1.01 (0.99–1.03) 1.00 (0.98–1.02) 
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are within the same range or CALE is less.  
†A (PILT) = 1 suggests that CALE exceeds self-reported survival expectation with treatment by one 
response category. 
‡A (PILT) >=2 suggests that CALE exceeds self-reported survival expectation with treatment by at least 
2 response categories (ie., 
about 10 years). All covariates in the ordinal logistic regression model are dened as continuous 
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patients (61.5 years) was similar to the range of 58 to 64 years of US patients currently 
undergoing radical prostatectomy.26 The mean Gleason grade was 6.6 in our patients, 
similar to other series in which almost half of screen-detected cancers were   
“insignificant.”27 By choosing treatment, these low-risk patients had accepted the treatment 
side effects in exchange for longer anticipated survival. Our questions were designed to find 
how much longer these patients expected to live by choosing treatment. These expectations 
were evaluated after the patients had discussed their treatment options with their urologists. 
Despite their mean baseline CALE of 22.9 years, without treatment, 26 of 170 patients 
expected to live <5 years and only 4 expected to live >20 years; with treatment, only 1 
expected to live <5 years and 107 patients expected to live >20 years.   
What should these patients really be expecting? Nearly 86% of all patients diagnosed 
through PSA screening are not expected to die because of prostate cancer.28 The Connecticut 
Tumor Registry found that almost 20% of patients with Gleason grade 6 or higher who 
chose observation died as a result of LPC during a period of 20 years.29 However, all the 
Registry’s patients had been clinically diagnosed; in contrast, patients diagnosed with 
screen-detected LPC are expected to have a longer survival because of a gain in lead time. 
Patients in another commonly cited natural history study30 were also not diagnosed by PSA 
screening. A review31 found that only one randomized, high-quality trial32 could find a 
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survival benefit of treatment, but in this trial 95% of patients had cancer that was clinically 
palpable (and not detected by PSA screening), putting this cohort in an intermediate- to 
high-risk category. A study of 44,630 men found a survival benefit of treatment, 33 but only 
2.1% of the patient sample had died of prostate cancer. If adjusted for lead time provided by 
screening and also for the impairment of HRQOL that follows treatment, treatment was 
projected to enhance quality-adjusted survival by only 0.5 year. 34   
Overtreatment would be expected if patients believe that treatment will lead to a much 
longer survival. Many studies have found that nearly every patient initially wants 
eradication of the cancer. 9 In qualitative studies, some patients accepted side effects for any 
gain in survival but they were convinced that treatment would improve survival.9 
Assuming that tumors would grow exponentially, urologists at the Mayo Clinic were also of 
the opinion that only 0.3% and 14.5% of screen-detected LPCs were “clinically 
insignificant.”35 Patient anxiety caused by the new diagnosis of cancer and the consensus 
advice of specialists that LPC patients with a CALE of >10 years should choose treatment or 
be offered treatment6 will lead to high treatment rates. In 70% to 90% of patients, a 
treatment plan is usually made in a single visit to the urologist after a positive biopsy.36   
The mean Gleason grade of our patients was 6.6, and in 87% of patients the mean PSA was 
<10, both of which are low-risk categories but for which national guidelines recommend 
either observation or treatment.8 Only 12.5% of patients in our study chose observation. 
Specialists frequently recommend treatment even in low-risk patients because over 10 to 15 
years the cancer may progress.29 To manage this risk, a strategy of active surveillance with 
deferred initial treatment28 is being increasingly recommended for patients at lower risk, ie, 
with cancers of Gleason grade <7, cancer stages T1c to T2a, and PSA <10. Almost half of 
patients with screen-detected cancer possess such characteristics. 27 In conjunction with 
specialists, primary care physicians (PCPs) can follow patients who choose this strategy. 
PCPs may also offer more balanced advice because they might be more knowledgeable 
about the patient’s preferences, co-morbidities, and baseline CALE.37 Patients with LPC may 
also want to review educational materials with their PCP. The American Cancer Society 
website was recommended because its content, accuracy, balance, and readability was rated 
the highest among 44 patient education materials about LPC.38 
Overtreatment can also be reduced with decreased screening, and several studies have 
shown that fewer patients want PSA screening if they are counseled before screening.39 
Enthusiasm for routine screening is high among specialists who treat LPC. In a random 
nationwide survey, 43% of 559 radiation oncologists recommended routine PSA screening in 
average-risk patients older than 80.6 Primary care physicians who frequently order PSA 
testing without much discussion about risks and benefits of testing cited reasons of lack of 
time, competing demands, limited patient health literacy, and fear of liability.40 Prescreening 
counseling is difficult because it is unclear what and how much discussion should occur. As 
yet, we cannot say that screening or treatment can improve survival. The deleterious effects 
of treatment on urinary, bowel, and sexual dysfunction are better known; however, their 
frequencies and severities after different treatment techniques have been reported in more 
than 800 publications,41 vary greatly, and are difficult to balance. We can also share with 
patients that there is a small risk of immediate morbidity and mortality associated with 
prostate biopsy and cancer treatment; that a new anxiety results from a positive PSA test, 
whether or not it is followed by a negative biopsy; and that we cannot compare the risk of 
death caused by co-morbid diseases with that of death caused by cancer without knowing 
the grade and stage of the cancer. However, patients must also know that, even if diagnosed 
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with cancer, no randomized controlled trial has shown that treatment can or cannot improve 
survival in patients with screen-detected cancer. Interestingly, a study found that more 
African American patients wanted PSA screening after the use of a decision aid, 39 
presumably because of the appreciation of the higher risk in African American patients.  
In our patients, age, CALE, depression, and anxiety were the most important predictors of 
PDLO or PILT. Though PSA level also influenced PDLO, PILT was related to social support. 
PDLO and PILT were not related to other factors such as race; income; education; health 
literacy; physical and mental summary SF-36 scores; urinary, bowel, and sexual symptoms; 
choice of treatment or observation; fear of cancer recurrence; functional capacity; and 
satisfaction with life, health, or with education by physicians in cancer treatment options. 
Although the association of PDLO and PILT with continuous depression scores was 
statistically significant, the importance of this finding is unclear given that 96.6% patients 
had a depression score of <7, which indicates no depression. 
Our findings may be difficult to generalize because our study sample was small. However, 
the differences we found between CALE and patient expectations of survival with and 
without treatment were large. Also, the mean age26 and mean cancer grade27 of patients 
newly diagnosed with LPC in large series and in our patients were similar. Our patients 
were treated by urologists in a private practice and more than 80% of urologists in the 
United States are in private practice.42 Our method of equating CCI scores with NCCN 
recommended health quartiles to estimate CALE is new and has not been previously 
validated. We used this method because we could not find any other validated method to 
estimate long-term health-adjusted life expectancy in individual ambulatory patients. 
Finally, we lost accuracy in the estimation of PDLO and PILT by asking patients to predict 
their survival in ordinal intervals rather than in a discrete number of years. We used ordinal 
intervals because it might be easier for patients to predict their survival this way, and the 
intervals allowed an estimation of PDLO and PILT of more than or less than 10 years. We 
have also published these findings earlier. 43 
We had also studied whether our patients had adequate Knowledge, Understanding and 
Judgment (KUJ) of their treatment options by using a KUJ 18-item questionnaire that we 
have developed; we found that although the vast majority of our patients were educated, 
had good health literacy and had higher income, over half of the patients incorrectly 
answered over half of the questions on the KUJ scale. These findings have been published 
separately.44 Additionally, we had studied whether our patients had chosen treatment or 
observation in accordance with current NCCN guidelines and we had found that a majority 
had chosen over-treatment, i.e., they had chosen treatment even though for their clinical 
situation the NCCN had recommended observation as an equal alternative. These findings 
were published recently, 45 and had demonstrated that with the use of our method to 
estimate CALE it becomes feasible to use NCCN guidelines in decision-making in 
individual patients. Based on our research and NCCN guidelines, in August 2011 we have 
published a comprehensive and easy-to-understand approach in the journal American Family 
Physician (AFP)46 which can be used by newly-diagnosed patients and their physicians in 
quickly reaching an evidence-based and guideline-driven treatment choice. Decision-
making is very hard especially for low-risk patients, traditionally primary care physicians 
are not involved in this process, and over 70% to 80% patients choose a treatment or 
observation in the first visit to the urologist after a positive biopsy. Although newer 
guidelines now recommend against PSA screening,47 this recommendation carries the risk of 
increasing mortality due to prostate cancer and prostate cancer is already the second most 
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survival benefit of treatment, but in this trial 95% of patients had cancer that was clinically 
palpable (and not detected by PSA screening), putting this cohort in an intermediate- to 
high-risk category. A study of 44,630 men found a survival benefit of treatment, 33 but only 
2.1% of the patient sample had died of prostate cancer. If adjusted for lead time provided by 
screening and also for the impairment of HRQOL that follows treatment, treatment was 
projected to enhance quality-adjusted survival by only 0.5 year. 34   
Overtreatment would be expected if patients believe that treatment will lead to a much 
longer survival. Many studies have found that nearly every patient initially wants 
eradication of the cancer. 9 In qualitative studies, some patients accepted side effects for any 
gain in survival but they were convinced that treatment would improve survival.9 
Assuming that tumors would grow exponentially, urologists at the Mayo Clinic were also of 
the opinion that only 0.3% and 14.5% of screen-detected LPCs were “clinically 
insignificant.”35 Patient anxiety caused by the new diagnosis of cancer and the consensus 
advice of specialists that LPC patients with a CALE of >10 years should choose treatment or 
be offered treatment6 will lead to high treatment rates. In 70% to 90% of patients, a 
treatment plan is usually made in a single visit to the urologist after a positive biopsy.36   
The mean Gleason grade of our patients was 6.6, and in 87% of patients the mean PSA was 
<10, both of which are low-risk categories but for which national guidelines recommend 
either observation or treatment.8 Only 12.5% of patients in our study chose observation. 
Specialists frequently recommend treatment even in low-risk patients because over 10 to 15 
years the cancer may progress.29 To manage this risk, a strategy of active surveillance with 
deferred initial treatment28 is being increasingly recommended for patients at lower risk, ie, 
with cancers of Gleason grade <7, cancer stages T1c to T2a, and PSA <10. Almost half of 
patients with screen-detected cancer possess such characteristics. 27 In conjunction with 
specialists, primary care physicians (PCPs) can follow patients who choose this strategy. 
PCPs may also offer more balanced advice because they might be more knowledgeable 
about the patient’s preferences, co-morbidities, and baseline CALE.37 Patients with LPC may 
also want to review educational materials with their PCP. The American Cancer Society 
website was recommended because its content, accuracy, balance, and readability was rated 
the highest among 44 patient education materials about LPC.38 
Overtreatment can also be reduced with decreased screening, and several studies have 
shown that fewer patients want PSA screening if they are counseled before screening.39 
Enthusiasm for routine screening is high among specialists who treat LPC. In a random 
nationwide survey, 43% of 559 radiation oncologists recommended routine PSA screening in 
average-risk patients older than 80.6 Primary care physicians who frequently order PSA 
testing without much discussion about risks and benefits of testing cited reasons of lack of 
time, competing demands, limited patient health literacy, and fear of liability.40 Prescreening 
counseling is difficult because it is unclear what and how much discussion should occur. As 
yet, we cannot say that screening or treatment can improve survival. The deleterious effects 
of treatment on urinary, bowel, and sexual dysfunction are better known; however, their 
frequencies and severities after different treatment techniques have been reported in more 
than 800 publications,41 vary greatly, and are difficult to balance. We can also share with 
patients that there is a small risk of immediate morbidity and mortality associated with 
prostate biopsy and cancer treatment; that a new anxiety results from a positive PSA test, 
whether or not it is followed by a negative biopsy; and that we cannot compare the risk of 
death caused by co-morbid diseases with that of death caused by cancer without knowing 
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with cancer, no randomized controlled trial has shown that treatment can or cannot improve 
survival in patients with screen-detected cancer. Interestingly, a study found that more 
African American patients wanted PSA screening after the use of a decision aid, 39 
presumably because of the appreciation of the higher risk in African American patients.  
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Although the association of PDLO and PILT with continuous depression scores was 
statistically significant, the importance of this finding is unclear given that 96.6% patients 
had a depression score of <7, which indicates no depression. 
Our findings may be difficult to generalize because our study sample was small. However, 
the differences we found between CALE and patient expectations of survival with and 
without treatment were large. Also, the mean age26 and mean cancer grade27 of patients 
newly diagnosed with LPC in large series and in our patients were similar. Our patients 
were treated by urologists in a private practice and more than 80% of urologists in the 
United States are in private practice.42 Our method of equating CCI scores with NCCN 
recommended health quartiles to estimate CALE is new and has not been previously 
validated. We used this method because we could not find any other validated method to 
estimate long-term health-adjusted life expectancy in individual ambulatory patients. 
Finally, we lost accuracy in the estimation of PDLO and PILT by asking patients to predict 
their survival in ordinal intervals rather than in a discrete number of years. We used ordinal 
intervals because it might be easier for patients to predict their survival this way, and the 
intervals allowed an estimation of PDLO and PILT of more than or less than 10 years. We 
have also published these findings earlier. 43 
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answered over half of the questions on the KUJ scale. These findings have been published 
separately.44 Additionally, we had studied whether our patients had chosen treatment or 
observation in accordance with current NCCN guidelines and we had found that a majority 
had chosen over-treatment, i.e., they had chosen treatment even though for their clinical 
situation the NCCN had recommended observation as an equal alternative. These findings 
were published recently, 45 and had demonstrated that with the use of our method to 
estimate CALE it becomes feasible to use NCCN guidelines in decision-making in 
individual patients. Based on our research and NCCN guidelines, in August 2011 we have 
published a comprehensive and easy-to-understand approach in the journal American Family 
Physician (AFP)46 which can be used by newly-diagnosed patients and their physicians in 
quickly reaching an evidence-based and guideline-driven treatment choice. Decision-
making is very hard especially for low-risk patients, traditionally primary care physicians 
are not involved in this process, and over 70% to 80% patients choose a treatment or 
observation in the first visit to the urologist after a positive biopsy. Although newer 
guidelines now recommend against PSA screening,47 this recommendation carries the risk of 
increasing mortality due to prostate cancer and prostate cancer is already the second most 
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common cause of cancer death in American men. The algorithm and tools provided in our 
publication in AFP can empower primary care physicians in counseling newly-diagnosed 
patients and reduce the risk of over-treatment by convincing low-risk patients to choose 
active surveillance. With this safeguard, patients and physicians can choose screening for 
prostate cancer with less hesitation.    
7. Conclusion 
In patients with newly diagnosed LPC, in whom the mean cancer grade was <7 and in 
whom education, income, and health literacy was intermediate to high, almost 38% of our 
patients had expectations of a reduction in survival of 10 or more years if they chose 
observation, and 48.8% patients expected an improvement in survival of 10 or more years 
through choosing treatment. These expectations are highly unrealistic because no study has 
shown that the cancer or its treatment can affect survival by even 1 year, especially in 
screen-detected patients with a cancer Gleason grade of <7. 
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Cancer is now the leading cause of death in the world. In the U.S., one in two men and 
one in three women will be diagnosed with a non-skin cancer in their lifetime. Cancer 
patients are living longer than ever before. For instance, when detected early, the five-
year survival for breast cancer is 98%, and it is about 84% in patients with regional 
disease. However, the diagnosis and treatment of cancer is very distressing. Cancer 
patients frequently suffer from pain, disfigurement, depression, fatigue, physical 
dysfunctions, frequent visits to doctors and hospitals, multiple tests and procedures with 
the possibility of treatment complications, and the financial impact of the diagnosis on 
their life. This book presents a number of ways that can help cancer patients to look, feel 
and become healthier, take care of specific symptoms such as hair loss, arm swelling, and 
shortness of breath, and improve their intimacy, sexuality, and fertility.
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